<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Insulin‐sensitising drugs (metformin, rosiglitazone, pioglitazone, D‐chiro‐inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility - Morley, LC - 2017 | Cochrane Library</title> <meta content="Insulin‐sensitising drugs (metformin, rosiglitazone, pioglitazone, D‐chiro‐inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility - Morley, LC - 2017 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003053.pub6/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Insulin‐sensitising drugs (metformin, rosiglitazone, pioglitazone, D‐chiro‐inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility - Morley, LC - 2017 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003053.pub6/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD003053.pub6" name="dc.identifier" scheme="DOI"/> <meta content="Insulin‐sensitising drugs (metformin, rosiglitazone, pioglitazone, D‐chiro‐inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility" name="citation_title"/> <meta content="Lara C Morley" name="citation_author"/> <meta content="The General Infirmary of Leeds" name="citation_author_institution"/> <meta content="Thomas Tang" name="citation_author"/> <meta content="Royal Jubilee Maternity Service" name="citation_author_institution"/> <meta content="t.m.h.tang@leeds.ac.uk" name="citation_author_email"/> <meta content="Ephia Yasmin" name="citation_author"/> <meta content="University College Hospital" name="citation_author_institution"/> <meta content="Robert J Norman" name="citation_author"/> <meta content="University of Adelaide" name="citation_author_institution"/> <meta content="Adam H Balen" name="citation_author"/> <meta content="The Leeds Centre for Reproductive Medicine, Seacroft Hospital" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="11" name="citation_issue"/> <meta content="10.1002/14651858.CD003053.pub6" name="citation_doi"/> <meta content="2017" name="citation_date"/> <meta content="2017/11/28" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003053.pub6/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003053.pub6/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003053.pub6/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="*Insulin Resistance; *Live Birth; Abortion, Spontaneous [epidemiology]; Anovulation [*drug therapy]; Clomiphene [therapeutic use]; Hypoglycemic Agents [adverse effects, *therapeutic use]; Infertility, Female [*drug therapy]; Inositol [therapeutic use]; Metformin [adverse effects, therapeutic use]; Ovulation Induction [statistics &amp; numerical data]; Pioglitazone; Polycystic Ovary Syndrome [*complications]; Pregnancy Rate; Randomized Controlled Trials as Topic; Rosiglitazone; Thiazolidinediones [therapeutic use]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003053.pub6&amp;doi=10.1002/14651858.CD003053.pub6&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003053.pub6&amp;doi=10.1002/14651858.CD003053.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003053.pub6&amp;doi=10.1002/14651858.CD003053.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003053.pub6&amp;doi=10.1002/14651858.CD003053.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003053.pub6&amp;doi=10.1002/14651858.CD003053.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003053.pub6&amp;doi=10.1002/14651858.CD003053.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003053.pub6&amp;doi=10.1002/14651858.CD003053.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003053.pub6&amp;doi=10.1002/14651858.CD003053.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003053.pub6&amp;doi=10.1002/14651858.CD003053.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003053.pub6&amp;doi=10.1002/14651858.CD003053.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003053.pub6&amp;doi=10.1002/14651858.CD003053.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003053.pub6&amp;doi=10.1002/14651858.CD003053.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003053.pub6&amp;doi=10.1002/14651858.CD003053.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003053.pub6&amp;doi=10.1002/14651858.CD003053.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003053.pub6&amp;doi=10.1002/14651858.CD003053.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003053.pub6&amp;doi=10.1002/14651858.CD003053.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003053.pub6&amp;doi=10.1002/14651858.CD003053.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003053.pub6&amp;doi=10.1002/14651858.CD003053.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003053.pub6&amp;doi=10.1002/14651858.CD003053.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003053.pub6&amp;doi=10.1002/14651858.CD003053.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003053.pub6&amp;doi=10.1002/14651858.CD003053.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003053.pub6&amp;doi=10.1002/14651858.CD003053.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003053.pub6&amp;doi=10.1002/14651858.CD003053.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773519000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773548000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000"}};Liferay.authToken="9mpoajSI";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD003053\x2epub6\x26doi\x3d10\x2e1002\x2f14651858\x2eCD003053\x2epub6\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003053\x2epub6\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003053\x2epub6\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513680837000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","de","pl","fa","zh_HANS"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD003053.pub6",title:"Insulin\\u2010sensitising drugs (metformin, rosiglitazone, pioglitazone, D\\u2010chiro\\u2010inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility",firstPublishedDate:"Nov 28, 2017 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Gynaecology and Fertility Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734739000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=9mpoajSI&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD003053.pub6&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD003053.pub6';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD003053.pub6/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD003053.pub6/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD003053.pub6%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD003053.PUB6" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Laienverständliche Zusammenfassung&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;pl&quot;,&quot;title&quot;:&quot;Streszczenie prostym językiem&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD003053.pub6/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD003053.PUB6" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD003053.pub6/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD003053.pub6/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>13671 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD003053.pub6" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003053.pub6/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003053.pub6/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003053.pub6/full#CD003053-abs-0003"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003053.pub6/full#CD003053-sec-0140"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003053.pub6/full#CD003053-sec-0022"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003053.pub6/full#CD003053-sec-0023"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003053.pub6/full#CD003053-sec-0028"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003053.pub6/full#CD003053-sec-0029"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003053.pub6/full#CD003053-sec-0055"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003053.pub6/full#CD003053-sec-0126"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003053.pub6/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003053.pub6/appendices#CD003053-sec-0145"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003053.pub6/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003053.pub6/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/table_n/CD003053StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/table_n/CD003053StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003053.pub6/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003053.pub6/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003053.pub6/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD003053.pub6/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD003053.pub6/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD003053.pub6/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2018 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Insulin‐sensitising drugs (metformin, rosiglitazone, pioglitazone, D‐chiro‐inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility </h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003053.pub6/information#CD003053-cr-0002">Lara C Morley</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003053.pub6/information#CD003053-cr-0003"><i class="icon corresponding-author fa fa-envelope"></i>Thomas Tang</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003053.pub6/information#CD003053-cr-0004">Ephia Yasmin</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003053.pub6/information#CD003053-cr-0005">Robert J Norman</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003053.pub6/information#CD003053-cr-0006">Adam H Balen</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/information/en#CD003053-sec-0155">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 28 November 2017 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD003053.pub6">https://doi.org/10.1002/14651858.CD003053.pub6</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD003053-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD003053-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD003053-abs-0002">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD003053-abs-0007">فارسی</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD003053-abs-0009">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD003053-abs-0001" lang="en"> <section id="CD003053-sec-0001"> <h3 class="title" id="CD003053-sec-0001">Background</h3> <p>Polycystic ovary syndrome (PCOS) is characterised by infrequent or absent ovulation, and high levels of androgens and insulin (hyperinsulinaemia). Hyperinsulinaemia occurs secondary to insulin resistance and is associated with increased risk of cardiovascular disease and diabetes mellitus. Insulin‐sensitising agents such as metformin may be effective in treating PCOS‐related anovulation. </p> </section> <section id="CD003053-sec-0002"> <h3 class="title" id="CD003053-sec-0002">Objectives</h3> <p>To evaluate the effectiveness and safety of insulin‐sensitising drugs in improving reproductive and metabolic outcomes for women with PCOS undergoing ovulation induction. </p> </section> <section id="CD003053-sec-0003"> <h3 class="title" id="CD003053-sec-0003">Search methods</h3> <p>We searched the following databases from inception to January 2017: Cochrane Gynaecology and Fertility Group Specialised Register, CENTRAL, MEDLINE, Embase, PsycINFO and CINAHL. We searched registers of ongoing trials and reference lists from relevant studies. </p> </section> <section id="CD003053-sec-0004"> <h3 class="title" id="CD003053-sec-0004">Selection criteria</h3> <p>We included randomised controlled trials of insulin‐sensitising drugs compared with placebo, no treatment, or an ovulation‐induction agent for women with oligo and anovulatory PCOS. </p> </section> <section id="CD003053-sec-0005"> <h3 class="title" id="CD003053-sec-0005">Data collection and analysis</h3> <p>Two review authors independently assessed studies for eligibility and bias. Primary outcomes were live birth rate and gastrointestinal adverse effects. Secondary outcomes included other pregnancy outcomes, menstrual frequency and metabolic effects. We combined data to calculate pooled odds ratios (ORs) and 95% confidence intervals (CIs). We assessed statistical heterogeneity using the I<sup>2</sup> statistic and reported quality of the evidence for primary outcomes using GRADE methodology. </p> </section> <section id="CD003053-sec-0006"> <h3 class="title" id="CD003053-sec-0006">Main results</h3> <p>We assessed the interventions metformin, clomiphene citrate, metformin plus clomiphene citrate, D‐chiro‐inositol, rosiglitazone and pioglitazone. We compared these with each other, placebo or no treatment. We included 48 studies (4451 women), 42 of which investigated metformin (4024 women). Evidence quality ranged from very low to moderate. Limitations were risk of bias (poor reporting of methodology and incomplete outcome data), imprecision and inconsistency. </p> <p><b>Metformin versus placebo or no treatment</b> </p> <p>The evidence suggests that metformin may improve live birth rates compared with placebo (OR 1.59, 95% CI 1.00 to 2.51, 4 studies, 435 women, I<sup>2</sup> = 0%, low‐quality evidence). The metformin group experienced more gastrointestinal side effects (OR 4.76, 95% CI 3.06 to 7.41, 7 studies, 670 women, I<sup>2</sup> = 61%, moderate‐quality evidence) but had higher rates of clinical pregnancy (OR 1.93, 95% CI 1.42 to 2.64, 9 studies, 1027 women, I<sup>2</sup> = 43%, moderate‐quality evidence), ovulation (OR 2.55, 95% CI 1.81 to 3.59, 14 studies, 701 women, I<sup>2</sup> = 58%, moderate‐quality evidence) and menstrual frequency (OR 1.72, 95% CI 1.14 to 2.61, 7 studies, 427 women, I<sup>2</sup> = 54%, low‐quality evidence). There was no clear evidence of a difference in miscarriage rates (OR 1.08, 95% CI 0.50 to 2.35, 4 studies, 748 women, I<sup>2</sup> = 0%, low‐quality evidence). </p> <p><b>Metformin plus clomiphene citrate versus clomiphene citrate alone</b> </p> <p>There was no conclusive evidence of a difference between the groups in live birth rates (OR 1.21, 95% CI 0.92 to 1.59, 9 studies, 1079 women, I<sup>2</sup> = 20%, low‐quality evidence), but gastrointestinal side effects were more common with combined therapy (OR 3.97, 95% CI 2.59 to 6.08, 3 studies, 591 women, I<sup>2</sup> = 47%, moderate‐quality evidence). However, the combined therapy group had higher rates of clinical pregnancy (OR 1.59, 95% CI 1.27 to 1.99, 16 studies, 1529 women, I<sup>2</sup> = 33%, moderate‐quality evidence) and ovulation (OR 1.57, 95% CI 1.28 to 1.92, 21 studies, 1624 women, I<sup>2</sup> = 64%, moderate‐quality evidence). There was a statistically significant difference in miscarriage rate per woman, with higher rates in the combined therapy group (OR 1.59, 95% CI 1.03 to 2.46, 9 studies, 1096 women, I<sup>2</sup> = 0%, low‐quality evidence) but this is of uncertain clinical significance due to low‐quality evidence, and no clear difference between groups when we analysed miscarriage per pregnancy (OR 1.30, 95% CI 0.80 to 2.12, 8 studies; 400 pregnancies, I<sup>2</sup> = 0%, low‐quality evidence). </p> <p><b>Metformin versus clomiphene citrate</b> </p> <p>When all studies were combined, findings for live birth were inconclusive and inconsistent (OR 0.71, 95% CI 0.49 to 1.01, 5 studies, 741 women, I<sup>2</sup> = 86%, very low‐quality evidence). In subgroup analysis by obesity status, obese women had a lower birth rate in the metformin group (OR 0.30, 95% CI 0.17 to 0.52, 2 studies, 500 women, I<sup>2</sup> = 0%, very low‐quality evidence), while data from the non‐obese group showed a possible benefit from metformin, with high heterogeneity (OR 1.71, 95% CI 1.00 to 2.94, 3 studies, 241 women, I<sup>2</sup> = 78%, very low‐quality evidence). Similarly, among obese women taking metformin there were lower rates of clinical pregnancy (OR 0.34, 95% CI 0.21 to 0.55, 2 studies, 500 women, I<sup>2</sup> = 0%, very low‐quality evidence) and ovulation (OR 0.29, 95% CI 0.20 to 0.43 2 studies, 500 women, I<sup>2</sup> = 0%, low‐quality evidence) while among non‐obese women, the metformin group had more pregnancies (OR 1.56, 95% CI 1.05 to 2.33, 5 studies, 490 women, I<sup>2</sup> = 41%, very low‐quality evidence) and no clear difference in ovulation rates (OR 0.81, 95% CI 0.51 to 1.28, 4 studies, 312 women, low‐quality evidence, I<sup>2</sup>=0%). There was no clear evidence of a difference in miscarriage rates (overall: OR 0.92, 95% CI 0.50 to 1.67, 5 studies, 741 women, I<sup>2</sup> = 52%, very low‐quality evidence). </p> <p><b>D‐chiro‐inositol (2 studies), rosiglitazone (1 study) or pioglitazone (1 study) versus placebo or no treatment</b> </p> <p>We were unable to draw conclusions regarding other insulin‐sensitising drugs as no studies reported primary outcomes. </p> </section> <section id="CD003053-sec-0007"> <h3 class="title" id="CD003053-sec-0007">Authors' conclusions</h3> <p>Our updated review suggests that metformin alone may be beneficial over placebo for live birth, although the evidence quality was low. When metformin was compared with clomiphene citrate, data for live birth were inconclusive, and our findings were limited by lack of evidence. Results differed by body mass index (BMI), emphasising the importance of stratifying results by BMI. An improvement in clinical pregnancy and ovulation suggests that clomiphene citrate remains preferable to metformin for ovulation induction in obese women with PCOS. </p> <p>An improved clinical pregnancy and ovulation rate with metformin and clomiphene citrate versus clomiphene citrate alone suggests that combined therapy may be useful although we do not know whether this translates into increased live births. Women taking metformin alone or with combined therapy should be advised that there is no evidence of increased miscarriages, but gastrointestinal side effects are more likely. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD003053-abs-0003" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD003053-abs-0003">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD003053-abs-0004">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD003053-abs-0006">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD003053-abs-0008">فارسی</a> </li> <li class="section-language"> <a class="" href="full/pl#CD003053-abs-0005">Polski</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD003053-abs-0010">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD003053-abs-0003" lang="en"> <h3>Insulin‐sensitising drugs for women with a diagnosis of polycystic ovary syndrome and subfertility </h3> <p><b>Review question</b> </p> <p>Researchers reviewed the evidence about the effectiveness and safety of metformin and other drugs that improve the body's sensitivity to insulin, for inducing ovulation in women with polycystic ovary syndrome (PCOS). Of interest were live birth rate, adverse effects and additional reproductive and metabolic outcomes. </p> <p><b>Background</b> </p> <p>Women with PCOS typically have infrequent or absent periods due to a lack of ovulation, which can result in infertility. Women with PCOS are also at risk of developing metabolic problems, such as diabetes, high blood pressure and high cholesterol levels. High insulin levels are thought to play a role in PCOS and are generally worse with obesity. The treatments, which increase the sensitivity to insulin that are considered in this review are metformin, rosiglitazone, pioglitazone and D‐chiro‐inositol. </p> <p><b>Study characteristics</b> </p> <p>The search for suitable studies was completed on 12 January 2017. We have analysed a total of 48 randomised controlled trials (4451 women) in this review. The current review update includes five additional studies, which all investigated metformin in women with PCOS. The studies compared insulin‐sensitising drugs with placebo, no treatment, or the ovulation‐induction agent, clomiphene citrate. </p> <p><b>Key results</b> </p> <p>Our updated review showed that metformin may be beneficial in improving the chances of having a live birth compared with either no treatment or placebo. It is not clear from the available evidence whether metformin or clomiphene citrate is superior for live birth rate, although pregnancy and ovulation rates are improved with clomiphene citrate, and women taking clomiphene citrate have fewer side effects. However, it is possible that a woman's body mass index may affect which treatment she should take for the greatest benefit, although further research is required to establish this. Metformin did not appear to increase the risk of miscarriage. </p> <p>The limited improvement in metabolic outcomes with metformin treatment highlights the importance of weight loss and lifestyle adjustment, particularly in overweight women with PCOS. </p> <p><b>Quality of the evidence</b> </p> <p>The quality of the evidence ranged from very low to moderate. Main limitations were risk of bias (associated with poor reporting of study methodology and incomplete outcome data), imprecision and inconsistency. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD003053-sec-0140" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD003053-sec-0140"></div> <h3 class="title" id="CD003053-sec-0141">Implications for practice</h3> <section id="CD003053-sec-0141"> <p>Our updated review suggests that metformin alone may have a beneficial effect over placebo for live birth, although the evidence quality was low. When metformin was compared with clomiphene citrate, data for live birth were inconclusive, and our findings were limited by a lack of evidence. Results differed by BMI, emphasising the need for future studies to stratify results by BMI. An improvement in clinical pregnancy and ovulation rates suggests that clomiphene citrate remains preferable to metformin for ovulation induction in obese women with polycystic ovary syndrome (PCOS). </p> <p>An improved rate of clinical pregnancy and ovulation rate with metformin and clomiphene citrate versus clomiphene citrate alone suggests that combined therapy may have a useful role although we do not know if this translates into an increased live birth rate. Women taking metformin alone or with combined therapy should be advised that there is no evidence of an increased miscarriage risk, but gastrointestinal side effects are more likely. </p> </section> <h3 class="title" id="CD003053-sec-0142">Implications for research</h3> <section id="CD003053-sec-0142"> <p>Possible future strategies for insulin‐sensitising drugs include glucagon‐like peptide 1 (GLP‐1) analogues, which have been studied recently in women with PCOS (<a href="./references#CD003053-bbs2-0116" title="JensterleM , KocjanT , PfeiferM , JanezA . Short‐term intervention with liraglutide improved eating behaviour in obese women with polycystic ovary syndrome. Endocrine Research2014;40:133‐8. ">Jensterle 2014</a>). These agents include exenatide and liraglutide and are currently only licensed for the treatment of type 2 diabetes mellitus. Future updates of this review may include comparative studies between metformin and these newer agents. The development of mitochondrial inhibitors may present an additional new therapeutic strategy for managing PCOS (<a href="./references#CD003053-bbs2-0095" title="ColcaJR , McDonaldWG , CaveyGS , ColeSL , HolewaDD , Brightwell‐ConradAS , et al. Identification of a mitochondrial target of thiazolidinedione insulin sensitizers (mTOT)‐‐relationship to newly identified mitochondrial pyruvate carrier proteins. PLoS One2013;8:Epub ahead of print. ">Colca 2013</a>; <a href="./references#CD003053-bbs2-0149" title="ZhangY , YeJ . Mitochondrial inhibitor as a new class of insulin sensitizer. Acta Pharmacologica Sinica2012;2:341‐9. ">Zhang 2012</a>). </p> <p>Future studies of metformin should include live birth rate as the primary outcome. Studies should subdivide data on reproductive outcomes by resistance to clomiphene citrate and body mass index (BMI) (accounting for women having bariatric surgery). The magnitude of insulin resistance is also influenced by ethnicity (<a href="./references#CD003053-bbs2-0146" title="WijeyaratneCN , BalenAH , BarthJH , BelchetzPE . Clinical manifestations and insulin resistance (IR) in polycystic ovary syndrome (PCOS) among South Asians and Caucasians: is there a difference?. Clinical Endocrinology (Oxford)2002;57:343‐50. ">Wijeyaratne 2002</a>; <a href="./references#CD003053-bbs2-0147" title="WijeyaratneCN , NirantharakumarK , BalenAH , BarthJH , SheriffR , BelchetzPE . Plasma homocysteine in polycystic ovary syndrome: does it correlate with insulin resistance and ethnicity?. Clinical Endocrinology (Oxford)2004;60:560‐7. ">Wijeyaratne 2004</a>). Trials should therefore perform subgroup analyses according to the ethnic origin of participants. These subgroups may reduce the heterogeneity in meta‐analyses. It may be prudent to investigate the efficacy of early intervention in young women or adolescents, or both, with a diagnosis of PCOS. Further data in this area may improve patient selection when determining the appropriate therapeutic strategy. Studies should also focus on the long‐term impact of lifestyle changes and the use of insulin‐sensitising drugs to modulate the risk of developing metabolic syndrome. </p> <p>Good‐quality studies of adequate power are required to investigate the efficacy and safety of any new insulin‐sensitising agents. Although there is no current evidence that metformin is teratogenic (<a href="./references#CD003053-bbs2-0092" title="CassinaM , DonàM , DiGianantonioE , LittaP , ClementiM . First‐trimester exposure to metformin and risk of birth defects: a systematic review and meta‐analysis. Human Reproduction Update2014;20:656‐69. ">Cassina 2014</a>), if it is used widely to treat anovulation then it is possible that rare effects may be unmasked. Metformin therapy therefore needs to be kept under continuing surveillance and adverse outcomes reported. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD003053-sec-0022" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD003053-sec-0022"></div> <div class="table" id="CD003053-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Metformin compared to placebo or no treatment for women with polycystic ovary syndrome</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Metformin compared to placebo or no treatment for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population</b> : women with polycystic ovary syndrome, oligo amenorrhoea and subfertility<br/> <b>Settings</b> : outpatient<br/> <b>Intervention</b> : metformin<br/> <b>Comparison</b>: placebo or no treatment </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Placebo or no treatment</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Metformin </b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Live birth rate per woman</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>141 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>208 per 1000<br/> (141 to 292) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 1.59</b> <br/> (1.00 to 2.51) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>435<br/> (4 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Adverse events</b> (gastrointestinal) per woman </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>106 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>362 per 1000</p> <p>(267 to 469)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR 4.76</p> <p>(3.06 to 7.41)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>670</p> <p>(7 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>a,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Clinical pregnancy rate per woman</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>110 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>193 per 1000<br/> (149 to 246) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 1.93</b> <br/> (1.42 to 2.64) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1027<br/> (9 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Menstrual frequency per woman</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>183 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>278 per 1000</p> <p>(203 to 368)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>OR 1.72</b> </p> <p>(1.14 to 2.61)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>427</p> <p>(7 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>a,d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Ovulation rate per woman</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>200 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>389 per 1000<br/> (312 to 473) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR</b> <br/> 2.55 </p> <p>(1.81 to 3.59)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>701<br/> (14 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Miscarriage rate per woman</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>40 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>43per 1000<br/> (20 to 89) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 1.08</b><br/> (0.50 to 2.35) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>748<br/> (4 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Miscarriage rate per pregnancy OR 0.58, 95% CI 0.25 to 1.34, 200 pregnancies</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> is the median control group risk across studies. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>OR:</b> odds ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence</p> <p><b>High quality</b>: we are very confident that the true effect lies close to that of the estimate of the effect </p> <p><b>Moderate quality</b>: we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of effect, but there is a possibility that it is substantially different </p> <p><b>Low quality</b>: our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect </p> <p><b>Very low quality</b>: we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level for serious risk of bias related to failure to report methods of randomisation and/or serious risk of attrition bias in some of the studies.<br/> <sup>b</sup>Downgraded one level for serious imprecision as the event rate is low and findings are compatible with benefit in one or both groups or with no meaningful difference between the groups.<br/> <sup>c</sup>Moderate inconsistency (I<sup>2</sup> = 61%), but not downgraded, as all heterogeneity is attributable to a single small study and the direction of effect largely consistent.<br/> <sup>d</sup>Downgraded one level for serious inconsistency (I<sup>2</sup>= 54%); largest study shows no evidence of effect. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD003053-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Metformin combined with clomiphene citrate versus clomiphene citrate alone for women with polycystic ovary syndrome</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>Metformin combined with clomiphene versus clomiphene alone for women with polycystic ovary syndrome </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Population</b> : women with polycystic ovary syndrome<br/> <b>Setting</b> : outpatient<br/> <b>Intervention</b> : metformin combined with ovulation induction agent clomiphene<br/> <b>Comparison</b>: clomiphene alone </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with clomiphene alone</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with metformin combined with clomiphene</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Live birth rate per woman</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>257 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>295 per 1000<br/> (241 to 355) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 1.21<br/> (0.92 to 1.59) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1079<br/> (9 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events</b> (gastrointestinal) per woman </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>134 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>381 per 1000<br/> (286 to 485) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 3.97<br/> (2.59 to 6.08) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>591<br/> (3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Clinical pregnancy rate per woman</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>243 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>338per 1000<br/> (330 to 436) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR 1.59<br/> (1.27 to 1.99) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1529<br/> (16 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Menstrual frequency per woman</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign=""> <p>Not reported by any of the included studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Ovulation rate per woman</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>381per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>491 per 1000<br/> (441to 542) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 1.57</p> <p>(1.28 to 1.92)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1624<br/> (21 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>a,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Miscarriage rate per woman</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Median rates not calculable as there were no events in the control group in 5/8 studies</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 1.59<br/> (1.03 to 2.46) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1096<br/> (9 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Miscarriage rate per pregnancy OR 1.30 95% CI 0.80 to 2.12, 400 pregnancies</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the median risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> confidence interval; <b>OR:</b> odds ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> we are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level for serious risk of bias related to failure to describe study methods and/or serious risk of attrition bias in several of the studies.<br/> <sup>b</sup>Downgraded one level for serious imprecision as findings are compatible with benefit in one or both groups or with no meaningful difference between the group.<br/> <sup>c</sup>High heterogeneity (I<sup>2</sup> = 62%), but not downgraded as direction of effect consistent and most inconsistency is due to a single small study. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD003053-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Metformin compared to clomiphene citrate for women with polycystic ovary syndrome</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>Metformin compared to clomiphene citrate for women with polycystic ovary syndrome</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Population</b> : women with polycystic ovary syndrome<br/> <b>Setting:</b> outpatient<br/> <b>Intervention</b> : metformin<br/> <b>Comparison</b>: clomiphene citrate </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with clomiphene citrate</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with metformin</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Live birth rate per woman</b> </p> <p>Participants with BMI &lt; 30 kg/m<sup>2</sup> or ≤ 32 kg/m<sup>2a</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>225 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>171 per 1000</p> <p>(124 to 227)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR 1.71 (1.00 to 2.94)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>241</p> <p>(3 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝</p> <p><b>very low</b><sup>c,d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>High heterogeneity (I<sup>2</sup> = 78%) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Live birth rate per woman</b> </p> <p>Participants with BMI ≥ 30 kg/m<sup>2a</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>198 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>69 per 1000</p> <p>(40 to 114)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR 0.30</p> <p>(0.17 to 0.52)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>500</p> <p>(2 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>c,d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>74 events</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Adverse events</b> </p> <p>(gastrointestinal)</p> </td> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign=""> <p>Not reported by any of the included studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Clinical pregnancy rate per woman</b> Participants with BMI &lt; 30 kg/m<sup>2</sup> or ≤ 32 kg/m<sup>2a</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>320 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>423 per 1000<br/> (331 to 523) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 1.56<br/> (1.05 to 2.33) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>490<br/> (5 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>c,d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>103 events</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Clinical pregnancy rate per woman</b> Participants with BMI ≥ 30 kg/m<sup>2a</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>234 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>94 per 1000<br/> (60 to 144) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 0.34<br/> (0.21 to 0.55) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>500<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>c,d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>98 events</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Menstrual frequency</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign=""> <p>Not reported by any of the included studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Ovulation rate per woman</b> </p> <p>Participants with BMI &lt; 30 kg/m<sup>2b</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>625 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>574 per 1000<br/> (459 to 681) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 0.81<br/> (0.51 to 1.28) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>312<br/> (4 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Ovulation rate per woman</b> </p> <p>Participants with BMI ≥ 30 kg/m<sup>2b</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>534per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>250per 1,000<br/> (187 to 330) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 0.29<br/> (0.20 to 0.43) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>500<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Miscarriage rate per woman</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>29 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>26 per 1000</p> <p>(15 to 47)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR 0.92 (0.50 to 1.67)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>741<br/> (5 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝</p> <p><b>very low</b><sup>c,e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>High heterogeneity (I<sup>2</sup> = 52%) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the median risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> confidence interval; <b>OR:</b> odds ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> we are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Data subgrouped by BMI, as pooling of BMI groups resulted in high heterogeneity (I<sup>2</sup> &gt; 85%) with differing directions of effect.<br/> <sup>b</sup>Data subgrouped by BMI, as pooling of BMI groups resulted in high heterogeneity (I<sup>2</sup> = 74%), though direction of effect was consistent.<br/> <sup>c</sup>Evidence downgraded two levels for very serious risk of bias, due to failure to report study methods and/or risk of attrition bias in one or more studies and because findings are based on subgroup analysis.<br/> <sup>d</sup>Evidence downgraded one level for serious imprecision: low event rate (total 74 events).<br/> eEvidence downgraded for serious inconsistency (where further downgrading feasible). </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD003053-sec-0023" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD003053-sec-0023"></div> <section id="CD003053-sec-0024"> <h3 class="title" id="CD003053-sec-0024">Description of the condition</h3> <p>Polycystic ovary syndrome (PCOS) is a common endocrine disorder affecting at least 5% to 15% of women of reproductive age (<a href="./references#CD003053-bbs2-0089" title="BalenAH . Infertility in Practice. 4th Edition. Boca Raton: CRC Press, 2014. [13:978‐1‐84184‐5] ">Balen 2014</a>; <a href="./references#CD003053-bbs2-0124" title="MarchWA , MooreVM , WillsonKJ , PhillipsDI , NormanRJ , DaviesMJ . The prevalence of polycystic ovary syndrome in a community sample assessed under contrasting diagnostic criteria. Human Reproduction2010;25:544‐51. ">March 2010</a>). The disorder is heterogeneous, encompassing a broad spectrum of signs and symptoms of ovarian dysfunction. The classic presentation, as described by Stein and Leventhal (<a href="./references#CD003053-bbs2-0139" title="Stein . Amenorrhea associated with bilateral polycystic ovaries. American Journal of Obstetrics and Gynecology1935;29:181‐91. ">Stein 1935</a>), with features of obesity, amenorrhoea and hirsutism is one end of the spectrum that, at the other end, includes women with normal menstrual cyclicity and yet with ultrasound evidence of a polycystic ovarian appearance (<a href="./references#CD003053-bbs2-0105" title="FauserBC , TarlatzisBC , RebarRW , LegroRS , BalenAH , LoboR , et al. Consensus on women's health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE/ASRM‐sponsored 3rd PCOS Consensus Workshop Group. Fertility and Sterility2012;97:28‐38. [PUBMED: 22153789] ">Fauser 2012</a>). Therefore, no single diagnostic criterion (such as hyperandrogenism or PCO) is sufficient for the clinical diagnosis. The 2003 Rotterdam consensus revised diagnostic criteria for a diagnosis of PCOS are as follows, with two of the following being required: <br/>1. oligo or anovulation, or both, that is, menstrual disturbance; <br/>2. clinical or biochemical signs, or both, of hyperandrogenism; <br/>3. PCO on ultrasound; <br/>4. exclusion of other aetiologies of menstrual disturbance and hyperandrogenism (such as congenital adrenal hyperplasia, androgen‐secreting tumours, Cushing's syndrome) (<a href="./references#CD003053-bbs2-0103" title="The Rotterdam ESHRE/ASRM‐sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long‐term health risks related to polycystic ovary syndrome (PCOS). Human Reproduction2004;19(1):41. ">ESHRE/ASRM 2004</a>). The Rotterdam consensus also defined the diagnostic criteria for ultrasound PCO morphology as either 12 or more follicles measuring 2 mm to 9 mm in diameter or increased ovarian volume, over 10 cm<sup>3</sup>, when using a transvaginal ultrasound scan (<a href="./references#CD003053-bbs2-0103" title="The Rotterdam ESHRE/ASRM‐sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long‐term health risks related to polycystic ovary syndrome (PCOS). Human Reproduction2004;19(1):41. ">ESHRE/ASRM 2004</a>). </p> <p>Although PCOS is the commonest cause of anovulatory infertility (<a href="./references#CD003053-bbs2-0089" title="BalenAH . Infertility in Practice. 4th Edition. Boca Raton: CRC Press, 2014. [13:978‐1‐84184‐5] ">Balen 2014</a>), many women may remain undiagnosed in the community. This was indicated by a prospective birth cohort study that investigated PCOS in 728 adult women and found that 69% of women with PCOS did not have a pre‐existing diagnosis (<a href="./references#CD003053-bbs2-0124" title="MarchWA , MooreVM , WillsonKJ , PhillipsDI , NormanRJ , DaviesMJ . The prevalence of polycystic ovary syndrome in a community sample assessed under contrasting diagnostic criteria. Human Reproduction2010;25:544‐51. ">March 2010</a>). </p> <p>The expression of PCOS symptoms is multifaceted, and the reduced conception rates associated with PCOS may be related to hyperandrogenism, obesity and insulin resistance (<a href="./references#CD003053-bbs2-0089" title="BalenAH . Infertility in Practice. 4th Edition. Boca Raton: CRC Press, 2014. [13:978‐1‐84184‐5] ">Balen 2014</a>). Over the last 20 years, the body of evidence indicating that increased insulin resistance and compensatory high insulin concentrations (hyperinsulinaemia) play a key role in the pathogenesis of PCOS has grown (<a href="./references#CD003053-bbs2-0089" title="BalenAH . Infertility in Practice. 4th Edition. Boca Raton: CRC Press, 2014. [13:978‐1‐84184‐5] ">Balen 2014</a>; <a href="./references#CD003053-bbs2-0100" title="Diamanti‐KandarakisE , ChristakouCD , KandarakisE , EconomouF . Metformin: an old medication of new fashion: evolving new molecular mechanisms and clinical implications in polycystic ovary syndrome. European Journal of Endocrinology2010;162:193‐212. ">Diamanti‐Kandarakis 2010</a>). Insulin resistance is more common in overweight women but can also occur in slim women with the disorder (<a href="./references#CD003053-bbs2-0085" title="AlebićMS , BulumT , StojanovićN , DuvnjakL . Definition of insulin resistance using the homeostasis model assessment (HOMA‐IR) in IVF patients diagnosed with polycystic ovary syndrome (PCOS) according to the Rotterdam criteria. Endocrine2014;47:625‐30. ">Alebic 2014</a>; <a href="./references#CD003053-bbs2-0140" title="SteptoNK , CassarS , JohamAE , HutchisonSK , HarrisonCL , GoldsteinRF , et al. Women with polycystic ovary syndrome have intrinsic insulin resistance on euglycaemic‐hyperinsulaemic clamp. Human Reproduction2013;28:544‐51. ">Stepto 2013</a>). </p> <p>The insulin resistance associated with PCOS can worsen both women's symptom profile and their likelihood of achieving a live birth. Women with insulin resistance have a significantly higher level of testosterone and increased prevalence of hirsutism than women with non‐insulin resistant PCOS (<a href="./references#CD003053-bbs2-0121" title="LegroRS . Type 2 diabetes and polycystic ovary syndrome. Fertility and Sterility2006;86 Suppl 1:16‐7. ">Legro 2006a</a>). In addition, <a href="./references#CD003053-bbs2-0134" title="RobinsonS , KiddyD , GeldingSV , WillisD , NiththyananthanR , BushA , et al. The relationship of insulin insensitivity to menstrual pattern in women with hyperandrogenism and polycystic ovaries. Clinical Endocrinology (Oxford)1993;39:351‐5. ">Robinson 1993</a> reported that women with PCOS who developed menstrual disturbance had lower insulin sensitivity than controls; whilst those with regular cycles had normal insulin sensitivity, similar to controls. Insulin resistant women with PCOS also have a lower ovulation rate and are more likely to develop resistance to ovulation induction with clomiphene citrate compared with women with non‐insulin resistant PCOS. </p> <p>The impaired glucose tolerance results in accelerated development of type 2 diabetes mellitus compared with the background population (<a href="./references#CD003053-bbs2-0094" title="CelikC , TasdemirN , AbaliR , BastuE , YilmazM . Progression to impaired glucose tolerance or type 2 diabetes mellitus in polycystic ovary syndrome: a controlled follow‐up study. Fertility and Sterility2014;101:1123‐8. ">Celik 2014</a>). <a href="./references#CD003053-bbs2-0094" title="CelikC , TasdemirN , AbaliR , BastuE , YilmazM . Progression to impaired glucose tolerance or type 2 diabetes mellitus in polycystic ovary syndrome: a controlled follow‐up study. Fertility and Sterility2014;101:1123‐8. ">Celik 2014</a> conducted a prospective study of insulin resistance in 84 women with PCOS, with a mean follow‐up period of 2.6 years. Of those with normal glucose tolerance, 11.5% converted to insulin resistance (annual incidence rate 4.5%). This compares to 2.3% in the healthy control population (n = 45), with an annual progression of 0.9%. For women with impaired glucose tolerance at the outset, 33.3% developed diabetes (annual incidence rate 10.4%).<br/> <br/> The prevalence of insulin resistance in women with PCOS is likely to be exacerbated by obesity; at least 50% of women with PCOS are obese (<a href="./references#CD003053-bbs2-0089" title="BalenAH . Infertility in Practice. 4th Edition. Boca Raton: CRC Press, 2014. [13:978‐1‐84184‐5] ">Balen 2014</a>). Correspondingly, a Spanish study found a 28% prevalence of PCOS in obese women versus 5% in normal‐weight women (<a href="./references#CD003053-bbs2-0086" title="Alvarez‐BlascoF , Botella‐CarreteroJI , San MillánJL , Escobar‐MorrealeHF . Prevalence and characteristics of the polycystic ovary syndrome in overweight and obese women. Archives of Internal Medicine2006;166:2081‐6. ">Alvarez‐Blasco 2006</a>). Obesity, and particularly abdominal obesity as indicated by an increased waist to hip ratio, is correlated with reduced fecundity (<a href="./references#CD003053-bbs2-0123" title="LordJ , WilkinT . Polycystic ovary syndrome and fat distribution: the central issue?. Hum Fertil (Camb)2002;5:67‐71. ">Lord 2002</a>; <a href="./references#CD003053-bbs2-0129" title="PasqualiR , PelusiC , GenghiniS , CacciariM , GambineriA . Obesity and reproductive disorders in women. Human Reproduction Update2003;9:359‐72. ">Pasquali 2003</a>). A small study demonstrated increased preterm birth and low birth‐weight infants in obese versus normal‐weight women with PCOS (<a href="./references#CD003053-bbs2-0098" title="DeFrèneV , VansteelandtS , T'SjoenG , GerrisJ , SomersS , VercruysseL , et al. A retrospective study of the pregnancy, delivery and neonatal outcome in overweight versus normal weight women with polycystic ovary syndrome. Human Reproduction2014;29:2333‐8. ">De Frene 2014</a>). Weight loss has been shown to improve the endocrine profile, menstrual cyclicity and the likelihood of ovulation (<a href="./references#CD003053-bbs2-0115" title="Huber‐BuchholzMM , CareyDG , NormanRJ . Restoration of reproductive potential by lifestyle modification in obese polycystic ovary syndrome: role of insulin sensitivity and luteinizing hormone. Journal of Clinical Endocrinology and Metabolism1999;84:1470‐4. ">Huber‐Buchholz 1999</a>; <a href="./references#CD003053-bbs2-0117" title="KiddyDS , Hamilton‐FairleyD , BushA , ShortF , AnyaokuV , ReedMJ , et al. Improvement in endocrine and ovarian function during dietary treatment of obese women with polycystic ovary syndrome. Clinical Endocrinology (Oxford)1992;36:105‐11. ">Kiddy 1992</a>). A meta‐analysis of six studies found that weight loss reduced testosterone and insulin resistance, although there was insufficient evidence to determine whether reproductive outcomes were improved (<a href="./references#CD003053-bbs2-0126" title="MoranLJ , HutchisonSK , NormanRJ , TeedeHJ . Lifestyle changes in women with polycystic ovary syndrome. Cochrane Database of Systematic Reviews2011, Issue 7. [DOI: 10.1002/14651858.CD007506.pub3] ">Moran 2011</a>).<br/> <br/> There is therefore considerable overlap between metabolic syndrome and the metabolic disturbances that feature in PCOS. Metabolic syndrome is a cluster of risk factors that confer an increased risk for cardiovascular disease and type II diabetes (<a href="./references#CD003053-bbs2-0087" title="ApridonidzeT , EssahPA , IuornoMJ , NestlerJE . Prevalence and characteristics of the metabolic syndrome in women with polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism2005;90:1929‐35. ">Apridonidze 2005</a>; <a href="./references#CD003053-bbs2-0107" title="FordES . The metabolic syndrome and mortality from cardiovascular disease and all‐causes: findings from the National Health and Nutrition Examination Survey II Mortality Study. Atherosclerosis2004;173:309‐14. ">Ford 2004</a>). Women with metabolic syndrome may have a higher mortality from cardiovascular disease overall, coronary heart disease and stroke compared to women without the syndrome (<a href="./references#CD003053-bbs2-0107" title="FordES . The metabolic syndrome and mortality from cardiovascular disease and all‐causes: findings from the National Health and Nutrition Examination Survey II Mortality Study. Atherosclerosis2004;173:309‐14. ">Ford 2004</a>). The prevalence of metabolic syndrome among women with PCOS was estimated to be nearly two‐fold higher than in the general population (43% versus 24%) (<a href="./references#CD003053-bbs2-0087" title="ApridonidzeT , EssahPA , IuornoMJ , NestlerJE . Prevalence and characteristics of the metabolic syndrome in women with polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism2005;90:1929‐35. ">Apridonidze 2005</a>). The prevalence also varies amongst different ethnic groups, which is likely to be influenced by the background prevalence of insulin resistance (<a href="./references#CD003053-bbs2-0112" title="HahnS , TanS , SackS , KimmigR , QuadbeckB , MannK , et al. Prevalence of the metabolic syndrome in German women with polycystic ovary syndrome. Experimental and Clinical Endocrinology &amp; Diabetes2007;115:130‐5. ">Hahn 2007</a>; <a href="./references#CD003053-bbs2-0138" title="SoaresEM , AzevedoGD , GadelhaRG , LemosTM , MaranhaoTM . Prevalence of the metabolic syndrome and its components in Brazilian women with polycystic ovary syndrome. Fertility and Sterility2007;88(5):1389‐95. ">Soares 2007</a>; <a href="./references#CD003053-bbs2-0145" title="WeerakietS , BunnagP , PhakdeekitcharoenB , WansumrithS , ChanprasertyothinS , JultanmasR , et al. Prevalence of the metabolic syndrome in Asian women with polycystic ovary syndrome: using the International Diabetes Federation criteria. Gynecological Endocrinology2007;23:153‐60. ">Weerakiet 2007</a>). Furthermore, women with PCOS and metabolic syndrome tend to have a higher body mass index (kg/m<sup>2</sup>) (BMI), waist circumference, blood pressure, fasting glucose and insulin concentration than those without (<a href="./references#CD003053-bbs2-0101" title="EhrmannDA , LiljenquistDR , KaszaK , AzzizR , LegroRS , GhazziMN . Prevalence and predictors of the metabolic syndrome in women with polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism2006;91:48‐53. ">Ehrmann 2006</a>). PCOS therefore affects reproductive outcomes and confers significant long‐term health risks to patients. PCOS also has a significant psychological impact, with associated with low self esteem, anxiety and depression (<a href="./references#CD003053-bbs2-0127" title="MoranLJ , DeeksAA , Gibson‐HelmME , TeedeHJ . Psychological parameters in the reproductive phenotypes of polycystic ovary syndrome. Human Reproduction2012;27:2082‐8. ">Moran 2012</a>).<br/> <br/> With the increasing prevalence of obesity in society, the prevalence of PCOS is likely to rise. There are therefore significant financial implications for the funding of PCOS management by health care providers. A 2005 study calculated approximately USD 4.36 billion are spent on managing reproductive‐age women with PCOS, of which USD 533 million is related to infertility (<a href="./references#CD003053-bbs2-0088" title="AzzizR , MarinC , HoqL , BadamgaravE , SongP . Health care‐related economic burden of the polycystic ovary syndrome during the reproductive life span. Journal of Clinical Endocrinology and Metabolism2005;90:4650‐8. ">Azziz 2005</a>). </p> </section> <section id="CD003053-sec-0025"> <h3 class="title" id="CD003053-sec-0025">Description of the intervention</h3> <p>Metformin is an antihyperglycaemic biguanide drug, widely used for the treatment of type 2 diabetes mellitus. However, the exact mechanism of action through which metformin has its glucose‐lowering effect, is still being explored (<a href="./references#CD003053-bbs2-0130" title="PernicovaI , KorbonitsM . Metformin‐‐mode of action and clinical implications for diabetes and cancer. Nature Reviews. Endocrinology2014;10:143‐56. [DOI: 10.1038/nrendo.2013.256] ">Pernicova 2014</a>). Metformin inhibits hepatic gluconeogenesis and reduces the action of glucagon, resulting in a reduction in circulating insulin and glucose. This is thought to occur via inhibition of mitochondrial complexes with downstream effects on cyclic (adenosine monophosphate) AMP and protein kinase signalling pathways. The effect on protein kinase may also modulate lipid synthesis. Metformin is known to exert its effect on several tissues affected by insulin resistance, including the liver, adipose tissue and the ovaries (<a href="./references#CD003053-bbs2-0130" title="PernicovaI , KorbonitsM . Metformin‐‐mode of action and clinical implications for diabetes and cancer. Nature Reviews. Endocrinology2014;10:143‐56. [DOI: 10.1038/nrendo.2013.256] ">Pernicova 2014</a>). </p> <p>The additional interventions considered in this review are thiazolidinediones including troglitazone, rosiglitazone and pioglitazone. Thiazolidinedione is a selective ligand of the nuclear transcription factor perioxisomes proliferator activated receptor γ. These are widely available, standard medications for the treatment of non‐insulin‐dependent diabetes mellitus (NIDDM). Whilst they lower elevated sugar levels in people with diabetes, when given to non‐diabetic people, insulin levels are lowered but blood glucose levels remain unchanged. </p> <p>Troglitazone had been used as a therapy for people with diabetes and in some trials involving women with PCOS. However, rare cases of liver damage were reported during its marketed use. The liver damage was usually reversible but very rare cases of hepatic failure, leading to death or liver transplant, were reported (<a href="./references#CD003053-bbs2-0111" title="GrahamDJ , GreenL , SeniorJR , NourjahP . Troglitazone‐induced liver failure: a case study. The American Journal of Medicine2003;114:299‐306. ">Graham 2003</a>). Injury occurred after short‐ and long‐term troglitazone treatment, leading to its withdrawal from the market in March 2000 (<a href="./references#CD003053-bbs2-0106" title="FDA (Federal Drug Administration). www.fda.gov Accessed 14 January 2003. ">FDA 2002</a>). </p> <p>Rosiglitazone and pioglitazone do not carry the same degree of risk of hepatotoxicity and are commonly used in clinical trials on women with PCOS. However, they are classified as pregnancy category C drugs according to the Food and Drug Administration (FDA) due to the potential risk of causing fetal growth restriction in animal experiments (<a href="./references#CD003053-bbs2-0148" title="Yki‐JarvinenH . Thiazolidinediones. New England Journal of Medicine2004;351:1106‐18. ">Yki‐Jarvinen 2004</a>). A high incidence of weight gain among the users further hampers their use in obese women with PCOS (<a href="./references#CD003053-bbs2-0002" title="BaillargeonJP , JakubowiczDJ , IuornoMJ , JakubowiczS , NestlerJE . Effects of metformin and rosiglitazone, alone and in combination, in nonobese women with polycystic ovary syndrome and normal indices of insulin sensitivity. Fertility and Sterility2004;82:893‐902. ">Baillargeon 2004</a>). Rosiglitazone is currently available in the USA but has been suspended from use in the European Union by the European Medicines Agency and has also been withdrawn from India, New Zealand and South Africa. Pioglitazone has been withdrawn from some countries due to an association with bladder cancer reported with long‐term use (<a href="./references#CD003053-bbs2-0102" title="European Medicines Agency. European Medicines Agency clarifies opinion on pioglitazone and the risk of bladder cancer. www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2011/10/news_detail_001368.jsp&amp;mid=WC0b01ac058004d5c1&amp;jsenabled=trueAccessed 2011. ">EMA 2011</a>). </p> </section> <section id="CD003053-sec-0026"> <h3 class="title" id="CD003053-sec-0026">How the intervention might work</h3> <p>Increased insulin resistance, hyperandrogenism and obesity have a significant impact on menstrual cyclicity and reproductive health. Metformin may therefore have beneficial effects on anovulatory infertility in PCOS, with reduced levels of circulating insulin acting on the ovaries. Within the ovary itself, metformin may also have a direct impact on cells to reduce excessive steroidogenesis and follicular growth, although the molecular mechanisms remain incompletely understood (<a href="./references#CD003053-bbs2-0100" title="Diamanti‐KandarakisE , ChristakouCD , KandarakisE , EconomouF . Metformin: an old medication of new fashion: evolving new molecular mechanisms and clinical implications in polycystic ovary syndrome. European Journal of Endocrinology2010;162:193‐212. ">Diamanti‐Kandarakis 2010</a>). </p> <p>As insulin resistance and resulting hyperinsulinaemia are key metabolic features in women with PCOS, their amelioration through either metformin or thiazolidinediones could improve PCOS‐associated symptoms and conception rates. </p> </section> <section id="CD003053-sec-0027"> <h3 class="title" id="CD003053-sec-0027">Why it is important to do this review</h3> <p>This is an update of a Cochrane Review first published in 2003, and previously updated in 2009 and 2012. For this third update, comparing the efficacy and safety of insulin‐sensitising drugs, such as metformin, against placebo or the commonly used clomiphene citrate, for ovulation induction in PCOS, remains clinically important and there are still unanswered questions. A focus of this review has been identifying high‐quality studies that report live birth as a primary outcome. </p> <p>The first Cochrane Review on the use of insulin‐sensitising drugs for PCOS indicated that metformin was an effective treatment for anovulation in women with PCOS (<a href="./references#CD003053-bbs2-0150" title="LordJM , FlightIH , NormanRJ . Insulin‐sensitising drugs (metformin, troglitazone, rosiglitazone, pioglitazone, D‐chiro‐inositol) for polycystic ovary syndrome. Cochrane Database of Systematic Reviews2003, Issue 3. [DOI: 10.1002/14651858.CD003053] ">Lord 2003</a>). However, the study populations in the review had a wide range of BMI. It was therefore difficult to interpret the findings when the results were combined for analysis. Furthermore, most of the included studies had a relatively small sample size, with the highest number recruited (94 women) in the study by <a href="./references#CD003053-bbs2-0011" title="FlemingR , HopkinsonZE , WallaceAM , GreerIA , SattarN . Ovarian function and metabolic factors in women with oligomenorrhea treated with metformin in a randomized double blind placebo‐controlled trial. Journal of Clinical Endocrinology and Metabolism2002;87(2):569‐74. FlemingR , HopkinsonZE , WallaceE , GreerIA , SattarN . Metformin treatment improves ovulation frequency in women with oligomenorrhoea: a randomized, double blind placebo trial. Human Fertility2000; Vol. 3, issue 4:389‐90. ">Fleming 2002</a>. The first updated review (<a href="./references#CD003053-bbs2-0151" title="TangT , LordJM , NormanRJ , YasminE , BalenAH . Insulin‐sensitising drugs (metformin, rosiglitazone, pioglitazone, D‐chiro‐inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility. Cochrane Database of Systematic Reviews2009, Issue 3. [DOI: 10.1002/14651858.CD003053.pub4; PUBMED: 20091537] ">Tang 2009</a>), included a number of large appropriately powered studies (<a href="./references#CD003053-bbs2-0022" title="CataldoN , BarnhartH , LegroR , MyersE , SchlaffW , CarrB , et al. Extended‐release metformin does not reduce the clomiphene citrate dose required to induce ovulation in polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism2008;93(8):3147‐7. LegroRS , BarnhartHX , SchlaffWD , CarrBR , DiamondMP , CarsonSA , et al. Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome. New England Journal of Medicine2007;356:551‐66. [original article] ">Legro 2007</a>; <a href="./references#CD003053-bbs2-0028" title="MollE , BossuytPM , KorevaarJC , LambalkCB , Van derVeenF . Effect of clomifene citrate plus metformin and clomifene citrate plus placebo on induction of ovulation in women with newly diagnosed polycystic ovary syndrome: randomised double blind clinical trial. BMJ2006;332:1485. [original article] MollE , KorevaarJC , BossuytPM , van derVeenF . Does adding metformin to clomifene citrate lead to higher pregnancy rates in a subset of women with polycystic ovary syndrome?. Human Reproduction2008;23(8):1830‐4. MollE , VanWelyM , LambalkCB , BossuytPM , Van derVeenF . Health‐related quality of life in women with newly diagnosed polycystic ovary syndrome randomized between clomifene citrate plus metformin or clomifene citrate plus placebo. Human Reproduction2012;27:3273‐8. ">Moll 2006</a>; <a href="./references#CD003053-bbs2-0043" title="TangT , GlanvilleJ , HaydenCJ , WhiteD , BarthJH , BalenAH . Combined lifestyle modification and metformin in obese patients with polycystic ovary syndrome. A randomized, placebo‐controlled, double‐blind multicentre study. Human Reproduction2006;21:80‐9. ">Tang 2006</a>). The current search has included studies up to January 2017. We have added five additional studies with a low risk of bias (<a href="./references#CD003053-bbs2-0001" title="AyazA , AlwanY , FarooqMU . Efficacy of combined metformin‐clomiphene citrate in comparison with clomiphene citrate alone in infertile women with polycystic ovarian syndrome (PCOS). Journal of Medicine and Life2013;6:199‐201. AyazA , AlwanY , FarooqMU . Metformin‐clomiphene citrate vs. clomiphene citrate alone: polycystic ovarian syndrome. Journal of Human Reproductive Sciences2013;6:15‐8. ">Ayaz 2013</a>; <a href="./references#CD003053-bbs2-0003" title="BegumH , ChowdhuryTA , BegumF , BegumSN , KabirN , HaqueMDA . Effect of metformin and clomiphene citrate in improving fertility in subfertility women with polycystic ovary syndrome: a randomised controlled trial. Bangladesh Journal of Obstetrics and Gynaecology2014;29:15‐20. ">Begum 2014</a>; <a href="./references#CD003053-bbs2-0017" title="KarS . Metabolic risks of the lean PCOS woman. Fertility and Sterility ASRM abstracts2013;100(S359):P‐730. KarS , SanchitaS . Clomiphene citrate, metformin or a combination of both as the first line ovulation induction drug for Asian Indian women with polycystic ovarian syndrome: a randomized controlled trial. Journal of Human Reproductive Science2015;8:197‐201. ">Kar 2015</a>; <a href="./references#CD003053-bbs2-0024" title="MachadoRC , MachadoNA , GeberS . Evaluation of the use of metformin for ovulation in patients with PCOS resistant to isolated use of clomiphene citrate. Brazilian Journal Assisted Reproduction2012;16(1):27‐31. ">Machado 2012</a>; <a href="./references#CD003053-bbs2-0029" title="Morin‐PapunenL , RantalaAS , Unkila‐KallioL , TiitinenA , HippeläinenM , PerheentupaA , et al. Metformin improves pregnancy and live‐birth rates in women with polycystic ovary syndrome (PCOS): a multicenter, double‐blind, placebo‐controlled randomized trial. Journal of Clinical Endocrinology and Metabolism2012;97:1492‐1500. ">Morin‐Papunen 2012</a>). No new studies investigating thiazolidinediones were identified. </p> <p>Details of abbreviations used in this review and conversion factors of biochemical results can be found in <a href="#CD003053-tbl-0004">Table 1</a> and <a href="#CD003053-tbl-0005">Table 2</a>, respectively. </p> <div class="table" id="CD003053-tbl-0004"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Abbreviations used</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Abbreviation</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Definition</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>BMI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Body mass index</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clomiphene citrate</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Confidence interval</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Computerised tomography scan</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>DHEAS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Dehydroepiandrosterone sulphate</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>FSH</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Follicle stimulating hormone</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>GTT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Glucose tolerance test</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>HbA1C</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Glycosylated haemoglobin</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>HDL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>High‐density lipoprotein cholesterol</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IGFBP‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Insulin growth factor binding protein 1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>LDL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low‐density lipoprotein cholesterol</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>LH</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Luteinising hormone</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NIDDM</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Non insulin dependent diabetes mellitus</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PAI‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Plasminogen activator inhibitor 1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PCO</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Polycystic ovary</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PCOS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Polycystic ovary syndrome</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Randomised controlled trial</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>rFSH</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Recombinant follicle stimulating hormone</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Standard deviation</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Standard error of the mean</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SHBG</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sex hormone‐binding globulin</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>VLDL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Very low density lipoprotein cholesterol</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>vs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Versus</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mean difference</p> </td> </tr> </tbody> </table> </div> <div class="table" id="CD003053-tbl-0005"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Conversion factors</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Convert from</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Convert to</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Conversion factor</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cholesterol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>mg/dL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>mmol/L</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.026</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Triglycerides</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>mg/dL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>mmol/L</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.11</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Insulin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>pmol/L</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>mIU/L (= microIU/mL)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.1667</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Glucose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>mg/dL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>mmol/L</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.056</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Progesterone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ng/mL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>nmol/L</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.18</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Testosterone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ng/dL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>nmol/L</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.03467</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Androstenedione</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ng/dL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>nmol/L</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.0349</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Estradiol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ng/dL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>pmol/L</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>36.71</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17‐beta oestradiol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ng/dL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>pmol/L</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>36.71</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Dehydroepiandrosterone sulphate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>microg/dL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>micromol/L</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.02714</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sex hormone‐binding globulin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>microg/dL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>nmol/L</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>34.7</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Standard deviation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Standard error</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Standard deviation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sqrt n</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Confidence intervals</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Confidence intervals</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Standard error</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(upper limit ‐ lower limit)/3.92</p> </td> </tr> </tbody> </table> </div> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD003053-sec-0028" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD003053-sec-0028"></div> <p>To evaluate the effectiveness and safety of insulin‐sensitising drugs in improving reproductive and metabolic outcomes for women with PCOS undergoing ovulation induction. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD003053-sec-0029" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD003053-sec-0029"></div> <section id="CD003053-sec-0030"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD003053-sec-0031"> <h4 class="title">Types of studies</h4> <p>Published and unpublished randomised controlled trials (RCTs) were eligible for inclusion. We excluded non‐randomised and quasi‐randomised studies due to the high risk of bias. Cross‐over studies were included but we only included data from the first phase in meta‐analyses. </p> </section> <section id="CD003053-sec-0032"> <h4 class="title">Types of participants</h4> <p>We included women with oligo and anovulatory PCOS, based on the diagnostic criteria set by the Rotterdam consensus (<a href="./references#CD003053-bbs2-0103" title="The Rotterdam ESHRE/ASRM‐sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long‐term health risks related to polycystic ovary syndrome (PCOS). Human Reproduction2004;19(1):41. ">ESHRE/ASRM 2004</a>), undergoing ovulation induction. Women having in vitro fertilisation (IVF) or intracytoplasmic spermatic injection (ICSI) were excluded, as this is covered in a separate Cochrane Review (<a href="./references#CD003053-bbs2-0142" title="TsoL , CostelloMF , AlbuquerqueLE , AndrioloRB , MacedoCR . Metformin treatment before and during IVF or ICSI in women with polycystic ovary syndrome. Cochrane Database of Systematic Reviews2014, Issue 11. [DOI: 10.1002/14651858.CD006105.pub3] ">Tso 2014</a>). </p> </section> <section id="CD003053-sec-0033"> <h4 class="title">Types of interventions</h4> <p> <ol id="CD003053-list-0001"> <li> <p>Metformin, rosiglitazone or pioglitazone versus placebo or no therapy</p> </li> <li> <p>Metformin, rosiglitazone or pioglitazone in conjunction with an ovulation induction agent versus the ovulation induction agent </p> </li> <li> <p>Metformin, rosiglitazone or pioglitazone versus clomiphene citrate</p> </li> </ol> </p> <p>Since troglitazone has been withdrawn from the market, we excluded studies involving troglitazone from the current review. The use of gonadotrophins, contraceptive pills or aromatase inhibitors, such as letrozole, for the treatment of PCOS are the subject of separate Cochrane Reviews (<a href="./references#CD003053-bbs2-0091" title="BordewijkEM , NahuisM , CostelloMF , Van derVeenF , TsoLO , MolBWJ , et al. Metformin during ovulation induction with gonadotrophins followed by timed intercourse or intrauterine insemination for subfertility associated with polycystic ovary syndrome. Cochrane Database of Systematic Reviews2017, Issue 1. [DOI: 10.1002/14651858.CD009090.pub2] ">Bordewijk 2017</a>; <a href="./references#CD003053-bbs2-0097" title="CostelloM , ShresthaB , EdenJ , SjoblomP , JohnsonN . Insulin‐sensitising drugs versus the combined oral contraceptive pill for hirsutism, acne and risk of diabetes, cardiovascular disease, and endometrial cancer in polycystic ovary syndrome. Cochrane Database of Systematic Reviews2007, Issue 1. [DOI: 10.1002/14651858.CD005552.pub2; PUBMED: 17253562] ">Costello 2007</a>; <a href="./references#CD003053-bbs2-0108" title="FranikS , KremerJAN , NelenW , FarquharC . Aromatase inhibitors for subfertile women with polycystic ovary syndrome. Cochrane Database of Systematic Reviews2014, Issue 2. [DOI: 10.1002/14651858.CD010287.pub2] ">Franik 2014</a>, respectively). </p> </section> <section id="CD003053-sec-0034"> <h4 class="title">Types of outcome measures</h4> <section id="CD003053-sec-0035"> <h5 class="title">Primary outcomes</h5> <p>1. Live birth rate, as defined by included studies</p> <p>2. Adverse events (gastrointestinal side effects)</p> </section> <section id="CD003053-sec-0036"> <h5 class="title">Secondary outcomes</h5> <p>3. Clinical pregnancy rate, as defined by included studies (biochemical pregnancies were excluded) </p> <p>4. Ovulation rate, as defined by included studies</p> <p>5. Menstrual frequency, as defined by included studies</p> <p>6. Miscarriage, as defined by included studies</p> <p>7. Multiple pregnancy</p> <p>8. Anthropometric outcomes:</p> <p>a) Body mass index (BMI)</p> <p>b) Waist to hip ratio</p> <p>c) Blood pressure</p> <p>9. Endocrine outcomes</p> <p>a) Serum testosterone</p> <p>b) Serum sex hormone‐binding globulin</p> <p>10. Metabolic outcomes</p> <p>a) Fasting blood glucose</p> <p>b) Fasting insulin</p> <p>c) Cholesterol</p> <p>d) Triglycerides</p> </section> </section> </section> <section id="CD003053-sec-0037"> <h3 class="title">Search methods for identification of studies</h3> <p>We searched for all published and unpublished RCTs without language restriction and in consultation with Cochrane Gynaecology and Fertility's (CGF) Information Specialist. The original search was conducted in 2003. The first updated search was completed on 11 September 2008, the second update was completed on 3 October 2011 and the current search was completed on 12 January 2017. </p> <section id="CD003053-sec-0038"> <h4 class="title">Electronic searches</h4> <p>We searched the CGF Specialised Register of Controlled Trials, PROCITE platform (searched 12 January 2017) (<a href="./appendices#CD003053-sec-0146">Appendix 1</a>); the Cochrane Central Register of Controlled Trials via the Cochrane Register of Studies Online (CRSO) (searched 12 January 2017) (<a href="./appendices#CD003053-sec-0147">Appendix 2</a>); MEDLINE Ovid (from 1946 to 12 January 2017) (<a href="./appendices#CD003053-sec-0148">Appendix 3</a>); Embase Ovid (from 1980 to 12 January 2017) (<a href="./appendices#CD003053-sec-0149">Appendix 4</a>); PsycINFO Ovid (from 1806 to 12 January 2017) (<a href="./appendices#CD003053-sec-0150">Appendix 5</a>); and CINAHL EBSCO platform (from 1961 to 12 January 2017) (<a href="./appendices#CD003053-sec-0151">Appendix 6</a>). </p> <p>We combined the MEDLINE search with the Cochrane highly sensitive search strategy for identifying randomised trials, which appears in the <i>Cochrane Handbook of Systematic Reviews of Interventions</i> (<a href="./references#CD003053-bbs2-0120" title="LefebvreC , ManheimerE , GlanvilleJ . Chapter 6: Searching for studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Lefebvre 2011</a>). The Embase, PsycINFO and CINAHL searches were combined with trial filters developed by the Scottish Intercollegiate Guidelines Network (SIGN) <a href="http://www.sign.ac.uk/search-filters.html" target="_blank">www.sign.ac.uk/search‐filters.html</a>. </p> <p>Other electronic sources of trials included:</p> <p> <ol id="CD003053-list-0002"> <li> <p>trial registers for ongoing and registered trials‐</p> <ol id="CD003053-list-0003"> <li> <p><a href="https://www.clinicaltrials.gov/" target="_blank">ClinicalTrials.gov</a> </p> </li> <li> <p>World Health Organization (WHO) International Clinical Trials Registry Platform (<a href="http://apps.who.int/trialsearch/Default.aspx" target="_blank">ICTRP</a>) </p> </li> </ol> </li> <li> <p>DARE (Database of Abstracts of Reviews of Effects) in the Cochrane Library</p> </li> <li> <p>Web of Science (http://metodologia.lilacs.bvsalud.org/php/)</p> </li> <li> <p>OpenGrey for unpublished literature from Europe (http://www.greynet.org/opengreyrepository.html)</p> </li> <li> <p>LILACS database for trials in Portuguese and Spanish (http://metodologia.lilacs.bvsalud.org/php/)</p> </li> <li> <p>PubMed and Google Scholar for recent trials not yet indexed in MEDLINE</p> </li> </ol> </p> </section> <section id="CD003053-sec-0039"> <h4 class="title">Searching other resources</h4> <p>We handsearched the reference sections of all trials obtained. In liaison with the CGF Information Specialist we searched relevant journal articles and conference abstracts that are not covered in the CGF register. </p> </section> </section> <section id="CD003053-sec-0040"> <h3 class="title" id="CD003053-sec-0040">Data collection and analysis</h3> <section id="CD003053-sec-0041"> <h4 class="title">Selection of studies</h4> <p>The first review of this subject (<a href="./references#CD003053-bbs2-0150" title="LordJM , FlightIH , NormanRJ . Insulin‐sensitising drugs (metformin, troglitazone, rosiglitazone, pioglitazone, D‐chiro‐inositol) for polycystic ovary syndrome. Cochrane Database of Systematic Reviews2003, Issue 3. [DOI: 10.1002/14651858.CD003053] ">Lord 2003</a>) was undertaken by three review authors (JML, IHF and RJN), two of whom work in reproductive medicine (JML, RJN). Three review authors (TT, EY, AHB) updated the review (<a href="./references#CD003053-bbs2-0151" title="TangT , LordJM , NormanRJ , YasminE , BalenAH . Insulin‐sensitising drugs (metformin, rosiglitazone, pioglitazone, D‐chiro‐inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility. Cochrane Database of Systematic Reviews2009, Issue 3. [DOI: 10.1002/14651858.CD003053.pub4; PUBMED: 20091537] ">Tang 2009</a>; <a href="./references#CD003053-bbs2-0152" title="TangT , LordJM , NormanRJ , YasminE , BalenAH . Insulin‐sensitising drugs (metformin, rosiglitazone, pioglitazone, D‐chiro‐inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility. Cochrane Database of Systematic Reviews2012, Issue 5. [DOI: 10.1002/14651858.CD003053.pub5] ">Tang 2012</a>). Three review authors (LCM, TT and AHB) performed the current update. We employed the search strategy described previously to obtain titles and, where possible, abstracts of studies that were potentially relevant to the review. Two review authors (LCM and TT) screened the titles and abstracts and then obtained copies of the relevant full‐text articles. Two review authors (LCM and TT) independently assessed whether the studies met the inclusion criteria, with disagreements resolved by discussion (for details of the screening and selection process see <a href="#CD003053-fig-0001">Figure 1</a>; <a href="#CD003053-fig-0002">Figure 2</a>). </p> <div class="figure" id="CD003053-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram since publication" data-id="CD003053-fig-0001" src="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/image_n/nCD003053-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram since publication</p> </div> </div> </div> <div class="figure" id="CD003053-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Study flow diagram 2017 update" data-id="CD003053-fig-0002" src="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/image_n/nCD003053-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram 2017 update</p> </div> </div> </div> </section> <section id="CD003053-sec-0042"> <h4 class="title">Data extraction and management</h4> <section id="CD003053-sec-0043"> <h5 class="title">Data collection process</h5> <p>Two review authors (LCM and TT) independently extracted data from eligible studies, and resolved any disagreements by discussion. We extracted data onto a pre‐designed form (see Data items). Further information was sought from the authors where papers contained insufficient information to make a decision about eligibility. </p> </section> <section id="CD003053-sec-0044"> <h5 class="title">Data items</h5> <p>We have presented a summary of included trials in the table 'Characteristics of included studies'. This information includes the following: </p> <p> <ol id="CD003053-list-0004"> <li> <p>Method of randomisation</p> </li> <li> <p>Blinding to treatment allocation</p> </li> <li> <p>Quality of allocation concealment</p> </li> <li> <p>Number of women randomised</p> </li> <li> <p>Location, duration and timing of the trial</p> </li> </ol> </p> <p>Characteristics of women</p> <p> <ol id="CD003053-list-0005"> <li> <p>Mean age, BMI, testosterone, fasting insulin and glucose levels</p> </li> <li> <p>Study inclusion and exclusion criteria</p> </li> <li> <p>Dropout rate</p> </li> </ol> </p> <p>Interventions</p> <p> <ol id="CD003053-list-0006"> <li> <p>Type of insulin‐sensitising drug</p> </li> <li> <p>Co‐interventions such as clomiphene citrate or lifestyle advice</p> </li> </ol> </p> <p>Outcomes</p> <p>As stated under '<a href="#CD003053-sec-0034">Types of outcome measures</a>' </p> </section> </section> <section id="CD003053-sec-0045"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>We performed risk of bias assessment in accordance with the Cochrane 'Risk of bias' assessment tool (<a href="./references#CD003053-bbs2-0114" title="HigginsJPT , AltmanDG , Sterne JAC(editors) . Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>). </p> <p>We judged the following items and summarised them in the 'Risk of bias' table (<a href="#CD003053-fig-0003">Figure 3</a>; <a href="#CD003053-fig-0004">Figure 4</a>). </p> <div class="figure" id="CD003053-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies" data-id="CD003053-fig-0003" src="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/image_n/nCD003053-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies </p> </div> </div> </div> <div class="figure" id="CD003053-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study" data-id="CD003053-fig-0004" src="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/image_n/nCD003053-AFig-FIG04.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study </p> </div> </div> </div> <p> <ol id="CD003053-list-0007"> <li> <p>Sequence generation</p> <ol id="CD003053-list-0008"> <li> <p>low risk (for example, computer‐generated random numbers, random number table)</p> </li> <li> <p>high risk (systematic methods such as alternation; assignment based on case record number, date of presentation or date of birth) </p> </li> <li> <p>unclear risk (insufficient information in the study or from the study author about the process of sequence generation) </p> </li> </ol> </li> <li> <p>Allocation concealment</p> <ol id="CD003053-list-0009"> <li> <p>low risk (for example, central randomisation, sequentially numbered, opaque, sealed envelopes) </p> </li> <li> <p>high risk (for example, open‐label trial, assignment based on case record number, date of presentation or date of birth) </p> </li> <li> <p>unclear risk (insufficient information in the study or from the study author about the process of allocation concealment) </p> </li> </ol> </li> <li> <p>Blinding</p> <ol id="CD003053-list-0010"> <li> <p>low risk (double‐blind study: participants, providers and assessors blinded)</p> </li> <li> <p>high risk (unblinded)</p> </li> <li> <p>unclear risk (insufficient information in the study or from the study author about the level of blinding) </p> </li> </ol> </li> <li> <p>Incomplete outcome data addressed</p> <ol id="CD003053-list-0011"> <li> <p>low risk (for example, no missing data, reasons for missing data were reported and were unlikely to influence the outcomes, or missing data were balanced across the groups) </p> </li> <li> <p>high risk (for example, reasons for missing data were not addressed, missing data likely to affect the outcomes, or data analysed per protocol) </p> </li> <li> <p>unclear risk (insufficient information in the study or from the author about the detail of incomplete outcome data) </p> </li> </ol> </li> <li> <p>Selective outcome reporting</p> <ol id="CD003053-list-0012"> <li> <p>low risk (for example, the study protocol was available, pre‐specified outcome measures were reported) </p> </li> <li> <p>high risk (for example, the study protocol was unavailable and pre‐specified outcome measures were not reported) </p> </li> <li> <p>unclear risk (insufficient information in the study or from the author about process of outcome reporting) </p> </li> </ol> </li> </ol> </p> </section> <section id="CD003053-sec-0046"> <h4 class="title">Measures of treatment effect</h4> <p>We used odds ratio (OR) as the measure of effect for each dichotomous outcome and the mean difference (MD) for each continuous outcome. We have presented 95% confidence intervals (CI) for all outcomes. </p> </section> <section id="CD003053-sec-0047"> <h4 class="title">Unit of analysis issues</h4> <p>The primary unit of analysis was each woman, for example, we calculated ovulation rate as rate of women in whom ovulation was confirmed. Where studies reported 'per‐cycle' data, we contacted the study authors to request 'per‐woman' data. When these data were not available, we have not pooled the per‐cycle ovulation data but presented them in additional tables (<a href="#CD003053-tbl-0006">Table 3</a>; <a href="#CD003053-tbl-0007">Table 4</a>; <a href="#CD003053-tbl-0008">Table 5</a>; <a href="#CD003053-tbl-0009">Table 6</a>; <a href="#CD003053-tbl-0010">Table 7</a>). The exceptions to this were miscarriage and multiple pregnancy rates, which we analysed per woman, followed by a sensitivity analysis using per‐pregnancy data. </p> <div class="table" id="CD003053-tbl-0006"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Metformin vs placebo: ovulation rate per cycle</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Study ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Metformin</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Placebo</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>P value</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Events</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Cycles</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Events</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Cycles</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>BMI &lt; 30 kg/m<sup>2</sup> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003053-bbs2-0002" title="BaillargeonJP , JakubowiczDJ , IuornoMJ , JakubowiczS , NestlerJE . Effects of metformin and rosiglitazone, alone and in combination, in nonobese women with polycystic ovary syndrome and normal indices of insulin sensitivity. Fertility and Sterility2004;82:893‐902. ">Baillargeon 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003053-bbs2-0007" title="CarminaE , LoboRA . Does metformin induce ovulation in normoandrogenic anovulatory women?. American Journal of Obstetrics and Gynecology2004;191:1580‐4. ">Carmina 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003053-bbs2-0032" title="NgEHY , WatNMS , HoPC . Effects of metformin on ovulation rate, hormonal and metabolic profiles in women with clomiphene‐resistant polycystic ovaries: a randomized, double‐blinded placebo‐controlled trial. Human Reproduction2001;16(8):1625‐31. ">Ng 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003053-bbs2-0033" title="OnalanG , GoktolgaU , CeyhanT , BagisT , OnalanR , PabuccuR . Predictive value of glucose‐insulin ratio in PCOS and profile of women who will benefit from metformin therapy: obese, lean, hyper or normoinsulinemic?. European Journal of Obstetrics, Gynecology, and Reproductive Biology2005;123:204‐11. ">Onalan 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>153</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>150</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003053-bbs2-0047" title="YaraliH , YildizBO , DemirolA , ZeynelogluHB , YigitN , BukulmezO , et al. Co‐administration of metformin during rFSH treatment in patients with clomiphene citrate‐resistant polycystic ovarian syndrome: a prospective randomized trial. Human Reproduction2002;17(2):289‐94. YaraliH , YyldyzB , DemirolA , ZeynelogluH , YigitN , BukulmezO . Co‐administration of metformin during recombinant follicle stimulating hormone (recombinant FSH) treatment using the low‐dose step protocol in patients with clomiphene citrate resistant polycystic ovary syndrome (PCOS): a prospective randomized trial. Fertility and Sterility2001;76 Suppl(3):36. ">Yarali 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>BMI ≥ 30 kg/m<sup>2</sup> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003053-bbs2-0011" title="FlemingR , HopkinsonZE , WallaceAM , GreerIA , SattarN . Ovarian function and metabolic factors in women with oligomenorrhea treated with metformin in a randomized double blind placebo‐controlled trial. Journal of Clinical Endocrinology and Metabolism2002;87(2):569‐74. FlemingR , HopkinsonZE , WallaceE , GreerIA , SattarN . Metformin treatment improves ovulation frequency in women with oligomenorrhoea: a randomized, double blind placebo trial. Human Fertility2000; Vol. 3, issue 4:389‐90. ">Fleming 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003053-bbs2-0014" title="HoegerKM , KochmanL , WixomN , CraigK , MillerRK , GuzickDS . A randomized, 48‐week, placebo‐controlled trial of intensive lifestyle modification and/or metformin therapy in overweight women with polycystic ovary syndrome: a pilot study. Fertility and Sterility2004;82:421‐9. ">Hoeger 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003053-bbs2-0014" title="HoegerKM , KochmanL , WixomN , CraigK , MillerRK , GuzickDS . A randomized, 48‐week, placebo‐controlled trial of intensive lifestyle modification and/or metformin therapy in overweight women with polycystic ovary syndrome: a pilot study. Fertility and Sterility2004;82:421‐9. ">Hoeger 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003053-bbs2-0016" title="JakubowiczDJ , SeppalaM , JakubowiczS , Rodriguez‐ArmasO , Rivas‐SantiagoA , KoistinenH , et al. Insulin reduction with metformin increases luteal phase serum glycodelin and insulin‐like growth factor‐binding protein 1 concentrations and enhances uterine vascularity and blood flow in the polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism2001;86(3):1126‐33. ">Jakubowicz 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003053-bbs2-0023" title="LordJ , ThomasR , FoxB , AcharyaU , WilkinT . The effect of metformin on fat distribution and the metabolic syndrome in women with polycystic ovary syndrome‐‐a randomised, double‐blind, placebo‐controlled trial. British Journal of Obstetrics and Gynaecology2006;113:817‐24. ">Lord 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003053-bbs2-0030" title="NestlerJE , JakubowiczDJ , EvansWS , PasqualiR . Effects of metformin on spontaneous and clomiphene‐induced ovulation in the polycystic ovary syndrome. New England Journal of Medicine1998;338(26):1876‐80. ">Nestler 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003053-bbs2-0033" title="OnalanG , GoktolgaU , CeyhanT , BagisT , OnalanR , PabuccuR . Predictive value of glucose‐insulin ratio in PCOS and profile of women who will benefit from metformin therapy: obese, lean, hyper or normoinsulinemic?. European Journal of Obstetrics, Gynecology, and Reproductive Biology2005;123:204‐11. ">Onalan 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>51</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003053-bbs2-0034" title="OttaCF , WiorM , IraciGS , KaplanR , TorresD , GaidoMI , et al. Clinical, metabolic, and endocrine parameters in response to metformin and lifestyle intervention in women with polycystic ovary syndrome: a randomized, double‐blind, and placebo control trial. Gynecological Endocrinology2010;26(3):173‐8. ">Otta 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003053-bbs2-0037" title="JohnsonNP , BontekoeS , StewartAW . Analysis of factors predicting success of metformin and clomiphene treatment for women with infertility owing to PCOS‐related ovulation dysfunction in a randomised controlled trial. Australian &amp; New Zealand Journal of Obstetrics &amp; Gynaecology2011;51:252‐6. JohnsonNP , StewartAW , FalkinerJ , FarquharCM , MilsomS , SinghV‐P , et al. on behalf of REACT‐NZ (REproduction And Collaborative Trials in New Zealand), a multi‐centre fertility trials group. PCOSMIC: a multi‐centre randomized trial in women with Polycystic Ovary Syndrome evaluating Metformin for Infertility with Clomiphene. Human Reproduction2010;25(7):1675‐83. [MEDLINE: 10.1093/humrep/deq100] ">PCOSMIC 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003053-bbs2-0042" title="SturrockNDC , LannonB , FayTN . Metformin does not enhance ovulation induction in clomiphene resistant polycystic ovary syndrome in clinical practice. British Journal of Clinical Pharmacology2002;53(5):469‐73. [MEDLINE: 2002180629] ">Sturrock 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003053-bbs2-0045" title="VandermolenDT , RattsVS , EvansWS , StovallDW , KaumaSW , NestlerJE . Metformin increases the ovulatory rate and pregnancy rate from clomiphene citrate in patients with polycystic ovary syndrome who are resistant to clomiphene citrate alone. Fertility and Sterility2001;75:310‐5. ">Vandermolen 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> </tbody> </table> </div> <div class="table" id="CD003053-tbl-0007"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Metformin + clomiphene citrate vs clomiphene citrate: ovulation rate per cycle</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Study ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Metformin +<br/> clomiphene citrate</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Clomiphene<br/> citrate alone</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>P value</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Events</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Cycles</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Events</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Cycles</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>BMI &lt; 30 kg/m<sup>2</sup> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003053-bbs2-0001" title="AyazA , AlwanY , FarooqMU . Efficacy of combined metformin‐clomiphene citrate in comparison with clomiphene citrate alone in infertile women with polycystic ovarian syndrome (PCOS). Journal of Medicine and Life2013;6:199‐201. AyazA , AlwanY , FarooqMU . Metformin‐clomiphene citrate vs. clomiphene citrate alone: polycystic ovarian syndrome. Journal of Human Reproductive Sciences2013;6:15‐8. ">Ayaz 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003053-bbs2-0004" title="Ben AyedB , Dammak Dit MlikS , Ben ArabH , TrabelssiH , ChahtourH , MathlouthiN . Metformin effects on clomifene‐induced ovulation in the polycystic ovary syndrome. Tunisie Medicale2009;87(1):43‐8. ">Ben Ayed 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003053-bbs2-0005" title="BoudhrâaK , JellouliMA , AmriM , FarhatM , TorkhaniF , GaraMF . Indication of metformin in the management of hormonal dysfunction secondary to polycystic ovarian syndrome: prospective comparative study of 63 cases. [La metformine dans la prise en charge de l'infertilite du SOPK hors FIV etude prospective comparative a propos de 63 cas]. Tunisie Medicale2010;88(5):335‐40. ">Boudhraa 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003053-bbs2-0010" title="El‐BielyMM , HabbaM . The use of metformin to augment the induction of ovulation in obese infertile patients with polycystic ovary syndrome. Middle East Fertility Society Journal2001;6(1):43‐9. ">El‐Biely 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003053-bbs2-0015" title="HwuYM , LinSY , HuangWY , LinMH , LeeRK . Ultra‐short metformin pretreatment for clomiphene citrate‐resistant polycystic ovary syndrome. International Journal of Gynaecology and Obstetrics2005;90:39‐43. ">Hwu 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003053-bbs2-0024" title="MachadoRC , MachadoNA , GeberS . Evaluation of the use of metformin for ovulation in patients with PCOS resistant to isolated use of clomiphene citrate. Brazilian Journal Assisted Reproduction2012;16(1):27‐31. ">Machado 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003053-bbs2-0026" title="MalkawiHY , QublanHS . The effect of metformin plus clomiphene citrate on ovulation and pregnancy rates in clomiphene‐resistant women with polycystic ovary syndrome. Saudi Medical Journal2002;23(6):663‐6. [MEDLINE: 22065897] ">Malkawi 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003053-bbs2-0028" title="MollE , BossuytPM , KorevaarJC , LambalkCB , Van derVeenF . Effect of clomifene citrate plus metformin and clomifene citrate plus placebo on induction of ovulation in women with newly diagnosed polycystic ovary syndrome: randomised double blind clinical trial. BMJ2006;332:1485. [original article] MollE , KorevaarJC , BossuytPM , van derVeenF . Does adding metformin to clomifene citrate lead to higher pregnancy rates in a subset of women with polycystic ovary syndrome?. Human Reproduction2008;23(8):1830‐4. MollE , VanWelyM , LambalkCB , BossuytPM , Van derVeenF . Health‐related quality of life in women with newly diagnosed polycystic ovary syndrome randomized between clomifene citrate plus metformin or clomifene citrate plus placebo. Human Reproduction2012;27:3273‐8. ">Moll 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>84</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>141</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>98</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>168</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003053-bbs2-0032" title="NgEHY , WatNMS , HoPC . Effects of metformin on ovulation rate, hormonal and metabolic profiles in women with clomiphene‐resistant polycystic ovaries: a randomized, double‐blinded placebo‐controlled trial. Human Reproduction2001;16(8):1625‐31. ">Ng 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003053-bbs2-0037" title="JohnsonNP , BontekoeS , StewartAW . Analysis of factors predicting success of metformin and clomiphene treatment for women with infertility owing to PCOS‐related ovulation dysfunction in a randomised controlled trial. Australian &amp; New Zealand Journal of Obstetrics &amp; Gynaecology2011;51:252‐6. JohnsonNP , StewartAW , FalkinerJ , FarquharCM , MilsomS , SinghV‐P , et al. on behalf of REACT‐NZ (REproduction And Collaborative Trials in New Zealand), a multi‐centre fertility trials group. PCOSMIC: a multi‐centre randomized trial in women with Polycystic Ovary Syndrome evaluating Metformin for Infertility with Clomiphene. Human Reproduction2010;25(7):1675‐83. [MEDLINE: 10.1093/humrep/deq100] ">PCOSMIC 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>BMI ≥ 30 kg/m<sup>2</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003053-bbs2-0016" title="JakubowiczDJ , SeppalaM , JakubowiczS , Rodriguez‐ArmasO , Rivas‐SantiagoA , KoistinenH , et al. Insulin reduction with metformin increases luteal phase serum glycodelin and insulin‐like growth factor‐binding protein 1 concentrations and enhances uterine vascularity and blood flow in the polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism2001;86(3):1126‐33. ">Jakubowicz 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003053-bbs2-0020" title="KhorramO , HelliwellJP , KatzS , BonpaneCM , JaramilloL Khorram O , et al. Two weeks of metformin improves clomiphene citrate‐induced ovulation and metabolic profiles in women with polycystic ovary syndrome. Fertility and Sterility2006;85:1448‐51. ">Khorram 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003053-bbs2-0022" title="CataldoN , BarnhartH , LegroR , MyersE , SchlaffW , CarrB , et al. Extended‐release metformin does not reduce the clomiphene citrate dose required to induce ovulation in polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism2008;93(8):3147‐7. LegroRS , BarnhartHX , SchlaffWD , CarrBR , DiamondMP , CarsonSA , et al. Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome. New England Journal of Medicine2007;356:551‐66. [original article] ">Legro 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>582</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>964</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>462</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>942</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003053-bbs2-0030" title="NestlerJE , JakubowiczDJ , EvansWS , PasqualiR . Effects of metformin on spontaneous and clomiphene‐induced ovulation in the polycystic ovary syndrome. New England Journal of Medicine1998;338(26):1876‐80. ">Nestler 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003053-bbs2-0040" title="SahinY , YirmibesU , KelestimurF , AygenE . The effects of metformin on insulin resistance, clomiphene‐induced ovulation and pregnancy rates in women with polycystic ovary syndrome. European Journal of Obstetrics, Gynecology, and Reproductive Biology2004;113:214‐20. ">Sahin 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>51</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003053-bbs2-0041" title="SiebertT , KrugerT , LombardC . Evaluating the equivalence of clomiphene citrate with and without metformin in ovulation induction in PCOS patients. Journal of Assisted Reproduction and Genetics2009;26(4):165‐71. ">Siebert 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003053-bbs2-0042" title="SturrockNDC , LannonB , FayTN . Metformin does not enhance ovulation induction in clomiphene resistant polycystic ovary syndrome in clinical practice. British Journal of Clinical Pharmacology2002;53(5):469‐73. [MEDLINE: 2002180629] ">Sturrock 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003053-bbs2-0045" title="VandermolenDT , RattsVS , EvansWS , StovallDW , KaumaSW , NestlerJE . Metformin increases the ovulatory rate and pregnancy rate from clomiphene citrate in patients with polycystic ovary syndrome who are resistant to clomiphene citrate alone. Fertility and Sterility2001;75:310‐5. ">Vandermolen 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003053-bbs2-0048" title="ZainMM , JamaluddinR , IbrahimA , NormanRJ . Comparison of clomiphene citrate, metformin, or the combination of both for first‐line ovulation induction, achievement of pregnancy, and live birth in Asian women with polycystic ovary syndrome: a randomized controlled trial. Fertility and Sterility2009;91(2):514‐21. ">Zain 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> </tbody> </table> </div> <div class="table" id="CD003053-tbl-0008"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Metformin vs clomiphene citrate: ovulation rate per cycle</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Metformin</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Clomiphene citrate</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Events</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Cycles</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Events</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Cycles</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>P value</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>BMI &lt; 30 kg/m<sup>2</sup> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003053-bbs2-0035" title="PalombaS , OrioFJr , FalboA , MangusoF , RussoT , CascellaT , et al. Prospective parallel randomized, double‐blind, double‐dummy controlled clinical trial comparing clomiphene citrate and metformin as the first‐line treatment for ovulation induction in nonobese anovulatory women with polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism2005;90(7):4068‐74. [original article] PalombaS , OrioFJr , FalboA , RussoT , TolinoA , ZulloF . Effects of metformin and clomiphene citrate on ovarian vascularity in patients with polycystic ovary syndrome. Fertility and Sterility2006;86:1694‐701. ">Palomba 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>129</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>205</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>148</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>221</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003053-bbs2-0037" title="JohnsonNP , BontekoeS , StewartAW . Analysis of factors predicting success of metformin and clomiphene treatment for women with infertility owing to PCOS‐related ovulation dysfunction in a randomised controlled trial. Australian &amp; New Zealand Journal of Obstetrics &amp; Gynaecology2011;51:252‐6. JohnsonNP , StewartAW , FalkinerJ , FarquharCM , MilsomS , SinghV‐P , et al. on behalf of REACT‐NZ (REproduction And Collaborative Trials in New Zealand), a multi‐centre fertility trials group. PCOSMIC: a multi‐centre randomized trial in women with Polycystic Ovary Syndrome evaluating Metformin for Infertility with Clomiphene. Human Reproduction2010;25(7):1675‐83. [MEDLINE: 10.1093/humrep/deq100] ">PCOSMIC 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>BMI ≥ 30 kg/m<sup>2</sup> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003053-bbs2-0022" title="CataldoN , BarnhartH , LegroR , MyersE , SchlaffW , CarrB , et al. Extended‐release metformin does not reduce the clomiphene citrate dose required to induce ovulation in polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism2008;93(8):3147‐7. LegroRS , BarnhartHX , SchlaffWD , CarrBR , DiamondMP , CarsonSA , et al. Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome. New England Journal of Medicine2007;356:551‐66. [original article] ">Legro 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>296</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1019</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>462</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>942</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003053-bbs2-0048" title="ZainMM , JamaluddinR , IbrahimA , NormanRJ . Comparison of clomiphene citrate, metformin, or the combination of both for first‐line ovulation induction, achievement of pregnancy, and live birth in Asian women with polycystic ovary syndrome: a randomized controlled trial. Fertility and Sterility2009;91(2):514‐21. ">Zain 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> </tbody> </table> </div> <div class="table" id="CD003053-tbl-0009"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">D‐Chiro‐inositol vs placebo: ovulation rate per cycle</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Inositol</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Placebo</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Events</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Cycles</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Events</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Cycles</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>P value</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>BMI &lt; 30 kg/m<sup>2</sup> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003053-bbs2-0012" title="GerliS , MignosaM , DiRenzoGC . Effects of inositol on ovarian function and metabolic factors in women with PCOS: a randomized double blind placebo‐controlled trial. European Review for Medical and Pharmacological Sciences2003;7:151‐9. [Original article] GerliS , PapaleoE , FerrariA , DiRenzoGC . Randomized, double blind placebo‐controlled trial: effects of myo‐inositol on ovarian function and metabolic factors in women with PCOS. European Review for Medical and Pharmacological Sciences2007;11(5):347‐54. ">Gerli 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>128</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>136</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>130</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>147</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003053-bbs2-0031" title="NestlerJE , JakubowiczDJ , ReamerP , GunnRD , AllanG . Ovulatory and metabolic effects of D‐chiro‐inositol in the polycystic ovary syndrome. New England Journal of Medicine1999;340(17):1314‐20. ">Nestler 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> </tbody> </table> </div> <div class="table" id="CD003053-tbl-0010"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 7.</span> <span class="table-title">Rosiglitazone vs placebo: ovulation rate per cycle</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Rosiglitazone</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Placebo</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Events</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Cycles</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Events</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Cycles</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>P value</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>BMI ≥ 30 kg/m<sup>2</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003053-bbs2-0002" title="BaillargeonJP , JakubowiczDJ , IuornoMJ , JakubowiczS , NestlerJE . Effects of metformin and rosiglitazone, alone and in combination, in nonobese women with polycystic ovary syndrome and normal indices of insulin sensitivity. Fertility and Sterility2004;82:893‐902. ">Baillargeon 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> </tbody> </table> </div> <p>In order to reduce a carry‐over of treatment effect in cross‐over trials, we only used data from the first phase (such as before cross‐over) when the washout period was less than two months. The rationale is that oligo amenorrhoea is usually accepted as a menstrual cycle length over five to eight weeks. Therefore, the washout period of treatment effect on ovulation should ideally be more than eight weeks. </p> </section> <section id="CD003053-sec-0048"> <h4 class="title">Dealing with missing data</h4> <p>We analysed the data on an intention‐to‐treat basis where possible and sought any missing data from the study authors. </p> <p>When this information was not available, we performed the analysis using the original number of women randomised. </p> </section> <section id="CD003053-sec-0049"> <h4 class="title">Assessment of heterogeneity</h4> <p>Heterogeneity reflects any type of variability among the studies in a systematic review. A consistent treatment effect among the included studies suggests there is sufficient homogeneity for pooled analysis. We used the I<sup>2</sup> statistic (<a href="./references#CD003053-bbs2-0113" title="HigginsJPT , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta‐analyses. BMJ2003;327:557‐60. ">Higgins 2003</a>) to quantify the inconsistency among the studies. We regarded an I<sup>2</sup> statistic of over 50% as indicative of substantial heterogeneity (<a href="./references#CD003053-bbs2-0099" title="DeeksJJ , HigginsJPT , Altman DG(editors) . Chapter 9: Analysing data and undertaking meta‐analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Deeks 2011</a>). </p> </section> <section id="CD003053-sec-0050"> <h4 class="title">Assessment of reporting biases</h4> <p>In view of the difficulty of detecting and correcting for publication bias and other reporting biases, we aimed to minimise the potential impact by ensuring a comprehensive search for eligible studies and by being alert for duplication of data. We planned to produce funnel plots for the primary outcome, live birth, which explore the possibility of small study effects (a tendency for estimates of the intervention effect to be more beneficial in smaller studies) (<a href="./references#CD003053-bbs2-0141" title="SterneJAC , EggerM , MoherD (editors) . Chapter 10: Addressing reporting biases. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Intervention. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Sterne 2011</a>). </p> </section> <section id="CD003053-sec-0051"> <h4 class="title">Data synthesis</h4> <p>We performed statistical analyses according to the statistical guidelines for review authors developed by Cochrane and published in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD003053-bbs2-0099" title="DeeksJJ , HigginsJPT , Altman DG(editors) . Chapter 9: Analysing data and undertaking meta‐analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Deeks 2011</a>). We used Review Manager 5 (RevMan 5) to perform all the statistical analyses (<a href="./references#CD003053-bbs2-0133" title="Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">RevMan 2014</a>). </p> <p>We used odds ratio (OR), with 95% confidence interval (CI), as the measure of effect for each dichotomous outcome using the Mantel‐Haenszel method; whilst we presented continuous outcome differences between the two groups as mean difference (MD) with 95% CI. We employed a fixed‐effect model in the analysis, and have commented on significant heterogeneity where it occurred. </p> <p>For clinical outcomes, we stratified comparisons by BMI, divided into obese and non‐obese groups, with an additional stratum for studies in which BMI was not reported. We defined 'obese' as BMI equal to or over 30 kg/m<sup>2</sup>. </p> </section> <section id="CD003053-sec-0052"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>As noted above, we subgrouped the primary analysis by BMI (obese or non‐obese), in order to assess any differences in effect within these subgroups. </p> <p>We also conducted subgroup analyses by sensitivity to clomiphene citrate (sensitive or resistant), in relevant analyses (i.e. including clomiphene citrate group) where substantial heterogeneity was detected (I<sup>2</sup> over 50%). </p> <p>We also planned to explore other possible explanations where heterogeneity was substantial, by examining other clinical or methodological differences between the studies. </p> </section> <section id="CD003053-sec-0053"> <h4 class="title">Sensitivity analysis</h4> <p>To determine that the conclusions of this review were robust, we performed sensitivity analyses after excluding studies with unclear or high risk of bias in sequence generation, allocation concealment or blinding method. We also performed a sensitivity analysis to compare the effect of reporting miscarriage and multiple pregnancy data 'per pregnancy'. </p> <section id="CD003053-sec-0054"> <h5 class="title">Overall quality of the body of evidence: 'Summary of findings' table</h5> <p>We prepared 'Summary of findings' tables using GRADEpro GDT software (<a href="./references#CD003053-bbs2-0110" title="McMaster University (developed by Evidence Prime). GRADEpro GDT. Hamilton (ON): McMaster University (developed by Evidence Prime), Accessed 2015‐2017. ">GRADEpro GDT 2015</a>). These tables evaluated the overall quality of the body of evidence for the main review outcomes (live birth, adverse events, clinical pregnancy, menstrual frequency, ovulation and miscarriage) with respect to the most clinically relevant comparisons (metformin versus placebo or no treatment, metformin with clomiphene citrate versus clomiphene citrate alone, metformin versus clomiphene citrate). Two review authors working independently evaluated the quality of the evidence using GRADE criteria (study limitations (i.e. risk of bias), consistency of effect, imprecision, indirectness and publication bias). Judgements about evidence quality (high, moderate, low or very low) were justified, documented, and incorporated into reporting of results for each outcome (<a href="./references#CD003053-bbs2-0135" title="SchünemannHJ , OxmanAD , HigginsJPT , VistGE , GlasziouP , GuyattGH . Chapter 11: Presenting results and ‘Summary of findings' tables. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Schünemann 2011</a>; <a href="./references#CD003053-bbs2-0136" title="SchünemannH , BrożekJ , GuyattG , OxmanA , editors. GRADE handbook for grading quality of evidence and strength of recommendations. Updated October 2013. The GRADE Working Group, 2013. Available from guidelinedevelopment.org/handbook. ">Schünemann 2013</a>). We resolved any disagreements by consensus. </p> <p>For one of our comparisons (metformin versus clomiphene citrate), there was high heterogeneity for some outcomes which was associated with BMI status, so for this comparison we decided as a post hoc measure to present the data by BMI subgroup. </p> <p>Details of abbreviations used in this review and conversion factors of biochemical results can be found in <a href="#CD003053-tbl-0004">Table 1</a> and <a href="#CD003053-tbl-0005">Table 2</a>, respectively. </p> </section> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD003053-sec-0055" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD003053-sec-0055"></div> <section id="CD003053-sec-0056"> <h3 class="title">Description of studies</h3> <p>See <a href="./references#CD003053-sec-0165" title="">Characteristics of included studies</a> and <a href="./references#CD003053-sec-0166" title="">Characteristics of excluded studies</a> for full details of the trials. </p> <section id="CD003053-sec-0057"> <h4 class="title">Results of the search</h4> <p>In this updated review there are 48 included studies and 35 excluded studies(<a href="#CD003053-fig-0002">Figure 2</a>). </p> <p>In the first review (<a href="./references#CD003053-bbs2-0150" title="LordJM , FlightIH , NormanRJ . Insulin‐sensitising drugs (metformin, troglitazone, rosiglitazone, pioglitazone, D‐chiro‐inositol) for polycystic ovary syndrome. Cochrane Database of Systematic Reviews2003, Issue 3. [DOI: 10.1002/14651858.CD003053] ">Lord 2003</a>), 24 RCTs met the initial eligibility criteria. Nine studies were excluded, leaving 15 to be included in the analysis. </p> <p>In the first update of the review (<a href="./references#CD003053-bbs2-0151" title="TangT , LordJM , NormanRJ , YasminE , BalenAH . Insulin‐sensitising drugs (metformin, rosiglitazone, pioglitazone, D‐chiro‐inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility. Cochrane Database of Systematic Reviews2009, Issue 3. [DOI: 10.1002/14651858.CD003053.pub4; PUBMED: 20091537] ">Tang 2009</a>) (search period January 2003 to September 2008), the review authors identified 37 RCTs, of which 20 were suitable for inclusion. They excluded four previously included studies (<a href="./references#CD003053-bbs2-0051" title="AzzizR , EhrmannD , LegroRS , WhitcombRW , HanleyR , FereshetianAG , et al. Troglitazone improves ovulation and hirsutism in the polycystic ovary syndrome: a multicenter, double blind, placebo‐controlled trial. Journal of Clinical Endocrinology and Metabolism2001;86(4):1626‐32. [original article] GuyattG , WeaverB , CroninL , DooleyJA , AzzizR . Health‐related quality of life in women with polycystic ovary syndrome, a self‐administered questionnaire, was validated. Journal of Clinical Epidemiology2004;57:1279‐87. LegroRS , AzzizR , EhrmannD , FereshetianAG , O'KeefeM , GhazziMN . Minimal response of circulating lipids in women with polycystic ovary syndrome to improvement in insulin sensitivity with troglitazone. Journal of Clinical Endocrinology and Metabolism2003;88:5137‐44. ">Azziz 2001</a>; <a href="./references#CD003053-bbs2-0067" title="KocakM , CaliskanE , SimsirC , HaberalA . Metformin therapy improves ovulatory rates, cervical scores, and pregnancy rates in clomiphene citrate‐resistant women with polycystic ovary syndrome. Fertility and Sterility2002;77(1):101‐6. ">Kocak 2002</a>; <a href="./references#CD003053-bbs2-0073" title="NestlerJE , JakubowiczDJ . Decreases in ovarian cytochrome P450c17 alpha activity and serum free testosterone after reduction of insulin secretion in polycystic ovary syndrome. New England Journal of Medicine1996;335(9):617‐23. ">Nestler 1996</a>; <a href="./references#CD003053-bbs2-0036" title="CasimirriF , BiscottiM , GambineriA , CalzoniF , ElianaB , PasqualiR . Metformin improves insulin, body fat distribution, and androgens in obese women with and without the polycystic ovary syndrome. International Journal of Obesity1997;21 Suppl 2:61. PasqualiR , GambineriA , BiscottiD , VicennatiV , GagliardiL , ColittaD , et al. Effect of long‐term treatment with metformin added to hypocaloric diet on body composition, fat distribution, and androgen and insulin levels in abdominally obese women with and without the polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism2000;85(8):2767‐74. ">Pasquali 2000</a>). Including the studies in the first review (<a href="./references#CD003053-bbs2-0150" title="LordJM , FlightIH , NormanRJ . Insulin‐sensitising drugs (metformin, troglitazone, rosiglitazone, pioglitazone, D‐chiro‐inositol) for polycystic ovary syndrome. Cochrane Database of Systematic Reviews2003, Issue 3. [DOI: 10.1002/14651858.CD003053] ">Lord 2003</a>; total amended to 11 studies), <a href="./references#CD003053-bbs2-0151" title="TangT , LordJM , NormanRJ , YasminE , BalenAH . Insulin‐sensitising drugs (metformin, rosiglitazone, pioglitazone, D‐chiro‐inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility. Cochrane Database of Systematic Reviews2009, Issue 3. [DOI: 10.1002/14651858.CD003053.pub4; PUBMED: 20091537] ">Tang 2009</a> included 31 studies in the analysis (<a href="#CD003053-fig-0001">Figure 1</a>). </p> <p>In the second update of the review (<a href="./references#CD003053-bbs2-0152" title="TangT , LordJM , NormanRJ , YasminE , BalenAH . Insulin‐sensitising drugs (metformin, rosiglitazone, pioglitazone, D‐chiro‐inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility. Cochrane Database of Systematic Reviews2012, Issue 5. [DOI: 10.1002/14651858.CD003053.pub5] ">Tang 2012</a>) (search period October 2008 to October 2011), the review authors identified 15 studies. They excluded four studies and one study awaited classification. Therefore, 10 new studies were identified for inclusion (<a href="./references#CD003053-bbs2-0004" title="Ben AyedB , Dammak Dit MlikS , Ben ArabH , TrabelssiH , ChahtourH , MathlouthiN . Metformin effects on clomifene‐induced ovulation in the polycystic ovary syndrome. Tunisie Medicale2009;87(1):43‐8. ">Ben Ayed 2009</a>; <a href="./references#CD003053-bbs2-0005" title="BoudhrâaK , JellouliMA , AmriM , FarhatM , TorkhaniF , GaraMF . Indication of metformin in the management of hormonal dysfunction secondary to polycystic ovarian syndrome: prospective comparative study of 63 cases. [La metformine dans la prise en charge de l'infertilite du SOPK hors FIV etude prospective comparative a propos de 63 cas]. Tunisie Medicale2010;88(5):335‐40. ">Boudhraa 2010</a>; <a href="./references#CD003053-bbs2-0019" title="KarimzadehMA , JavedaniM . An assessment of lifestyle modification versus medical treatment with clomiphene citrate, metformin, and clomiphene citrate‐metformin in patients with polycystic ovary syndrome. Fertility and Sterility2010;94(1):216‐20. ">Karimzadeh 2010</a>; <a href="./references#CD003053-bbs2-0068" title="LadsonG , DodsonWC , SweetSD , ArchibongAE , KunselmanAR , DemersLM , et al. The effects of metformin with lifestyle therapy in polycystic ovary syndrome: a randomized double‐blind study. Fertility and Sterility2011;95(3):1059‐66. ">Ladson 2011</a>; <a href="./references#CD003053-bbs2-0021" title="LamPM , TamWH , MaRC , CheungLP , TsuiMH , TongPC , et al. The reproductive and metabolic effect of rosiglitazone on Chinese women with polycystic ovarian syndrome ‐ a double‐blind randomized placebo‐controlled study. Fertility and Sterility2011;96(2):445‐51. ">Lam 2011</a>; <a href="./references#CD003053-bbs2-0034" title="OttaCF , WiorM , IraciGS , KaplanR , TorresD , GaidoMI , et al. Clinical, metabolic, and endocrine parameters in response to metformin and lifestyle intervention in women with polycystic ovary syndrome: a randomized, double‐blind, and placebo control trial. Gynecological Endocrinology2010;26(3):173‐8. ">Otta 2010</a>; <a href="./references#CD003053-bbs2-0037" title="JohnsonNP , BontekoeS , StewartAW . Analysis of factors predicting success of metformin and clomiphene treatment for women with infertility owing to PCOS‐related ovulation dysfunction in a randomised controlled trial. Australian &amp; New Zealand Journal of Obstetrics &amp; Gynaecology2011;51:252‐6. JohnsonNP , StewartAW , FalkinerJ , FarquharCM , MilsomS , SinghV‐P , et al. on behalf of REACT‐NZ (REproduction And Collaborative Trials in New Zealand), a multi‐centre fertility trials group. PCOSMIC: a multi‐centre randomized trial in women with Polycystic Ovary Syndrome evaluating Metformin for Infertility with Clomiphene. Human Reproduction2010;25(7):1675‐83. [MEDLINE: 10.1093/humrep/deq100] ">PCOSMIC 2010</a>; <a href="./references#CD003053-bbs2-0039" title="RomualdiD , GiulianiM , CristelloF , FulghesuAM , SelvaggiL , LanzoneA , et al. Metformin effects on ovarian ultrasound appearance and steroidogenic function in normal‐weight normoinsulinemic women with polycystic ovary syndrome: a randomized double‐blind placebo‐controlled clinical trial. Fertility and Sterility2010;93(7):2303‐10. ">Romualdi 2010</a>; <a href="./references#CD003053-bbs2-0041" title="SiebertT , KrugerT , LombardC . Evaluating the equivalence of clomiphene citrate with and without metformin in ovulation induction in PCOS patients. Journal of Assisted Reproduction and Genetics2009;26(4):165‐71. ">Siebert 2009</a>; <a href="./references#CD003053-bbs2-0046" title="WilliamsSC , PastoreLM , ShellyWB , BaileyAP , BarasDC , BatemanBG . A randomized, placebo‐controlled study of the influence of instant‐release metformin on response to clomiphene citrate and time to conception in polycystic ovary syndrome. Fertility and Sterility2009;92 Suppl(3):105. ">Williams 2009</a>) (<a href="#CD003053-fig-0001">Figure 1</a>). After further consideration, they re‐included five previously excluded studies (<a href="./references#CD003053-bbs2-0006" title="AignerE , BachofnerN , KleinK , DeGeyterC , HohlaF , PatschW , et al. Retinol‐binding protein 4 in polycystic ovary syndrome‐‐association with steroid hormones and response to pioglitazone treatment. Journal of Clinical Endocrinology and Metabolism2009;94(4):1229‐35. BrettenthalerN , DeGeyterC , HuberPR , KellerU . Effect of the insulin sensitizer pioglitazone on insulin resistance, hyperandrogenism, and ovulatory dysfunction in women with polycystic ovary syndrome. Journal of Clinical Epidemiology2004;89:3835‐40. ">Brettenthaler 2004</a>; <a href="./references#CD003053-bbs2-0007" title="CarminaE , LoboRA . Does metformin induce ovulation in normoandrogenic anovulatory women?. American Journal of Obstetrics and Gynecology2004;191:1580‐4. ">Carmina 2004</a>; <a href="./references#CD003053-bbs2-0020" title="KhorramO , HelliwellJP , KatzS , BonpaneCM , JaramilloL Khorram O , et al. Two weeks of metformin improves clomiphene citrate‐induced ovulation and metabolic profiles in women with polycystic ovary syndrome. Fertility and Sterility2006;85:1448‐51. ">Khorram 2006</a>; <a href="./references#CD003053-bbs2-0036" title="CasimirriF , BiscottiM , GambineriA , CalzoniF , ElianaB , PasqualiR . Metformin improves insulin, body fat distribution, and androgens in obese women with and without the polycystic ovary syndrome. International Journal of Obesity1997;21 Suppl 2:61. PasqualiR , GambineriA , BiscottiD , VicennatiV , GagliardiL , ColittaD , et al. Effect of long‐term treatment with metformin added to hypocaloric diet on body composition, fat distribution, and androgen and insulin levels in abdominally obese women with and without the polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism2000;85(8):2767‐74. ">Pasquali 2000</a>; <a href="./references#CD003053-bbs2-0040" title="SahinY , YirmibesU , KelestimurF , AygenE . The effects of metformin on insulin resistance, clomiphene‐induced ovulation and pregnancy rates in women with polycystic ovary syndrome. European Journal of Obstetrics, Gynecology, and Reproductive Biology2004;113:214‐20. ">Sahin 2004</a>). Furthermore, they re‐classified two publications in the first updated review (<a href="./references#CD003053-bbs2-0151" title="TangT , LordJM , NormanRJ , YasminE , BalenAH . Insulin‐sensitising drugs (metformin, rosiglitazone, pioglitazone, D‐chiro‐inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility. Cochrane Database of Systematic Reviews2009, Issue 3. [DOI: 10.1002/14651858.CD003053.pub4; PUBMED: 20091537] ">Tang 2009</a>) into a single study (<a href="./references#CD003053-bbs2-0038" title="RautioK , TapanainenJS , RuokonenA , Morin‐PapunenLC . Endocrine and metabolic effects of rosiglitazone in overweight women with PCOS: a randomized placebo‐controlled study. Human Reproduction2006;21:1400‐7. RautioK , TapanainenJS , RuokonenA , Morin‐PapunenLC . Rosiglitazone treatment alleviates inflammation and improves liver function in overweight women with polycystic ovary syndrome: a randomized placebo‐controlled study. Fertility and Sterility2007;87(1):202‐6. ">Rautio 2006</a>; formerly Rautio 2006a and Rautio 2006b) and removed <a href="./references#CD003053-bbs2-0066" title="KellyCJ , GordonD . The effect of metformin on hirsutism in polycystic ovary syndrome. European Journal of Endocrinology2002;147(2):217‐21. [MEDLINE: 782] ">Kelly 2002</a>, after a protocol update removed hirsutism from secondary outcomes. Hence, Tang 2012 included a total of 44 studies in the analysis (<a href="#CD003053-fig-0001">Figure 1</a>). </p> <p>In the current review update, (third update, search period January 2011 to January 2017), we considered the full texts of 13 articles (<a href="#CD003053-fig-0002">Figure 2</a>). Of these, we excluded nine (<a href="./references#CD003053-bbs2-0049" title="AbuelgharWM , ElkadyOS , KhameesAA . Clomiphene citrate alone, in combination with metformin or in combination with pioglitazone as first line therapy in induction of ovulation in infertile women with polycystic ovary syndrome, a randomised controlled trial. Middle East Fertility Society Journal2013;18:135‐41. ">Abuelghar 2013</a>; <a href="./references#CD003053-bbs2-0057" title="CuriDD , FonsecaAM , MarcondesJA , AlmeidaJA , BagnoliVR , SoaresJMJr , et al. Metformin versus lifestyle changes in treating women with polycystic ovary syndrome. Gynecological Endocrinology2010;28:182‐5. ">Curi 2012</a>; <a href="./references#CD003053-bbs2-0053" title="ChaudhryI , NisaSU , NiaSU . Comparison between pioglitazone and metformin in terms of efficacy in patients with polycystic ovarian syndrome. Pakistan Journal of Medical and Health Sciences2016;10:574‐7. ">Chaudhry 2016</a>; <a href="./references#CD003053-bbs2-0062" title="HeathcoteG , ForbesK , LeeA , GregorM , LuscombeG , BoothroydC . Live birth rate after metformin and clomiphene vs clomiphene alone in polycystic ovary syndrome (PCOS): a randomized, double‐blind, placebo‐controlled trial. Draft paper supplied by authors. ">Heathcote 2013</a>;<a href="./references#CD003053-bbs2-0069" title="LeanzaV , CocoL , GrassoF , LeanzaG , ZarboG , PalumboM . Ovulation induction with clomiphene citrate and metformin in women with polycystic ovary syndrome. Minerva Ginecologica2014;66(3):299‐301. ">Leanza 2014</a>; <a href="./references#CD003053-bbs2-0075" title="PalombaS , FalboA , DiCelloA , CappielloF , TolinoA , ZulloF . Does metformin affect the ovarian response to gonadotropins for in vitro fertilization treatment in patients with polycystic ovary syndrome and reduced ovarian reserve? A randomized controlled trial. Fertility and Sterility2011;96:1128‐33. ">Palomba 2011</a>; <a href="./references#CD003053-bbs2-0076" title="PapaleoE , UnferV , BaillargeonJP , FusiF , OcchiF , DeSantisL . Myo‐inositol may improve oocyte quality in intracytoplasmic sperm injection cycles. A prospective, controlled, randomized trial. Fertility and Sterility2009;91:1750‐4. ">Papaleo 2009</a>; <a href="./references#CD003053-bbs2-0080" title="SalmanSA , FarghalyTA , AttallahDA , Abdel‐HafeezHA , ShaabanOM . Insulin sensitizing agent (metformin) improves clinical pregnancy rate in clomiphene citrate resistant polycystic ovarian syndrome patients with acanthosis nigricans. Fertility and Sterility2014;102(Supplement 3):e139. ">Salman 2014</a>; <a href="./references#CD003053-bbs2-0083" title="UnferV , CarlomagnoG , RizzoP , RaffoneE , RoseffS . Myo‐inositol rather than D‐chiro‐inositol is able to improve oocyte quality in intracytoplasmic sperm injection cycles. A prospective, controlled, randomized trial. European Review for Medical and Pharmacological Sciences2011;15:452‐7. ">Unfer 2011</a>) and included four (<a href="./references#CD003053-bbs2-0001" title="AyazA , AlwanY , FarooqMU . Efficacy of combined metformin‐clomiphene citrate in comparison with clomiphene citrate alone in infertile women with polycystic ovarian syndrome (PCOS). Journal of Medicine and Life2013;6:199‐201. AyazA , AlwanY , FarooqMU . Metformin‐clomiphene citrate vs. clomiphene citrate alone: polycystic ovarian syndrome. Journal of Human Reproductive Sciences2013;6:15‐8. ">Ayaz 2013</a>; <a href="./references#CD003053-bbs2-0024" title="MachadoRC , MachadoNA , GeberS . Evaluation of the use of metformin for ovulation in patients with PCOS resistant to isolated use of clomiphene citrate. Brazilian Journal Assisted Reproduction2012;16(1):27‐31. ">Machado 2012</a>; <a href="./references#CD003053-bbs2-0017" title="KarS . Metabolic risks of the lean PCOS woman. Fertility and Sterility ASRM abstracts2013;100(S359):P‐730. KarS , SanchitaS . Clomiphene citrate, metformin or a combination of both as the first line ovulation induction drug for Asian Indian women with polycystic ovarian syndrome: a randomized controlled trial. Journal of Human Reproductive Science2015;8:197‐201. ">Kar 2015</a>; <a href="./references#CD003053-bbs2-0003" title="BegumH , ChowdhuryTA , BegumF , BegumSN , KabirN , HaqueMDA . Effect of metformin and clomiphene citrate in improving fertility in subfertility women with polycystic ovary syndrome: a randomised controlled trial. Bangladesh Journal of Obstetrics and Gynaecology2014;29:15‐20. ">Begum 2014</a>). <a href="./references#CD003053-bbs2-0029" title="Morin‐PapunenL , RantalaAS , Unkila‐KallioL , TiitinenA , HippeläinenM , PerheentupaA , et al. Metformin improves pregnancy and live‐birth rates in women with polycystic ovary syndrome (PCOS): a multicenter, double‐blind, placebo‐controlled randomized trial. Journal of Clinical Endocrinology and Metabolism2012;97:1492‐1500. ">Morin‐Papunen 2012</a> was the study awaiting classification from the previous update, and we have now included it in this update, therefore we have included a total of five additional studies in this review. </p> </section> <section id="CD003053-sec-0058"> <h4 class="title">Included studies</h4> <section id="CD003053-sec-0059"> <h5 class="title">Study design and Setting</h5> <p>The newly included studies for this current update (<a href="./references#CD003053-bbs2-0001" title="AyazA , AlwanY , FarooqMU . Efficacy of combined metformin‐clomiphene citrate in comparison with clomiphene citrate alone in infertile women with polycystic ovarian syndrome (PCOS). Journal of Medicine and Life2013;6:199‐201. AyazA , AlwanY , FarooqMU . Metformin‐clomiphene citrate vs. clomiphene citrate alone: polycystic ovarian syndrome. Journal of Human Reproductive Sciences2013;6:15‐8. ">Ayaz 2013</a>; <a href="./references#CD003053-bbs2-0003" title="BegumH , ChowdhuryTA , BegumF , BegumSN , KabirN , HaqueMDA . Effect of metformin and clomiphene citrate in improving fertility in subfertility women with polycystic ovary syndrome: a randomised controlled trial. Bangladesh Journal of Obstetrics and Gynaecology2014;29:15‐20. ">Begum 2014</a>; <a href="./references#CD003053-bbs2-0017" title="KarS . Metabolic risks of the lean PCOS woman. Fertility and Sterility ASRM abstracts2013;100(S359):P‐730. KarS , SanchitaS . Clomiphene citrate, metformin or a combination of both as the first line ovulation induction drug for Asian Indian women with polycystic ovarian syndrome: a randomized controlled trial. Journal of Human Reproductive Science2015;8:197‐201. ">Kar 2015</a>; <a href="./references#CD003053-bbs2-0024" title="MachadoRC , MachadoNA , GeberS . Evaluation of the use of metformin for ovulation in patients with PCOS resistant to isolated use of clomiphene citrate. Brazilian Journal Assisted Reproduction2012;16(1):27‐31. ">Machado 2012;</a><a href="./references#CD003053-bbs2-0029" title="Morin‐PapunenL , RantalaAS , Unkila‐KallioL , TiitinenA , HippeläinenM , PerheentupaA , et al. Metformin improves pregnancy and live‐birth rates in women with polycystic ovary syndrome (PCOS): a multicenter, double‐blind, placebo‐controlled randomized trial. Journal of Clinical Endocrinology and Metabolism2012;97:1492‐1500. ">Morin‐Papunen 2012</a>) all recorded pregnancy outcomes following treatment. In these studies, metformin was investigated with, and without the addition of clomiphene citrate. </p> <p>Twenty‐three of the included studies were documented as being double blind. Five studies were not double blind: <a href="./references#CD003053-bbs2-0015" title="HwuYM , LinSY , HuangWY , LinMH , LeeRK . Ultra‐short metformin pretreatment for clomiphene citrate‐resistant polycystic ovary syndrome. International Journal of Gynaecology and Obstetrics2005;90:39‐43. ">Hwu 2005</a>;<a href="./references#CD003053-bbs2-0020" title="KhorramO , HelliwellJP , KatzS , BonpaneCM , JaramilloL Khorram O , et al. Two weeks of metformin improves clomiphene citrate‐induced ovulation and metabolic profiles in women with polycystic ovary syndrome. Fertility and Sterility2006;85:1448‐51. ">Khorram 2006</a>;<a href="./references#CD003053-bbs2-0030" title="NestlerJE , JakubowiczDJ , EvansWS , PasqualiR . Effects of metformin on spontaneous and clomiphene‐induced ovulation in the polycystic ovary syndrome. New England Journal of Medicine1998;338(26):1876‐80. ">Nestler 1998</a>;<a href="./references#CD003053-bbs2-0041" title="SiebertT , KrugerT , LombardC . Evaluating the equivalence of clomiphene citrate with and without metformin in ovulation induction in PCOS patients. Journal of Assisted Reproduction and Genetics2009;26(4):165‐71. ">Siebert 2009</a>;<a href="./references#CD003053-bbs2-0048" title="ZainMM , JamaluddinR , IbrahimA , NormanRJ . Comparison of clomiphene citrate, metformin, or the combination of both for first‐line ovulation induction, achievement of pregnancy, and live birth in Asian women with polycystic ovary syndrome: a randomized controlled trial. Fertility and Sterility2009;91(2):514‐21. ">Zain 2009</a>; and the remainder were classified as unclear. </p> <p>Two of the studies were cross‐over trials (<a href="./references#CD003053-bbs2-0042" title="SturrockNDC , LannonB , FayTN . Metformin does not enhance ovulation induction in clomiphene resistant polycystic ovary syndrome in clinical practice. British Journal of Clinical Pharmacology2002;53(5):469‐73. [MEDLINE: 2002180629] ">Sturrock 2002</a>; <a href="./references#CD003053-bbs2-0044" title="TrolleB , FlyvbjergA , KesmodelU , LauszusFF . Efficacy of metformin in obese and non‐obese women with polycystic ovary syndrome: a randomized, double‐blinded, placebo‐controlled cross‐over trial. Human Reproduction2007;22(11):2967‐73. [original article] TrolleB , FlyvbjergA , KesmodelU , LauszusFF . Efficacy of metformin in obese and non‐obese women with polycystic ovary syndrome: a randomized, double‐blinded, placebo‐controlled cross‐over trial. Obstetrics and Gynecological Survey2008;63(2):96‐8. ">Trolle 2007</a>). We only analysed the first phase from <a href="./references#CD003053-bbs2-0042" title="SturrockNDC , LannonB , FayTN . Metformin does not enhance ovulation induction in clomiphene resistant polycystic ovary syndrome in clinical practice. British Journal of Clinical Pharmacology2002;53(5):469‐73. [MEDLINE: 2002180629] ">Sturrock 2002</a> as we considered the washout period to be short (four weeks). Although the study by <a href="./references#CD003053-bbs2-0044" title="TrolleB , FlyvbjergA , KesmodelU , LauszusFF . Efficacy of metformin in obese and non‐obese women with polycystic ovary syndrome: a randomized, double‐blinded, placebo‐controlled cross‐over trial. Human Reproduction2007;22(11):2967‐73. [original article] TrolleB , FlyvbjergA , KesmodelU , LauszusFF . Efficacy of metformin in obese and non‐obese women with polycystic ovary syndrome: a randomized, double‐blinded, placebo‐controlled cross‐over trial. Obstetrics and Gynecological Survey2008;63(2):96‐8. ">Trolle 2007</a> was also a cross‐over study, there was an eight‐week washout period and no women became pregnant during the trial period. We therefore decided to include the published data of this study after the cross‐over period (second phase). </p> <p>The included studies originated from a number of countries, including Argentina, Bangladesh, Brazil, Denmark, Egypt, Finland, Germany, Hong Kong, India, Iran, Italy, Malaysia, the Netherlands, New Zealand, Saudi Arabia, South Africa, Tunisia, Turkey, UK, USA and Venezuela. </p> </section> <section id="CD003053-sec-0060"> <h5 class="title">Participants</h5> <p>The number of women in the studies ranged from 19 to 626. In total, 4451 women (4014 participants had metformin, 497 participants had other insulin‐sensitising drugs) were included in this updated review. The range of BMI in included participants was (24.3 to 39.4 kg/m<sup>2</sup>). </p> <p>All the women had a diagnosis of PCOS based upon standardised criteria; two out of three of PCOS on ultrasound, oligo or anovulation, clinical or biochemical signs of hyperandrogenism (<a href="./references#CD003053-bbs2-0103" title="The Rotterdam ESHRE/ASRM‐sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long‐term health risks related to polycystic ovary syndrome (PCOS). Human Reproduction2004;19(1):41. ">ESHRE/ASRM 2004</a>). The age range of participants was 24.2 to 32.8 years with the range of fasting insulin concentrations between 6.3 and 54.67 mIU/L and testosterone levels of 1.3 to 4.67 nmol/L. However, several studies did not provide these data. </p> <p>Most women recruited in the studies using rosiglitazone, pioglitazone or D‐chiro‐inositol (<a href="./references#CD003053-bbs2-0006" title="AignerE , BachofnerN , KleinK , DeGeyterC , HohlaF , PatschW , et al. Retinol‐binding protein 4 in polycystic ovary syndrome‐‐association with steroid hormones and response to pioglitazone treatment. Journal of Clinical Endocrinology and Metabolism2009;94(4):1229‐35. BrettenthalerN , DeGeyterC , HuberPR , KellerU . Effect of the insulin sensitizer pioglitazone on insulin resistance, hyperandrogenism, and ovulatory dysfunction in women with polycystic ovary syndrome. Journal of Clinical Epidemiology2004;89:3835‐40. ">Brettenthaler 2004</a>; <a href="./references#CD003053-bbs2-0013" title="GlintborgD , FrystykJ , HojlundK , AndersenKK , HenriksenJE , HermannA , et al. Total and high molecular weight (HMW) adiponectin levels and measures of glucose and lipid metabolism following pioglitazone treatment in a randomized placebo‐controlled study in polycystic ovary syndrome. Clinical Endocrinology (Oxford)2008;68(2):165‐74. GlintborgD , HermannAP , AndersenM , HagenC , Beck‐NielsenH , VeldhuisJD , et al. Effect of pioglitazone on glucose metabolism and luteinizing hormone secretion in women with polycystic ovary syndrome. Fertility and Sterility2006;86:385‐97. GlintborgD , HojlundK , AndersenM , HenriksenJE , Beck‐NielsenH , HandbergA . Soluble CD36 and risk markers of insulin resistance and atherosclerosis are elevated in polycystic ovary syndrome and significantly reduced during pioglitazone treatment. Diabetes Care2008;31:328‐34. GlintborgD , StovingRK , HagenC , HermannAP , FrystykJ , VeldhuisJD , et al. Pioglitazone treatment increases spontaneous growth hormone (GH) secretion and stimulated GH levels in polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism2005;90:5605‐12. [original article] ">Glintborg 2005</a>; <a href="./references#CD003053-bbs2-0021" title="LamPM , TamWH , MaRC , CheungLP , TsuiMH , TongPC , et al. The reproductive and metabolic effect of rosiglitazone on Chinese women with polycystic ovarian syndrome ‐ a double‐blind randomized placebo‐controlled study. Fertility and Sterility2011;96(2):445‐51. ">Lam 2011</a>; <a href="./references#CD003053-bbs2-0038" title="RautioK , TapanainenJS , RuokonenA , Morin‐PapunenLC . Endocrine and metabolic effects of rosiglitazone in overweight women with PCOS: a randomized placebo‐controlled study. Human Reproduction2006;21:1400‐7. RautioK , TapanainenJS , RuokonenA , Morin‐PapunenLC . Rosiglitazone treatment alleviates inflammation and improves liver function in overweight women with polycystic ovary syndrome: a randomized placebo‐controlled study. Fertility and Sterility2007;87(1):202‐6. ">Rautio 2006</a>) were not planning a pregnancy due to the uncertainty of the safety of using these products in pregnancy. </p> </section> <section id="CD003053-sec-0061"> <h5 class="title">Interventions</h5> <p>In total, including the first review and the last update, 42 out of 48 trials assessed the benefits of using metformin for women with PCOS. Eighteen trials compared metformin alone with placebo or no treatment (<a href="./references#CD003053-bbs2-0002" title="BaillargeonJP , JakubowiczDJ , IuornoMJ , JakubowiczS , NestlerJE . Effects of metformin and rosiglitazone, alone and in combination, in nonobese women with polycystic ovary syndrome and normal indices of insulin sensitivity. Fertility and Sterility2004;82:893‐902. ">Baillargeon 2004</a>; <a href="./references#CD003053-bbs2-0007" title="CarminaE , LoboRA . Does metformin induce ovulation in normoandrogenic anovulatory women?. American Journal of Obstetrics and Gynecology2004;191:1580‐4. ">Carmina 2004</a>; <a href="./references#CD003053-bbs2-0011" title="FlemingR , HopkinsonZE , WallaceAM , GreerIA , SattarN . Ovarian function and metabolic factors in women with oligomenorrhea treated with metformin in a randomized double blind placebo‐controlled trial. Journal of Clinical Endocrinology and Metabolism2002;87(2):569‐74. FlemingR , HopkinsonZE , WallaceE , GreerIA , SattarN . Metformin treatment improves ovulation frequency in women with oligomenorrhoea: a randomized, double blind placebo trial. Human Fertility2000; Vol. 3, issue 4:389‐90. ">Fleming 2002</a>; <a href="./references#CD003053-bbs2-0014" title="HoegerKM , KochmanL , WixomN , CraigK , MillerRK , GuzickDS . A randomized, 48‐week, placebo‐controlled trial of intensive lifestyle modification and/or metformin therapy in overweight women with polycystic ovary syndrome: a pilot study. Fertility and Sterility2004;82:421‐9. ">Hoeger 2004</a>; <a href="./references#CD003053-bbs2-0016" title="JakubowiczDJ , SeppalaM , JakubowiczS , Rodriguez‐ArmasO , Rivas‐SantiagoA , KoistinenH , et al. Insulin reduction with metformin increases luteal phase serum glycodelin and insulin‐like growth factor‐binding protein 1 concentrations and enhances uterine vascularity and blood flow in the polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism2001;86(3):1126‐33. ">Jakubowicz 2001</a>; <a href="./references#CD003053-bbs2-0018" title="KarimzadehM , TayebiN , EftekharM , SakhavatL , TaheripanahR , ZareF . The effect of administration of metformin on lipid profile changes and insulin resistance in patients with polycystic ovary syndrome. Middle East Fertility Society Journal2007;12(3):174‐8. ">Karimzadeh 2007</a>; <a href="./references#CD003053-bbs2-0019" title="KarimzadehMA , JavedaniM . An assessment of lifestyle modification versus medical treatment with clomiphene citrate, metformin, and clomiphene citrate‐metformin in patients with polycystic ovary syndrome. Fertility and Sterility2010;94(1):216‐20. ">Karimzadeh 2010</a>; <a href="./references#CD003053-bbs2-0023" title="LordJ , ThomasR , FoxB , AcharyaU , WilkinT . The effect of metformin on fat distribution and the metabolic syndrome in women with polycystic ovary syndrome‐‐a randomised, double‐blind, placebo‐controlled trial. British Journal of Obstetrics and Gynaecology2006;113:817‐24. ">Lord 2006</a>; <a href="./references#CD003053-bbs2-0029" title="Morin‐PapunenL , RantalaAS , Unkila‐KallioL , TiitinenA , HippeläinenM , PerheentupaA , et al. Metformin improves pregnancy and live‐birth rates in women with polycystic ovary syndrome (PCOS): a multicenter, double‐blind, placebo‐controlled randomized trial. Journal of Clinical Endocrinology and Metabolism2012;97:1492‐1500. ">Morin‐Papunen 2012</a>; <a href="./references#CD003053-bbs2-0030" title="NestlerJE , JakubowiczDJ , EvansWS , PasqualiR . Effects of metformin on spontaneous and clomiphene‐induced ovulation in the polycystic ovary syndrome. New England Journal of Medicine1998;338(26):1876‐80. ">Nestler 1998</a>; <a href="./references#CD003053-bbs2-0032" title="NgEHY , WatNMS , HoPC . Effects of metformin on ovulation rate, hormonal and metabolic profiles in women with clomiphene‐resistant polycystic ovaries: a randomized, double‐blinded placebo‐controlled trial. Human Reproduction2001;16(8):1625‐31. ">Ng 2001</a>; <a href="./references#CD003053-bbs2-0033" title="OnalanG , GoktolgaU , CeyhanT , BagisT , OnalanR , PabuccuR . Predictive value of glucose‐insulin ratio in PCOS and profile of women who will benefit from metformin therapy: obese, lean, hyper or normoinsulinemic?. European Journal of Obstetrics, Gynecology, and Reproductive Biology2005;123:204‐11. ">Onalan 2005</a>; <a href="./references#CD003053-bbs2-0034" title="OttaCF , WiorM , IraciGS , KaplanR , TorresD , GaidoMI , et al. Clinical, metabolic, and endocrine parameters in response to metformin and lifestyle intervention in women with polycystic ovary syndrome: a randomized, double‐blind, and placebo control trial. Gynecological Endocrinology2010;26(3):173‐8. ">Otta 2010</a>; <a href="./references#CD003053-bbs2-0036" title="CasimirriF , BiscottiM , GambineriA , CalzoniF , ElianaB , PasqualiR . Metformin improves insulin, body fat distribution, and androgens in obese women with and without the polycystic ovary syndrome. International Journal of Obesity1997;21 Suppl 2:61. PasqualiR , GambineriA , BiscottiD , VicennatiV , GagliardiL , ColittaD , et al. Effect of long‐term treatment with metformin added to hypocaloric diet on body composition, fat distribution, and androgen and insulin levels in abdominally obese women with and without the polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism2000;85(8):2767‐74. ">Pasquali 2000</a>; <a href="./references#CD003053-bbs2-0037" title="JohnsonNP , BontekoeS , StewartAW . Analysis of factors predicting success of metformin and clomiphene treatment for women with infertility owing to PCOS‐related ovulation dysfunction in a randomised controlled trial. Australian &amp; New Zealand Journal of Obstetrics &amp; Gynaecology2011;51:252‐6. JohnsonNP , StewartAW , FalkinerJ , FarquharCM , MilsomS , SinghV‐P , et al. on behalf of REACT‐NZ (REproduction And Collaborative Trials in New Zealand), a multi‐centre fertility trials group. PCOSMIC: a multi‐centre randomized trial in women with Polycystic Ovary Syndrome evaluating Metformin for Infertility with Clomiphene. Human Reproduction2010;25(7):1675‐83. [MEDLINE: 10.1093/humrep/deq100] ">PCOSMIC 2010</a>; <a href="./references#CD003053-bbs2-0043" title="TangT , GlanvilleJ , HaydenCJ , WhiteD , BarthJH , BalenAH . Combined lifestyle modification and metformin in obese patients with polycystic ovary syndrome. A randomized, placebo‐controlled, double‐blind multicentre study. Human Reproduction2006;21:80‐9. ">Tang 2006</a>; <a href="./references#CD003053-bbs2-0045" title="VandermolenDT , RattsVS , EvansWS , StovallDW , KaumaSW , NestlerJE . Metformin increases the ovulatory rate and pregnancy rate from clomiphene citrate in patients with polycystic ovary syndrome who are resistant to clomiphene citrate alone. Fertility and Sterility2001;75:310‐5. ">Vandermolen 2001</a>; <a href="./references#CD003053-bbs2-0047" title="YaraliH , YildizBO , DemirolA , ZeynelogluHB , YigitN , BukulmezO , et al. Co‐administration of metformin during rFSH treatment in patients with clomiphene citrate‐resistant polycystic ovarian syndrome: a prospective randomized trial. Human Reproduction2002;17(2):289‐94. YaraliH , YyldyzB , DemirolA , ZeynelogluH , YigitN , BukulmezO . Co‐administration of metformin during recombinant follicle stimulating hormone (recombinant FSH) treatment using the low‐dose step protocol in patients with clomiphene citrate resistant polycystic ovary syndrome (PCOS): a prospective randomized trial. Fertility and Sterility2001;76 Suppl(3):36. ">Yarali 2002</a>). </p> <p>Twenty‐two studies investigated the benefits of using metformin combined with clomiphene citrate on reproductive outcomes (<a href="./references#CD003053-bbs2-0001" title="AyazA , AlwanY , FarooqMU . Efficacy of combined metformin‐clomiphene citrate in comparison with clomiphene citrate alone in infertile women with polycystic ovarian syndrome (PCOS). Journal of Medicine and Life2013;6:199‐201. AyazA , AlwanY , FarooqMU . Metformin‐clomiphene citrate vs. clomiphene citrate alone: polycystic ovarian syndrome. Journal of Human Reproductive Sciences2013;6:15‐8. ">Ayaz 2013</a>; <a href="./references#CD003053-bbs2-0004" title="Ben AyedB , Dammak Dit MlikS , Ben ArabH , TrabelssiH , ChahtourH , MathlouthiN . Metformin effects on clomifene‐induced ovulation in the polycystic ovary syndrome. Tunisie Medicale2009;87(1):43‐8. ">Ben Ayed 2009</a>; <a href="./references#CD003053-bbs2-0005" title="BoudhrâaK , JellouliMA , AmriM , FarhatM , TorkhaniF , GaraMF . Indication of metformin in the management of hormonal dysfunction secondary to polycystic ovarian syndrome: prospective comparative study of 63 cases. [La metformine dans la prise en charge de l'infertilite du SOPK hors FIV etude prospective comparative a propos de 63 cas]. Tunisie Medicale2010;88(5):335‐40. ">Boudhraa 2010</a>; <a href="./references#CD003053-bbs2-0010" title="El‐BielyMM , HabbaM . The use of metformin to augment the induction of ovulation in obese infertile patients with polycystic ovary syndrome. Middle East Fertility Society Journal2001;6(1):43‐9. ">El‐Biely 2001</a>; <a href="./references#CD003053-bbs2-0015" title="HwuYM , LinSY , HuangWY , LinMH , LeeRK . Ultra‐short metformin pretreatment for clomiphene citrate‐resistant polycystic ovary syndrome. International Journal of Gynaecology and Obstetrics2005;90:39‐43. ">Hwu 2005</a>; <a href="./references#CD003053-bbs2-0016" title="JakubowiczDJ , SeppalaM , JakubowiczS , Rodriguez‐ArmasO , Rivas‐SantiagoA , KoistinenH , et al. Insulin reduction with metformin increases luteal phase serum glycodelin and insulin‐like growth factor‐binding protein 1 concentrations and enhances uterine vascularity and blood flow in the polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism2001;86(3):1126‐33. ">Jakubowicz 2001</a>; <a href="./references#CD003053-bbs2-0017" title="KarS . Metabolic risks of the lean PCOS woman. Fertility and Sterility ASRM abstracts2013;100(S359):P‐730. KarS , SanchitaS . Clomiphene citrate, metformin or a combination of both as the first line ovulation induction drug for Asian Indian women with polycystic ovarian syndrome: a randomized controlled trial. Journal of Human Reproductive Science2015;8:197‐201. ">Kar 2015</a>; <a href="./references#CD003053-bbs2-0019" title="KarimzadehMA , JavedaniM . An assessment of lifestyle modification versus medical treatment with clomiphene citrate, metformin, and clomiphene citrate‐metformin in patients with polycystic ovary syndrome. Fertility and Sterility2010;94(1):216‐20. ">Karimzadeh 2010</a>; <a href="./references#CD003053-bbs2-0020" title="KhorramO , HelliwellJP , KatzS , BonpaneCM , JaramilloL Khorram O , et al. Two weeks of metformin improves clomiphene citrate‐induced ovulation and metabolic profiles in women with polycystic ovary syndrome. Fertility and Sterility2006;85:1448‐51. ">Khorram 2006</a>; <a href="./references#CD003053-bbs2-0022" title="CataldoN , BarnhartH , LegroR , MyersE , SchlaffW , CarrB , et al. Extended‐release metformin does not reduce the clomiphene citrate dose required to induce ovulation in polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism2008;93(8):3147‐7. LegroRS , BarnhartHX , SchlaffWD , CarrBR , DiamondMP , CarsonSA , et al. Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome. New England Journal of Medicine2007;356:551‐66. [original article] ">Legro 2007</a>; <a href="./references#CD003053-bbs2-0024" title="MachadoRC , MachadoNA , GeberS . Evaluation of the use of metformin for ovulation in patients with PCOS resistant to isolated use of clomiphene citrate. Brazilian Journal Assisted Reproduction2012;16(1):27‐31. ">Machado 2012</a>; <a href="./references#CD003053-bbs2-0026" title="MalkawiHY , QublanHS . The effect of metformin plus clomiphene citrate on ovulation and pregnancy rates in clomiphene‐resistant women with polycystic ovary syndrome. Saudi Medical Journal2002;23(6):663‐6. [MEDLINE: 22065897] ">Malkawi 2002</a>; <a href="./references#CD003053-bbs2-0028" title="MollE , BossuytPM , KorevaarJC , LambalkCB , Van derVeenF . Effect of clomifene citrate plus metformin and clomifene citrate plus placebo on induction of ovulation in women with newly diagnosed polycystic ovary syndrome: randomised double blind clinical trial. BMJ2006;332:1485. [original article] MollE , KorevaarJC , BossuytPM , van derVeenF . Does adding metformin to clomifene citrate lead to higher pregnancy rates in a subset of women with polycystic ovary syndrome?. Human Reproduction2008;23(8):1830‐4. MollE , VanWelyM , LambalkCB , BossuytPM , Van derVeenF . Health‐related quality of life in women with newly diagnosed polycystic ovary syndrome randomized between clomifene citrate plus metformin or clomifene citrate plus placebo. Human Reproduction2012;27:3273‐8. ">Moll 2006</a>; <a href="./references#CD003053-bbs2-0030" title="NestlerJE , JakubowiczDJ , EvansWS , PasqualiR . Effects of metformin on spontaneous and clomiphene‐induced ovulation in the polycystic ovary syndrome. New England Journal of Medicine1998;338(26):1876‐80. ">Nestler 1998</a>; <a href="./references#CD003053-bbs2-0032" title="NgEHY , WatNMS , HoPC . Effects of metformin on ovulation rate, hormonal and metabolic profiles in women with clomiphene‐resistant polycystic ovaries: a randomized, double‐blinded placebo‐controlled trial. Human Reproduction2001;16(8):1625‐31. ">Ng 2001</a>; <a href="./references#CD003053-bbs2-0037" title="JohnsonNP , BontekoeS , StewartAW . Analysis of factors predicting success of metformin and clomiphene treatment for women with infertility owing to PCOS‐related ovulation dysfunction in a randomised controlled trial. Australian &amp; New Zealand Journal of Obstetrics &amp; Gynaecology2011;51:252‐6. JohnsonNP , StewartAW , FalkinerJ , FarquharCM , MilsomS , SinghV‐P , et al. on behalf of REACT‐NZ (REproduction And Collaborative Trials in New Zealand), a multi‐centre fertility trials group. PCOSMIC: a multi‐centre randomized trial in women with Polycystic Ovary Syndrome evaluating Metformin for Infertility with Clomiphene. Human Reproduction2010;25(7):1675‐83. [MEDLINE: 10.1093/humrep/deq100] ">PCOSMIC 2010</a>; <a href="./references#CD003053-bbs2-0040" title="SahinY , YirmibesU , KelestimurF , AygenE . The effects of metformin on insulin resistance, clomiphene‐induced ovulation and pregnancy rates in women with polycystic ovary syndrome. European Journal of Obstetrics, Gynecology, and Reproductive Biology2004;113:214‐20. ">Sahin 2004</a>, <a href="./references#CD003053-bbs2-0041" title="SiebertT , KrugerT , LombardC . Evaluating the equivalence of clomiphene citrate with and without metformin in ovulation induction in PCOS patients. Journal of Assisted Reproduction and Genetics2009;26(4):165‐71. ">Siebert 2009</a>; <a href="./references#CD003053-bbs2-0042" title="SturrockNDC , LannonB , FayTN . Metformin does not enhance ovulation induction in clomiphene resistant polycystic ovary syndrome in clinical practice. British Journal of Clinical Pharmacology2002;53(5):469‐73. [MEDLINE: 2002180629] ">Sturrock 2002</a>; <a href="./references#CD003053-bbs2-0045" title="VandermolenDT , RattsVS , EvansWS , StovallDW , KaumaSW , NestlerJE . Metformin increases the ovulatory rate and pregnancy rate from clomiphene citrate in patients with polycystic ovary syndrome who are resistant to clomiphene citrate alone. Fertility and Sterility2001;75:310‐5. ">Vandermolen 2001</a>; <a href="./references#CD003053-bbs2-0046" title="WilliamsSC , PastoreLM , ShellyWB , BaileyAP , BarasDC , BatemanBG . A randomized, placebo‐controlled study of the influence of instant‐release metformin on response to clomiphene citrate and time to conception in polycystic ovary syndrome. Fertility and Sterility2009;92 Suppl(3):105. ">Williams 2009</a>; <a href="./references#CD003053-bbs2-0048" title="ZainMM , JamaluddinR , IbrahimA , NormanRJ . Comparison of clomiphene citrate, metformin, or the combination of both for first‐line ovulation induction, achievement of pregnancy, and live birth in Asian women with polycystic ovary syndrome: a randomized controlled trial. Fertility and Sterility2009;91(2):514‐21. ">Zain 2009</a>). Five studies compared metformin versus clomiphene citrate (<a href="./references#CD003053-bbs2-0003" title="BegumH , ChowdhuryTA , BegumF , BegumSN , KabirN , HaqueMDA . Effect of metformin and clomiphene citrate in improving fertility in subfertility women with polycystic ovary syndrome: a randomised controlled trial. Bangladesh Journal of Obstetrics and Gynaecology2014;29:15‐20. ">Begum 2014</a>; <a href="./references#CD003053-bbs2-0019" title="KarimzadehMA , JavedaniM . An assessment of lifestyle modification versus medical treatment with clomiphene citrate, metformin, and clomiphene citrate‐metformin in patients with polycystic ovary syndrome. Fertility and Sterility2010;94(1):216‐20. ">Karimzadeh 2010</a>; <a href="./references#CD003053-bbs2-0022" title="CataldoN , BarnhartH , LegroR , MyersE , SchlaffW , CarrB , et al. Extended‐release metformin does not reduce the clomiphene citrate dose required to induce ovulation in polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism2008;93(8):3147‐7. LegroRS , BarnhartHX , SchlaffWD , CarrBR , DiamondMP , CarsonSA , et al. Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome. New England Journal of Medicine2007;356:551‐66. [original article] ">Legro 2007</a>; <a href="./references#CD003053-bbs2-0035" title="PalombaS , OrioFJr , FalboA , MangusoF , RussoT , CascellaT , et al. Prospective parallel randomized, double‐blind, double‐dummy controlled clinical trial comparing clomiphene citrate and metformin as the first‐line treatment for ovulation induction in nonobese anovulatory women with polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism2005;90(7):4068‐74. [original article] PalombaS , OrioFJr , FalboA , RussoT , TolinoA , ZulloF . Effects of metformin and clomiphene citrate on ovarian vascularity in patients with polycystic ovary syndrome. Fertility and Sterility2006;86:1694‐701. ">Palomba 2005</a>; <a href="./references#CD003053-bbs2-0048" title="ZainMM , JamaluddinR , IbrahimA , NormanRJ . Comparison of clomiphene citrate, metformin, or the combination of both for first‐line ovulation induction, achievement of pregnancy, and live birth in Asian women with polycystic ovary syndrome: a randomized controlled trial. Fertility and Sterility2009;91(2):514‐21. ">Zain 2009</a>). </p> <p>Specific advice on lifestyle modification was included in the study protocol in ten trials (<a href="./references#CD003053-bbs2-0004" title="Ben AyedB , Dammak Dit MlikS , Ben ArabH , TrabelssiH , ChahtourH , MathlouthiN . Metformin effects on clomifene‐induced ovulation in the polycystic ovary syndrome. Tunisie Medicale2009;87(1):43‐8. ">Ben Ayed 2009</a>; <a href="./references#CD003053-bbs2-0005" title="BoudhrâaK , JellouliMA , AmriM , FarhatM , TorkhaniF , GaraMF . Indication of metformin in the management of hormonal dysfunction secondary to polycystic ovarian syndrome: prospective comparative study of 63 cases. [La metformine dans la prise en charge de l'infertilite du SOPK hors FIV etude prospective comparative a propos de 63 cas]. Tunisie Medicale2010;88(5):335‐40. ">Boudhraa 2010</a>; <a href="./references#CD003053-bbs2-0006" title="AignerE , BachofnerN , KleinK , DeGeyterC , HohlaF , PatschW , et al. Retinol‐binding protein 4 in polycystic ovary syndrome‐‐association with steroid hormones and response to pioglitazone treatment. Journal of Clinical Endocrinology and Metabolism2009;94(4):1229‐35. BrettenthalerN , DeGeyterC , HuberPR , KellerU . Effect of the insulin sensitizer pioglitazone on insulin resistance, hyperandrogenism, and ovulatory dysfunction in women with polycystic ovary syndrome. Journal of Clinical Epidemiology2004;89:3835‐40. ">Brettenthaler 2004</a>; <a href="./references#CD003053-bbs2-0014" title="HoegerKM , KochmanL , WixomN , CraigK , MillerRK , GuzickDS . A randomized, 48‐week, placebo‐controlled trial of intensive lifestyle modification and/or metformin therapy in overweight women with polycystic ovary syndrome: a pilot study. Fertility and Sterility2004;82:421‐9. ">Hoeger 2004</a>; <a href="./references#CD003053-bbs2-0019" title="KarimzadehMA , JavedaniM . An assessment of lifestyle modification versus medical treatment with clomiphene citrate, metformin, and clomiphene citrate‐metformin in patients with polycystic ovary syndrome. Fertility and Sterility2010;94(1):216‐20. ">Karimzadeh 2010</a>; <a href="./references#CD003053-bbs2-0034" title="OttaCF , WiorM , IraciGS , KaplanR , TorresD , GaidoMI , et al. Clinical, metabolic, and endocrine parameters in response to metformin and lifestyle intervention in women with polycystic ovary syndrome: a randomized, double‐blind, and placebo control trial. Gynecological Endocrinology2010;26(3):173‐8. ">Otta 2010</a>; <a href="./references#CD003053-bbs2-0036" title="CasimirriF , BiscottiM , GambineriA , CalzoniF , ElianaB , PasqualiR . Metformin improves insulin, body fat distribution, and androgens in obese women with and without the polycystic ovary syndrome. International Journal of Obesity1997;21 Suppl 2:61. PasqualiR , GambineriA , BiscottiD , VicennatiV , GagliardiL , ColittaD , et al. Effect of long‐term treatment with metformin added to hypocaloric diet on body composition, fat distribution, and androgen and insulin levels in abdominally obese women with and without the polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism2000;85(8):2767‐74. ">Pasquali 2000</a>; <a href="./references#CD003053-bbs2-0037" title="JohnsonNP , BontekoeS , StewartAW . Analysis of factors predicting success of metformin and clomiphene treatment for women with infertility owing to PCOS‐related ovulation dysfunction in a randomised controlled trial. Australian &amp; New Zealand Journal of Obstetrics &amp; Gynaecology2011;51:252‐6. JohnsonNP , StewartAW , FalkinerJ , FarquharCM , MilsomS , SinghV‐P , et al. on behalf of REACT‐NZ (REproduction And Collaborative Trials in New Zealand), a multi‐centre fertility trials group. PCOSMIC: a multi‐centre randomized trial in women with Polycystic Ovary Syndrome evaluating Metformin for Infertility with Clomiphene. Human Reproduction2010;25(7):1675‐83. [MEDLINE: 10.1093/humrep/deq100] ">PCOSMIC 2010</a>; <a href="./references#CD003053-bbs2-0039" title="RomualdiD , GiulianiM , CristelloF , FulghesuAM , SelvaggiL , LanzoneA , et al. Metformin effects on ovarian ultrasound appearance and steroidogenic function in normal‐weight normoinsulinemic women with polycystic ovary syndrome: a randomized double‐blind placebo‐controlled clinical trial. Fertility and Sterility2010;93(7):2303‐10. ">Romualdi 2010</a>; <a href="./references#CD003053-bbs2-0043" title="TangT , GlanvilleJ , HaydenCJ , WhiteD , BarthJH , BalenAH . Combined lifestyle modification and metformin in obese patients with polycystic ovary syndrome. A randomized, placebo‐controlled, double‐blind multicentre study. Human Reproduction2006;21:80‐9. ">Tang 2006</a>). </p> <p>The duration of the trials ranged from 4 to 48 weeks with an average of 19.5 weeks. The median daily dose of metformin used in the trials was 1500 mg. </p> </section> <section id="CD003053-sec-0062"> <h5 class="title">Outcomes</h5> <p>Most trials reported clinical pregnancy rate but only 11 studies reported live birth rates (<a href="./references#CD003053-bbs2-0005" title="BoudhrâaK , JellouliMA , AmriM , FarhatM , TorkhaniF , GaraMF . Indication of metformin in the management of hormonal dysfunction secondary to polycystic ovarian syndrome: prospective comparative study of 63 cases. [La metformine dans la prise en charge de l'infertilite du SOPK hors FIV etude prospective comparative a propos de 63 cas]. Tunisie Medicale2010;88(5):335‐40. ">Boudhraa 2010</a>; <a href="./references#CD003053-bbs2-0017" title="KarS . Metabolic risks of the lean PCOS woman. Fertility and Sterility ASRM abstracts2013;100(S359):P‐730. KarS , SanchitaS . Clomiphene citrate, metformin or a combination of both as the first line ovulation induction drug for Asian Indian women with polycystic ovarian syndrome: a randomized controlled trial. Journal of Human Reproductive Science2015;8:197‐201. ">Kar 2015</a>; <a href="./references#CD003053-bbs2-0022" title="CataldoN , BarnhartH , LegroR , MyersE , SchlaffW , CarrB , et al. Extended‐release metformin does not reduce the clomiphene citrate dose required to induce ovulation in polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism2008;93(8):3147‐7. LegroRS , BarnhartHX , SchlaffWD , CarrBR , DiamondMP , CarsonSA , et al. Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome. New England Journal of Medicine2007;356:551‐66. [original article] ">Legro 2007</a>; <a href="./references#CD003053-bbs2-0028" title="MollE , BossuytPM , KorevaarJC , LambalkCB , Van derVeenF . Effect of clomifene citrate plus metformin and clomifene citrate plus placebo on induction of ovulation in women with newly diagnosed polycystic ovary syndrome: randomised double blind clinical trial. BMJ2006;332:1485. [original article] MollE , KorevaarJC , BossuytPM , van derVeenF . Does adding metformin to clomifene citrate lead to higher pregnancy rates in a subset of women with polycystic ovary syndrome?. Human Reproduction2008;23(8):1830‐4. MollE , VanWelyM , LambalkCB , BossuytPM , Van derVeenF . Health‐related quality of life in women with newly diagnosed polycystic ovary syndrome randomized between clomifene citrate plus metformin or clomifene citrate plus placebo. Human Reproduction2012;27:3273‐8. ">Moll 2006</a>; <a href="./references#CD003053-bbs2-0029" title="Morin‐PapunenL , RantalaAS , Unkila‐KallioL , TiitinenA , HippeläinenM , PerheentupaA , et al. Metformin improves pregnancy and live‐birth rates in women with polycystic ovary syndrome (PCOS): a multicenter, double‐blind, placebo‐controlled randomized trial. Journal of Clinical Endocrinology and Metabolism2012;97:1492‐1500. ">Morin‐Papunen 2012</a>; <a href="./references#CD003053-bbs2-0032" title="NgEHY , WatNMS , HoPC . Effects of metformin on ovulation rate, hormonal and metabolic profiles in women with clomiphene‐resistant polycystic ovaries: a randomized, double‐blinded placebo‐controlled trial. Human Reproduction2001;16(8):1625‐31. ">Ng 2001</a>; <a href="./references#CD003053-bbs2-0037" title="JohnsonNP , BontekoeS , StewartAW . Analysis of factors predicting success of metformin and clomiphene treatment for women with infertility owing to PCOS‐related ovulation dysfunction in a randomised controlled trial. Australian &amp; New Zealand Journal of Obstetrics &amp; Gynaecology2011;51:252‐6. JohnsonNP , StewartAW , FalkinerJ , FarquharCM , MilsomS , SinghV‐P , et al. on behalf of REACT‐NZ (REproduction And Collaborative Trials in New Zealand), a multi‐centre fertility trials group. PCOSMIC: a multi‐centre randomized trial in women with Polycystic Ovary Syndrome evaluating Metformin for Infertility with Clomiphene. Human Reproduction2010;25(7):1675‐83. [MEDLINE: 10.1093/humrep/deq100] ">PCOSMIC 2010</a>; <a href="./references#CD003053-bbs2-0040" title="SahinY , YirmibesU , KelestimurF , AygenE . The effects of metformin on insulin resistance, clomiphene‐induced ovulation and pregnancy rates in women with polycystic ovary syndrome. European Journal of Obstetrics, Gynecology, and Reproductive Biology2004;113:214‐20. ">Sahin 2004</a>; <a href="./references#CD003053-bbs2-0045" title="VandermolenDT , RattsVS , EvansWS , StovallDW , KaumaSW , NestlerJE . Metformin increases the ovulatory rate and pregnancy rate from clomiphene citrate in patients with polycystic ovary syndrome who are resistant to clomiphene citrate alone. Fertility and Sterility2001;75:310‐5. ">Vandermolen 2001</a>; <a href="./references#CD003053-bbs2-0047" title="YaraliH , YildizBO , DemirolA , ZeynelogluHB , YigitN , BukulmezO , et al. Co‐administration of metformin during rFSH treatment in patients with clomiphene citrate‐resistant polycystic ovarian syndrome: a prospective randomized trial. Human Reproduction2002;17(2):289‐94. YaraliH , YyldyzB , DemirolA , ZeynelogluH , YigitN , BukulmezO . Co‐administration of metformin during recombinant follicle stimulating hormone (recombinant FSH) treatment using the low‐dose step protocol in patients with clomiphene citrate resistant polycystic ovary syndrome (PCOS): a prospective randomized trial. Fertility and Sterility2001;76 Suppl(3):36. ">Yarali 2002</a>; <a href="./references#CD003053-bbs2-0048" title="ZainMM , JamaluddinR , IbrahimA , NormanRJ . Comparison of clomiphene citrate, metformin, or the combination of both for first‐line ovulation induction, achievement of pregnancy, and live birth in Asian women with polycystic ovary syndrome: a randomized controlled trial. Fertility and Sterility2009;91(2):514‐21. ">Zain 2009</a>). The four studies listed largest studies reporting live birth rate were <a href="./references#CD003053-bbs2-0022" title="CataldoN , BarnhartH , LegroR , MyersE , SchlaffW , CarrB , et al. Extended‐release metformin does not reduce the clomiphene citrate dose required to induce ovulation in polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism2008;93(8):3147‐7. LegroRS , BarnhartHX , SchlaffWD , CarrBR , DiamondMP , CarsonSA , et al. Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome. New England Journal of Medicine2007;356:551‐66. [original article] ">Legro 2007</a>; <a href="./references#CD003053-bbs2-0028" title="MollE , BossuytPM , KorevaarJC , LambalkCB , Van derVeenF . Effect of clomifene citrate plus metformin and clomifene citrate plus placebo on induction of ovulation in women with newly diagnosed polycystic ovary syndrome: randomised double blind clinical trial. BMJ2006;332:1485. [original article] MollE , KorevaarJC , BossuytPM , van derVeenF . Does adding metformin to clomifene citrate lead to higher pregnancy rates in a subset of women with polycystic ovary syndrome?. Human Reproduction2008;23(8):1830‐4. MollE , VanWelyM , LambalkCB , BossuytPM , Van derVeenF . Health‐related quality of life in women with newly diagnosed polycystic ovary syndrome randomized between clomifene citrate plus metformin or clomifene citrate plus placebo. Human Reproduction2012;27:3273‐8. ">Moll 2006</a>; <a href="./references#CD003053-bbs2-0029" title="Morin‐PapunenL , RantalaAS , Unkila‐KallioL , TiitinenA , HippeläinenM , PerheentupaA , et al. Metformin improves pregnancy and live‐birth rates in women with polycystic ovary syndrome (PCOS): a multicenter, double‐blind, placebo‐controlled randomized trial. Journal of Clinical Endocrinology and Metabolism2012;97:1492‐1500. ">Morin‐Papunen 2012</a>; <a href="./references#CD003053-bbs2-0037" title="JohnsonNP , BontekoeS , StewartAW . Analysis of factors predicting success of metformin and clomiphene treatment for women with infertility owing to PCOS‐related ovulation dysfunction in a randomised controlled trial. Australian &amp; New Zealand Journal of Obstetrics &amp; Gynaecology2011;51:252‐6. JohnsonNP , StewartAW , FalkinerJ , FarquharCM , MilsomS , SinghV‐P , et al. on behalf of REACT‐NZ (REproduction And Collaborative Trials in New Zealand), a multi‐centre fertility trials group. PCOSMIC: a multi‐centre randomized trial in women with Polycystic Ovary Syndrome evaluating Metformin for Infertility with Clomiphene. Human Reproduction2010;25(7):1675‐83. [MEDLINE: 10.1093/humrep/deq100] ">PCOSMIC 2010</a>. Only two studies (<a href="./references#CD003053-bbs2-0022" title="CataldoN , BarnhartH , LegroR , MyersE , SchlaffW , CarrB , et al. Extended‐release metformin does not reduce the clomiphene citrate dose required to induce ovulation in polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism2008;93(8):3147‐7. LegroRS , BarnhartHX , SchlaffWD , CarrBR , DiamondMP , CarsonSA , et al. Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome. New England Journal of Medicine2007;356:551‐66. [original article] ">Legro 2007</a>; <a href="./references#CD003053-bbs2-0037" title="JohnsonNP , BontekoeS , StewartAW . Analysis of factors predicting success of metformin and clomiphene treatment for women with infertility owing to PCOS‐related ovulation dysfunction in a randomised controlled trial. Australian &amp; New Zealand Journal of Obstetrics &amp; Gynaecology2011;51:252‐6. JohnsonNP , StewartAW , FalkinerJ , FarquharCM , MilsomS , SinghV‐P , et al. on behalf of REACT‐NZ (REproduction And Collaborative Trials in New Zealand), a multi‐centre fertility trials group. PCOSMIC: a multi‐centre randomized trial in women with Polycystic Ovary Syndrome evaluating Metformin for Infertility with Clomiphene. Human Reproduction2010;25(7):1675‐83. [MEDLINE: 10.1093/humrep/deq100] ">PCOSMIC 2010</a>) identified live birth rate as a primary outcome measure. Eight studies that were suitable for meta‐analysis reported adverse events (<a href="./references#CD003053-bbs2-0011" title="FlemingR , HopkinsonZE , WallaceAM , GreerIA , SattarN . Ovarian function and metabolic factors in women with oligomenorrhea treated with metformin in a randomized double blind placebo‐controlled trial. Journal of Clinical Endocrinology and Metabolism2002;87(2):569‐74. FlemingR , HopkinsonZE , WallaceE , GreerIA , SattarN . Metformin treatment improves ovulation frequency in women with oligomenorrhoea: a randomized, double blind placebo trial. Human Fertility2000; Vol. 3, issue 4:389‐90. ">Fleming 2002</a>; <a href="./references#CD003053-bbs2-0027" title="MoghettiP , CastelloR , NegriC , TosiF , PerroneF , CaputoM , et al. Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized, double‐blind, placebo‐controlled 6‐month trial, followed by open, long‐term clinical evaluation. Journal of Clinical Endocrinology and Metabolism2000;85(1):139‐46. ">Moghetti 2000</a>; <a href="./references#CD003053-bbs2-0028" title="MollE , BossuytPM , KorevaarJC , LambalkCB , Van derVeenF . Effect of clomifene citrate plus metformin and clomifene citrate plus placebo on induction of ovulation in women with newly diagnosed polycystic ovary syndrome: randomised double blind clinical trial. BMJ2006;332:1485. [original article] MollE , KorevaarJC , BossuytPM , van derVeenF . Does adding metformin to clomifene citrate lead to higher pregnancy rates in a subset of women with polycystic ovary syndrome?. Human Reproduction2008;23(8):1830‐4. MollE , VanWelyM , LambalkCB , BossuytPM , Van derVeenF . Health‐related quality of life in women with newly diagnosed polycystic ovary syndrome randomized between clomifene citrate plus metformin or clomifene citrate plus placebo. Human Reproduction2012;27:3273‐8. ">Moll 2006</a>; <a href="./references#CD003053-bbs2-0029" title="Morin‐PapunenL , RantalaAS , Unkila‐KallioL , TiitinenA , HippeläinenM , PerheentupaA , et al. Metformin improves pregnancy and live‐birth rates in women with polycystic ovary syndrome (PCOS): a multicenter, double‐blind, placebo‐controlled randomized trial. Journal of Clinical Endocrinology and Metabolism2012;97:1492‐1500. ">Morin‐Papunen 2012</a>; <a href="./references#CD003053-bbs2-0032" title="NgEHY , WatNMS , HoPC . Effects of metformin on ovulation rate, hormonal and metabolic profiles in women with clomiphene‐resistant polycystic ovaries: a randomized, double‐blinded placebo‐controlled trial. Human Reproduction2001;16(8):1625‐31. ">Ng 2001</a>; <a href="./references#CD003053-bbs2-0037" title="JohnsonNP , BontekoeS , StewartAW . Analysis of factors predicting success of metformin and clomiphene treatment for women with infertility owing to PCOS‐related ovulation dysfunction in a randomised controlled trial. Australian &amp; New Zealand Journal of Obstetrics &amp; Gynaecology2011;51:252‐6. JohnsonNP , StewartAW , FalkinerJ , FarquharCM , MilsomS , SinghV‐P , et al. on behalf of REACT‐NZ (REproduction And Collaborative Trials in New Zealand), a multi‐centre fertility trials group. PCOSMIC: a multi‐centre randomized trial in women with Polycystic Ovary Syndrome evaluating Metformin for Infertility with Clomiphene. Human Reproduction2010;25(7):1675‐83. [MEDLINE: 10.1093/humrep/deq100] ">PCOSMIC 2010</a>; <a href="./references#CD003053-bbs2-0044" title="TrolleB , FlyvbjergA , KesmodelU , LauszusFF . Efficacy of metformin in obese and non‐obese women with polycystic ovary syndrome: a randomized, double‐blinded, placebo‐controlled cross‐over trial. Human Reproduction2007;22(11):2967‐73. [original article] TrolleB , FlyvbjergA , KesmodelU , LauszusFF . Efficacy of metformin in obese and non‐obese women with polycystic ovary syndrome: a randomized, double‐blinded, placebo‐controlled cross‐over trial. Obstetrics and Gynecological Survey2008;63(2):96‐8. ">Trolle 2007</a>; <a href="./references#CD003053-bbs2-0047" title="YaraliH , YildizBO , DemirolA , ZeynelogluHB , YigitN , BukulmezO , et al. Co‐administration of metformin during rFSH treatment in patients with clomiphene citrate‐resistant polycystic ovarian syndrome: a prospective randomized trial. Human Reproduction2002;17(2):289‐94. YaraliH , YyldyzB , DemirolA , ZeynelogluH , YigitN , BukulmezO . Co‐administration of metformin during recombinant follicle stimulating hormone (recombinant FSH) treatment using the low‐dose step protocol in patients with clomiphene citrate resistant polycystic ovary syndrome (PCOS): a prospective randomized trial. Fertility and Sterility2001;76 Suppl(3):36. ">Yarali 2002</a>). </p> </section> </section> <section id="CD003053-sec-0063"> <h4 class="title">Excluded studies</h4> <p>In the previous update of the review (<a href="./references#CD003053-bbs2-0152" title="TangT , LordJM , NormanRJ , YasminE , BalenAH . Insulin‐sensitising drugs (metformin, rosiglitazone, pioglitazone, D‐chiro‐inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility. Cochrane Database of Systematic Reviews2012, Issue 5. [DOI: 10.1002/14651858.CD003053.pub5] ">Tang 2012</a>), the review authors excluded a total of 22 studies. Of these, they excluded two studies due to lack of randomisation (<a href="./references#CD003053-bbs2-0050" title="ArodaV , CiaraldiT , BurkeP , MudaliarS , CloptonP , PhillipsS , et al. Metabolic and hormonal changes induced by pioglitazone in polycystic ovary syndrome: a randomized, placebo‐controlled clinical trial. Journal of Clinical Endocrinology and Metabolism2009;94(2):469‐76. ">Aroda 2009</a>; <a href="./references#CD003053-bbs2-0081" title="SantonocitoV , RapisardaV , AbruzzoSRM , PollicinoR , CocoL , ZarboG . Comparison between clomiphene citrate and metformin for induction of ovulatory cycles in infertile nonobese women with polycystic ovary syndrome. Giornale Italiano di Ostetricia e Ginecologia2009;31(11‐12):455‐60. ">Santonocito 2009</a>) and four studies (<a href="./references#CD003053-bbs2-0051" title="AzzizR , EhrmannD , LegroRS , WhitcombRW , HanleyR , FereshetianAG , et al. Troglitazone improves ovulation and hirsutism in the polycystic ovary syndrome: a multicenter, double blind, placebo‐controlled trial. Journal of Clinical Endocrinology and Metabolism2001;86(4):1626‐32. [original article] GuyattG , WeaverB , CroninL , DooleyJA , AzzizR . Health‐related quality of life in women with polycystic ovary syndrome, a self‐administered questionnaire, was validated. Journal of Clinical Epidemiology2004;57:1279‐87. LegroRS , AzzizR , EhrmannD , FereshetianAG , O'KeefeM , GhazziMN . Minimal response of circulating lipids in women with polycystic ovary syndrome to improvement in insulin sensitivity with troglitazone. Journal of Clinical Endocrinology and Metabolism2003;88:5137‐44. ">Azziz 2001</a>; <a href="./references#CD003053-bbs2-0052" title="AzzizR , EhrmannDA , LegroRS , FereshetianAG , O'KeefeM , GhazziMN . Troglitazone decreases adrenal androgen levels in women with polycystic ovary syndrome. Fertility and Sterility2003;79:932‐7. ">Azziz 2003</a>; <a href="./references#CD003053-bbs2-0059" title="DunaifA , ScottD , FinegoodD , QuintanaB , WhitcombR . The insulin‐sensitizing agent troglitazone improves metabolic and reproductive abnormalities in the polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism1996;81(9):3299‐306. ">Dunaif 1996</a>; <a href="./references#CD003053-bbs2-0070" title="MantzorosCS , DunaifA , FlierJS . Leptin concentrations in the polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism1997;82(6):1687‐91. ">Mantzoros 1997</a>) because troglitazone had been withdrawn from the market. Another study, <a href="./references#CD003053-bbs2-0066" title="KellyCJ , GordonD . The effect of metformin on hirsutism in polycystic ovary syndrome. European Journal of Endocrinology2002;147(2):217‐21. [MEDLINE: 782] ">Kelly 2002</a> was excluded because the revised protocol had removed hirsutism from the outcomes. </p> <p>In this third update of the review, we excluded four of the studies previously awaiting classification due to inadequate information (<a href="./references#CD003053-bbs2-0054" title="ChaudhuryK , ChaudhuryS , ChowdhuryS . Does metformin augment the ovulation inducing effects of clomiphene in non‐obese women with polycystic ovary syndrome?. Journal of the Indian Medical Association2008;106(10):643‐8. ">Chaudhury 2008</a>; <a href="./references#CD003053-bbs2-0055" title="CostantinoD , MinozziG , MinozziF , GuaraldiC . Metabolic and hormonal effects of myo‐inositol in women with polycystic ovary syndrome: a double‐blind trial. European Review for Medical and Pharmacological Sciences2009;13(2):105‐10. ">Constantino 2009</a>; <a href="./references#CD003053-bbs2-0061" title="FarzadiL , SalmanS . Metformin‐therapy effects in 50 clomiphene citrate resistant PCOS patients. Journal of Medical Science2006;6:765‐71. ">Farzadi 2006;</a><a href="./references#CD003053-bbs2-0078" title="RefaieA , IbrahimG , OashS . Characteristics of polycystic ovary syndrome with and without insulin resistance and the role of insulin sensitizing drug (metformin) in its management. Middle East Fertility Society Jounal2005;10:142‐9. ">Refaie 2005</a>). In the updated search (January 2011 to January 2017), we identified 13 studies for possible inclusion, of which nine were excluded (<a href="./references#CD003053-bbs2-0049" title="AbuelgharWM , ElkadyOS , KhameesAA . Clomiphene citrate alone, in combination with metformin or in combination with pioglitazone as first line therapy in induction of ovulation in infertile women with polycystic ovary syndrome, a randomised controlled trial. Middle East Fertility Society Journal2013;18:135‐41. ">Abuelghar 2013</a>; <a href="./references#CD003053-bbs2-0053" title="ChaudhryI , NisaSU , NiaSU . Comparison between pioglitazone and metformin in terms of efficacy in patients with polycystic ovarian syndrome. Pakistan Journal of Medical and Health Sciences2016;10:574‐7. ">Chaudhry 2016</a>; <a href="./references#CD003053-bbs2-0057" title="CuriDD , FonsecaAM , MarcondesJA , AlmeidaJA , BagnoliVR , SoaresJMJr , et al. Metformin versus lifestyle changes in treating women with polycystic ovary syndrome. Gynecological Endocrinology2010;28:182‐5. ">Curi 2012</a>; <a href="./references#CD003053-bbs2-0062" title="HeathcoteG , ForbesK , LeeA , GregorM , LuscombeG , BoothroydC . Live birth rate after metformin and clomiphene vs clomiphene alone in polycystic ovary syndrome (PCOS): a randomized, double‐blind, placebo‐controlled trial. Draft paper supplied by authors. ">Heathcote 2013</a>; <a href="./references#CD003053-bbs2-0069" title="LeanzaV , CocoL , GrassoF , LeanzaG , ZarboG , PalumboM . Ovulation induction with clomiphene citrate and metformin in women with polycystic ovary syndrome. Minerva Ginecologica2014;66(3):299‐301. ">Leanza 2014</a>; <a href="./references#CD003053-bbs2-0075" title="PalombaS , FalboA , DiCelloA , CappielloF , TolinoA , ZulloF . Does metformin affect the ovarian response to gonadotropins for in vitro fertilization treatment in patients with polycystic ovary syndrome and reduced ovarian reserve? A randomized controlled trial. Fertility and Sterility2011;96:1128‐33. ">Palomba 2011</a>; <a href="./references#CD003053-bbs2-0076" title="PapaleoE , UnferV , BaillargeonJP , FusiF , OcchiF , DeSantisL . Myo‐inositol may improve oocyte quality in intracytoplasmic sperm injection cycles. A prospective, controlled, randomized trial. Fertility and Sterility2009;91:1750‐4. ">Papaleo 2009</a>; <a href="./references#CD003053-bbs2-0080" title="SalmanSA , FarghalyTA , AttallahDA , Abdel‐HafeezHA , ShaabanOM . Insulin sensitizing agent (metformin) improves clinical pregnancy rate in clomiphene citrate resistant polycystic ovarian syndrome patients with acanthosis nigricans. Fertility and Sterility2014;102(Supplement 3):e139. ">Salman 2014</a>; <a href="./references#CD003053-bbs2-0083" title="UnferV , CarlomagnoG , RizzoP , RaffoneE , RoseffS . Myo‐inositol rather than D‐chiro‐inositol is able to improve oocyte quality in intracytoplasmic sperm injection cycles. A prospective, controlled, randomized trial. European Review for Medical and Pharmacological Sciences2011;15:452‐7. ">Unfer 2011</a>). We excluded <a href="./references#CD003053-bbs2-0075" title="PalombaS , FalboA , DiCelloA , CappielloF , TolinoA , ZulloF . Does metformin affect the ovarian response to gonadotropins for in vitro fertilization treatment in patients with polycystic ovary syndrome and reduced ovarian reserve? A randomized controlled trial. Fertility and Sterility2011;96:1128‐33. ">Palomba 2011</a> as participants were undergoing in vitro fertilisation, which does not meet the inclusion criteria for this review (<a href="#CD003053-sec-0032">Types of participants</a>). </p> <p>A summary of studies included and excluded in the different versions of this review can be found in <a href="#CD003053-fig-0002">Figure 2</a>. </p> </section> </section> <section id="CD003053-sec-0064"> <h3 class="title">Risk of bias in included studies</h3> <p>See <a href="#CD003053-fig-0003">Figure 3</a> for risk of bias and <a href="#CD003053-fig-0004">Figure 4</a> for a summary of the risk of bias. </p> <p>We carried out sensitivity analysis by including data only from studies with low risk of bias, determined by sequence generation, allocation concealment and blinding method. Only 18 out of 48 studies met this criterion (<a href="./references#CD003053-bbs2-0002" title="BaillargeonJP , JakubowiczDJ , IuornoMJ , JakubowiczS , NestlerJE . Effects of metformin and rosiglitazone, alone and in combination, in nonobese women with polycystic ovary syndrome and normal indices of insulin sensitivity. Fertility and Sterility2004;82:893‐902. ">Baillargeon 2004</a>; <a href="./references#CD003053-bbs2-0008" title="ChouKH , vonEye CorletaH , CappE , SpritzerPM . Clinical, metabolic and endocrine parameters in response to metformin in obese women with polycystic ovary syndrome: a randomized, double‐blind and placebo‐controlled trial. Hormone and Metabolic Research2003;35:86‐91. ">Chou 2003</a>; <a href="./references#CD003053-bbs2-0009" title="EisenhardtS , SchwarzmannN , HenschelV , GermeyerA , vonWolffM , HamannA , et al. Early effects of metformin in women with polycystic ovary syndrome: a prospective randomized, double‐blind, placebo‐controlled trial. Journal of Clinical Endocrinology and Metabolism2006;91:946‐52. ">Eisenhardt 2006</a>; <a href="./references#CD003053-bbs2-0011" title="FlemingR , HopkinsonZE , WallaceAM , GreerIA , SattarN . Ovarian function and metabolic factors in women with oligomenorrhea treated with metformin in a randomized double blind placebo‐controlled trial. Journal of Clinical Endocrinology and Metabolism2002;87(2):569‐74. FlemingR , HopkinsonZE , WallaceE , GreerIA , SattarN . Metformin treatment improves ovulation frequency in women with oligomenorrhoea: a randomized, double blind placebo trial. Human Fertility2000; Vol. 3, issue 4:389‐90. ">Fleming 2002</a>; <a href="./references#CD003053-bbs2-0013" title="GlintborgD , FrystykJ , HojlundK , AndersenKK , HenriksenJE , HermannA , et al. Total and high molecular weight (HMW) adiponectin levels and measures of glucose and lipid metabolism following pioglitazone treatment in a randomized placebo‐controlled study in polycystic ovary syndrome. Clinical Endocrinology (Oxford)2008;68(2):165‐74. GlintborgD , HermannAP , AndersenM , HagenC , Beck‐NielsenH , VeldhuisJD , et al. Effect of pioglitazone on glucose metabolism and luteinizing hormone secretion in women with polycystic ovary syndrome. Fertility and Sterility2006;86:385‐97. GlintborgD , HojlundK , AndersenM , HenriksenJE , Beck‐NielsenH , HandbergA . Soluble CD36 and risk markers of insulin resistance and atherosclerosis are elevated in polycystic ovary syndrome and significantly reduced during pioglitazone treatment. Diabetes Care2008;31:328‐34. GlintborgD , StovingRK , HagenC , HermannAP , FrystykJ , VeldhuisJD , et al. Pioglitazone treatment increases spontaneous growth hormone (GH) secretion and stimulated GH levels in polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism2005;90:5605‐12. [original article] ">Glintborg 2005</a>; <a href="./references#CD003053-bbs2-0014" title="HoegerKM , KochmanL , WixomN , CraigK , MillerRK , GuzickDS . A randomized, 48‐week, placebo‐controlled trial of intensive lifestyle modification and/or metformin therapy in overweight women with polycystic ovary syndrome: a pilot study. Fertility and Sterility2004;82:421‐9. ">Hoeger 2004</a>; <a href="./references#CD003053-bbs2-0018" title="KarimzadehM , TayebiN , EftekharM , SakhavatL , TaheripanahR , ZareF . The effect of administration of metformin on lipid profile changes and insulin resistance in patients with polycystic ovary syndrome. Middle East Fertility Society Journal2007;12(3):174‐8. ">Karimzadeh 2007</a>; <a href="./references#CD003053-bbs2-0021" title="LamPM , TamWH , MaRC , CheungLP , TsuiMH , TongPC , et al. The reproductive and metabolic effect of rosiglitazone on Chinese women with polycystic ovarian syndrome ‐ a double‐blind randomized placebo‐controlled study. Fertility and Sterility2011;96(2):445‐51. ">Lam 2011</a>; <a href="./references#CD003053-bbs2-0022" title="CataldoN , BarnhartH , LegroR , MyersE , SchlaffW , CarrB , et al. Extended‐release metformin does not reduce the clomiphene citrate dose required to induce ovulation in polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism2008;93(8):3147‐7. LegroRS , BarnhartHX , SchlaffWD , CarrBR , DiamondMP , CarsonSA , et al. Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome. New England Journal of Medicine2007;356:551‐66. [original article] ">Legro 2007</a>; <a href="./references#CD003053-bbs2-0023" title="LordJ , ThomasR , FoxB , AcharyaU , WilkinT . The effect of metformin on fat distribution and the metabolic syndrome in women with polycystic ovary syndrome‐‐a randomised, double‐blind, placebo‐controlled trial. British Journal of Obstetrics and Gynaecology2006;113:817‐24. ">Lord 2006</a>; <a href="./references#CD003053-bbs2-0024" title="MachadoRC , MachadoNA , GeberS . Evaluation of the use of metformin for ovulation in patients with PCOS resistant to isolated use of clomiphene citrate. Brazilian Journal Assisted Reproduction2012;16(1):27‐31. ">Machado 2012</a>; <a href="./references#CD003053-bbs2-0025" title="MacielGA , Soares JrJM , Alves da MottaEL , Abi HaidarM , deLimaGR , BaracatEC , et al. Nonobese women with polycystic ovary syndrome respond better than obese women to treatment with metformin. Fertility and Sterility2004;81:355‐60. ">Maciel 2004</a>; <a href="./references#CD003053-bbs2-0028" title="MollE , BossuytPM , KorevaarJC , LambalkCB , Van derVeenF . Effect of clomifene citrate plus metformin and clomifene citrate plus placebo on induction of ovulation in women with newly diagnosed polycystic ovary syndrome: randomised double blind clinical trial. BMJ2006;332:1485. [original article] MollE , KorevaarJC , BossuytPM , van derVeenF . Does adding metformin to clomifene citrate lead to higher pregnancy rates in a subset of women with polycystic ovary syndrome?. Human Reproduction2008;23(8):1830‐4. MollE , VanWelyM , LambalkCB , BossuytPM , Van derVeenF . Health‐related quality of life in women with newly diagnosed polycystic ovary syndrome randomized between clomifene citrate plus metformin or clomifene citrate plus placebo. Human Reproduction2012;27:3273‐8. ">Moll 2006</a>; <a href="./references#CD003053-bbs2-0029" title="Morin‐PapunenL , RantalaAS , Unkila‐KallioL , TiitinenA , HippeläinenM , PerheentupaA , et al. Metformin improves pregnancy and live‐birth rates in women with polycystic ovary syndrome (PCOS): a multicenter, double‐blind, placebo‐controlled randomized trial. Journal of Clinical Endocrinology and Metabolism2012;97:1492‐1500. ">Morin‐Papunen 2012</a>; <a href="./references#CD003053-bbs2-0032" title="NgEHY , WatNMS , HoPC . Effects of metformin on ovulation rate, hormonal and metabolic profiles in women with clomiphene‐resistant polycystic ovaries: a randomized, double‐blinded placebo‐controlled trial. Human Reproduction2001;16(8):1625‐31. ">Ng 2001</a>; <a href="./references#CD003053-bbs2-0036" title="CasimirriF , BiscottiM , GambineriA , CalzoniF , ElianaB , PasqualiR . Metformin improves insulin, body fat distribution, and androgens in obese women with and without the polycystic ovary syndrome. International Journal of Obesity1997;21 Suppl 2:61. PasqualiR , GambineriA , BiscottiD , VicennatiV , GagliardiL , ColittaD , et al. Effect of long‐term treatment with metformin added to hypocaloric diet on body composition, fat distribution, and androgen and insulin levels in abdominally obese women with and without the polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism2000;85(8):2767‐74. ">Pasquali 2000</a>; <a href="./references#CD003053-bbs2-0037" title="JohnsonNP , BontekoeS , StewartAW . Analysis of factors predicting success of metformin and clomiphene treatment for women with infertility owing to PCOS‐related ovulation dysfunction in a randomised controlled trial. Australian &amp; New Zealand Journal of Obstetrics &amp; Gynaecology2011;51:252‐6. JohnsonNP , StewartAW , FalkinerJ , FarquharCM , MilsomS , SinghV‐P , et al. on behalf of REACT‐NZ (REproduction And Collaborative Trials in New Zealand), a multi‐centre fertility trials group. PCOSMIC: a multi‐centre randomized trial in women with Polycystic Ovary Syndrome evaluating Metformin for Infertility with Clomiphene. Human Reproduction2010;25(7):1675‐83. [MEDLINE: 10.1093/humrep/deq100] ">PCOSMIC 2010</a>; <a href="./references#CD003053-bbs2-0043" title="TangT , GlanvilleJ , HaydenCJ , WhiteD , BarthJH , BalenAH . Combined lifestyle modification and metformin in obese patients with polycystic ovary syndrome. A randomized, placebo‐controlled, double‐blind multicentre study. Human Reproduction2006;21:80‐9. ">Tang 2006</a>) with 15 out of the 18 studies investigating the effects of metformin. Three out of the 10 newly included studies, in the search period between October 2008 and October 2011, met this criterion (<a href="./references#CD003053-bbs2-0068" title="LadsonG , DodsonWC , SweetSD , ArchibongAE , KunselmanAR , DemersLM , et al. The effects of metformin with lifestyle therapy in polycystic ovary syndrome: a randomized double‐blind study. Fertility and Sterility2011;95(3):1059‐66. ">Ladson 2011</a>; <a href="./references#CD003053-bbs2-0021" title="LamPM , TamWH , MaRC , CheungLP , TsuiMH , TongPC , et al. The reproductive and metabolic effect of rosiglitazone on Chinese women with polycystic ovarian syndrome ‐ a double‐blind randomized placebo‐controlled study. Fertility and Sterility2011;96(2):445‐51. ">Lam 2011</a>; <a href="./references#CD003053-bbs2-0037" title="JohnsonNP , BontekoeS , StewartAW . Analysis of factors predicting success of metformin and clomiphene treatment for women with infertility owing to PCOS‐related ovulation dysfunction in a randomised controlled trial. Australian &amp; New Zealand Journal of Obstetrics &amp; Gynaecology2011;51:252‐6. JohnsonNP , StewartAW , FalkinerJ , FarquharCM , MilsomS , SinghV‐P , et al. on behalf of REACT‐NZ (REproduction And Collaborative Trials in New Zealand), a multi‐centre fertility trials group. PCOSMIC: a multi‐centre randomized trial in women with Polycystic Ovary Syndrome evaluating Metformin for Infertility with Clomiphene. Human Reproduction2010;25(7):1675‐83. [MEDLINE: 10.1093/humrep/deq100] ">PCOSMIC 2010</a>). Two studies from the January 2011 to January 2017 update met the criteria for subgroup analysis; <a href="./references#CD003053-bbs2-0024" title="MachadoRC , MachadoNA , GeberS . Evaluation of the use of metformin for ovulation in patients with PCOS resistant to isolated use of clomiphene citrate. Brazilian Journal Assisted Reproduction2012;16(1):27‐31. ">Machado 2012</a> and <a href="./references#CD003053-bbs2-0029" title="Morin‐PapunenL , RantalaAS , Unkila‐KallioL , TiitinenA , HippeläinenM , PerheentupaA , et al. Metformin improves pregnancy and live‐birth rates in women with polycystic ovary syndrome (PCOS): a multicenter, double‐blind, placebo‐controlled randomized trial. Journal of Clinical Endocrinology and Metabolism2012;97:1492‐1500. ">Morin‐Papunen 2012</a>. </p> <section id="CD003053-sec-0065"> <h4 class="title">Allocation</h4> <section id="CD003053-sec-0066"> <h5 class="title">Sequence generation</h5> <p>Sequence generation was unclear in 18 studies (<a href="./references#CD003053-bbs2-0001" title="AyazA , AlwanY , FarooqMU . Efficacy of combined metformin‐clomiphene citrate in comparison with clomiphene citrate alone in infertile women with polycystic ovarian syndrome (PCOS). Journal of Medicine and Life2013;6:199‐201. AyazA , AlwanY , FarooqMU . Metformin‐clomiphene citrate vs. clomiphene citrate alone: polycystic ovarian syndrome. Journal of Human Reproductive Sciences2013;6:15‐8. ">Ayaz 2013</a>; <a href="./references#CD003053-bbs2-0003" title="BegumH , ChowdhuryTA , BegumF , BegumSN , KabirN , HaqueMDA . Effect of metformin and clomiphene citrate in improving fertility in subfertility women with polycystic ovary syndrome: a randomised controlled trial. Bangladesh Journal of Obstetrics and Gynaecology2014;29:15‐20. ">Begum 2014</a>; <a href="./references#CD003053-bbs2-0004" title="Ben AyedB , Dammak Dit MlikS , Ben ArabH , TrabelssiH , ChahtourH , MathlouthiN . Metformin effects on clomifene‐induced ovulation in the polycystic ovary syndrome. Tunisie Medicale2009;87(1):43‐8. ">Ben Ayed 2009</a>; <a href="./references#CD003053-bbs2-0005" title="BoudhrâaK , JellouliMA , AmriM , FarhatM , TorkhaniF , GaraMF . Indication of metformin in the management of hormonal dysfunction secondary to polycystic ovarian syndrome: prospective comparative study of 63 cases. [La metformine dans la prise en charge de l'infertilite du SOPK hors FIV etude prospective comparative a propos de 63 cas]. Tunisie Medicale2010;88(5):335‐40. ">Boudhraa 2010</a>; <a href="./references#CD003053-bbs2-0006" title="AignerE , BachofnerN , KleinK , DeGeyterC , HohlaF , PatschW , et al. Retinol‐binding protein 4 in polycystic ovary syndrome‐‐association with steroid hormones and response to pioglitazone treatment. Journal of Clinical Endocrinology and Metabolism2009;94(4):1229‐35. BrettenthalerN , DeGeyterC , HuberPR , KellerU . Effect of the insulin sensitizer pioglitazone on insulin resistance, hyperandrogenism, and ovulatory dysfunction in women with polycystic ovary syndrome. Journal of Clinical Epidemiology2004;89:3835‐40. ">Brettenthaler 2004</a>; <a href="./references#CD003053-bbs2-0007" title="CarminaE , LoboRA . Does metformin induce ovulation in normoandrogenic anovulatory women?. American Journal of Obstetrics and Gynecology2004;191:1580‐4. ">Carmina 2004</a>; <a href="./references#CD003053-bbs2-0016" title="JakubowiczDJ , SeppalaM , JakubowiczS , Rodriguez‐ArmasO , Rivas‐SantiagoA , KoistinenH , et al. Insulin reduction with metformin increases luteal phase serum glycodelin and insulin‐like growth factor‐binding protein 1 concentrations and enhances uterine vascularity and blood flow in the polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism2001;86(3):1126‐33. ">Jakubowicz 2001</a>; <a href="./references#CD003053-bbs2-0017" title="KarS . Metabolic risks of the lean PCOS woman. Fertility and Sterility ASRM abstracts2013;100(S359):P‐730. KarS , SanchitaS . Clomiphene citrate, metformin or a combination of both as the first line ovulation induction drug for Asian Indian women with polycystic ovarian syndrome: a randomized controlled trial. Journal of Human Reproductive Science2015;8:197‐201. ">Kar 2015</a>; <a href="./references#CD003053-bbs2-0019" title="KarimzadehMA , JavedaniM . An assessment of lifestyle modification versus medical treatment with clomiphene citrate, metformin, and clomiphene citrate‐metformin in patients with polycystic ovary syndrome. Fertility and Sterility2010;94(1):216‐20. ">Karimzadeh 2010</a>; <a href="./references#CD003053-bbs2-0026" title="MalkawiHY , QublanHS . The effect of metformin plus clomiphene citrate on ovulation and pregnancy rates in clomiphene‐resistant women with polycystic ovary syndrome. Saudi Medical Journal2002;23(6):663‐6. [MEDLINE: 22065897] ">Malkawi 2002</a>; <a href="./references#CD003053-bbs2-0027" title="MoghettiP , CastelloR , NegriC , TosiF , PerroneF , CaputoM , et al. Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized, double‐blind, placebo‐controlled 6‐month trial, followed by open, long‐term clinical evaluation. Journal of Clinical Endocrinology and Metabolism2000;85(1):139‐46. ">Moghetti 2000</a>; <a href="./references#CD003053-bbs2-0030" title="NestlerJE , JakubowiczDJ , EvansWS , PasqualiR . Effects of metformin on spontaneous and clomiphene‐induced ovulation in the polycystic ovary syndrome. New England Journal of Medicine1998;338(26):1876‐80. ">Nestler 1998</a>; <a href="./references#CD003053-bbs2-0031" title="NestlerJE , JakubowiczDJ , ReamerP , GunnRD , AllanG . Ovulatory and metabolic effects of D‐chiro‐inositol in the polycystic ovary syndrome. New England Journal of Medicine1999;340(17):1314‐20. ">Nestler 1999</a>; <a href="./references#CD003053-bbs2-0039" title="RomualdiD , GiulianiM , CristelloF , FulghesuAM , SelvaggiL , LanzoneA , et al. Metformin effects on ovarian ultrasound appearance and steroidogenic function in normal‐weight normoinsulinemic women with polycystic ovary syndrome: a randomized double‐blind placebo‐controlled clinical trial. Fertility and Sterility2010;93(7):2303‐10. ">Romualdi 2010</a>; <a href="./references#CD003053-bbs2-0040" title="SahinY , YirmibesU , KelestimurF , AygenE . The effects of metformin on insulin resistance, clomiphene‐induced ovulation and pregnancy rates in women with polycystic ovary syndrome. European Journal of Obstetrics, Gynecology, and Reproductive Biology2004;113:214‐20. ">Sahin 2004</a>; <a href="./references#CD003053-bbs2-0042" title="SturrockNDC , LannonB , FayTN . Metformin does not enhance ovulation induction in clomiphene resistant polycystic ovary syndrome in clinical practice. British Journal of Clinical Pharmacology2002;53(5):469‐73. [MEDLINE: 2002180629] ">Sturrock 2002</a>; <a href="./references#CD003053-bbs2-0046" title="WilliamsSC , PastoreLM , ShellyWB , BaileyAP , BarasDC , BatemanBG . A randomized, placebo‐controlled study of the influence of instant‐release metformin on response to clomiphene citrate and time to conception in polycystic ovary syndrome. Fertility and Sterility2009;92 Suppl(3):105. ">Williams 2009</a>; <a href="./references#CD003053-bbs2-0048" title="ZainMM , JamaluddinR , IbrahimA , NormanRJ . Comparison of clomiphene citrate, metformin, or the combination of both for first‐line ovulation induction, achievement of pregnancy, and live birth in Asian women with polycystic ovary syndrome: a randomized controlled trial. Fertility and Sterility2009;91(2):514‐21. ">Zain 2009</a>). </p> </section> <section id="CD003053-sec-0067"> <h5 class="title">Allocation concealment</h5> <p>Allocation concealment was unclear in 25 studies (<a href="./references#CD003053-bbs2-0003" title="BegumH , ChowdhuryTA , BegumF , BegumSN , KabirN , HaqueMDA . Effect of metformin and clomiphene citrate in improving fertility in subfertility women with polycystic ovary syndrome: a randomised controlled trial. Bangladesh Journal of Obstetrics and Gynaecology2014;29:15‐20. ">Begum 2014</a>; <a href="./references#CD003053-bbs2-0004" title="Ben AyedB , Dammak Dit MlikS , Ben ArabH , TrabelssiH , ChahtourH , MathlouthiN . Metformin effects on clomifene‐induced ovulation in the polycystic ovary syndrome. Tunisie Medicale2009;87(1):43‐8. ">Ben Ayed 2009</a>; <a href="./references#CD003053-bbs2-0005" title="BoudhrâaK , JellouliMA , AmriM , FarhatM , TorkhaniF , GaraMF . Indication of metformin in the management of hormonal dysfunction secondary to polycystic ovarian syndrome: prospective comparative study of 63 cases. [La metformine dans la prise en charge de l'infertilite du SOPK hors FIV etude prospective comparative a propos de 63 cas]. Tunisie Medicale2010;88(5):335‐40. ">Boudhraa 2010</a>; <a href="./references#CD003053-bbs2-0006" title="AignerE , BachofnerN , KleinK , DeGeyterC , HohlaF , PatschW , et al. Retinol‐binding protein 4 in polycystic ovary syndrome‐‐association with steroid hormones and response to pioglitazone treatment. Journal of Clinical Endocrinology and Metabolism2009;94(4):1229‐35. BrettenthalerN , DeGeyterC , HuberPR , KellerU . Effect of the insulin sensitizer pioglitazone on insulin resistance, hyperandrogenism, and ovulatory dysfunction in women with polycystic ovary syndrome. Journal of Clinical Epidemiology2004;89:3835‐40. ">Brettenthaler 2004</a>; <a href="./references#CD003053-bbs2-0007" title="CarminaE , LoboRA . Does metformin induce ovulation in normoandrogenic anovulatory women?. American Journal of Obstetrics and Gynecology2004;191:1580‐4. ">Carmina 2004</a>; <a href="./references#CD003053-bbs2-0010" title="El‐BielyMM , HabbaM . The use of metformin to augment the induction of ovulation in obese infertile patients with polycystic ovary syndrome. Middle East Fertility Society Journal2001;6(1):43‐9. ">El‐Biely 2001</a>; <a href="./references#CD003053-bbs2-0012" title="GerliS , MignosaM , DiRenzoGC . Effects of inositol on ovarian function and metabolic factors in women with PCOS: a randomized double blind placebo‐controlled trial. European Review for Medical and Pharmacological Sciences2003;7:151‐9. [Original article] GerliS , PapaleoE , FerrariA , DiRenzoGC . Randomized, double blind placebo‐controlled trial: effects of myo‐inositol on ovarian function and metabolic factors in women with PCOS. European Review for Medical and Pharmacological Sciences2007;11(5):347‐54. ">Gerli 2003</a>; <a href="./references#CD003053-bbs2-0015" title="HwuYM , LinSY , HuangWY , LinMH , LeeRK . Ultra‐short metformin pretreatment for clomiphene citrate‐resistant polycystic ovary syndrome. International Journal of Gynaecology and Obstetrics2005;90:39‐43. ">Hwu 2005</a>; <a href="./references#CD003053-bbs2-0017" title="KarS . Metabolic risks of the lean PCOS woman. Fertility and Sterility ASRM abstracts2013;100(S359):P‐730. KarS , SanchitaS . Clomiphene citrate, metformin or a combination of both as the first line ovulation induction drug for Asian Indian women with polycystic ovarian syndrome: a randomized controlled trial. Journal of Human Reproductive Science2015;8:197‐201. ">Kar 2015</a>; <a href="./references#CD003053-bbs2-0019" title="KarimzadehMA , JavedaniM . An assessment of lifestyle modification versus medical treatment with clomiphene citrate, metformin, and clomiphene citrate‐metformin in patients with polycystic ovary syndrome. Fertility and Sterility2010;94(1):216‐20. ">Karimzadeh 2010</a>; <a href="./references#CD003053-bbs2-0020" title="KhorramO , HelliwellJP , KatzS , BonpaneCM , JaramilloL Khorram O , et al. Two weeks of metformin improves clomiphene citrate‐induced ovulation and metabolic profiles in women with polycystic ovary syndrome. Fertility and Sterility2006;85:1448‐51. ">Khorram 2006</a>; <a href="./references#CD003053-bbs2-0026" title="MalkawiHY , QublanHS . The effect of metformin plus clomiphene citrate on ovulation and pregnancy rates in clomiphene‐resistant women with polycystic ovary syndrome. Saudi Medical Journal2002;23(6):663‐6. [MEDLINE: 22065897] ">Malkawi 2002</a>; <a href="./references#CD003053-bbs2-0030" title="NestlerJE , JakubowiczDJ , EvansWS , PasqualiR . Effects of metformin on spontaneous and clomiphene‐induced ovulation in the polycystic ovary syndrome. New England Journal of Medicine1998;338(26):1876‐80. ">Nestler 1998</a>; <a href="./references#CD003053-bbs2-0033" title="OnalanG , GoktolgaU , CeyhanT , BagisT , OnalanR , PabuccuR . Predictive value of glucose‐insulin ratio in PCOS and profile of women who will benefit from metformin therapy: obese, lean, hyper or normoinsulinemic?. European Journal of Obstetrics, Gynecology, and Reproductive Biology2005;123:204‐11. ">Onalan 2005</a>; <a href="./references#CD003053-bbs2-0034" title="OttaCF , WiorM , IraciGS , KaplanR , TorresD , GaidoMI , et al. Clinical, metabolic, and endocrine parameters in response to metformin and lifestyle intervention in women with polycystic ovary syndrome: a randomized, double‐blind, and placebo control trial. Gynecological Endocrinology2010;26(3):173‐8. ">Otta 2010</a>; <a href="./references#CD003053-bbs2-0035" title="PalombaS , OrioFJr , FalboA , MangusoF , RussoT , CascellaT , et al. Prospective parallel randomized, double‐blind, double‐dummy controlled clinical trial comparing clomiphene citrate and metformin as the first‐line treatment for ovulation induction in nonobese anovulatory women with polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism2005;90(7):4068‐74. [original article] PalombaS , OrioFJr , FalboA , RussoT , TolinoA , ZulloF . Effects of metformin and clomiphene citrate on ovarian vascularity in patients with polycystic ovary syndrome. Fertility and Sterility2006;86:1694‐701. ">Palomba 2005</a>; <a href="./references#CD003053-bbs2-0038" title="RautioK , TapanainenJS , RuokonenA , Morin‐PapunenLC . Endocrine and metabolic effects of rosiglitazone in overweight women with PCOS: a randomized placebo‐controlled study. Human Reproduction2006;21:1400‐7. RautioK , TapanainenJS , RuokonenA , Morin‐PapunenLC . Rosiglitazone treatment alleviates inflammation and improves liver function in overweight women with polycystic ovary syndrome: a randomized placebo‐controlled study. Fertility and Sterility2007;87(1):202‐6. ">Rautio 2006</a>; <a href="./references#CD003053-bbs2-0040" title="SahinY , YirmibesU , KelestimurF , AygenE . The effects of metformin on insulin resistance, clomiphene‐induced ovulation and pregnancy rates in women with polycystic ovary syndrome. European Journal of Obstetrics, Gynecology, and Reproductive Biology2004;113:214‐20. ">Sahin 2004</a>; <a href="./references#CD003053-bbs2-0041" title="SiebertT , KrugerT , LombardC . Evaluating the equivalence of clomiphene citrate with and without metformin in ovulation induction in PCOS patients. Journal of Assisted Reproduction and Genetics2009;26(4):165‐71. ">Siebert 2009</a>; <a href="./references#CD003053-bbs2-0042" title="SturrockNDC , LannonB , FayTN . Metformin does not enhance ovulation induction in clomiphene resistant polycystic ovary syndrome in clinical practice. British Journal of Clinical Pharmacology2002;53(5):469‐73. [MEDLINE: 2002180629] ">Sturrock 2002</a>; <a href="./references#CD003053-bbs2-0044" title="TrolleB , FlyvbjergA , KesmodelU , LauszusFF . Efficacy of metformin in obese and non‐obese women with polycystic ovary syndrome: a randomized, double‐blinded, placebo‐controlled cross‐over trial. Human Reproduction2007;22(11):2967‐73. [original article] TrolleB , FlyvbjergA , KesmodelU , LauszusFF . Efficacy of metformin in obese and non‐obese women with polycystic ovary syndrome: a randomized, double‐blinded, placebo‐controlled cross‐over trial. Obstetrics and Gynecological Survey2008;63(2):96‐8. ">Trolle 2007</a>; <a href="./references#CD003053-bbs2-0045" title="VandermolenDT , RattsVS , EvansWS , StovallDW , KaumaSW , NestlerJE . Metformin increases the ovulatory rate and pregnancy rate from clomiphene citrate in patients with polycystic ovary syndrome who are resistant to clomiphene citrate alone. Fertility and Sterility2001;75:310‐5. ">Vandermolen 2001</a>; <a href="./references#CD003053-bbs2-0046" title="WilliamsSC , PastoreLM , ShellyWB , BaileyAP , BarasDC , BatemanBG . A randomized, placebo‐controlled study of the influence of instant‐release metformin on response to clomiphene citrate and time to conception in polycystic ovary syndrome. Fertility and Sterility2009;92 Suppl(3):105. ">Williams 2009</a>; <a href="./references#CD003053-bbs2-0047" title="YaraliH , YildizBO , DemirolA , ZeynelogluHB , YigitN , BukulmezO , et al. Co‐administration of metformin during rFSH treatment in patients with clomiphene citrate‐resistant polycystic ovarian syndrome: a prospective randomized trial. Human Reproduction2002;17(2):289‐94. YaraliH , YyldyzB , DemirolA , ZeynelogluH , YigitN , BukulmezO . Co‐administration of metformin during recombinant follicle stimulating hormone (recombinant FSH) treatment using the low‐dose step protocol in patients with clomiphene citrate resistant polycystic ovary syndrome (PCOS): a prospective randomized trial. Fertility and Sterility2001;76 Suppl(3):36. ">Yarali 2002</a>; <a href="./references#CD003053-bbs2-0048" title="ZainMM , JamaluddinR , IbrahimA , NormanRJ . Comparison of clomiphene citrate, metformin, or the combination of both for first‐line ovulation induction, achievement of pregnancy, and live birth in Asian women with polycystic ovary syndrome: a randomized controlled trial. Fertility and Sterility2009;91(2):514‐21. ">Zain 2009</a>). We included one open label‐trial (<a href="./references#CD003053-bbs2-0015" title="HwuYM , LinSY , HuangWY , LinMH , LeeRK . Ultra‐short metformin pretreatment for clomiphene citrate‐resistant polycystic ovary syndrome. International Journal of Gynaecology and Obstetrics2005;90:39‐43. ">Hwu 2005</a>). </p> </section> </section> <section id="CD003053-sec-0068"> <h4 class="title">Blinding</h4> <p>The majority of the studies (38/48) were described as double‐blinded. However, the risk of bias related to the method of blinding was unclear for 18 of the 48 (<a href="./references#CD003053-bbs2-0001" title="AyazA , AlwanY , FarooqMU . Efficacy of combined metformin‐clomiphene citrate in comparison with clomiphene citrate alone in infertile women with polycystic ovarian syndrome (PCOS). Journal of Medicine and Life2013;6:199‐201. AyazA , AlwanY , FarooqMU . Metformin‐clomiphene citrate vs. clomiphene citrate alone: polycystic ovarian syndrome. Journal of Human Reproductive Sciences2013;6:15‐8. ">Ayaz 2013</a>; <a href="./references#CD003053-bbs2-0003" title="BegumH , ChowdhuryTA , BegumF , BegumSN , KabirN , HaqueMDA . Effect of metformin and clomiphene citrate in improving fertility in subfertility women with polycystic ovary syndrome: a randomised controlled trial. Bangladesh Journal of Obstetrics and Gynaecology2014;29:15‐20. ">Begum 2014</a>; <a href="./references#CD003053-bbs2-0004" title="Ben AyedB , Dammak Dit MlikS , Ben ArabH , TrabelssiH , ChahtourH , MathlouthiN . Metformin effects on clomifene‐induced ovulation in the polycystic ovary syndrome. Tunisie Medicale2009;87(1):43‐8. ">Ben Ayed 2009</a>; <a href="./references#CD003053-bbs2-0005" title="BoudhrâaK , JellouliMA , AmriM , FarhatM , TorkhaniF , GaraMF . Indication of metformin in the management of hormonal dysfunction secondary to polycystic ovarian syndrome: prospective comparative study of 63 cases. [La metformine dans la prise en charge de l'infertilite du SOPK hors FIV etude prospective comparative a propos de 63 cas]. Tunisie Medicale2010;88(5):335‐40. ">Boudhraa 2010</a>; <a href="./references#CD003053-bbs2-0006" title="AignerE , BachofnerN , KleinK , DeGeyterC , HohlaF , PatschW , et al. Retinol‐binding protein 4 in polycystic ovary syndrome‐‐association with steroid hormones and response to pioglitazone treatment. Journal of Clinical Endocrinology and Metabolism2009;94(4):1229‐35. BrettenthalerN , DeGeyterC , HuberPR , KellerU . Effect of the insulin sensitizer pioglitazone on insulin resistance, hyperandrogenism, and ovulatory dysfunction in women with polycystic ovary syndrome. Journal of Clinical Epidemiology2004;89:3835‐40. ">Brettenthaler 2004</a>; <a href="./references#CD003053-bbs2-0007" title="CarminaE , LoboRA . Does metformin induce ovulation in normoandrogenic anovulatory women?. American Journal of Obstetrics and Gynecology2004;191:1580‐4. ">Carmina 2004</a>; <a href="./references#CD003053-bbs2-0010" title="El‐BielyMM , HabbaM . The use of metformin to augment the induction of ovulation in obese infertile patients with polycystic ovary syndrome. Middle East Fertility Society Journal2001;6(1):43‐9. ">El‐Biely 2001</a>; <a href="./references#CD003053-bbs2-0012" title="GerliS , MignosaM , DiRenzoGC . Effects of inositol on ovarian function and metabolic factors in women with PCOS: a randomized double blind placebo‐controlled trial. European Review for Medical and Pharmacological Sciences2003;7:151‐9. [Original article] GerliS , PapaleoE , FerrariA , DiRenzoGC . Randomized, double blind placebo‐controlled trial: effects of myo‐inositol on ovarian function and metabolic factors in women with PCOS. European Review for Medical and Pharmacological Sciences2007;11(5):347‐54. ">Gerli 2003</a>; <a href="./references#CD003053-bbs2-0019" title="KarimzadehMA , JavedaniM . An assessment of lifestyle modification versus medical treatment with clomiphene citrate, metformin, and clomiphene citrate‐metformin in patients with polycystic ovary syndrome. Fertility and Sterility2010;94(1):216‐20. ">Karimzadeh 2010</a>; <a href="./references#CD003053-bbs2-0026" title="MalkawiHY , QublanHS . The effect of metformin plus clomiphene citrate on ovulation and pregnancy rates in clomiphene‐resistant women with polycystic ovary syndrome. Saudi Medical Journal2002;23(6):663‐6. [MEDLINE: 22065897] ">Malkawi 2002</a>; <a href="./references#CD003053-bbs2-0033" title="OnalanG , GoktolgaU , CeyhanT , BagisT , OnalanR , PabuccuR . Predictive value of glucose‐insulin ratio in PCOS and profile of women who will benefit from metformin therapy: obese, lean, hyper or normoinsulinemic?. European Journal of Obstetrics, Gynecology, and Reproductive Biology2005;123:204‐11. ">Onalan 2005</a>; <a href="./references#CD003053-bbs2-0034" title="OttaCF , WiorM , IraciGS , KaplanR , TorresD , GaidoMI , et al. Clinical, metabolic, and endocrine parameters in response to metformin and lifestyle intervention in women with polycystic ovary syndrome: a randomized, double‐blind, and placebo control trial. Gynecological Endocrinology2010;26(3):173‐8. ">Otta 2010</a>; <a href="./references#CD003053-bbs2-0035" title="PalombaS , OrioFJr , FalboA , MangusoF , RussoT , CascellaT , et al. Prospective parallel randomized, double‐blind, double‐dummy controlled clinical trial comparing clomiphene citrate and metformin as the first‐line treatment for ovulation induction in nonobese anovulatory women with polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism2005;90(7):4068‐74. [original article] PalombaS , OrioFJr , FalboA , RussoT , TolinoA , ZulloF . Effects of metformin and clomiphene citrate on ovarian vascularity in patients with polycystic ovary syndrome. Fertility and Sterility2006;86:1694‐701. ">Palomba 2005</a>; <a href="./references#CD003053-bbs2-0038" title="RautioK , TapanainenJS , RuokonenA , Morin‐PapunenLC . Endocrine and metabolic effects of rosiglitazone in overweight women with PCOS: a randomized placebo‐controlled study. Human Reproduction2006;21:1400‐7. RautioK , TapanainenJS , RuokonenA , Morin‐PapunenLC . Rosiglitazone treatment alleviates inflammation and improves liver function in overweight women with polycystic ovary syndrome: a randomized placebo‐controlled study. Fertility and Sterility2007;87(1):202‐6. ">Rautio 2006</a>; <a href="./references#CD003053-bbs2-0040" title="SahinY , YirmibesU , KelestimurF , AygenE . The effects of metformin on insulin resistance, clomiphene‐induced ovulation and pregnancy rates in women with polycystic ovary syndrome. European Journal of Obstetrics, Gynecology, and Reproductive Biology2004;113:214‐20. ">Sahin 2004</a>;<a href="./references#CD003053-bbs2-0042" title="SturrockNDC , LannonB , FayTN . Metformin does not enhance ovulation induction in clomiphene resistant polycystic ovary syndrome in clinical practice. British Journal of Clinical Pharmacology2002;53(5):469‐73. [MEDLINE: 2002180629] ">Sturrock 2002</a>; <a href="./references#CD003053-bbs2-0046" title="WilliamsSC , PastoreLM , ShellyWB , BaileyAP , BarasDC , BatemanBG . A randomized, placebo‐controlled study of the influence of instant‐release metformin on response to clomiphene citrate and time to conception in polycystic ovary syndrome. Fertility and Sterility2009;92 Suppl(3):105. ">Williams 2009</a>; <a href="./references#CD003053-bbs2-0047" title="YaraliH , YildizBO , DemirolA , ZeynelogluHB , YigitN , BukulmezO , et al. Co‐administration of metformin during rFSH treatment in patients with clomiphene citrate‐resistant polycystic ovarian syndrome: a prospective randomized trial. Human Reproduction2002;17(2):289‐94. YaraliH , YyldyzB , DemirolA , ZeynelogluH , YigitN , BukulmezO . Co‐administration of metformin during recombinant follicle stimulating hormone (recombinant FSH) treatment using the low‐dose step protocol in patients with clomiphene citrate resistant polycystic ovary syndrome (PCOS): a prospective randomized trial. Fertility and Sterility2001;76 Suppl(3):36. ">Yarali 2002</a>). We clarified allocation concealment and blinding in the <a href="./references#CD003053-bbs2-0024" title="MachadoRC , MachadoNA , GeberS . Evaluation of the use of metformin for ovulation in patients with PCOS resistant to isolated use of clomiphene citrate. Brazilian Journal Assisted Reproduction2012;16(1):27‐31. ">Machado 2012</a> study through correspondence with the study authors. We classified the risk of bias in five studies as high for this domain (<a href="./references#CD003053-bbs2-0015" title="HwuYM , LinSY , HuangWY , LinMH , LeeRK . Ultra‐short metformin pretreatment for clomiphene citrate‐resistant polycystic ovary syndrome. International Journal of Gynaecology and Obstetrics2005;90:39‐43. ">Hwu 2005</a>; <a href="./references#CD003053-bbs2-0020" title="KhorramO , HelliwellJP , KatzS , BonpaneCM , JaramilloL Khorram O , et al. Two weeks of metformin improves clomiphene citrate‐induced ovulation and metabolic profiles in women with polycystic ovary syndrome. Fertility and Sterility2006;85:1448‐51. ">Khorram 2006</a>; <a href="./references#CD003053-bbs2-0030" title="NestlerJE , JakubowiczDJ , EvansWS , PasqualiR . Effects of metformin on spontaneous and clomiphene‐induced ovulation in the polycystic ovary syndrome. New England Journal of Medicine1998;338(26):1876‐80. ">Nestler 1998</a>; <a href="./references#CD003053-bbs2-0041" title="SiebertT , KrugerT , LombardC . Evaluating the equivalence of clomiphene citrate with and without metformin in ovulation induction in PCOS patients. Journal of Assisted Reproduction and Genetics2009;26(4):165‐71. ">Siebert 2009</a>; <a href="./references#CD003053-bbs2-0048" title="ZainMM , JamaluddinR , IbrahimA , NormanRJ . Comparison of clomiphene citrate, metformin, or the combination of both for first‐line ovulation induction, achievement of pregnancy, and live birth in Asian women with polycystic ovary syndrome: a randomized controlled trial. Fertility and Sterility2009;91(2):514‐21. ">Zain 2009</a>). </p> </section> <section id="CD003053-sec-0069"> <h4 class="title">Incomplete outcome data</h4> <p>Fifteen studies were at high risk of attrition bias due to high dropout rates, unequal dropouts between the groups, reasons of missing data not provided or use of per‐protocol analysis (<a href="./references#CD003053-bbs2-0002" title="BaillargeonJP , JakubowiczDJ , IuornoMJ , JakubowiczS , NestlerJE . Effects of metformin and rosiglitazone, alone and in combination, in nonobese women with polycystic ovary syndrome and normal indices of insulin sensitivity. Fertility and Sterility2004;82:893‐902. ">Baillargeon 2004</a>; <a href="./references#CD003053-bbs2-0006" title="AignerE , BachofnerN , KleinK , DeGeyterC , HohlaF , PatschW , et al. Retinol‐binding protein 4 in polycystic ovary syndrome‐‐association with steroid hormones and response to pioglitazone treatment. Journal of Clinical Endocrinology and Metabolism2009;94(4):1229‐35. BrettenthalerN , DeGeyterC , HuberPR , KellerU . Effect of the insulin sensitizer pioglitazone on insulin resistance, hyperandrogenism, and ovulatory dysfunction in women with polycystic ovary syndrome. Journal of Clinical Epidemiology2004;89:3835‐40. ">Brettenthaler 2004</a>; <a href="./references#CD003053-bbs2-0008" title="ChouKH , vonEye CorletaH , CappE , SpritzerPM . Clinical, metabolic and endocrine parameters in response to metformin in obese women with polycystic ovary syndrome: a randomized, double‐blind and placebo‐controlled trial. Hormone and Metabolic Research2003;35:86‐91. ">Chou 2003</a>; <a href="./references#CD003053-bbs2-0011" title="FlemingR , HopkinsonZE , WallaceAM , GreerIA , SattarN . Ovarian function and metabolic factors in women with oligomenorrhea treated with metformin in a randomized double blind placebo‐controlled trial. Journal of Clinical Endocrinology and Metabolism2002;87(2):569‐74. FlemingR , HopkinsonZE , WallaceE , GreerIA , SattarN . Metformin treatment improves ovulation frequency in women with oligomenorrhoea: a randomized, double blind placebo trial. Human Fertility2000; Vol. 3, issue 4:389‐90. ">Fleming 2002</a>; <a href="./references#CD003053-bbs2-0012" title="GerliS , MignosaM , DiRenzoGC . Effects of inositol on ovarian function and metabolic factors in women with PCOS: a randomized double blind placebo‐controlled trial. European Review for Medical and Pharmacological Sciences2003;7:151‐9. [Original article] GerliS , PapaleoE , FerrariA , DiRenzoGC . Randomized, double blind placebo‐controlled trial: effects of myo‐inositol on ovarian function and metabolic factors in women with PCOS. European Review for Medical and Pharmacological Sciences2007;11(5):347‐54. ">Gerli 2003</a>; <a href="./references#CD003053-bbs2-0016" title="JakubowiczDJ , SeppalaM , JakubowiczS , Rodriguez‐ArmasO , Rivas‐SantiagoA , KoistinenH , et al. Insulin reduction with metformin increases luteal phase serum glycodelin and insulin‐like growth factor‐binding protein 1 concentrations and enhances uterine vascularity and blood flow in the polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism2001;86(3):1126‐33. ">Jakubowicz 2001</a>; <a href="./references#CD003053-bbs2-0017" title="KarS . Metabolic risks of the lean PCOS woman. Fertility and Sterility ASRM abstracts2013;100(S359):P‐730. KarS , SanchitaS . Clomiphene citrate, metformin or a combination of both as the first line ovulation induction drug for Asian Indian women with polycystic ovarian syndrome: a randomized controlled trial. Journal of Human Reproductive Science2015;8:197‐201. ">Kar 2015</a>; <a href="./references#CD003053-bbs2-0021" title="LamPM , TamWH , MaRC , CheungLP , TsuiMH , TongPC , et al. The reproductive and metabolic effect of rosiglitazone on Chinese women with polycystic ovarian syndrome ‐ a double‐blind randomized placebo‐controlled study. Fertility and Sterility2011;96(2):445‐51. ">Lam 2011</a>; <a href="./references#CD003053-bbs2-0030" title="NestlerJE , JakubowiczDJ , EvansWS , PasqualiR . Effects of metformin on spontaneous and clomiphene‐induced ovulation in the polycystic ovary syndrome. New England Journal of Medicine1998;338(26):1876‐80. ">Nestler 1998</a>; <a href="./references#CD003053-bbs2-0033" title="OnalanG , GoktolgaU , CeyhanT , BagisT , OnalanR , PabuccuR . Predictive value of glucose‐insulin ratio in PCOS and profile of women who will benefit from metformin therapy: obese, lean, hyper or normoinsulinemic?. European Journal of Obstetrics, Gynecology, and Reproductive Biology2005;123:204‐11. ">Onalan 2005</a>; <a href="./references#CD003053-bbs2-0034" title="OttaCF , WiorM , IraciGS , KaplanR , TorresD , GaidoMI , et al. Clinical, metabolic, and endocrine parameters in response to metformin and lifestyle intervention in women with polycystic ovary syndrome: a randomized, double‐blind, and placebo control trial. Gynecological Endocrinology2010;26(3):173‐8. ">Otta 2010</a>; <a href="./references#CD003053-bbs2-0036" title="CasimirriF , BiscottiM , GambineriA , CalzoniF , ElianaB , PasqualiR . Metformin improves insulin, body fat distribution, and androgens in obese women with and without the polycystic ovary syndrome. International Journal of Obesity1997;21 Suppl 2:61. PasqualiR , GambineriA , BiscottiD , VicennatiV , GagliardiL , ColittaD , et al. Effect of long‐term treatment with metformin added to hypocaloric diet on body composition, fat distribution, and androgen and insulin levels in abdominally obese women with and without the polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism2000;85(8):2767‐74. ">Pasquali 2000</a>; <a href="./references#CD003053-bbs2-0042" title="SturrockNDC , LannonB , FayTN . Metformin does not enhance ovulation induction in clomiphene resistant polycystic ovary syndrome in clinical practice. British Journal of Clinical Pharmacology2002;53(5):469‐73. [MEDLINE: 2002180629] ">Sturrock 2002</a>; <a href="./references#CD003053-bbs2-0043" title="TangT , GlanvilleJ , HaydenCJ , WhiteD , BarthJH , BalenAH . Combined lifestyle modification and metformin in obese patients with polycystic ovary syndrome. A randomized, placebo‐controlled, double‐blind multicentre study. Human Reproduction2006;21:80‐9. ">Tang 2006</a>; <a href="./references#CD003053-bbs2-0048" title="ZainMM , JamaluddinR , IbrahimA , NormanRJ . Comparison of clomiphene citrate, metformin, or the combination of both for first‐line ovulation induction, achievement of pregnancy, and live birth in Asian women with polycystic ovary syndrome: a randomized controlled trial. Fertility and Sterility2009;91(2):514‐21. ">Zain 2009</a>). Nineteen studies were at low risk of attrition bias (<a href="./references#CD003053-bbs2-0001" title="AyazA , AlwanY , FarooqMU . Efficacy of combined metformin‐clomiphene citrate in comparison with clomiphene citrate alone in infertile women with polycystic ovarian syndrome (PCOS). Journal of Medicine and Life2013;6:199‐201. AyazA , AlwanY , FarooqMU . Metformin‐clomiphene citrate vs. clomiphene citrate alone: polycystic ovarian syndrome. Journal of Human Reproductive Sciences2013;6:15‐8. ">Ayaz 2013</a>; <a href="./references#CD003053-bbs2-0013" title="GlintborgD , FrystykJ , HojlundK , AndersenKK , HenriksenJE , HermannA , et al. Total and high molecular weight (HMW) adiponectin levels and measures of glucose and lipid metabolism following pioglitazone treatment in a randomized placebo‐controlled study in polycystic ovary syndrome. Clinical Endocrinology (Oxford)2008;68(2):165‐74. GlintborgD , HermannAP , AndersenM , HagenC , Beck‐NielsenH , VeldhuisJD , et al. Effect of pioglitazone on glucose metabolism and luteinizing hormone secretion in women with polycystic ovary syndrome. Fertility and Sterility2006;86:385‐97. GlintborgD , HojlundK , AndersenM , HenriksenJE , Beck‐NielsenH , HandbergA . Soluble CD36 and risk markers of insulin resistance and atherosclerosis are elevated in polycystic ovary syndrome and significantly reduced during pioglitazone treatment. Diabetes Care2008;31:328‐34. GlintborgD , StovingRK , HagenC , HermannAP , FrystykJ , VeldhuisJD , et al. Pioglitazone treatment increases spontaneous growth hormone (GH) secretion and stimulated GH levels in polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism2005;90:5605‐12. [original article] ">Glintborg 2005</a>; <a href="./references#CD003053-bbs2-0014" title="HoegerKM , KochmanL , WixomN , CraigK , MillerRK , GuzickDS . A randomized, 48‐week, placebo‐controlled trial of intensive lifestyle modification and/or metformin therapy in overweight women with polycystic ovary syndrome: a pilot study. Fertility and Sterility2004;82:421‐9. ">Hoeger 2004</a>; <a href="./references#CD003053-bbs2-0015" title="HwuYM , LinSY , HuangWY , LinMH , LeeRK . Ultra‐short metformin pretreatment for clomiphene citrate‐resistant polycystic ovary syndrome. International Journal of Gynaecology and Obstetrics2005;90:39‐43. ">Hwu 2005</a>; <a href="./references#CD003053-bbs2-0020" title="KhorramO , HelliwellJP , KatzS , BonpaneCM , JaramilloL Khorram O , et al. Two weeks of metformin improves clomiphene citrate‐induced ovulation and metabolic profiles in women with polycystic ovary syndrome. Fertility and Sterility2006;85:1448‐51. ">Khorram 2006</a>; <a href="./references#CD003053-bbs2-0022" title="CataldoN , BarnhartH , LegroR , MyersE , SchlaffW , CarrB , et al. Extended‐release metformin does not reduce the clomiphene citrate dose required to induce ovulation in polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism2008;93(8):3147‐7. LegroRS , BarnhartHX , SchlaffWD , CarrBR , DiamondMP , CarsonSA , et al. Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome. New England Journal of Medicine2007;356:551‐66. [original article] ">Legro 2007</a>; <a href="./references#CD003053-bbs2-0024" title="MachadoRC , MachadoNA , GeberS . Evaluation of the use of metformin for ovulation in patients with PCOS resistant to isolated use of clomiphene citrate. Brazilian Journal Assisted Reproduction2012;16(1):27‐31. ">Machado 2012</a>; <a href="./references#CD003053-bbs2-0025" title="MacielGA , Soares JrJM , Alves da MottaEL , Abi HaidarM , deLimaGR , BaracatEC , et al. Nonobese women with polycystic ovary syndrome respond better than obese women to treatment with metformin. Fertility and Sterility2004;81:355‐60. ">Maciel 2004</a>; <a href="./references#CD003053-bbs2-0026" title="MalkawiHY , QublanHS . The effect of metformin plus clomiphene citrate on ovulation and pregnancy rates in clomiphene‐resistant women with polycystic ovary syndrome. Saudi Medical Journal2002;23(6):663‐6. [MEDLINE: 22065897] ">Malkawi 2002</a>; <a href="./references#CD003053-bbs2-0027" title="MoghettiP , CastelloR , NegriC , TosiF , PerroneF , CaputoM , et al. Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized, double‐blind, placebo‐controlled 6‐month trial, followed by open, long‐term clinical evaluation. Journal of Clinical Endocrinology and Metabolism2000;85(1):139‐46. ">Moghetti 2000</a>; <a href="./references#CD003053-bbs2-0029" title="Morin‐PapunenL , RantalaAS , Unkila‐KallioL , TiitinenA , HippeläinenM , PerheentupaA , et al. Metformin improves pregnancy and live‐birth rates in women with polycystic ovary syndrome (PCOS): a multicenter, double‐blind, placebo‐controlled randomized trial. Journal of Clinical Endocrinology and Metabolism2012;97:1492‐1500. ">Morin‐Papunen 2012</a>; <a href="./references#CD003053-bbs2-0031" title="NestlerJE , JakubowiczDJ , ReamerP , GunnRD , AllanG . Ovulatory and metabolic effects of D‐chiro‐inositol in the polycystic ovary syndrome. New England Journal of Medicine1999;340(17):1314‐20. ">Nestler 1999</a>; <a href="./references#CD003053-bbs2-0035" title="PalombaS , OrioFJr , FalboA , MangusoF , RussoT , CascellaT , et al. Prospective parallel randomized, double‐blind, double‐dummy controlled clinical trial comparing clomiphene citrate and metformin as the first‐line treatment for ovulation induction in nonobese anovulatory women with polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism2005;90(7):4068‐74. [original article] PalombaS , OrioFJr , FalboA , RussoT , TolinoA , ZulloF . Effects of metformin and clomiphene citrate on ovarian vascularity in patients with polycystic ovary syndrome. Fertility and Sterility2006;86:1694‐701. ">Palomba 2005</a>; <a href="./references#CD003053-bbs2-0037" title="JohnsonNP , BontekoeS , StewartAW . Analysis of factors predicting success of metformin and clomiphene treatment for women with infertility owing to PCOS‐related ovulation dysfunction in a randomised controlled trial. Australian &amp; New Zealand Journal of Obstetrics &amp; Gynaecology2011;51:252‐6. JohnsonNP , StewartAW , FalkinerJ , FarquharCM , MilsomS , SinghV‐P , et al. on behalf of REACT‐NZ (REproduction And Collaborative Trials in New Zealand), a multi‐centre fertility trials group. PCOSMIC: a multi‐centre randomized trial in women with Polycystic Ovary Syndrome evaluating Metformin for Infertility with Clomiphene. Human Reproduction2010;25(7):1675‐83. [MEDLINE: 10.1093/humrep/deq100] ">PCOSMIC 2010</a>; <a href="./references#CD003053-bbs2-0038" title="RautioK , TapanainenJS , RuokonenA , Morin‐PapunenLC . Endocrine and metabolic effects of rosiglitazone in overweight women with PCOS: a randomized placebo‐controlled study. Human Reproduction2006;21:1400‐7. RautioK , TapanainenJS , RuokonenA , Morin‐PapunenLC . Rosiglitazone treatment alleviates inflammation and improves liver function in overweight women with polycystic ovary syndrome: a randomized placebo‐controlled study. Fertility and Sterility2007;87(1):202‐6. ">Rautio 2006</a>; <a href="./references#CD003053-bbs2-0039" title="RomualdiD , GiulianiM , CristelloF , FulghesuAM , SelvaggiL , LanzoneA , et al. Metformin effects on ovarian ultrasound appearance and steroidogenic function in normal‐weight normoinsulinemic women with polycystic ovary syndrome: a randomized double‐blind placebo‐controlled clinical trial. Fertility and Sterility2010;93(7):2303‐10. ">Romualdi 2010</a>; <a href="./references#CD003053-bbs2-0041" title="SiebertT , KrugerT , LombardC . Evaluating the equivalence of clomiphene citrate with and without metformin in ovulation induction in PCOS patients. Journal of Assisted Reproduction and Genetics2009;26(4):165‐71. ">Siebert 2009</a>; <a href="./references#CD003053-bbs2-0044" title="TrolleB , FlyvbjergA , KesmodelU , LauszusFF . Efficacy of metformin in obese and non‐obese women with polycystic ovary syndrome: a randomized, double‐blinded, placebo‐controlled cross‐over trial. Human Reproduction2007;22(11):2967‐73. [original article] TrolleB , FlyvbjergA , KesmodelU , LauszusFF . Efficacy of metformin in obese and non‐obese women with polycystic ovary syndrome: a randomized, double‐blinded, placebo‐controlled cross‐over trial. Obstetrics and Gynecological Survey2008;63(2):96‐8. ">Trolle 2007</a>; <a href="./references#CD003053-bbs2-0047" title="YaraliH , YildizBO , DemirolA , ZeynelogluHB , YigitN , BukulmezO , et al. Co‐administration of metformin during rFSH treatment in patients with clomiphene citrate‐resistant polycystic ovarian syndrome: a prospective randomized trial. Human Reproduction2002;17(2):289‐94. YaraliH , YyldyzB , DemirolA , ZeynelogluH , YigitN , BukulmezO . Co‐administration of metformin during recombinant follicle stimulating hormone (recombinant FSH) treatment using the low‐dose step protocol in patients with clomiphene citrate resistant polycystic ovary syndrome (PCOS): a prospective randomized trial. Fertility and Sterility2001;76 Suppl(3):36. ">Yarali 2002</a>). </p> </section> <section id="CD003053-sec-0070"> <h4 class="title">Selective reporting</h4> <p>Low risk of selective reporting was found in fifteen studies (<a href="./references#CD003053-bbs2-0009" title="EisenhardtS , SchwarzmannN , HenschelV , GermeyerA , vonWolffM , HamannA , et al. Early effects of metformin in women with polycystic ovary syndrome: a prospective randomized, double‐blind, placebo‐controlled trial. Journal of Clinical Endocrinology and Metabolism2006;91:946‐52. ">Eisenhardt 2006</a>; <a href="./references#CD003053-bbs2-0013" title="GlintborgD , FrystykJ , HojlundK , AndersenKK , HenriksenJE , HermannA , et al. Total and high molecular weight (HMW) adiponectin levels and measures of glucose and lipid metabolism following pioglitazone treatment in a randomized placebo‐controlled study in polycystic ovary syndrome. Clinical Endocrinology (Oxford)2008;68(2):165‐74. GlintborgD , HermannAP , AndersenM , HagenC , Beck‐NielsenH , VeldhuisJD , et al. Effect of pioglitazone on glucose metabolism and luteinizing hormone secretion in women with polycystic ovary syndrome. Fertility and Sterility2006;86:385‐97. GlintborgD , HojlundK , AndersenM , HenriksenJE , Beck‐NielsenH , HandbergA . Soluble CD36 and risk markers of insulin resistance and atherosclerosis are elevated in polycystic ovary syndrome and significantly reduced during pioglitazone treatment. Diabetes Care2008;31:328‐34. GlintborgD , StovingRK , HagenC , HermannAP , FrystykJ , VeldhuisJD , et al. Pioglitazone treatment increases spontaneous growth hormone (GH) secretion and stimulated GH levels in polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism2005;90:5605‐12. [original article] ">Glintborg 2005</a>; <a href="./references#CD003053-bbs2-0014" title="HoegerKM , KochmanL , WixomN , CraigK , MillerRK , GuzickDS . A randomized, 48‐week, placebo‐controlled trial of intensive lifestyle modification and/or metformin therapy in overweight women with polycystic ovary syndrome: a pilot study. Fertility and Sterility2004;82:421‐9. ">Hoeger 2004</a>; <a href="./references#CD003053-bbs2-0019" title="KarimzadehMA , JavedaniM . An assessment of lifestyle modification versus medical treatment with clomiphene citrate, metformin, and clomiphene citrate‐metformin in patients with polycystic ovary syndrome. Fertility and Sterility2010;94(1):216‐20. ">Karimzadeh 2010</a>; <a href="./references#CD003053-bbs2-0021" title="LamPM , TamWH , MaRC , CheungLP , TsuiMH , TongPC , et al. The reproductive and metabolic effect of rosiglitazone on Chinese women with polycystic ovarian syndrome ‐ a double‐blind randomized placebo‐controlled study. Fertility and Sterility2011;96(2):445‐51. ">Lam 2011</a>; <a href="./references#CD003053-bbs2-0022" title="CataldoN , BarnhartH , LegroR , MyersE , SchlaffW , CarrB , et al. Extended‐release metformin does not reduce the clomiphene citrate dose required to induce ovulation in polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism2008;93(8):3147‐7. LegroRS , BarnhartHX , SchlaffWD , CarrBR , DiamondMP , CarsonSA , et al. Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome. New England Journal of Medicine2007;356:551‐66. [original article] ">Legro 2007</a>; <a href="./references#CD003053-bbs2-0023" title="LordJ , ThomasR , FoxB , AcharyaU , WilkinT . The effect of metformin on fat distribution and the metabolic syndrome in women with polycystic ovary syndrome‐‐a randomised, double‐blind, placebo‐controlled trial. British Journal of Obstetrics and Gynaecology2006;113:817‐24. ">Lord 2006</a>; <a href="./references#CD003053-bbs2-0027" title="MoghettiP , CastelloR , NegriC , TosiF , PerroneF , CaputoM , et al. Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized, double‐blind, placebo‐controlled 6‐month trial, followed by open, long‐term clinical evaluation. Journal of Clinical Endocrinology and Metabolism2000;85(1):139‐46. ">Moghetti 2000</a>; <a href="./references#CD003053-bbs2-0028" title="MollE , BossuytPM , KorevaarJC , LambalkCB , Van derVeenF . Effect of clomifene citrate plus metformin and clomifene citrate plus placebo on induction of ovulation in women with newly diagnosed polycystic ovary syndrome: randomised double blind clinical trial. BMJ2006;332:1485. [original article] MollE , KorevaarJC , BossuytPM , van derVeenF . Does adding metformin to clomifene citrate lead to higher pregnancy rates in a subset of women with polycystic ovary syndrome?. Human Reproduction2008;23(8):1830‐4. MollE , VanWelyM , LambalkCB , BossuytPM , Van derVeenF . Health‐related quality of life in women with newly diagnosed polycystic ovary syndrome randomized between clomifene citrate plus metformin or clomifene citrate plus placebo. Human Reproduction2012;27:3273‐8. ">Moll 2006</a>; <a href="./references#CD003053-bbs2-0032" title="NgEHY , WatNMS , HoPC . Effects of metformin on ovulation rate, hormonal and metabolic profiles in women with clomiphene‐resistant polycystic ovaries: a randomized, double‐blinded placebo‐controlled trial. Human Reproduction2001;16(8):1625‐31. ">Ng 2001</a>; <a href="./references#CD003053-bbs2-0036" title="CasimirriF , BiscottiM , GambineriA , CalzoniF , ElianaB , PasqualiR . Metformin improves insulin, body fat distribution, and androgens in obese women with and without the polycystic ovary syndrome. International Journal of Obesity1997;21 Suppl 2:61. PasqualiR , GambineriA , BiscottiD , VicennatiV , GagliardiL , ColittaD , et al. Effect of long‐term treatment with metformin added to hypocaloric diet on body composition, fat distribution, and androgen and insulin levels in abdominally obese women with and without the polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism2000;85(8):2767‐74. ">Pasquali 2000</a>; <a href="./references#CD003053-bbs2-0037" title="JohnsonNP , BontekoeS , StewartAW . Analysis of factors predicting success of metformin and clomiphene treatment for women with infertility owing to PCOS‐related ovulation dysfunction in a randomised controlled trial. Australian &amp; New Zealand Journal of Obstetrics &amp; Gynaecology2011;51:252‐6. JohnsonNP , StewartAW , FalkinerJ , FarquharCM , MilsomS , SinghV‐P , et al. on behalf of REACT‐NZ (REproduction And Collaborative Trials in New Zealand), a multi‐centre fertility trials group. PCOSMIC: a multi‐centre randomized trial in women with Polycystic Ovary Syndrome evaluating Metformin for Infertility with Clomiphene. Human Reproduction2010;25(7):1675‐83. [MEDLINE: 10.1093/humrep/deq100] ">PCOSMIC 2010</a>; <a href="./references#CD003053-bbs2-0039" title="RomualdiD , GiulianiM , CristelloF , FulghesuAM , SelvaggiL , LanzoneA , et al. Metformin effects on ovarian ultrasound appearance and steroidogenic function in normal‐weight normoinsulinemic women with polycystic ovary syndrome: a randomized double‐blind placebo‐controlled clinical trial. Fertility and Sterility2010;93(7):2303‐10. ">Romualdi 2010</a>; <a href="./references#CD003053-bbs2-0043" title="TangT , GlanvilleJ , HaydenCJ , WhiteD , BarthJH , BalenAH . Combined lifestyle modification and metformin in obese patients with polycystic ovary syndrome. A randomized, placebo‐controlled, double‐blind multicentre study. Human Reproduction2006;21:80‐9. ">Tang 2006</a>; <a href="./references#CD003053-bbs2-0044" title="TrolleB , FlyvbjergA , KesmodelU , LauszusFF . Efficacy of metformin in obese and non‐obese women with polycystic ovary syndrome: a randomized, double‐blinded, placebo‐controlled cross‐over trial. Human Reproduction2007;22(11):2967‐73. [original article] TrolleB , FlyvbjergA , KesmodelU , LauszusFF . Efficacy of metformin in obese and non‐obese women with polycystic ovary syndrome: a randomized, double‐blinded, placebo‐controlled cross‐over trial. Obstetrics and Gynecological Survey2008;63(2):96‐8. ">Trolle 2007</a>). </p> </section> <section id="CD003053-sec-0071"> <h4 class="title">Other potential sources of bias</h4> <p>Overall four studies appeared to be at high risk of other sources of bias (<a href="./references#CD003053-bbs2-0015" title="HwuYM , LinSY , HuangWY , LinMH , LeeRK . Ultra‐short metformin pretreatment for clomiphene citrate‐resistant polycystic ovary syndrome. International Journal of Gynaecology and Obstetrics2005;90:39‐43. ">Hwu 2005</a>; <a href="./references#CD003053-bbs2-0022" title="CataldoN , BarnhartH , LegroR , MyersE , SchlaffW , CarrB , et al. Extended‐release metformin does not reduce the clomiphene citrate dose required to induce ovulation in polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism2008;93(8):3147‐7. LegroRS , BarnhartHX , SchlaffWD , CarrBR , DiamondMP , CarsonSA , et al. Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome. New England Journal of Medicine2007;356:551‐66. [original article] ">Legro 2007</a>; <a href="./references#CD003053-bbs2-0027" title="MoghettiP , CastelloR , NegriC , TosiF , PerroneF , CaputoM , et al. Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized, double‐blind, placebo‐controlled 6‐month trial, followed by open, long‐term clinical evaluation. Journal of Clinical Endocrinology and Metabolism2000;85(1):139‐46. ">Moghetti 2000</a>; <a href="./references#CD003053-bbs2-0044" title="TrolleB , FlyvbjergA , KesmodelU , LauszusFF . Efficacy of metformin in obese and non‐obese women with polycystic ovary syndrome: a randomized, double‐blinded, placebo‐controlled cross‐over trial. Human Reproduction2007;22(11):2967‐73. [original article] TrolleB , FlyvbjergA , KesmodelU , LauszusFF . Efficacy of metformin in obese and non‐obese women with polycystic ovary syndrome: a randomized, double‐blinded, placebo‐controlled cross‐over trial. Obstetrics and Gynecological Survey2008;63(2):96‐8. ">Trolle 2007</a>) although the majority of the studies did not provide sufficient information for analysis. We have presented forest plots for the primary outcome live birth rate in <a href="#CD003053-fig-0005">Figure 5</a>; <a href="#CD003053-fig-0006">Figure 6</a>; <a href="#CD003053-fig-0007">Figure 7</a>, for <a href="./references#CD003053-fig-0008" title="">Analysis 1.1</a>, <a href="./references#CD003053-fig-0025" title="">Analysis 2.1</a> and <a href="./references#CD003053-fig-0034" title="">Analysis 3.1</a>, respectively. </p> <div class="figure" id="CD003053-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Metformin versus placebo or no treatment, outcome: 1.1 Live birth rate" data-id="CD003053-fig-0005" src="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/image_n/nCD003053-AFig-FIG05.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Metformin versus placebo or no treatment, outcome: 1.1 Live birth rate </p> </div> </div> </div> <div class="figure" id="CD003053-fig-0006"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 6</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 2 Metformin combined with clomiphene citrate versus clomiphene citrate alone, outcome: 2.1 Live birth rate" data-id="CD003053-fig-0006" src="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/image_n/nCD003053-AFig-FIG06.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 2 Metformin combined with clomiphene citrate versus clomiphene citrate alone, outcome: 2.1 Live birth rate </p> </div> </div> </div> <div class="figure" id="CD003053-fig-0007"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 7</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 3 Metformin versus clomiphene citrate, outcome: 3.1 Live birth." data-id="CD003053-fig-0007" src="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/image_n/nCD003053-AFig-FIG07.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 3 Metformin versus clomiphene citrate, outcome: 3.1 Live birth. </p> </div> </div> </div> </section> </section> <section id="CD003053-sec-0072"> <h3 class="title" id="CD003053-sec-0072">Effects of interventions</h3> <p>See: <a href="./full#CD003053-tbl-0001"><b>Summary of findings for the main comparison</b> Metformin compared to placebo or no treatment for women with polycystic ovary syndrome</a>; <a href="./full#CD003053-tbl-0002"><b>Summary of findings 2</b> Metformin combined with clomiphene citrate versus clomiphene citrate alone for women with polycystic ovary syndrome</a>; <a href="./full#CD003053-tbl-0003"><b>Summary of findings 3</b> Metformin compared to clomiphene citrate for women with polycystic ovary syndrome</a> </p> <section id="CD003053-sec-0073"> <h4 class="title">1. Metformin versus placebo or no treatment</h4> <section id="CD003053-sec-0074"> <h5 class="title">1.1 Live birth rate</h5> <p>(<a href="./references#CD003053-fig-0008" title="">Analysis 1.1</a>, <a href="#CD003053-fig-0005">Figure 5</a>) </p> <p>When we compared metformin to placebo, only a limited number of studies reported live birth rate (<a href="./references#CD003053-bbs2-0029" title="Morin‐PapunenL , RantalaAS , Unkila‐KallioL , TiitinenA , HippeläinenM , PerheentupaA , et al. Metformin improves pregnancy and live‐birth rates in women with polycystic ovary syndrome (PCOS): a multicenter, double‐blind, placebo‐controlled randomized trial. Journal of Clinical Endocrinology and Metabolism2012;97:1492‐1500. ">Morin‐Papunen 2012</a>; <a href="./references#CD003053-bbs2-0032" title="NgEHY , WatNMS , HoPC . Effects of metformin on ovulation rate, hormonal and metabolic profiles in women with clomiphene‐resistant polycystic ovaries: a randomized, double‐blinded placebo‐controlled trial. Human Reproduction2001;16(8):1625‐31. ">Ng 2001</a>; <a href="./references#CD003053-bbs2-0037" title="JohnsonNP , BontekoeS , StewartAW . Analysis of factors predicting success of metformin and clomiphene treatment for women with infertility owing to PCOS‐related ovulation dysfunction in a randomised controlled trial. Australian &amp; New Zealand Journal of Obstetrics &amp; Gynaecology2011;51:252‐6. JohnsonNP , StewartAW , FalkinerJ , FarquharCM , MilsomS , SinghV‐P , et al. on behalf of REACT‐NZ (REproduction And Collaborative Trials in New Zealand), a multi‐centre fertility trials group. PCOSMIC: a multi‐centre randomized trial in women with Polycystic Ovary Syndrome evaluating Metformin for Infertility with Clomiphene. Human Reproduction2010;25(7):1675‐83. [MEDLINE: 10.1093/humrep/deq100] ">PCOSMIC 2010</a>; <a href="./references#CD003053-bbs2-0047" title="YaraliH , YildizBO , DemirolA , ZeynelogluHB , YigitN , BukulmezO , et al. Co‐administration of metformin during rFSH treatment in patients with clomiphene citrate‐resistant polycystic ovarian syndrome: a prospective randomized trial. Human Reproduction2002;17(2):289‐94. YaraliH , YyldyzB , DemirolA , ZeynelogluH , YigitN , BukulmezO . Co‐administration of metformin during recombinant follicle stimulating hormone (recombinant FSH) treatment using the low‐dose step protocol in patients with clomiphene citrate resistant polycystic ovary syndrome (PCOS): a prospective randomized trial. Fertility and Sterility2001;76 Suppl(3):36. ">Yarali 2002</a>). When we pooled these four studies, there was marginal evidence of a difference in live birth rate favouring metformin, with a number needed to treat for an additional beneficial outcome of 13 women (OR 1.59, 95% CI 1.00 to 2.51, 4 studies, 435 women, I<sup>2</sup> = 0%, low‐quality evidence (<a href="./references#CD003053-fig-0008" title="">Analysis 1.1</a>). However, the wide‐ranging confidence intervals and low evidence quality make the advantage offered by metformin difficult to interpret clinically. </p> <p>In the subgroup analysis by obesity status the test for subgroup differences showed no evidence of a difference between the subgroups. There was no clear evidence of a difference in live birth rate in either subgroup (BMI of &lt; 30 kg/m<sup>2</sup>: OR 1.51, 95% CI 0.94 to 2.44, 3 studies, 370 women, I<sup>2</sup> = 0% or BMI &gt; 30 kg/m<sup>2</sup>: OR 2.87, 95% CI 0.51 to 16.01, 1 study, 65 women, I<sup>2</sup> = 0%) (<a href="./references#CD003053-fig-0008" title="">Analysis 1.1</a>). However, the broad confidence intervals due to reducing the number of combined studies for this analysis, render the results unclear. A sensitivity analysis, which excluded studies with unclear or high risk of bias left two studies remaining (<a href="./references#CD003053-bbs2-0029" title="Morin‐PapunenL , RantalaAS , Unkila‐KallioL , TiitinenA , HippeläinenM , PerheentupaA , et al. Metformin improves pregnancy and live‐birth rates in women with polycystic ovary syndrome (PCOS): a multicenter, double‐blind, placebo‐controlled randomized trial. Journal of Clinical Endocrinology and Metabolism2012;97:1492‐1500. ">Morin‐Papunen 2012</a>; <a href="./references#CD003053-bbs2-0037" title="JohnsonNP , BontekoeS , StewartAW . Analysis of factors predicting success of metformin and clomiphene treatment for women with infertility owing to PCOS‐related ovulation dysfunction in a randomised controlled trial. Australian &amp; New Zealand Journal of Obstetrics &amp; Gynaecology2011;51:252‐6. JohnsonNP , StewartAW , FalkinerJ , FarquharCM , MilsomS , SinghV‐P , et al. on behalf of REACT‐NZ (REproduction And Collaborative Trials in New Zealand), a multi‐centre fertility trials group. PCOSMIC: a multi‐centre randomized trial in women with Polycystic Ovary Syndrome evaluating Metformin for Infertility with Clomiphene. Human Reproduction2010;25(7):1675‐83. [MEDLINE: 10.1093/humrep/deq100] ">PCOSMIC 2010</a>) (OR 1.64, 95% CI 1.02 to 2.63, 2 studies, 385 women, I<sup>2</sup> = 0%). It should be noted that the women in these two studies had a BMI greater than 30 kg/m<sup>2</sup>. The large and good‐quality study by <a href="./references#CD003053-bbs2-0029" title="Morin‐PapunenL , RantalaAS , Unkila‐KallioL , TiitinenA , HippeläinenM , PerheentupaA , et al. Metformin improves pregnancy and live‐birth rates in women with polycystic ovary syndrome (PCOS): a multicenter, double‐blind, placebo‐controlled randomized trial. Journal of Clinical Endocrinology and Metabolism2012;97:1492‐1500. ">Morin‐Papunen 2012</a> contributed 93.8% of the weight of the result (OR 0.95, 95% CI 0.95 to 2.55, 320 women). These results therefore suggest a potential benefit in live birth rate when using metformin compared with placebo, although the number of studies were small. </p> </section> <section id="CD003053-sec-0075"> <h5 class="title">1.2 Adverse events</h5> <p>(<a href="./references#CD003053-fig-0009" title="">Analysis 1.2</a>) </p> <p>Women in the metformin group experienced a higher incidence of gastrointestinal side effects than the placebo group (OR 4.76, 95% CI 3.06 to 7.41, 7 studies, 670 women, I<sup>2</sup> = 61%, moderate‐quality evidence). In the subgroup analysis by obesity status, the test for subgroup differences showed no evidence of a difference between the subgroups. Sensitivity analysis, which excluded studies with unclear or high risk of bias did not change the inference. </p> </section> <section id="CD003053-sec-0076"> <h5 class="title">1.3 Clinical pregnancy rate</h5> <p>(<a href="./references#CD003053-fig-0010" title="">Analysis 1.3</a>) </p> <p>Nine trials reported clinical pregnancy rates (<a href="./references#CD003053-bbs2-0011" title="FlemingR , HopkinsonZE , WallaceAM , GreerIA , SattarN . Ovarian function and metabolic factors in women with oligomenorrhea treated with metformin in a randomized double blind placebo‐controlled trial. Journal of Clinical Endocrinology and Metabolism2002;87(2):569‐74. FlemingR , HopkinsonZE , WallaceE , GreerIA , SattarN . Metformin treatment improves ovulation frequency in women with oligomenorrhoea: a randomized, double blind placebo trial. Human Fertility2000; Vol. 3, issue 4:389‐90. ">Fleming 2002</a>; <a href="./references#CD003053-bbs2-0018" title="KarimzadehM , TayebiN , EftekharM , SakhavatL , TaheripanahR , ZareF . The effect of administration of metformin on lipid profile changes and insulin resistance in patients with polycystic ovary syndrome. Middle East Fertility Society Journal2007;12(3):174‐8. ">Karimzadeh 2007</a>; <a href="./references#CD003053-bbs2-0019" title="KarimzadehMA , JavedaniM . An assessment of lifestyle modification versus medical treatment with clomiphene citrate, metformin, and clomiphene citrate‐metformin in patients with polycystic ovary syndrome. Fertility and Sterility2010;94(1):216‐20. ">Karimzadeh 2010</a>; <a href="./references#CD003053-bbs2-0023" title="LordJ , ThomasR , FoxB , AcharyaU , WilkinT . The effect of metformin on fat distribution and the metabolic syndrome in women with polycystic ovary syndrome‐‐a randomised, double‐blind, placebo‐controlled trial. British Journal of Obstetrics and Gynaecology2006;113:817‐24. ">Lord 2006</a>; <a href="./references#CD003053-bbs2-0029" title="Morin‐PapunenL , RantalaAS , Unkila‐KallioL , TiitinenA , HippeläinenM , PerheentupaA , et al. Metformin improves pregnancy and live‐birth rates in women with polycystic ovary syndrome (PCOS): a multicenter, double‐blind, placebo‐controlled randomized trial. Journal of Clinical Endocrinology and Metabolism2012;97:1492‐1500. ">Morin‐Papunen 2012</a>; <a href="./references#CD003053-bbs2-0032" title="NgEHY , WatNMS , HoPC . Effects of metformin on ovulation rate, hormonal and metabolic profiles in women with clomiphene‐resistant polycystic ovaries: a randomized, double‐blinded placebo‐controlled trial. Human Reproduction2001;16(8):1625‐31. ">Ng 2001</a>; <a href="./references#CD003053-bbs2-0037" title="JohnsonNP , BontekoeS , StewartAW . Analysis of factors predicting success of metformin and clomiphene treatment for women with infertility owing to PCOS‐related ovulation dysfunction in a randomised controlled trial. Australian &amp; New Zealand Journal of Obstetrics &amp; Gynaecology2011;51:252‐6. JohnsonNP , StewartAW , FalkinerJ , FarquharCM , MilsomS , SinghV‐P , et al. on behalf of REACT‐NZ (REproduction And Collaborative Trials in New Zealand), a multi‐centre fertility trials group. PCOSMIC: a multi‐centre randomized trial in women with Polycystic Ovary Syndrome evaluating Metformin for Infertility with Clomiphene. Human Reproduction2010;25(7):1675‐83. [MEDLINE: 10.1093/humrep/deq100] ">PCOSMIC 2010</a>; <a href="./references#CD003053-bbs2-0043" title="TangT , GlanvilleJ , HaydenCJ , WhiteD , BarthJH , BalenAH . Combined lifestyle modification and metformin in obese patients with polycystic ovary syndrome. A randomized, placebo‐controlled, double‐blind multicentre study. Human Reproduction2006;21:80‐9. ">Tang 2006</a>; <a href="./references#CD003053-bbs2-0047" title="YaraliH , YildizBO , DemirolA , ZeynelogluHB , YigitN , BukulmezO , et al. Co‐administration of metformin during rFSH treatment in patients with clomiphene citrate‐resistant polycystic ovarian syndrome: a prospective randomized trial. Human Reproduction2002;17(2):289‐94. YaraliH , YyldyzB , DemirolA , ZeynelogluH , YigitN , BukulmezO . Co‐administration of metformin during recombinant follicle stimulating hormone (recombinant FSH) treatment using the low‐dose step protocol in patients with clomiphene citrate resistant polycystic ovary syndrome (PCOS): a prospective randomized trial. Fertility and Sterility2001;76 Suppl(3):36. ">Yarali 2002</a>) (<a href="./references#CD003053-fig-0010" title="">Analysis 1.3</a>). Pregnancy rates were higher in the metformin arm (OR 1.93, 95% CI 1.42 to 2.64, 9 studies, 1027 women, I<sup>2</sup> = 43%, moderate‐quality evidence). In subgroup analysis by obesity status the test for subgroup differences showed no evidence of a difference between the subgroups. In an attempt to improve heterogeneity we performed a sensitivity analysis, which excluded studies with unclear or high risk of bias, including the following studies (<a href="./references#CD003053-bbs2-0011" title="FlemingR , HopkinsonZE , WallaceAM , GreerIA , SattarN . Ovarian function and metabolic factors in women with oligomenorrhea treated with metformin in a randomized double blind placebo‐controlled trial. Journal of Clinical Endocrinology and Metabolism2002;87(2):569‐74. FlemingR , HopkinsonZE , WallaceE , GreerIA , SattarN . Metformin treatment improves ovulation frequency in women with oligomenorrhoea: a randomized, double blind placebo trial. Human Fertility2000; Vol. 3, issue 4:389‐90. ">Fleming 2002</a>; <a href="./references#CD003053-bbs2-0018" title="KarimzadehM , TayebiN , EftekharM , SakhavatL , TaheripanahR , ZareF . The effect of administration of metformin on lipid profile changes and insulin resistance in patients with polycystic ovary syndrome. Middle East Fertility Society Journal2007;12(3):174‐8. ">Karimzadeh 2007</a>; <a href="./references#CD003053-bbs2-0023" title="LordJ , ThomasR , FoxB , AcharyaU , WilkinT . The effect of metformin on fat distribution and the metabolic syndrome in women with polycystic ovary syndrome‐‐a randomised, double‐blind, placebo‐controlled trial. British Journal of Obstetrics and Gynaecology2006;113:817‐24. ">Lord 2006</a>; <a href="./references#CD003053-bbs2-0024" title="MachadoRC , MachadoNA , GeberS . Evaluation of the use of metformin for ovulation in patients with PCOS resistant to isolated use of clomiphene citrate. Brazilian Journal Assisted Reproduction2012;16(1):27‐31. ">Machado 2012</a>; <a href="./references#CD003053-bbs2-0029" title="Morin‐PapunenL , RantalaAS , Unkila‐KallioL , TiitinenA , HippeläinenM , PerheentupaA , et al. Metformin improves pregnancy and live‐birth rates in women with polycystic ovary syndrome (PCOS): a multicenter, double‐blind, placebo‐controlled randomized trial. Journal of Clinical Endocrinology and Metabolism2012;97:1492‐1500. ">Morin‐Papunen 2012</a>; <a href="./references#CD003053-bbs2-0032" title="NgEHY , WatNMS , HoPC . Effects of metformin on ovulation rate, hormonal and metabolic profiles in women with clomiphene‐resistant polycystic ovaries: a randomized, double‐blinded placebo‐controlled trial. Human Reproduction2001;16(8):1625‐31. ">Ng 2001</a>; <a href="./references#CD003053-bbs2-0037" title="JohnsonNP , BontekoeS , StewartAW . Analysis of factors predicting success of metformin and clomiphene treatment for women with infertility owing to PCOS‐related ovulation dysfunction in a randomised controlled trial. Australian &amp; New Zealand Journal of Obstetrics &amp; Gynaecology2011;51:252‐6. JohnsonNP , StewartAW , FalkinerJ , FarquharCM , MilsomS , SinghV‐P , et al. on behalf of REACT‐NZ (REproduction And Collaborative Trials in New Zealand), a multi‐centre fertility trials group. PCOSMIC: a multi‐centre randomized trial in women with Polycystic Ovary Syndrome evaluating Metformin for Infertility with Clomiphene. Human Reproduction2010;25(7):1675‐83. [MEDLINE: 10.1093/humrep/deq100] ">PCOSMIC 2010</a>; <a href="./references#CD003053-bbs2-0043" title="TangT , GlanvilleJ , HaydenCJ , WhiteD , BarthJH , BalenAH . Combined lifestyle modification and metformin in obese patients with polycystic ovary syndrome. A randomized, placebo‐controlled, double‐blind multicentre study. Human Reproduction2006;21:80‐9. ">Tang 2006</a>). However, this did not alter the inference or improve heterogeneity. </p> </section> <section id="CD003053-sec-0077"> <h5 class="title">1.4 Ovulation rate</h5> <p>(<a href="./references#CD003053-fig-0011" title="">Analysis 1.4</a>) </p> <p>There was evidence of a benefit from metformin with respect to the ovulation rate per participant (OR 2.55, 95% CI 1.81 to 3.59, 14 studies, 701 women, I<sup>2</sup> = 58%, moderate‐quality evidence). We have presented ovulation rate per cycle in an additional table (<a href="#CD003053-tbl-0006">Table 3</a>)<b>.</b> Subgroup analysis by obesity status suggested a significant difference between the subgroups (test for subgroup differences: Chi² = 4.11, df = 1, P = 0.04, I² = 75.7%), with a stronger benefit from metformin in the non‐obese group (OR 4.15, 95% CI 2.31 to 7.45). However heterogeneity in this subgroup was very high (I<sup>2</sup> = 82%) and was attributable to a single study (<a href="./references#CD003053-bbs2-0002" title="BaillargeonJP , JakubowiczDJ , IuornoMJ , JakubowiczS , NestlerJE . Effects of metformin and rosiglitazone, alone and in combination, in nonobese women with polycystic ovary syndrome and normal indices of insulin sensitivity. Fertility and Sterility2004;82:893‐902. ">Baillargeon 2004</a>); when this study was excluded from analysis there was no longer any suggestion of a difference between the subgroups (I<sup>2</sup> = 0%). When both subgroups were pooled, heterogeneity was improved after sensitivity analysis by study quality, which included only five studies (<a href="./references#CD003053-bbs2-0011" title="FlemingR , HopkinsonZE , WallaceAM , GreerIA , SattarN . Ovarian function and metabolic factors in women with oligomenorrhea treated with metformin in a randomized double blind placebo‐controlled trial. Journal of Clinical Endocrinology and Metabolism2002;87(2):569‐74. FlemingR , HopkinsonZE , WallaceE , GreerIA , SattarN . Metformin treatment improves ovulation frequency in women with oligomenorrhoea: a randomized, double blind placebo trial. Human Fertility2000; Vol. 3, issue 4:389‐90. ">Fleming 2002</a>; <a href="./references#CD003053-bbs2-0014" title="HoegerKM , KochmanL , WixomN , CraigK , MillerRK , GuzickDS . A randomized, 48‐week, placebo‐controlled trial of intensive lifestyle modification and/or metformin therapy in overweight women with polycystic ovary syndrome: a pilot study. Fertility and Sterility2004;82:421‐9. ">Hoeger 2004</a>; <a href="./references#CD003053-bbs2-0023" title="LordJ , ThomasR , FoxB , AcharyaU , WilkinT . The effect of metformin on fat distribution and the metabolic syndrome in women with polycystic ovary syndrome‐‐a randomised, double‐blind, placebo‐controlled trial. British Journal of Obstetrics and Gynaecology2006;113:817‐24. ">Lord 2006</a>; <a href="./references#CD003053-bbs2-0032" title="NgEHY , WatNMS , HoPC . Effects of metformin on ovulation rate, hormonal and metabolic profiles in women with clomiphene‐resistant polycystic ovaries: a randomized, double‐blinded placebo‐controlled trial. Human Reproduction2001;16(8):1625‐31. ">Ng 2001</a>; <a href="./references#CD003053-bbs2-0037" title="JohnsonNP , BontekoeS , StewartAW . Analysis of factors predicting success of metformin and clomiphene treatment for women with infertility owing to PCOS‐related ovulation dysfunction in a randomised controlled trial. Australian &amp; New Zealand Journal of Obstetrics &amp; Gynaecology2011;51:252‐6. JohnsonNP , StewartAW , FalkinerJ , FarquharCM , MilsomS , SinghV‐P , et al. on behalf of REACT‐NZ (REproduction And Collaborative Trials in New Zealand), a multi‐centre fertility trials group. PCOSMIC: a multi‐centre randomized trial in women with Polycystic Ovary Syndrome evaluating Metformin for Infertility with Clomiphene. Human Reproduction2010;25(7):1675‐83. [MEDLINE: 10.1093/humrep/deq100] ">PCOSMIC 2010</a>), with an overall I<sup>2</sup> of 0% . However, the overall inference remained unchanged. </p> </section> <section id="CD003053-sec-0078"> <h5 class="title">1.5 Menstrual frequency</h5> <p>(<a href="./references#CD003053-fig-0012" title="">Analysis 1.5</a>) </p> <p>There was evidence of a beneficial effect of metformin on menstrual frequency with an OR of 1.72 (95% CI 1.14 to 2.61, 7 studies, 427 women, I<sup>2</sup> = 54%). Due to only one trial in the non‐obese group, subgroup analysis did not improve the heterogeneity. In subgroup analysis by obesity status the test for subgroup differences showed no evidence of a difference between the subgroups. Sensitivity analysis, which excluded studies with unclear or high risk of bias, included five studies (<a href="./references#CD003053-bbs2-0008" title="ChouKH , vonEye CorletaH , CappE , SpritzerPM . Clinical, metabolic and endocrine parameters in response to metformin in obese women with polycystic ovary syndrome: a randomized, double‐blind and placebo‐controlled trial. Hormone and Metabolic Research2003;35:86‐91. ">Chou 2003</a>; <a href="./references#CD003053-bbs2-0009" title="EisenhardtS , SchwarzmannN , HenschelV , GermeyerA , vonWolffM , HamannA , et al. Early effects of metformin in women with polycystic ovary syndrome: a prospective randomized, double‐blind, placebo‐controlled trial. Journal of Clinical Endocrinology and Metabolism2006;91:946‐52. ">Eisenhardt 2006</a>; <a href="./references#CD003053-bbs2-0011" title="FlemingR , HopkinsonZE , WallaceAM , GreerIA , SattarN . Ovarian function and metabolic factors in women with oligomenorrhea treated with metformin in a randomized double blind placebo‐controlled trial. Journal of Clinical Endocrinology and Metabolism2002;87(2):569‐74. FlemingR , HopkinsonZE , WallaceE , GreerIA , SattarN . Metformin treatment improves ovulation frequency in women with oligomenorrhoea: a randomized, double blind placebo trial. Human Fertility2000; Vol. 3, issue 4:389‐90. ">Fleming 2002</a>; <a href="./references#CD003053-bbs2-0014" title="HoegerKM , KochmanL , WixomN , CraigK , MillerRK , GuzickDS . A randomized, 48‐week, placebo‐controlled trial of intensive lifestyle modification and/or metformin therapy in overweight women with polycystic ovary syndrome: a pilot study. Fertility and Sterility2004;82:421‐9. ">Hoeger 2004</a>; <a href="./references#CD003053-bbs2-0043" title="TangT , GlanvilleJ , HaydenCJ , WhiteD , BarthJH , BalenAH . Combined lifestyle modification and metformin in obese patients with polycystic ovary syndrome. A randomized, placebo‐controlled, double‐blind multicentre study. Human Reproduction2006;21:80‐9. ">Tang 2006</a>); this did not improve heterogeneity and did not change the inference. </p> </section> <section id="CD003053-sec-0079"> <h5 class="title">1.6 Miscarriage</h5> <p>(<a href="./references#CD003053-fig-0013" title="">Analysis 1.6</a>) </p> <p>Four studies reported on miscarriage and there was no conclusive evidence of a difference between metformin and placebo in miscarriage rate per woman (OR 1.08, 95% CI 0.50 to 2.35, 4 studies, 748 women, I<sup>2</sup> = 0%). A sensitivity analysis using per pregnancy rates was also inconclusive (OR 0.58, 95% CI 0.25 to 1.34, 4 studies, 200 pregnancies, I<sup>2</sup> = 0%, low‐quality evidence). A subgroup analysis by obesity status showed no evidence of a difference between the subgroups. However, only one study was available with women with BMI more than 30 kg/m<sup>2</sup> (<a href="./references#CD003053-bbs2-0037" title="JohnsonNP , BontekoeS , StewartAW . Analysis of factors predicting success of metformin and clomiphene treatment for women with infertility owing to PCOS‐related ovulation dysfunction in a randomised controlled trial. Australian &amp; New Zealand Journal of Obstetrics &amp; Gynaecology2011;51:252‐6. JohnsonNP , StewartAW , FalkinerJ , FarquharCM , MilsomS , SinghV‐P , et al. on behalf of REACT‐NZ (REproduction And Collaborative Trials in New Zealand), a multi‐centre fertility trials group. PCOSMIC: a multi‐centre randomized trial in women with Polycystic Ovary Syndrome evaluating Metformin for Infertility with Clomiphene. Human Reproduction2010;25(7):1675‐83. [MEDLINE: 10.1093/humrep/deq100] ">PCOSMIC 2010</a>). </p> </section> <section id="CD003053-sec-0080"> <h5 class="title">1.7 Multiple pregnancy</h5> <p>Data were not available for this outcome.</p> </section> <section id="CD003053-sec-0081"> <h5 class="title">1.8 Anthropometric outcomes</h5> <section id="CD003053-sec-0082"> <h6 class="title">BMI</h6> <p>There was no clear evidence of an effect of metformin on BMI (MD ‐0.08, 95% CI ‐0.33 to 0.17, 16 studies, 827 women, I<sup>2</sup> = 2%) (<a href="./references#CD003053-fig-0015" title="">Analysis 1.8</a>) with an average duration of treatment of 5.75 months and average dose of 1500 mg. <a href="./references#CD003053-bbs2-0002" title="BaillargeonJP , JakubowiczDJ , IuornoMJ , JakubowiczS , NestlerJE . Effects of metformin and rosiglitazone, alone and in combination, in nonobese women with polycystic ovary syndrome and normal indices of insulin sensitivity. Fertility and Sterility2004;82:893‐902. ">Baillargeon 2004</a> provided 82% of the weight of this analysis, which found no significant evidence of a difference in BMI (MD 0.00, 95% CI ‐0.28 to 0.28). The other studies are smaller as reflected in their broader confidence intervals. Overall heterogeneity was low (I<sup>2</sup> = 2%); but was moderately high in the non‐obese group (I<sup>2</sup> = 54%). Sensitivity analysis by study quality (<a href="./references#CD003053-bbs2-0002" title="BaillargeonJP , JakubowiczDJ , IuornoMJ , JakubowiczS , NestlerJE . Effects of metformin and rosiglitazone, alone and in combination, in nonobese women with polycystic ovary syndrome and normal indices of insulin sensitivity. Fertility and Sterility2004;82:893‐902. ">Baillargeon 2004</a>; <a href="./references#CD003053-bbs2-0008" title="ChouKH , vonEye CorletaH , CappE , SpritzerPM . Clinical, metabolic and endocrine parameters in response to metformin in obese women with polycystic ovary syndrome: a randomized, double‐blind and placebo‐controlled trial. Hormone and Metabolic Research2003;35:86‐91. ">Chou 2003</a>; <a href="./references#CD003053-bbs2-0011" title="FlemingR , HopkinsonZE , WallaceAM , GreerIA , SattarN . Ovarian function and metabolic factors in women with oligomenorrhea treated with metformin in a randomized double blind placebo‐controlled trial. Journal of Clinical Endocrinology and Metabolism2002;87(2):569‐74. FlemingR , HopkinsonZE , WallaceE , GreerIA , SattarN . Metformin treatment improves ovulation frequency in women with oligomenorrhoea: a randomized, double blind placebo trial. Human Fertility2000; Vol. 3, issue 4:389‐90. ">Fleming 2002</a>; <a href="./references#CD003053-bbs2-0014" title="HoegerKM , KochmanL , WixomN , CraigK , MillerRK , GuzickDS . A randomized, 48‐week, placebo‐controlled trial of intensive lifestyle modification and/or metformin therapy in overweight women with polycystic ovary syndrome: a pilot study. Fertility and Sterility2004;82:421‐9. ">Hoeger 2004</a>; <a href="./references#CD003053-bbs2-0023" title="LordJ , ThomasR , FoxB , AcharyaU , WilkinT . The effect of metformin on fat distribution and the metabolic syndrome in women with polycystic ovary syndrome‐‐a randomised, double‐blind, placebo‐controlled trial. British Journal of Obstetrics and Gynaecology2006;113:817‐24. ">Lord 2006</a>; <a href="./references#CD003053-bbs2-0025" title="MacielGA , Soares JrJM , Alves da MottaEL , Abi HaidarM , deLimaGR , BaracatEC , et al. Nonobese women with polycystic ovary syndrome respond better than obese women to treatment with metformin. Fertility and Sterility2004;81:355‐60. ">Maciel 2004</a>; <a href="./references#CD003053-bbs2-0029" title="Morin‐PapunenL , RantalaAS , Unkila‐KallioL , TiitinenA , HippeläinenM , PerheentupaA , et al. Metformin improves pregnancy and live‐birth rates in women with polycystic ovary syndrome (PCOS): a multicenter, double‐blind, placebo‐controlled randomized trial. Journal of Clinical Endocrinology and Metabolism2012;97:1492‐1500. ">Morin‐Papunen 2012</a>; <a href="./references#CD003053-bbs2-0032" title="NgEHY , WatNMS , HoPC . Effects of metformin on ovulation rate, hormonal and metabolic profiles in women with clomiphene‐resistant polycystic ovaries: a randomized, double‐blinded placebo‐controlled trial. Human Reproduction2001;16(8):1625‐31. ">Ng 2001</a>; <a href="./references#CD003053-bbs2-0036" title="CasimirriF , BiscottiM , GambineriA , CalzoniF , ElianaB , PasqualiR . Metformin improves insulin, body fat distribution, and androgens in obese women with and without the polycystic ovary syndrome. International Journal of Obesity1997;21 Suppl 2:61. PasqualiR , GambineriA , BiscottiD , VicennatiV , GagliardiL , ColittaD , et al. Effect of long‐term treatment with metformin added to hypocaloric diet on body composition, fat distribution, and androgen and insulin levels in abdominally obese women with and without the polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism2000;85(8):2767‐74. ">Pasquali 2000</a>; <a href="./references#CD003053-bbs2-0043" title="TangT , GlanvilleJ , HaydenCJ , WhiteD , BarthJH , BalenAH . Combined lifestyle modification and metformin in obese patients with polycystic ovary syndrome. A randomized, placebo‐controlled, double‐blind multicentre study. Human Reproduction2006;21:80‐9. ">Tang 2006</a>) improved heterogeneity (non‐obese group I<sup>2</sup> = 0%; obese group I<sup>2</sup> = 0%) but did not change the inference. </p> </section> <section id="CD003053-sec-0083"> <h6 class="title">Waist to hip ratio</h6> <p>There was evidence of a marginal benefit from metformin on waist to hip ratio (MD ‐0.01, 95% CI ‐0.01 to 0.00, 11 studies, 702 women) (<a href="./references#CD003053-fig-0016" title="">Analysis 1.9</a>). The magnitude of heterogeneity was low in both the non‐obese and the obese subgroups (I<sup>2</sup> = 0% and I<sup>2</sup> = 12%, respectively). The sensitivity analysis by study quality (<a href="./references#CD003053-bbs2-0002" title="BaillargeonJP , JakubowiczDJ , IuornoMJ , JakubowiczS , NestlerJE . Effects of metformin and rosiglitazone, alone and in combination, in nonobese women with polycystic ovary syndrome and normal indices of insulin sensitivity. Fertility and Sterility2004;82:893‐902. ">Baillargeon 2004</a>; <a href="./references#CD003053-bbs2-0008" title="ChouKH , vonEye CorletaH , CappE , SpritzerPM . Clinical, metabolic and endocrine parameters in response to metformin in obese women with polycystic ovary syndrome: a randomized, double‐blind and placebo‐controlled trial. Hormone and Metabolic Research2003;35:86‐91. ">Chou 2003</a>; <a href="./references#CD003053-bbs2-0011" title="FlemingR , HopkinsonZE , WallaceAM , GreerIA , SattarN . Ovarian function and metabolic factors in women with oligomenorrhea treated with metformin in a randomized double blind placebo‐controlled trial. Journal of Clinical Endocrinology and Metabolism2002;87(2):569‐74. FlemingR , HopkinsonZE , WallaceE , GreerIA , SattarN . Metformin treatment improves ovulation frequency in women with oligomenorrhoea: a randomized, double blind placebo trial. Human Fertility2000; Vol. 3, issue 4:389‐90. ">Fleming 2002</a>; <a href="./references#CD003053-bbs2-0023" title="LordJ , ThomasR , FoxB , AcharyaU , WilkinT . The effect of metformin on fat distribution and the metabolic syndrome in women with polycystic ovary syndrome‐‐a randomised, double‐blind, placebo‐controlled trial. British Journal of Obstetrics and Gynaecology2006;113:817‐24. ">Lord 2006</a>; <a href="./references#CD003053-bbs2-0029" title="Morin‐PapunenL , RantalaAS , Unkila‐KallioL , TiitinenA , HippeläinenM , PerheentupaA , et al. Metformin improves pregnancy and live‐birth rates in women with polycystic ovary syndrome (PCOS): a multicenter, double‐blind, placebo‐controlled randomized trial. Journal of Clinical Endocrinology and Metabolism2012;97:1492‐1500. ">Morin‐Papunen 2012</a>; <a href="./references#CD003053-bbs2-0036" title="CasimirriF , BiscottiM , GambineriA , CalzoniF , ElianaB , PasqualiR . Metformin improves insulin, body fat distribution, and androgens in obese women with and without the polycystic ovary syndrome. International Journal of Obesity1997;21 Suppl 2:61. PasqualiR , GambineriA , BiscottiD , VicennatiV , GagliardiL , ColittaD , et al. Effect of long‐term treatment with metformin added to hypocaloric diet on body composition, fat distribution, and androgen and insulin levels in abdominally obese women with and without the polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism2000;85(8):2767‐74. ">Pasquali 2000</a>; <a href="./references#CD003053-bbs2-0043" title="TangT , GlanvilleJ , HaydenCJ , WhiteD , BarthJH , BalenAH . Combined lifestyle modification and metformin in obese patients with polycystic ovary syndrome. A randomized, placebo‐controlled, double‐blind multicentre study. Human Reproduction2006;21:80‐9. ">Tang 2006</a>) demonstrated a similar inference. </p> </section> <section id="CD003053-sec-0084"> <h6 class="title">Blood pressure</h6> <p>Metformin reduced systolic blood pressure with a mean difference of ‐3.59 mm Hg (95% CI ‐5.13 to ‐2.04, 7 studies, 379 women) (<a href="./references#CD003053-fig-0017" title="">Analysis 1.10</a>) and significant heterogeneity (I<sup>2</sup> = 57%). However, we did not observe a similar benefit in the diastolic blood pressure (MD ‐0.14, 95% CI ‐1.35 to 1.07, 6 studies, 292 women, I<sup>2</sup> = 21% (<a href="./references#CD003053-fig-0018" title="">Analysis 1.11</a>). Furthermore, neither subgroup analysis (<a href="./references#CD003053-fig-0017" title="">Analysis 1.10</a>) nor sensitivity analysis by study quality (<a href="./references#CD003053-bbs2-0002" title="BaillargeonJP , JakubowiczDJ , IuornoMJ , JakubowiczS , NestlerJE . Effects of metformin and rosiglitazone, alone and in combination, in nonobese women with polycystic ovary syndrome and normal indices of insulin sensitivity. Fertility and Sterility2004;82:893‐902. ">Baillargeon 2004</a>; <a href="./references#CD003053-bbs2-0008" title="ChouKH , vonEye CorletaH , CappE , SpritzerPM . Clinical, metabolic and endocrine parameters in response to metformin in obese women with polycystic ovary syndrome: a randomized, double‐blind and placebo‐controlled trial. Hormone and Metabolic Research2003;35:86‐91. ">Chou 2003</a>; <a href="./references#CD003053-bbs2-0023" title="LordJ , ThomasR , FoxB , AcharyaU , WilkinT . The effect of metformin on fat distribution and the metabolic syndrome in women with polycystic ovary syndrome‐‐a randomised, double‐blind, placebo‐controlled trial. British Journal of Obstetrics and Gynaecology2006;113:817‐24. ">Lord 2006</a>; <a href="./references#CD003053-bbs2-0025" title="MacielGA , Soares JrJM , Alves da MottaEL , Abi HaidarM , deLimaGR , BaracatEC , et al. Nonobese women with polycystic ovary syndrome respond better than obese women to treatment with metformin. Fertility and Sterility2004;81:355‐60. ">Maciel 2004</a>; <a href="./references#CD003053-bbs2-0043" title="TangT , GlanvilleJ , HaydenCJ , WhiteD , BarthJH , BalenAH . Combined lifestyle modification and metformin in obese patients with polycystic ovary syndrome. A randomized, placebo‐controlled, double‐blind multicentre study. Human Reproduction2006;21:80‐9. ">Tang 2006</a>) improved heterogeneity in the systolic blood pressure analysis. </p> </section> </section> <section id="CD003053-sec-0085"> <h5 class="title">1.9 Endocrine outcomes</h5> <section id="CD003053-sec-0086"> <h6 class="title">Testosterone</h6> <p>There was evidence that metformin reduced serum total testosterone levels with a MD of ‐0.49 nmol/L (95% CI ‐0.59 to ‐0.39, 15 studies, 863 women, I<sup>2</sup> = 92%) (<a href="./references#CD003053-fig-0019" title="">Analysis 1.12</a>). However, we observed high heterogeneity (I<sup>2</sup> = 92%). In subgroup analysis by BMI, there was evidence of a difference between the subgroups (test for subgroup differences: Chi² = 15.68, df = 1, P = &lt; 0.00001, I<sup>2</sup> = 93.6%) with metformin having a stronger effect in the non‐obese group (MD ‐0.71 versus ‐0.29 nmol/L). Linear regression analysis did not demonstrate any correlation between the baseline mean BMI and the mean fasting insulin concentrations among all the included studies (data not shown). Furthermore, we did not observe a positive correlation between the baseline mean fasting insulin concentrations and the mean testosterone concentrations (data not shown). These data suggested that the heterogeneity may have been caused by the different background prevalence in hyperandrogenism and insulin resistance among different study populations (<a href="./references#CD003053-bbs2-0146" title="WijeyaratneCN , BalenAH , BarthJH , BelchetzPE . Clinical manifestations and insulin resistance (IR) in polycystic ovary syndrome (PCOS) among South Asians and Caucasians: is there a difference?. Clinical Endocrinology (Oxford)2002;57:343‐50. ">Wijeyaratne 2002</a>; <a href="./references#CD003053-bbs2-0147" title="WijeyaratneCN , NirantharakumarK , BalenAH , BarthJH , SheriffR , BelchetzPE . Plasma homocysteine in polycystic ovary syndrome: does it correlate with insulin resistance and ethnicity?. Clinical Endocrinology (Oxford)2004;60:560‐7. ">Wijeyaratne 2004</a>). Furthermore, different biochemical assays used in different studies could contribute towards this heterogeneity. Sensitivity analysis by study quality did not improve the heterogeneity. However, removing the two extreme results (<a href="./references#CD003053-bbs2-0002" title="BaillargeonJP , JakubowiczDJ , IuornoMJ , JakubowiczS , NestlerJE . Effects of metformin and rosiglitazone, alone and in combination, in nonobese women with polycystic ovary syndrome and normal indices of insulin sensitivity. Fertility and Sterility2004;82:893‐902. ">Baillargeon 2004</a>; <a href="./references#CD003053-bbs2-0016" title="JakubowiczDJ , SeppalaM , JakubowiczS , Rodriguez‐ArmasO , Rivas‐SantiagoA , KoistinenH , et al. Insulin reduction with metformin increases luteal phase serum glycodelin and insulin‐like growth factor‐binding protein 1 concentrations and enhances uterine vascularity and blood flow in the polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism2001;86(3):1126‐33. ">Jakubowicz 2001</a>) improved heterogeneity (non‐obese group I<sup>2</sup> = 49%; obese group I<sup>2</sup> = 44%) without altering the inference. </p> </section> <section id="CD003053-sec-0087"> <h6 class="title">Sex hormone‐binding globulin</h6> <p>There was no convincing evidence of an effect of metformin on serum sex hormone‐binding globulin levels (MD 0.49, 95% CI ‐1.82 to 2.81, 15 studies, 823 women, I<sup>2</sup> = 62%) (<a href="./references#CD003053-fig-0020" title="">Analysis 1.13</a>). Neither the subgroup analysis nor the sensitivity analysis by study quality improved heterogeneity or changed the inference. </p> </section> </section> <section id="CD003053-sec-0088"> <h5 class="title">1.10 Metabolic outcomes</h5> <section id="CD003053-sec-0089"> <h6 class="title">Glucose</h6> <p>There was evidence of a reduction in fasting glucose levels with metformin compared to placebo (MD ‐0.14 mmol/L, 95% CI ‐0.21 to ‐0.07, 15 studies, 849 women, I<sup>2</sup> = 38%) (<a href="./references#CD003053-fig-0021" title="">Analysis 1.14</a>). Subgroup analysis only improved heterogeneity in the obese group (I<sup>2</sup> = 14%) without changing the inference. Sensitivity analysis by study quality (<a href="./references#CD003053-bbs2-0002" title="BaillargeonJP , JakubowiczDJ , IuornoMJ , JakubowiczS , NestlerJE . Effects of metformin and rosiglitazone, alone and in combination, in nonobese women with polycystic ovary syndrome and normal indices of insulin sensitivity. Fertility and Sterility2004;82:893‐902. ">Baillargeon 2004</a>; <a href="./references#CD003053-bbs2-0008" title="ChouKH , vonEye CorletaH , CappE , SpritzerPM . Clinical, metabolic and endocrine parameters in response to metformin in obese women with polycystic ovary syndrome: a randomized, double‐blind and placebo‐controlled trial. Hormone and Metabolic Research2003;35:86‐91. ">Chou 2003</a>; <a href="./references#CD003053-bbs2-0011" title="FlemingR , HopkinsonZE , WallaceAM , GreerIA , SattarN . Ovarian function and metabolic factors in women with oligomenorrhea treated with metformin in a randomized double blind placebo‐controlled trial. Journal of Clinical Endocrinology and Metabolism2002;87(2):569‐74. FlemingR , HopkinsonZE , WallaceE , GreerIA , SattarN . Metformin treatment improves ovulation frequency in women with oligomenorrhoea: a randomized, double blind placebo trial. Human Fertility2000; Vol. 3, issue 4:389‐90. ">Fleming 2002</a>; <a href="./references#CD003053-bbs2-0014" title="HoegerKM , KochmanL , WixomN , CraigK , MillerRK , GuzickDS . A randomized, 48‐week, placebo‐controlled trial of intensive lifestyle modification and/or metformin therapy in overweight women with polycystic ovary syndrome: a pilot study. Fertility and Sterility2004;82:421‐9. ">Hoeger 2004</a>; <a href="./references#CD003053-bbs2-0025" title="MacielGA , Soares JrJM , Alves da MottaEL , Abi HaidarM , deLimaGR , BaracatEC , et al. Nonobese women with polycystic ovary syndrome respond better than obese women to treatment with metformin. Fertility and Sterility2004;81:355‐60. ">Maciel 2004</a>; <a href="./references#CD003053-bbs2-0029" title="Morin‐PapunenL , RantalaAS , Unkila‐KallioL , TiitinenA , HippeläinenM , PerheentupaA , et al. Metformin improves pregnancy and live‐birth rates in women with polycystic ovary syndrome (PCOS): a multicenter, double‐blind, placebo‐controlled randomized trial. Journal of Clinical Endocrinology and Metabolism2012;97:1492‐1500. ">Morin‐Papunen 2012</a>; <a href="./references#CD003053-bbs2-0036" title="CasimirriF , BiscottiM , GambineriA , CalzoniF , ElianaB , PasqualiR . Metformin improves insulin, body fat distribution, and androgens in obese women with and without the polycystic ovary syndrome. International Journal of Obesity1997;21 Suppl 2:61. PasqualiR , GambineriA , BiscottiD , VicennatiV , GagliardiL , ColittaD , et al. Effect of long‐term treatment with metformin added to hypocaloric diet on body composition, fat distribution, and androgen and insulin levels in abdominally obese women with and without the polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism2000;85(8):2767‐74. ">Pasquali 2000</a>; <a href="./references#CD003053-bbs2-0043" title="TangT , GlanvilleJ , HaydenCJ , WhiteD , BarthJH , BalenAH . Combined lifestyle modification and metformin in obese patients with polycystic ovary syndrome. A randomized, placebo‐controlled, double‐blind multicentre study. Human Reproduction2006;21:80‐9. ">Tang 2006</a>) eliminated overall heterogeneity (I<sup>2</sup> = 0%) and the results indicated no evidence of metformin on fasting glucose concentrations (MD 0 mmol/L, 95% CI ‐0.13 to 0.12). </p> </section> <section id="CD003053-sec-0090"> <h6 class="title">Insulin</h6> <p>Metformin reduced fasting insulin levels with a MD of ‐4.13 mIU/L (95% CI ‐5.67 to ‐2.58, 14 studies, 573 women) (<a href="./references#CD003053-fig-0022" title="">Analysis 1.15</a>) but with significant heterogeneity (I<sup>2</sup> = 63%). In subgroup analysis by BMI the test for subgroup differences showed no evidence of a difference between the subgroups. Sensitivity analysis by study quality (<a href="./references#CD003053-bbs2-0008" title="ChouKH , vonEye CorletaH , CappE , SpritzerPM . Clinical, metabolic and endocrine parameters in response to metformin in obese women with polycystic ovary syndrome: a randomized, double‐blind and placebo‐controlled trial. Hormone and Metabolic Research2003;35:86‐91. ">Chou 2003</a>; <a href="./references#CD003053-bbs2-0011" title="FlemingR , HopkinsonZE , WallaceAM , GreerIA , SattarN . Ovarian function and metabolic factors in women with oligomenorrhea treated with metformin in a randomized double blind placebo‐controlled trial. Journal of Clinical Endocrinology and Metabolism2002;87(2):569‐74. FlemingR , HopkinsonZE , WallaceE , GreerIA , SattarN . Metformin treatment improves ovulation frequency in women with oligomenorrhoea: a randomized, double blind placebo trial. Human Fertility2000; Vol. 3, issue 4:389‐90. ">Fleming 2002</a>; <a href="./references#CD003053-bbs2-0014" title="HoegerKM , KochmanL , WixomN , CraigK , MillerRK , GuzickDS . A randomized, 48‐week, placebo‐controlled trial of intensive lifestyle modification and/or metformin therapy in overweight women with polycystic ovary syndrome: a pilot study. Fertility and Sterility2004;82:421‐9. ">Hoeger 2004</a>; <a href="./references#CD003053-bbs2-0023" title="LordJ , ThomasR , FoxB , AcharyaU , WilkinT . The effect of metformin on fat distribution and the metabolic syndrome in women with polycystic ovary syndrome‐‐a randomised, double‐blind, placebo‐controlled trial. British Journal of Obstetrics and Gynaecology2006;113:817‐24. ">Lord 2006</a>; <a href="./references#CD003053-bbs2-0025" title="MacielGA , Soares JrJM , Alves da MottaEL , Abi HaidarM , deLimaGR , BaracatEC , et al. Nonobese women with polycystic ovary syndrome respond better than obese women to treatment with metformin. Fertility and Sterility2004;81:355‐60. ">Maciel 2004</a>; <a href="./references#CD003053-bbs2-0029" title="Morin‐PapunenL , RantalaAS , Unkila‐KallioL , TiitinenA , HippeläinenM , PerheentupaA , et al. Metformin improves pregnancy and live‐birth rates in women with polycystic ovary syndrome (PCOS): a multicenter, double‐blind, placebo‐controlled randomized trial. Journal of Clinical Endocrinology and Metabolism2012;97:1492‐1500. ">Morin‐Papunen 2012</a>; <a href="./references#CD003053-bbs2-0032" title="NgEHY , WatNMS , HoPC . Effects of metformin on ovulation rate, hormonal and metabolic profiles in women with clomiphene‐resistant polycystic ovaries: a randomized, double‐blinded placebo‐controlled trial. Human Reproduction2001;16(8):1625‐31. ">Ng 2001</a>; <a href="./references#CD003053-bbs2-0036" title="CasimirriF , BiscottiM , GambineriA , CalzoniF , ElianaB , PasqualiR . Metformin improves insulin, body fat distribution, and androgens in obese women with and without the polycystic ovary syndrome. International Journal of Obesity1997;21 Suppl 2:61. PasqualiR , GambineriA , BiscottiD , VicennatiV , GagliardiL , ColittaD , et al. Effect of long‐term treatment with metformin added to hypocaloric diet on body composition, fat distribution, and androgen and insulin levels in abdominally obese women with and without the polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism2000;85(8):2767‐74. ">Pasquali 2000</a>; <a href="./references#CD003053-bbs2-0043" title="TangT , GlanvilleJ , HaydenCJ , WhiteD , BarthJH , BalenAH . Combined lifestyle modification and metformin in obese patients with polycystic ovary syndrome. A randomized, placebo‐controlled, double‐blind multicentre study. Human Reproduction2006;21:80‐9. ">Tang 2006</a>) did not improve the heterogeneity. Once again, the heterogeneity was likely to be caused by variations in background prevalences of hyperandrogenism and insulin resistance among different study populations. </p> </section> <section id="CD003053-sec-0091"> <h6 class="title">Cholesterol</h6> <p>When we combined 11 studies, there was no conclusive evidence of a difference in serum cholesterol with the use of metformin (MD ‐0.14 mmol/L, 95% CI ‐0.31 to 0.02, 11 studies, 562 women, I<sup>2</sup> = 62%, <a href="./references#CD003053-fig-0023" title="">Analysis 1.16</a>). However, in subgroup analysis by BMI,the test for subgroup differences showed no conclusive evidence of a difference between the subgroups (test for subgroup differences: Chi² = 2.02, df = 1, P = 0.15, I² = 50.6%). </p> </section> <section id="CD003053-sec-0092"> <h6 class="title">Triglycerides</h6> <p>In general, the current review showed that there was no conclusive evidence of a difference in serum triglycerides with the use of metformin (MD 0.14 mmol/L, 95% CI ‐0.05 to 0.32, 7 studies, 309 women, I<sup>2</sup> = 0%) (<a href="./references#CD003053-fig-0024" title="">Analysis 1.17</a>). Neither subgroup analysis nor sensitivity analysis by study quality changed the inference, however the number of participants was low, and the results show broad confidence intervals. </p> </section> </section> </section> <section id="CD003053-sec-0093"> <h4 class="title">2. Metformin with clomiphene citrate versus clomiphene citrate alone</h4> <section id="CD003053-sec-0094"> <h5 class="title">2.1 Live birth rate</h5> <p>(<a href="./references#CD003053-fig-0025" title="">Analysis 2.1</a>, <a href="#CD003053-fig-0006">Figure 6</a>) </p> <p>There was no conclusive evidence of a difference in live births when metformin in combination with clomiphene citrate was compared with clomiphene citrate alone (OR 1.21, 95% CI 0.92 to 1.59, 9 studies, 1079 women, I<sup>2</sup> = 20%, low‐quality evidence). </p> <p>In subgroup analysis, the test for subgroup differences showed no evidence of a difference between the subgroups: obese group (OR 1.28, 95% CI 0.86 to 1.91, 4 studies, 548 women), non‐obese group (OR 1.14, 95% CI 0.78 to 1.67, 5 studies, 531 women). </p> <p>Sensitivity analysis by evidence quality (<a href="./references#CD003053-bbs2-0022" title="CataldoN , BarnhartH , LegroR , MyersE , SchlaffW , CarrB , et al. Extended‐release metformin does not reduce the clomiphene citrate dose required to induce ovulation in polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism2008;93(8):3147‐7. LegroRS , BarnhartHX , SchlaffWD , CarrBR , DiamondMP , CarsonSA , et al. Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome. New England Journal of Medicine2007;356:551‐66. [original article] ">Legro 2007</a>; <a href="./references#CD003053-bbs2-0028" title="MollE , BossuytPM , KorevaarJC , LambalkCB , Van derVeenF . Effect of clomifene citrate plus metformin and clomifene citrate plus placebo on induction of ovulation in women with newly diagnosed polycystic ovary syndrome: randomised double blind clinical trial. BMJ2006;332:1485. [original article] MollE , KorevaarJC , BossuytPM , van derVeenF . Does adding metformin to clomifene citrate lead to higher pregnancy rates in a subset of women with polycystic ovary syndrome?. Human Reproduction2008;23(8):1830‐4. MollE , VanWelyM , LambalkCB , BossuytPM , Van derVeenF . Health‐related quality of life in women with newly diagnosed polycystic ovary syndrome randomized between clomifene citrate plus metformin or clomifene citrate plus placebo. Human Reproduction2012;27:3273‐8. ">Moll 2006</a>; <a href="./references#CD003053-bbs2-0029" title="Morin‐PapunenL , RantalaAS , Unkila‐KallioL , TiitinenA , HippeläinenM , PerheentupaA , et al. Metformin improves pregnancy and live‐birth rates in women with polycystic ovary syndrome (PCOS): a multicenter, double‐blind, placebo‐controlled randomized trial. Journal of Clinical Endocrinology and Metabolism2012;97:1492‐1500. ">Morin‐Papunen 2012</a>; <a href="./references#CD003053-bbs2-0037" title="JohnsonNP , BontekoeS , StewartAW . Analysis of factors predicting success of metformin and clomiphene treatment for women with infertility owing to PCOS‐related ovulation dysfunction in a randomised controlled trial. Australian &amp; New Zealand Journal of Obstetrics &amp; Gynaecology2011;51:252‐6. JohnsonNP , StewartAW , FalkinerJ , FarquharCM , MilsomS , SinghV‐P , et al. on behalf of REACT‐NZ (REproduction And Collaborative Trials in New Zealand), a multi‐centre fertility trials group. PCOSMIC: a multi‐centre randomized trial in women with Polycystic Ovary Syndrome evaluating Metformin for Infertility with Clomiphene. Human Reproduction2010;25(7):1675‐83. [MEDLINE: 10.1093/humrep/deq100] ">PCOSMIC 2010</a>), with 816 women, also did not change the inference nor improve heterogeneity. </p> </section> <section id="CD003053-sec-0095"> <h5 class="title">2.2 Adverse events</h5> <p>(<a href="./references#CD003053-fig-0026" title="">Analysis 2.2</a>) </p> <p>There was evidence of more frequent gastrointestinal side effects in the metformin group, including nausea and vomiting (OR 3.97, 95% CI 2.59 to 6.08, 3 studies, 591 women, I<sup>2</sup> = 47%, moderate‐quality evidence) compared with the control group. All participants in this analysis were non‐obese. Sensitivity analysis by study quality did not change our findings. </p> </section> <section id="CD003053-sec-0096"> <h5 class="title">2.3 Clinical pregnancy rate</h5> <p>(<a href="./references#CD003053-fig-0027" title="">Analysis 2.3</a>) </p> <p>When combined with clomiphene citrate, there was evidence that metformin had a beneficial effect on pregnancy rate compared to clomiphene citrate alone (OR 1.59, 95% CI 1.27 to 1.99, 16 studies, 1529 women, I<sup>2</sup> = 33%, moderate‐quality evidence). </p> <p>In subgroup analysis, the test for subgroup differences showed no evidence of a difference between the subgroups: the effect on pregnancy rates was seen in both analyses: obese group (OR 1.76, 95% CI 1.26 to 2.47, 7 studies, 695 women) and non‐obese group (OR 1.46, 95% CI 1.08 to 1.98, 9 studies, 834 women). Sensitivity analysis by study quality (<a href="./references#CD003053-bbs2-0022" title="CataldoN , BarnhartH , LegroR , MyersE , SchlaffW , CarrB , et al. Extended‐release metformin does not reduce the clomiphene citrate dose required to induce ovulation in polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism2008;93(8):3147‐7. LegroRS , BarnhartHX , SchlaffWD , CarrBR , DiamondMP , CarsonSA , et al. Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome. New England Journal of Medicine2007;356:551‐66. [original article] ">Legro 2007</a>; <a href="./references#CD003053-bbs2-0028" title="MollE , BossuytPM , KorevaarJC , LambalkCB , Van derVeenF . Effect of clomifene citrate plus metformin and clomifene citrate plus placebo on induction of ovulation in women with newly diagnosed polycystic ovary syndrome: randomised double blind clinical trial. BMJ2006;332:1485. [original article] MollE , KorevaarJC , BossuytPM , van derVeenF . Does adding metformin to clomifene citrate lead to higher pregnancy rates in a subset of women with polycystic ovary syndrome?. Human Reproduction2008;23(8):1830‐4. MollE , VanWelyM , LambalkCB , BossuytPM , Van derVeenF . Health‐related quality of life in women with newly diagnosed polycystic ovary syndrome randomized between clomifene citrate plus metformin or clomifene citrate plus placebo. Human Reproduction2012;27:3273‐8. ">Moll 2006</a>; <a href="./references#CD003053-bbs2-0029" title="Morin‐PapunenL , RantalaAS , Unkila‐KallioL , TiitinenA , HippeläinenM , PerheentupaA , et al. Metformin improves pregnancy and live‐birth rates in women with polycystic ovary syndrome (PCOS): a multicenter, double‐blind, placebo‐controlled randomized trial. Journal of Clinical Endocrinology and Metabolism2012;97:1492‐1500. ">Morin‐Papunen 2012</a>), with 745 participants, did not change the inference or improve heterogeneity. </p> </section> <section id="CD003053-sec-0097"> <h5 class="title">2.4 Ovulation rate</h5> <p>(<a href="./references#CD003053-fig-0028" title="">Analysis 2.4</a>; <a href="./references#CD003053-fig-0029" title="">Analysis 2.5</a>) </p> <p>There was evidence of a beneficial effect for metformin combined with clomiphene citrate versus clomiphene citrate alone on ovulation per woman, (OR 1.57, 95% CI 1.28 to 1.92, 21 studies, 1624 women, I<sup>2</sup> = 64%, moderate‐quality evidence). We have presented ovulation rate per cycle in an additional table (<a href="#CD003053-tbl-0007">Table 4</a>). In subgroup analysis, the test for subgroup differences showed no evidence of a difference between the subgroups. Heterogenity remained high (I<sup>2</sup> = 70%) in the obese sub group, but the direction of effect was consistent. We conducted a subgroup analysis based on sensitivity to clomiphene citrate. Seven studies were available that had recorded clomiphene citrate‐resistance status. Six of these included women with clomiphene citrate resistance (<a href="./references#CD003053-bbs2-0015" title="HwuYM , LinSY , HuangWY , LinMH , LeeRK . Ultra‐short metformin pretreatment for clomiphene citrate‐resistant polycystic ovary syndrome. International Journal of Gynaecology and Obstetrics2005;90:39‐43. ">Hwu 2005</a>; <a href="./references#CD003053-bbs2-0024" title="MachadoRC , MachadoNA , GeberS . Evaluation of the use of metformin for ovulation in patients with PCOS resistant to isolated use of clomiphene citrate. Brazilian Journal Assisted Reproduction2012;16(1):27‐31. ">Machado 2012</a>; <a href="./references#CD003053-bbs2-0026" title="MalkawiHY , QublanHS . The effect of metformin plus clomiphene citrate on ovulation and pregnancy rates in clomiphene‐resistant women with polycystic ovary syndrome. Saudi Medical Journal2002;23(6):663‐6. [MEDLINE: 22065897] ">Malkawi 2002</a>; <a href="./references#CD003053-bbs2-0032" title="NgEHY , WatNMS , HoPC . Effects of metformin on ovulation rate, hormonal and metabolic profiles in women with clomiphene‐resistant polycystic ovaries: a randomized, double‐blinded placebo‐controlled trial. Human Reproduction2001;16(8):1625‐31. ">Ng 2001</a>; <a href="./references#CD003053-bbs2-0042" title="SturrockNDC , LannonB , FayTN . Metformin does not enhance ovulation induction in clomiphene resistant polycystic ovary syndrome in clinical practice. British Journal of Clinical Pharmacology2002;53(5):469‐73. [MEDLINE: 2002180629] ">Sturrock 2002</a>; <a href="./references#CD003053-bbs2-0045" title="VandermolenDT , RattsVS , EvansWS , StovallDW , KaumaSW , NestlerJE . Metformin increases the ovulatory rate and pregnancy rate from clomiphene citrate in patients with polycystic ovary syndrome who are resistant to clomiphene citrate alone. Fertility and Sterility2001;75:310‐5. ">Vandermolen 2001</a>). This analysis showed an improvement in ovulation rate with combined therapy (OR 4.89, 95% CI 2.62 to 9.13, 6 studies, 215 women, I<sup>2</sup> = 0%, moderate‐quality evidence). Only one small study of clomiphene citrate‐sensitive women was available, and a conclusion cannot be drawn from the result (OR 3.55, 95% CI 0.65 to 19.37, 56 women). Sensitivity analysis by study quality (<a href="./references#CD003053-bbs2-0022" title="CataldoN , BarnhartH , LegroR , MyersE , SchlaffW , CarrB , et al. Extended‐release metformin does not reduce the clomiphene citrate dose required to induce ovulation in polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism2008;93(8):3147‐7. LegroRS , BarnhartHX , SchlaffWD , CarrBR , DiamondMP , CarsonSA , et al. Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome. New England Journal of Medicine2007;356:551‐66. [original article] ">Legro 2007</a>; <a href="./references#CD003053-bbs2-0028" title="MollE , BossuytPM , KorevaarJC , LambalkCB , Van derVeenF . Effect of clomifene citrate plus metformin and clomifene citrate plus placebo on induction of ovulation in women with newly diagnosed polycystic ovary syndrome: randomised double blind clinical trial. BMJ2006;332:1485. [original article] MollE , KorevaarJC , BossuytPM , van derVeenF . Does adding metformin to clomifene citrate lead to higher pregnancy rates in a subset of women with polycystic ovary syndrome?. Human Reproduction2008;23(8):1830‐4. MollE , VanWelyM , LambalkCB , BossuytPM , Van derVeenF . Health‐related quality of life in women with newly diagnosed polycystic ovary syndrome randomized between clomifene citrate plus metformin or clomifene citrate plus placebo. Human Reproduction2012;27:3273‐8. ">Moll 2006</a>; <a href="./references#CD003053-bbs2-0032" title="NgEHY , WatNMS , HoPC . Effects of metformin on ovulation rate, hormonal and metabolic profiles in women with clomiphene‐resistant polycystic ovaries: a randomized, double‐blinded placebo‐controlled trial. Human Reproduction2001;16(8):1625‐31. ">Ng 2001</a>; <a href="./references#CD003053-bbs2-0037" title="JohnsonNP , BontekoeS , StewartAW . Analysis of factors predicting success of metformin and clomiphene treatment for women with infertility owing to PCOS‐related ovulation dysfunction in a randomised controlled trial. Australian &amp; New Zealand Journal of Obstetrics &amp; Gynaecology2011;51:252‐6. JohnsonNP , StewartAW , FalkinerJ , FarquharCM , MilsomS , SinghV‐P , et al. on behalf of REACT‐NZ (REproduction And Collaborative Trials in New Zealand), a multi‐centre fertility trials group. PCOSMIC: a multi‐centre randomized trial in women with Polycystic Ovary Syndrome evaluating Metformin for Infertility with Clomiphene. Human Reproduction2010;25(7):1675‐83. [MEDLINE: 10.1093/humrep/deq100] ">PCOSMIC 2010</a>) did not alter our findings. </p> </section> <section id="CD003053-sec-0098"> <h5 class="title">2.5 Menstrual frequency</h5> <p>Data were not available for this outcome.</p> </section> <section id="CD003053-sec-0099"> <h5 class="title">2.6 Miscarriage rate</h5> <p>(<a href="./references#CD003053-fig-0030" title="">Analysis 2.6</a>; <a href="./references#CD003053-fig-0031" title="">Analysis 2.7</a>) </p> <p>When we pooled the data from nine studies, we detected a difference in miscarriage rate per woman (OR 1.59, 95% CI 1.03 to 2.46, 9 studies, 1096 women I<sup>2</sup> = 0%, low‐quality evidence). This suggests that the likelihood of miscarriage may be greater with combined therapy than when clomiphene citrate is used alone. When we analysed a subgroup by BMI, the test for subgroup differences showed no evidence of a difference between the subgroups. When we performed an analysis of miscarriage rate per pregnancy, there was no clear evidence of a difference between the groups (OR 1.30, 95% CI 0.80 to 2.12, 400 pregnancies, I<sup>2</sup> = 0%), still with no evidence of a difference between the BMI subgroups. Sensitivity analysis by study quality (<a href="./references#CD003053-bbs2-0022" title="CataldoN , BarnhartH , LegroR , MyersE , SchlaffW , CarrB , et al. Extended‐release metformin does not reduce the clomiphene citrate dose required to induce ovulation in polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism2008;93(8):3147‐7. LegroRS , BarnhartHX , SchlaffWD , CarrBR , DiamondMP , CarsonSA , et al. Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome. New England Journal of Medicine2007;356:551‐66. [original article] ">Legro 2007</a>; <a href="./references#CD003053-bbs2-0028" title="MollE , BossuytPM , KorevaarJC , LambalkCB , Van derVeenF . Effect of clomifene citrate plus metformin and clomifene citrate plus placebo on induction of ovulation in women with newly diagnosed polycystic ovary syndrome: randomised double blind clinical trial. BMJ2006;332:1485. [original article] MollE , KorevaarJC , BossuytPM , van derVeenF . Does adding metformin to clomifene citrate lead to higher pregnancy rates in a subset of women with polycystic ovary syndrome?. Human Reproduction2008;23(8):1830‐4. MollE , VanWelyM , LambalkCB , BossuytPM , Van derVeenF . Health‐related quality of life in women with newly diagnosed polycystic ovary syndrome randomized between clomifene citrate plus metformin or clomifene citrate plus placebo. Human Reproduction2012;27:3273‐8. ">Moll 2006</a>; <a href="./references#CD003053-bbs2-0029" title="Morin‐PapunenL , RantalaAS , Unkila‐KallioL , TiitinenA , HippeläinenM , PerheentupaA , et al. Metformin improves pregnancy and live‐birth rates in women with polycystic ovary syndrome (PCOS): a multicenter, double‐blind, placebo‐controlled randomized trial. Journal of Clinical Endocrinology and Metabolism2012;97:1492‐1500. ">Morin‐Papunen 2012</a>; <a href="./references#CD003053-bbs2-0037" title="JohnsonNP , BontekoeS , StewartAW . Analysis of factors predicting success of metformin and clomiphene treatment for women with infertility owing to PCOS‐related ovulation dysfunction in a randomised controlled trial. Australian &amp; New Zealand Journal of Obstetrics &amp; Gynaecology2011;51:252‐6. JohnsonNP , StewartAW , FalkinerJ , FarquharCM , MilsomS , SinghV‐P , et al. on behalf of REACT‐NZ (REproduction And Collaborative Trials in New Zealand), a multi‐centre fertility trials group. PCOSMIC: a multi‐centre randomized trial in women with Polycystic Ovary Syndrome evaluating Metformin for Infertility with Clomiphene. Human Reproduction2010;25(7):1675‐83. [MEDLINE: 10.1093/humrep/deq100] ">PCOSMIC 2010</a>) also did not alter the inference. Any increase in miscarriage conferred by using clomiphene citrate therapy in isolation is therefore difficult to interpret and apply clinically. </p> </section> <section id="CD003053-sec-0100"> <h5 class="title">2.7 Multiple pregnancy rate</h5> <p>(<a href="./references#CD003053-fig-0032" title="">Analysis 2.8</a>; <a href="./references#CD003053-fig-0033" title="">Analysis 2.9</a>) </p> <p>There was no conclusive evidence of a difference between metformin combined with clomiphene citrate versus clomiphene citrate alone (OR 0.56, 95% CI 0.18 to 1.68, 6 studies, 1003 women, I<sup>2</sup>=0%). Sensitivity analysis using per pregnancy rates did not produce different findings </p> <p>(OR 0.46, 95% CI 0.15 to 1.42, 6 studies, 342 pregnancies, I<sup>2</sup> = 0%). Sensitivity analysis by study quality (<a href="./references#CD003053-bbs2-0022" title="CataldoN , BarnhartH , LegroR , MyersE , SchlaffW , CarrB , et al. Extended‐release metformin does not reduce the clomiphene citrate dose required to induce ovulation in polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism2008;93(8):3147‐7. LegroRS , BarnhartHX , SchlaffWD , CarrBR , DiamondMP , CarsonSA , et al. Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome. New England Journal of Medicine2007;356:551‐66. [original article] ">Legro 2007</a>; <a href="./references#CD003053-bbs2-0028" title="MollE , BossuytPM , KorevaarJC , LambalkCB , Van derVeenF . Effect of clomifene citrate plus metformin and clomifene citrate plus placebo on induction of ovulation in women with newly diagnosed polycystic ovary syndrome: randomised double blind clinical trial. BMJ2006;332:1485. [original article] MollE , KorevaarJC , BossuytPM , van derVeenF . Does adding metformin to clomifene citrate lead to higher pregnancy rates in a subset of women with polycystic ovary syndrome?. Human Reproduction2008;23(8):1830‐4. MollE , VanWelyM , LambalkCB , BossuytPM , Van derVeenF . Health‐related quality of life in women with newly diagnosed polycystic ovary syndrome randomized between clomifene citrate plus metformin or clomifene citrate plus placebo. Human Reproduction2012;27:3273‐8. ">Moll 2006</a>; <a href="./references#CD003053-bbs2-0037" title="JohnsonNP , BontekoeS , StewartAW . Analysis of factors predicting success of metformin and clomiphene treatment for women with infertility owing to PCOS‐related ovulation dysfunction in a randomised controlled trial. Australian &amp; New Zealand Journal of Obstetrics &amp; Gynaecology2011;51:252‐6. JohnsonNP , StewartAW , FalkinerJ , FarquharCM , MilsomS , SinghV‐P , et al. on behalf of REACT‐NZ (REproduction And Collaborative Trials in New Zealand), a multi‐centre fertility trials group. PCOSMIC: a multi‐centre randomized trial in women with Polycystic Ovary Syndrome evaluating Metformin for Infertility with Clomiphene. Human Reproduction2010;25(7):1675‐83. [MEDLINE: 10.1093/humrep/deq100] ">PCOSMIC 2010</a>) did not alter the inference either. </p> </section> <section id="CD003053-sec-0101"> <h5 class="title">Other outcomes</h5> <p>Data were not available for anthropometric, endocrine or metabolic outcomes.</p> </section> </section> <section id="CD003053-sec-0102"> <h4 class="title">3. Metformin versus clomiphene citrate</h4> <section id="CD003053-sec-0103"> <h5 class="title">3.1 Live birth rate</h5> <p>(<a href="./references#CD003053-fig-0034" title="">Analysis 3.1</a>, <a href="#CD003053-fig-0007">Figure 7</a>) </p> <p>When we combined the data from five studies (<a href="./references#CD003053-bbs2-0017" title="KarS . Metabolic risks of the lean PCOS woman. Fertility and Sterility ASRM abstracts2013;100(S359):P‐730. KarS , SanchitaS . Clomiphene citrate, metformin or a combination of both as the first line ovulation induction drug for Asian Indian women with polycystic ovarian syndrome: a randomized controlled trial. Journal of Human Reproductive Science2015;8:197‐201. ">Kar 2015</a>; <a href="./references#CD003053-bbs2-0022" title="CataldoN , BarnhartH , LegroR , MyersE , SchlaffW , CarrB , et al. Extended‐release metformin does not reduce the clomiphene citrate dose required to induce ovulation in polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism2008;93(8):3147‐7. LegroRS , BarnhartHX , SchlaffWD , CarrBR , DiamondMP , CarsonSA , et al. Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome. New England Journal of Medicine2007;356:551‐66. [original article] ">Legro 2007</a>; <a href="./references#CD003053-bbs2-0035" title="PalombaS , OrioFJr , FalboA , MangusoF , RussoT , CascellaT , et al. Prospective parallel randomized, double‐blind, double‐dummy controlled clinical trial comparing clomiphene citrate and metformin as the first‐line treatment for ovulation induction in nonobese anovulatory women with polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism2005;90(7):4068‐74. [original article] PalombaS , OrioFJr , FalboA , RussoT , TolinoA , ZulloF . Effects of metformin and clomiphene citrate on ovarian vascularity in patients with polycystic ovary syndrome. Fertility and Sterility2006;86:1694‐701. ">Palomba 2005</a>; <a href="./references#CD003053-bbs2-0037" title="JohnsonNP , BontekoeS , StewartAW . Analysis of factors predicting success of metformin and clomiphene treatment for women with infertility owing to PCOS‐related ovulation dysfunction in a randomised controlled trial. Australian &amp; New Zealand Journal of Obstetrics &amp; Gynaecology2011;51:252‐6. JohnsonNP , StewartAW , FalkinerJ , FarquharCM , MilsomS , SinghV‐P , et al. on behalf of REACT‐NZ (REproduction And Collaborative Trials in New Zealand), a multi‐centre fertility trials group. PCOSMIC: a multi‐centre randomized trial in women with Polycystic Ovary Syndrome evaluating Metformin for Infertility with Clomiphene. Human Reproduction2010;25(7):1675‐83. [MEDLINE: 10.1093/humrep/deq100] ">PCOSMIC 2010</a>; <a href="./references#CD003053-bbs2-0048" title="ZainMM , JamaluddinR , IbrahimA , NormanRJ . Comparison of clomiphene citrate, metformin, or the combination of both for first‐line ovulation induction, achievement of pregnancy, and live birth in Asian women with polycystic ovary syndrome: a randomized controlled trial. Fertility and Sterility2009;91(2):514‐21. ">Zain 2009</a>), there was no conclusive evidence of a difference between the groups, with high heterogeneity (OR 0.71, 95% CI 0.49 to 1.01, 5 studies, 741 women, I<sup>2</sup> = 86%, very low‐quality evidence) (<a href="./references#CD003053-fig-0034" title="">Analysis 3.1</a>). However, in the subgroup analysis by obesity status, there was evidence of a difference between the subgroups (test for subgroup differences: Chi² = 19.41, df = 1, P &lt; 0.0001, I<sup>2</sup> = 94.8%). Among obese women, live births were lower in the metformin group (OR 0.30, 95% CI 0.17 to 0.52, 2 studies, 500 women); 62% of the weight of this finding was provided by a single study (<a href="./references#CD003053-bbs2-0022" title="CataldoN , BarnhartH , LegroR , MyersE , SchlaffW , CarrB , et al. Extended‐release metformin does not reduce the clomiphene citrate dose required to induce ovulation in polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism2008;93(8):3147‐7. LegroRS , BarnhartHX , SchlaffWD , CarrBR , DiamondMP , CarsonSA , et al. Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome. New England Journal of Medicine2007;356:551‐66. [original article] ">Legro 2007</a>). In the non‐obese subgroup the direction of effect favoured metformin with high heterogeneity (OR 1.71, 95% CI 1.00 to 2.94, 3 studies, 241 women, I<sup>2</sup> = 78%, very low‐quality evidence). </p> </section> <section id="CD003053-sec-0104"> <h5 class="title">3.2 Adverse events</h5> <p>Data were not available for this outcome.</p> </section> <section id="CD003053-sec-0105"> <h5 class="title">3.3 Clinical pregnancy rate</h5> <p>(<a href="./references#CD003053-fig-0035" title="">Analysis 3.2</a>) </p> <p>The overall heterogeneity was high (I<sup>2</sup> = 86%) and the data were not appropriate to be pooled. However, subgroup analysis by obesity status showed evidence of a difference between the subgroups (test for subgroup differences: Chi² = 22.94, df = 1, P &lt; 0.00001, I<sup>2</sup> = 95.6%). In the non‐obese group, there was evidence of higher pregnancy rates in women who took metformin compared to those who took clomiphene citrate (OR 1.56, 95% CI 1.05 to 2.33, 5 studies, 490 women, I<sup>2</sup> = 41%, very low‐quality evidence) whilst a different effect was observed in the obese group (OR 0.34, 95% CI 0.21 to 0.55, 2 studies, 500 women, I<sup>2</sup> = 0%, very low‐quality evidence). Sensitivity analysis by study quality did not change the inference. </p> </section> <section id="CD003053-sec-0106"> <h5 class="title">3.4 Ovulation rate</h5> <p>(<a href="./references#CD003053-fig-0036" title="">Analysis 3.3</a>) </p> <p>The overall heterogeneity was high (I<sup>2</sup> = 74%) and the data were not appropriate to be pooled. </p> <p>Subgroup analysis by obesity status again showed evidence of a difference between the subgroups (test for subgroup differences: Chi² = 11.23, df = 1, P = 0.0008, I² = 91.1%). In the obese group, combining the results from <a href="./references#CD003053-bbs2-0022" title="CataldoN , BarnhartH , LegroR , MyersE , SchlaffW , CarrB , et al. Extended‐release metformin does not reduce the clomiphene citrate dose required to induce ovulation in polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism2008;93(8):3147‐7. LegroRS , BarnhartHX , SchlaffWD , CarrBR , DiamondMP , CarsonSA , et al. Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome. New England Journal of Medicine2007;356:551‐66. [original article] ">Legro 2007</a> and <a href="./references#CD003053-bbs2-0048" title="ZainMM , JamaluddinR , IbrahimA , NormanRJ . Comparison of clomiphene citrate, metformin, or the combination of both for first‐line ovulation induction, achievement of pregnancy, and live birth in Asian women with polycystic ovary syndrome: a randomized controlled trial. Fertility and Sterility2009;91(2):514‐21. ">Zain 2009</a> found improved ovulation rates with clomiphene citrate therapy (OR 0.29, 95% CI 0.20 to 0.43, 2 studies, 500 women, 2044 cycles, I<sup>2</sup> = 0%). In the non‐obese group, the data were inconclusive. Sensitivity analysis by study quality did not change the inference. We have presented ovulation rate per cycle in an additional table (<a href="#CD003053-tbl-0008">Table 5</a>). </p> </section> <section id="CD003053-sec-0107"> <h5 class="title">3.5 Menstrual frequency</h5> <p>Data were not available for this outcome.</p> </section> <section id="CD003053-sec-0108"> <h5 class="title">3.6 Miscarriage rate</h5> <p>(<a href="./references#CD003053-fig-0037" title="">Analysis 3.4</a>; <a href="./references#CD003053-fig-0038" title="">Analysis 3.5</a>) </p> <p>The data regarding miscarriage rate with either clomiphene citrate or metformin treatment were inconclusive across both BMI groups (OR 0.92, 95% CI 0.50 to 1.67, 5 studies, 741 women, I<sup>2</sup> = 52%). </p> <p>Per‐pregnancy data were unsuitable for pooling in a subgroup analysis due to high heterogeneity (I<sup>2</sup> = 78%) and differing directions of effect, so no conclusions could be drawn. Neither subgroup analysis by obesity status nor sensitivity analysis by study quality improved the heterogeneity in the per‐pregnancy analysis. </p> </section> <section id="CD003053-sec-0109"> <h5 class="title">3.7 Multiple pregnancy rate</h5> <p>(<a href="./references#CD003053-fig-0039" title="">Analysis 3.6</a>; <a href="./references#CD003053-fig-0040" title="">Analysis 3.7</a>) </p> <p>There was no conclusive evidence of a difference between the groups (0.29, 95% CI 0.06 to 1.43, 5 studies, 858 women, I<sup>2</sup> = 0%). In the subgroup analysis by obesity status, there was no evidence of a difference between the subgroups. Sensitivity analysis by study quality did not change the inference. </p> </section> <section id="CD003053-sec-0110"> <h5 class="title">Other outcomes</h5> <p>Data were not available for anthropometric, endocrine or metabolic outcomes.</p> </section> </section> <section id="CD003053-sec-0111"> <h4 class="title">4 D‐chiro‐inositol versus placebo or no treatment</h4> <p>Although two trials were included (<a href="./references#CD003053-bbs2-0012" title="GerliS , MignosaM , DiRenzoGC . Effects of inositol on ovarian function and metabolic factors in women with PCOS: a randomized double blind placebo‐controlled trial. European Review for Medical and Pharmacological Sciences2003;7:151‐9. [Original article] GerliS , PapaleoE , FerrariA , DiRenzoGC . Randomized, double blind placebo‐controlled trial: effects of myo‐inositol on ovarian function and metabolic factors in women with PCOS. European Review for Medical and Pharmacological Sciences2007;11(5):347‐54. ">Gerli 2003</a>; <a href="./references#CD003053-bbs2-0031" title="NestlerJE , JakubowiczDJ , ReamerP , GunnRD , AllanG . Ovulatory and metabolic effects of D‐chiro‐inositol in the polycystic ovary syndrome. New England Journal of Medicine1999;340(17):1314‐20. ">Nestler 1999</a>), the number of women in the analysis remained small. Furthermore, one of the trials (<a href="./references#CD003053-bbs2-0012" title="GerliS , MignosaM , DiRenzoGC . Effects of inositol on ovarian function and metabolic factors in women with PCOS: a randomized double blind placebo‐controlled trial. European Review for Medical and Pharmacological Sciences2003;7:151‐9. [Original article] GerliS , PapaleoE , FerrariA , DiRenzoGC . Randomized, double blind placebo‐controlled trial: effects of myo‐inositol on ovarian function and metabolic factors in women with PCOS. European Review for Medical and Pharmacological Sciences2007;11(5):347‐54. ">Gerli 2003</a>) reported analysable data for only one outcome of interest (ovulation rate, moderate‐quality evidence). It would be difficult to make any conclusions based on the current findings. </p> <section id="CD003053-sec-0112"> <h5 class="title">4.1 Live birth</h5> <p>Data were not available for this outcome.</p> </section> <section id="CD003053-sec-0113"> <h5 class="title">4.2 Adverse events</h5> <p>Data were not available for this outcome.</p> </section> <section id="CD003053-sec-0114"> <h5 class="title">4.3 Clinical pregnancy</h5> <p>Data were not available for this outcome.</p> </section> <section id="CD003053-sec-0115"> <h5 class="title">4.4 Ovulation rate</h5> <p>(<a href="./references#CD003053-fig-0041" title="">Analysis 4.1</a>) </p> <p>The data suggested that D‐chiro‐inositol may improve ovulation rates per woman (OR 3.57, 95% CI 1.72 to 7.45; 2 studies, 327 women, I<sup>2</sup> = 81%), however there were only two studies and the results correspondingly show very wide confidence intervals. Neither a subgroup analysis nor sensitivity analysis were possible due to the inadequate number of studies. We have presented ovulation rate per cycle in an additional table (<a href="#CD003053-tbl-0009">Table 6</a>). </p> </section> <section id="CD003053-sec-0116"> <h5 class="title">Other outcomes</h5> <p>Data were not available for other reproductive outcomes.</p> </section> <section id="CD003053-sec-0117"> <h5 class="title">1.8 Anthropometric outcomes</h5> <p>(<a href="./references#CD003053-fig-0042" title="">Analysis 4.2</a>; <a href="./references#CD003053-fig-0043" title="">Analysis 4.3</a>; <a href="./references#CD003053-fig-0044" title="">Analysis 4.4</a>; <a href="./references#CD003053-fig-0045" title="">Analysis 4.5</a>) </p> <p>Only one study, with 44 women (<a href="./references#CD003053-bbs2-0031" title="NestlerJE , JakubowiczDJ , ReamerP , GunnRD , AllanG . Ovulatory and metabolic effects of D‐chiro‐inositol in the polycystic ovary syndrome. New England Journal of Medicine1999;340(17):1314‐20. ">Nestler 1999</a>) was included in the analysis. There was no conclusive evidence that D‐chiro‐inositol had an effect on BMI, waist to hip ratio or blood pressure. </p> </section> <section id="CD003053-sec-0118"> <h5 class="title">1.9, 1.10 Endocrine and metabolic outcomes</h5> <p>(<a href="./references#CD003053-fig-0046" title="">Analysis 4.6</a>; <a href="./references#CD003053-fig-0047" title="">Analysis 4.7</a>; <a href="./references#CD003053-fig-0048" title="">Analysis 4.8</a>; <a href="./references#CD003053-fig-0049" title="">Analysis 4.9</a>; <a href="./references#CD003053-fig-0050" title="">Analysis 4.10</a>; <a href="./references#CD003053-fig-0051" title="">Analysis 4.11</a>) </p> <p>Only one study (<a href="./references#CD003053-bbs2-0031" title="NestlerJE , JakubowiczDJ , ReamerP , GunnRD , AllanG . Ovulatory and metabolic effects of D‐chiro‐inositol in the polycystic ovary syndrome. New England Journal of Medicine1999;340(17):1314‐20. ">Nestler 1999</a>) was included in the analysis. There was no conclusive evidence that D‐chiro‐inositol had an effect on these parameters (i.e. testosterone, sex hormone‐binding globulin, fasting glucose, fasting insulin, lipids (total cholesterol, triglycerides) except for serum sex hormone‐binding globulin levels. </p> </section> </section> <section id="CD003053-sec-0119"> <h4 class="title">5 Rosiglitazone versus placebo or no treatment</h4> <p>Three trials were included in the current review. Due to the withdrawal of troglitazone from the market, the drug used in the trials was either rosiglitazone or pioglitazone. </p> <p>Data were not available for primary outcomes, but were available for some secondary outcomes, including ovulation rate, menstrual frequency and anthropometric, endocrine and metabolic outcomes. </p> <section id="CD003053-sec-0120"> <h5 class="title">5.4 Ovulation rate</h5> <p>(<a href="./references#CD003053-fig-0052" title="">Analysis 5.1</a>) </p> <p>Only the <a href="./references#CD003053-bbs2-0002" title="BaillargeonJP , JakubowiczDJ , IuornoMJ , JakubowiczS , NestlerJE . Effects of metformin and rosiglitazone, alone and in combination, in nonobese women with polycystic ovary syndrome and normal indices of insulin sensitivity. Fertility and Sterility2004;82:893‐902. ">Baillargeon 2004</a> study of 64 women was available for this outcome (OR 1.91, 95% CI 0.70 to 5.22, 64 women, very low‐quality evidence), so no conclusions can be drawn. We have presented ovulation rate per cycle in an additional table (<a href="#CD003053-tbl-0010">Table 7</a>). </p> </section> <section id="CD003053-sec-0121"> <h5 class="title">5.5 Menstrual frequency</h5> <p>(<a href="./references#CD003053-fig-0053" title="">Analysis 5.2</a>) </p> <p>Evidence of an improvement in menstrual pattern with rosiglitazone was observed in two studies (OR 5.59, 95% CI 2.20 to 14.19; 2 studies, 100 women, I<sup>2</sup> = 12%). </p> </section> <section id="CD003053-sec-0122"> <h5 class="title">5.8 Anthropometric outcomes</h5> <p>Women who took rosiglitazone were found to have an increased BMI (MD 0.68, 95% CI 0.40 to 0.96, 3 studies, 132 women, I<sup>2</sup> = 15%) (<a href="./references#CD003053-fig-0054" title="">Analysis 5.3</a> ). </p> <p>Rosiglitazone was found to have a marginal benefit on waist to hip ratio (MD ‐0.01, 95% CI ‐0.02 to 0.00, 3 studies, 132 women, I<sup>2</sup> = 0%, <a href="./references#CD003053-fig-0055" title="">Analysis 5.4</a>). </p> <p>Based on one study (<a href="./references#CD003053-bbs2-0002" title="BaillargeonJP , JakubowiczDJ , IuornoMJ , JakubowiczS , NestlerJE . Effects of metformin and rosiglitazone, alone and in combination, in nonobese women with polycystic ovary syndrome and normal indices of insulin sensitivity. Fertility and Sterility2004;82:893‐902. ">Baillargeon 2004</a>), the effect on blood pressure was small (<a href="./references#CD003053-fig-0056" title="">Analysis 5.5</a>; <a href="./references#CD003053-fig-0057" title="">Analysis 5.6</a>). </p> </section> <section id="CD003053-sec-0123"> <h5 class="title">5.9, 5.10 Endocrine and metabolic outcomes</h5> <p>The effects on testosterone, sex hormone‐binding globulin, insulin, glucose, cholesterol and triglyceride were found to be minimal (<a href="./references#CD003053-fig-0058" title="">Analysis 5.7</a>; <a href="./references#CD003053-fig-0059" title="">Analysis 5.8</a>; <a href="./references#CD003053-fig-0060" title="">Analysis 5.9</a>; <a href="./references#CD003053-fig-0061" title="">Analysis 5.10</a>; <a href="./references#CD003053-fig-0062" title="">Analysis 5.11</a>; <a href="./references#CD003053-fig-0063" title="">Analysis 5.12</a>). </p> </section> </section> <section id="CD003053-sec-0124"> <h4 class="title">6 Pioglitazone versus placebo or no treatment</h4> <p>Data were not available for primary outcomes, but were available for some secondary outcomes, including menstrual frequency and anthropometric, endocrine and metabolic outcomes. There was evidence that pioglitazone improved the menstrual pattern (OR 8.88, 95% CI 2.35 to 33.61, 2 studies, 70 women, I<sup>2</sup> = 0%, moderate‐quality evidence) (<a href="./references#CD003053-fig-0064" title="">Analysis 6.1</a>). The studies differed in obesity status (only one study in each category), and both found an benefit in the intervention group. </p> <p>There was no evidence of a difference between the groups for anthropometric outcomes (BMI (<a href="./references#CD003053-fig-0065" title="">Analysis 6.2</a>); waist to hip ratio (<a href="./references#CD003053-fig-0066" title="">Analysis 6.3</a>)), endocrine outcomes (testosterone (<a href="./references#CD003053-fig-0067" title="">Analysis 6.4</a>); sex hormone‐binding globulin (<a href="./references#CD003053-fig-0068" title="">Analysis 6.5</a>)) or metabolic outcomes (fasting insulin (<a href="./references#CD003053-fig-0069" title="">Analysis 6.6</a>)). </p> </section> <section id="CD003053-sec-0125"> <h4 class="title">Publication bias</h4> <p>We planned to assess publication bias using a funnel plot but no analyses of primary outcomes had sufficient included studies. </p> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD003053-sec-0126" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD003053-sec-0126"></div> <section id="CD003053-sec-0127"> <h3 class="title" id="CD003053-sec-0127">Summary of main results</h3> <p>Our findings suggest that metformin is associated with a beneficial effect on ovulation and clinical pregnancy rates, regardless of BMI, when compared with placebo. The addition of newer data to this review shows a potential benefit of metformin over placebo for live birth rate. However, more high‐quality studies that report live birth as a primary outcome are required. When comparing outcomes following the use of metformin or clomiphene citrate, higher ovulation rates suggest that clomiphene citrate is beneficial over metformin, alongside a reduced side‐effect profile. However, there was no evidence to suggest that either treatment would increase the likelihood of a live birth over the other. Further data stratified by the BMI of participants are required to determine the subgroups of women who may achieve improved outcomes with metformin or clomiphene citrate treatment. </p> <p>Women who are known to be resistant to clomiphene citrate therapy may benefit from improved ovulation with the addition of metformin to clomiphene citrate. However, data were not available to determine if this would improve live birth rates in this group of women. Women taking metformin should be advised that there does not appear to be an increased miscarriage risk with treatment, but the likelihood of gastrointestinal side effects is higher than with placebo or clomiphene citrate. The use of metformin needs to be placed in the context of the principal first line therapies for ovulation induction for anovulatory women with PCOS, namely the use of clomiphene citrate and the aromatase inhibitor (letrozole) (<a href="./references#CD003053-bbs2-0090" title="BalenAH , MorleyLC , MissoM , FranksS , LegroRS , WijeyaratneCN , et al. The management of anovulatory infertility in women with polycystic ovary syndrome: an analysis of the evidence to support the development of global WHO guidance. Human Reproduction Update2016;22:687‐708. [DOI: 10.1093/humupd/dmw025] ">Balen 2016</a>). </p> <section id="CD003053-sec-0128"> <h4 class="title">Reproductive outcomes</h4> <p>When compared with placebo, the results suggest a possible benefit from using metformin treatment in improving live birth rates (<a href="./references#CD003053-fig-0008" title="">Analysis 1.1</a>). One high‐quality study included in this updated review contributed the majority of the weight to this finding (<a href="./references#CD003053-bbs2-0029" title="Morin‐PapunenL , RantalaAS , Unkila‐KallioL , TiitinenA , HippeläinenM , PerheentupaA , et al. Metformin improves pregnancy and live‐birth rates in women with polycystic ovary syndrome (PCOS): a multicenter, double‐blind, placebo‐controlled randomized trial. Journal of Clinical Endocrinology and Metabolism2012;97:1492‐1500. ">Morin‐Papunen 2012</a>). However, the wide‐ranging confidence intervals and lower‐quality evidence when the <a href="./references#CD003053-bbs2-0029" title="Morin‐PapunenL , RantalaAS , Unkila‐KallioL , TiitinenA , HippeläinenM , PerheentupaA , et al. Metformin improves pregnancy and live‐birth rates in women with polycystic ovary syndrome (PCOS): a multicenter, double‐blind, placebo‐controlled randomized trial. Journal of Clinical Endocrinology and Metabolism2012;97:1492‐1500. ">Morin‐Papunen 2012</a> results were combined with other included studies, makes the advantage offered by metformin difficult to interpret clinically. However, clinical pregnancy rates were higher with the use of metformin for ovulation induction (<a href="./references#CD003053-fig-0010" title="">Analysis 1.3</a>). Menstrual frequency also appeared to be improved with metformin versus placebo (<a href="./references#CD003053-fig-0012" title="">Analysis 1.5</a>). This resulted in a benefit in ovulation rate, which persisted following a subgroup analysis by BMI (<a href="./references#CD003053-fig-0011" title="">Analysis 1.4</a>). </p> <p>There was no conclusive evidence that adding metformin in combination with clomiphene citrate, increased live birth compared to clomiphene citrate monotherapy (<a href="./references#CD003053-fig-0025" title="">Analysis 2.1</a>). However, clinical pregnancy and ovulation rates were improved with combination treatment in both BMI groups (<a href="./references#CD003053-fig-0027" title="">Analysis 2.3</a>; <a href="./references#CD003053-fig-0028" title="">Analysis 2.4</a>). We attempted to analyse data depending on whether women were known to be sensitive or resistant to clomiphene citrate. Unfortunately, these data were only available for ovulation rate (<a href="./references#CD003053-fig-0029" title="">Analysis 2.5</a>). The test for subgroup differences showed no evidence of a difference between the subgroups. </p> <p>When metformin was compared to clomiphene citrate, findings were complicated by a difference based on the obesity status of the participants. Here, women in the non‐obese group were more likely to achieve a live birth rate with metformin, whilst the obese women appeared to benefit from clomiphene citrate therapy. This pattern was also evident for clinical pregnancy and ovulation rate, although these analyses were hampered by a paucity of data (<a href="./references#CD003053-fig-0035" title="">Analysis 3.2</a>; <a href="./references#CD003053-fig-0036" title="">Analysis 3.3</a>). </p> <p>Miscarriage was not commonly reported as an outcome in the studies included in this review. When analysing the available data, the use of metformin monotherapy did not appear to increase the rate of miscarriage (<a href="./references#CD003053-fig-0013" title="">Analysis 1.6</a>). The comparison between metformin and clomiphene citrate found no conclusive evidence of a difference in the likelihood of miscarriage between the two treatments (<a href="./references#CD003053-fig-0037" title="">Analysis 3.4</a>). There was evidence to suggest an increase in miscarriage when clomiphene citrate was combined with metformin rather than used in isolation , although this effect did not persist after subgroup analysis per pregnancy, by BMI or study quality (<a href="./references#CD003053-fig-0030" title="">Analysis 2.6</a>; <a href="./references#CD003053-fig-0031" title="">Analysis 2.7</a>). Any increase in miscarriage conferred by using combined clomiphene citrate therapy is therefore difficult to interpret and apply clinically. </p> <p>For the outcome multiple pregnancy, there was no available data regarding metformin versus placebo. The results were inconclusive for combination therapy versus clomiphene citrate monotherapy, and for the comparison between metformin and clomiphene citrate (<a href="./references#CD003053-fig-0032" title="">Analysis 2.8</a>; <a href="./references#CD003053-fig-0039" title="">Analysis 3.6</a>). </p> </section> <section id="CD003053-sec-0129"> <h4 class="title">Adverse effects</h4> <p>There was evidence that use of metformin was associated with higher rates of gastrointestinal disturbance than placebo, and that adding in metformin therapy increased rates of gastrointestinal side effects compared with clomiphene citrate alone (<a href="./references#CD003053-fig-0009" title="">Analysis 1.2</a>; <a href="./references#CD003053-fig-0026" title="">Analysis 2.2</a>). Data on adverse effects comparing metformin versus clomiphene citrate were not available. </p> </section> <section id="CD003053-sec-0130"> <h4 class="title">Metabolic and anthropometric outcomes</h4> <p>Data on the effect of metformin on anthropometric outcomes were only available for the comparison between metformin and placebo. There was no conclusive evidence that metformin resulted in reduction in BMI, although there was an effect on waist to hip ratio (<a href="./references#CD003053-fig-0015" title="">Analysis 1.8</a>; <a href="./references#CD003053-fig-0016" title="">Analysis 1.9</a>). Similarly, there was an effect on systolic blood pressure, but the evidence was not conclusive for diastolic blood pressure (<a href="./references#CD003053-fig-0017" title="">Analysis 1.10</a>; <a href="./references#CD003053-fig-0018" title="">Analysis 1.11</a>) or cholesterol (<a href="./references#CD003053-fig-0023" title="">Analysis 1.16</a>). </p> <p>With regards to endocrine outcomes, we observed a treatment effect on serum testosterone concentration, although this was seen only in the non‐obese women (<a href="./references#CD003053-fig-0019" title="">Analysis 1.12</a>). We also found an effect on reducing fasting insulin levels in both BMI groups (<a href="./references#CD003053-fig-0022" title="">Analysis 1.15</a>). There was no conclusive evidence of an effect of metformin on serum lipid profiles (<a href="./references#CD003053-fig-0024" title="">Analysis 1.17</a>). </p> <p>It is therefore unclear whether these metabolic and endocrine effects would be of any clinical benefit to women with PCOS. The data on these outcomes also tended to be associated with high heterogeneity. </p> <p>The role of metformin in reducing the risk of developing metabolic syndrome in women with PCOS remains unclear. Given the significant negative impact of obesity on pregnancy outcomes (<a href="./references#CD003053-bbs2-0093" title="CedergrenMI . Maternal morbid obesity and the risk of adverse pregnancy outcome. Obstetrics and Gynecology2004;103:219‐24. ">Cedergren 2004</a>; <a href="./references#CD003053-bbs2-0022" title="CataldoN , BarnhartH , LegroR , MyersE , SchlaffW , CarrB , et al. Extended‐release metformin does not reduce the clomiphene citrate dose required to induce ovulation in polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism2008;93(8):3147‐7. LegroRS , BarnhartHX , SchlaffWD , CarrBR , DiamondMP , CarsonSA , et al. Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome. New England Journal of Medicine2007;356:551‐66. [original article] ">Legro 2007</a>) and longer‐term cardiovascular health, anovulatory obese women with PCOS should still be advised to undergo lifestyle changes before any fertility treatment (<a href="./references#CD003053-bbs2-0104" title="The Thessaloniki ESHRE/ASRM‐sponsored PCOS consensus workshop group. Consensus on infertility treatment related to polycystic ovary syndrome. Human Reproduction2008;23:462‐77. ">ESHRE/ASRM 2008</a>). </p> </section> <section id="CD003053-sec-0131"> <h4 class="title">Limitations</h4> <p>See <a href="#CD003053-sec-0135">Quality of the evidence</a> and <a href="#CD003053-sec-0136">Potential biases in the review process</a>. </p> </section> </section> <section id="CD003053-sec-0132"> <h3 class="title" id="CD003053-sec-0132">Overall completeness and applicability of evidence</h3> <p>This review includes a large number of women, all meeting the Rotterdam diagnostic criteria for PCOS (<a href="./references#CD003053-bbs2-0103" title="The Rotterdam ESHRE/ASRM‐sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long‐term health risks related to polycystic ovary syndrome (PCOS). Human Reproduction2004;19(1):41. ">ESHRE/ASRM 2004</a>). However, we still observed significant heterogeneity in many of the analyses. This was particularly evident in the biochemical outcomes, even after adjustment for BMI, dosage of metformin and duration of treatment. Heterogeneity remained unchanged after sensitivity analysis by study quality. However, the prevalence and magnitude of insulin resistance are influenced by ethnicity (<a href="./references#CD003053-bbs2-0146" title="WijeyaratneCN , BalenAH , BarthJH , BelchetzPE . Clinical manifestations and insulin resistance (IR) in polycystic ovary syndrome (PCOS) among South Asians and Caucasians: is there a difference?. Clinical Endocrinology (Oxford)2002;57:343‐50. ">Wijeyaratne 2002</a>; <a href="./references#CD003053-bbs2-0147" title="WijeyaratneCN , NirantharakumarK , BalenAH , BarthJH , SheriffR , BelchetzPE . Plasma homocysteine in polycystic ovary syndrome: does it correlate with insulin resistance and ethnicity?. Clinical Endocrinology (Oxford)2004;60:560‐7. ">Wijeyaratne 2004</a>), therefore, combining trials from different study populations would introduce heterogeneity despite all meeting the diagnostic criteria of PCOS. Another factor is the range of biochemical assays used in different studies, which may introduce some heterogeneity </p> <p>The efficacy of metformin in PCOS was first described by <a href="./references#CD003053-bbs2-0144" title="VelazquezE , AcostaA , MendozaSG . Menstrual cyclicity after metformin therapy in polycystic ovary syndrome. Obstetrics and Gynecology1997;90:392‐5. ">Velazquez 1997</a>. A number of small, and often short‐duration, observational studies followed, which showed variable outcomes. Indeed, in a systematic review by <a href="./references#CD003053-bbs2-0096" title="CostelloMF , EdenJA . A systematic review of the reproductive system effects of metformin in patients with polycystic ovary syndrome. Fertility and Sterility2003;79:1‐13. ">Costello 2003</a> nine out of the 12 published studies on the effects of metformin alone on the menstrual cycle in women with PCOS had a sample size of fewer than 30 women. The first Cochrane Review by <a href="./references#CD003053-bbs2-0150" title="LordJM , FlightIH , NormanRJ . Insulin‐sensitising drugs (metformin, troglitazone, rosiglitazone, pioglitazone, D‐chiro‐inositol) for polycystic ovary syndrome. Cochrane Database of Systematic Reviews2003, Issue 3. [DOI: 10.1002/14651858.CD003053] ">Lord 2003</a> included nearly 1000 women from 15 RCTs. However, most of the studies had relatively small sample sizes with the largest one containing 94 women (<a href="./references#CD003053-bbs2-0011" title="FlemingR , HopkinsonZE , WallaceAM , GreerIA , SattarN . Ovarian function and metabolic factors in women with oligomenorrhea treated with metformin in a randomized double blind placebo‐controlled trial. Journal of Clinical Endocrinology and Metabolism2002;87(2):569‐74. FlemingR , HopkinsonZE , WallaceE , GreerIA , SattarN . Metformin treatment improves ovulation frequency in women with oligomenorrhoea: a randomized, double blind placebo trial. Human Fertility2000; Vol. 3, issue 4:389‐90. ">Fleming 2002</a>). In this third updated review, we included 48 RCTs (4451 women) with the two largest studies of high quality being by <a href="./references#CD003053-bbs2-0029" title="Morin‐PapunenL , RantalaAS , Unkila‐KallioL , TiitinenA , HippeläinenM , PerheentupaA , et al. Metformin improves pregnancy and live‐birth rates in women with polycystic ovary syndrome (PCOS): a multicenter, double‐blind, placebo‐controlled randomized trial. Journal of Clinical Endocrinology and Metabolism2012;97:1492‐1500. ">Morin‐Papunen 2012</a> and <a href="./references#CD003053-bbs2-0022" title="CataldoN , BarnhartH , LegroR , MyersE , SchlaffW , CarrB , et al. Extended‐release metformin does not reduce the clomiphene citrate dose required to induce ovulation in polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism2008;93(8):3147‐7. LegroRS , BarnhartHX , SchlaffWD , CarrBR , DiamondMP , CarsonSA , et al. Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome. New England Journal of Medicine2007;356:551‐66. [original article] ">Legro 2007</a>, with sample sizes of 320 and 626 women, respectively. </p> <section id="CD003053-sec-0133"> <h4 class="title">Reproductive outcomes</h4> <p>The primary outcome of this updated review is the effect of metformin for ovulation induction on live birth rate. When compared to placebo, there was a potential benefit in live birth when using metformin, with a number needed to treat for an additional beneficial outcome of 13. This is supported by the corresponding increase in clinical pregnancy rate, ovulation rate and menstrual frequency with treatment. These results were seen in both obese and non‐obese BMI groupings. As such, BMI does not appear to be a discriminatory factor in predicting ovulation success with metformin treatment compared with placebo, although the moderate degree of heterogeneity observed in the data should be noted. The heterogeneity between the non‐obese and the obese groups could be explained by the limited effect of metformin on reducing serum insulin concentrations in the obese group compared with the non‐obese group of women with PCOS (<a href="./references#CD003053-fig-0011" title="">Analysis 1.4</a>). Furthermore, obese women with PCOS have a higher insulin resistance (higher serum insulin concentrations) than non‐obese women with PCOS (<a href="./references#CD003053-bbs2-0043" title="TangT , GlanvilleJ , HaydenCJ , WhiteD , BarthJH , BalenAH . Combined lifestyle modification and metformin in obese patients with polycystic ovary syndrome. A randomized, placebo‐controlled, double‐blind multicentre study. Human Reproduction2006;21:80‐9. ">Tang 2006</a>). </p> <p>The suggestion of an improvement in live births with metformin differs from the previous review, due to the inclusion of the new, high‐quality study, <a href="./references#CD003053-bbs2-0029" title="Morin‐PapunenL , RantalaAS , Unkila‐KallioL , TiitinenA , HippeläinenM , PerheentupaA , et al. Metformin improves pregnancy and live‐birth rates in women with polycystic ovary syndrome (PCOS): a multicenter, double‐blind, placebo‐controlled randomized trial. Journal of Clinical Endocrinology and Metabolism2012;97:1492‐1500. ">Morin‐Papunen 2012</a>. However, there are still only four studies reporting live birth available for analysis, and the overall quality of the evidence is low. Given the wide‐ranging confidence intervals and evidence quality, the advantage offered by metformin remains difficult to interpret clinically. Therefore more high‐quality studies are required investigating the use of metformin, with live birth rate as the primary outcome. </p> <p>Clomiphene citrate is traditionally employed as the first line ovulation induction therapy for anovulatory women with PCOS. However, there was a paucity of data comparing the efficacy and safety of metformin against clomiphene citrate therapy. When we combined the five available studies, we regarded the data as very low quality and with high heterogeneity. The results here differed by BMI, whereby clomiphene citrate appeared to increase live births in the obese group, with a large weighting attributed to the study by <a href="./references#CD003053-bbs2-0022" title="CataldoN , BarnhartH , LegroR , MyersE , SchlaffW , CarrB , et al. Extended‐release metformin does not reduce the clomiphene citrate dose required to induce ovulation in polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism2008;93(8):3147‐7. LegroRS , BarnhartHX , SchlaffWD , CarrBR , DiamondMP , CarsonSA , et al. Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome. New England Journal of Medicine2007;356:551‐66. [original article] ">Legro 2007</a>. In the non‐obese group however, metformin was superior, although this analysis included only small studies of low quality. As such, more high‐quality studies with a larger number of participants are required to assess metformin versus clomiphene citrate for live birth rate. </p> <p>The beneficial effect of combination treatment with metformin and clomiphene citrate versus clomiphene citrate alone on live birth rate was not supported by the current evidence. Combination therapy appeared to improve clinical pregnancy rate and ovulation per woman. In our subgroup analysis, women who previously developed clomiphene citrate resistance had a larger effect with combined therapy than women who were clomiphene citrate sensitive or of undefined status. In addition, heterogeneity was low in the analysis of ovulation rates in the clomiphene citrate resistant group (I<sup>2</sup> = 0%). Therefore, clomiphene citrate resistance can be a useful discriminatory factor to predict the response to the combined therapy. Future studies of the effect of metformin and clomiphene citrate on live birth rate should therefore be presenting the clomiphene citrate sensitivity of participants. In a subgroup analysis by BMI, the level of heterogeneity was very high in both groups. In addition, the number of women needed to treat to achieve ovulation in both the non‐obese and obese groups was high, 7.7 and 10 respectively. This compares to a number of women needed to treat of 3 in women with known clomiphene citrate resistance. Given that, in clinical practice, women would often receive only six cycles of clomiphene citrate treatment, the benefit afforded by metformin co‐therapy may be limited. </p> <p>A large proportion of the women included in this review fall into the high‐BMI grouping. Given that the aim is for a pregnancy in these women, and that metformin does not have a conclusive effect on BMI, it is worth considering the impact of obesity on their reproductive outcomes. <a href="./references#CD003053-bbs2-0093" title="CedergrenMI . Maternal morbid obesity and the risk of adverse pregnancy outcome. Obstetrics and Gynecology2004;103:219‐24. ">Cedergren 2004</a> conducted a prospective population‐based study on over 3000 morbidly obese mothers (BMI &gt; 40 kg/m<sup>2</sup>) and demonstrated higher incidences of adverse pregnancy outcomes compared with a group of normal weight, including pre‐eclampsia, stillbirth, large‐for‐gestational‐age babies, fetal distress and early neonatal death. This emphasises the importance of weight loss in any obese women aiming for a pregnancy, alongside any additional treatment for ovulation induction. Lifestyle modification should therefore form an integral part of managing obese PCOS women suffering from anovulatory infertility (<a href="./references#CD003053-bbs2-0043" title="TangT , GlanvilleJ , HaydenCJ , WhiteD , BarthJH , BalenAH . Combined lifestyle modification and metformin in obese patients with polycystic ovary syndrome. A randomized, placebo‐controlled, double‐blind multicentre study. Human Reproduction2006;21:80‐9. ">Tang 2006</a>). </p> <p>In this review, there was no convincing evidence of an effect on miscarriage or multiple pregnancy rates attributable to metformin. However, women should be counselled on the increased side‐effect profile with metformin, which may hamper clinical compliance, and the longer duration of treatment required with metformin. </p> </section> <section id="CD003053-sec-0134"> <h4 class="title">Metabolic and anthropometric outcomes</h4> <p>There is yet to be any long‐term data on the use of metformin for women with PCOS in reducing the risk of developing diabetes or metabolic syndrome. Our analyses found no evidence of an effect of metformin on reducing BMI or improving lipid profiles. There was however, a reduction in cholesterol compared to placebo and reduced waist to hip ratio in the non‐obese group. There was also reduction in fasting glucose and fasting insulin levels when compared to placebo. However, the clinical relevance of these differences for the long‐term prevention of diabetes remains unclear. We saw an effect on systolic blood pressure but the magnitude of effect (MD ‐3.59 mm Hg) is unlikely to be clinically significant. </p> <p>Metformin had a beneficial effect on serum testosterone, with a greater mean difference in the non‐obese group. However, meta‐regression did not support any effect of the daily dose or the duration of metformin treatment on the magnitude of the reduction in testosterone levels. High insulin levels stimulate an increase in androgen production from the ovaries and therefore an inadequate reduction of insulin concentrations induced by metformin in obese women with PCOS may be a reason why the reduction of testosterone was less marked in the obese group. The effect of metformin on serum testosterone could therefore benefit women with hirsutism. However, a Cochrane Review (<a href="./references#CD003053-bbs2-0097" title="CostelloM , ShresthaB , EdenJ , SjoblomP , JohnsonN . Insulin‐sensitising drugs versus the combined oral contraceptive pill for hirsutism, acne and risk of diabetes, cardiovascular disease, and endometrial cancer in polycystic ovary syndrome. Cochrane Database of Systematic Reviews2007, Issue 1. [DOI: 10.1002/14651858.CD005552.pub2; PUBMED: 17253562] ">Costello 2007</a>) indicated that limited data were available comparing the effects of metformin with combined oral contraceptives for hirsutism. Given the increased efficacy of combined oral contraceptives at reducing serum testosterone (MD 0.54, 95% CI 0.22 to 0.86) and the free androgen index (MD 3.69, 95% CI 2.56 to 4.83) in their review, metformin is unlikely to become a first‐line therapy for hirsutism. </p> <p>In respect to the use of rosiglitazone and pioglitazone in women with PCOS, our analysis, with a limited number of trials, showed that these drugs improve ovulation rate without evidence of an effect on biochemical parameters. Given that these drugs are classified as category C (<a href="./references#CD003053-bbs2-0106" title="FDA (Federal Drug Administration). www.fda.gov Accessed 14 January 2003. ">FDA 2002</a>) and hence most recruited women were not planning a pregnancy, it would be difficult to assess pregnancy outcomes. Furthermore, a high incidence of weight gain (<a href="./references#CD003053-fig-0054" title="">Analysis 5.3</a>) among the users further hampers their use in obese women with PCOS (<a href="./references#CD003053-bbs2-0002" title="BaillargeonJP , JakubowiczDJ , IuornoMJ , JakubowiczS , NestlerJE . Effects of metformin and rosiglitazone, alone and in combination, in nonobese women with polycystic ovary syndrome and normal indices of insulin sensitivity. Fertility and Sterility2004;82:893‐902. ">Baillargeon 2004</a>). There is also concern about links between rosiglitazone and increased risk of myocardial infarction (<a href="./references#CD003053-bbs2-0119" title="LagoRM , SinghPP , NestoRW . Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta‐analysis of randomised clinical trials. Lancet2007;370(9593):1129‐36. ">Lago 2007</a>). </p> </section> </section> <section id="CD003053-sec-0135"> <h3 class="title" id="CD003053-sec-0135">Quality of the evidence</h3> <p>Overall, we graded only 18 out of the 48 included studies as having low risk of bias related to sequence generation, allocation concealment and blinding. The main limitation of the comparisons in this review is therefore the risk of bias and imprecision within the included studies, as discussed in <a href="./full#CD003053-tbl-0001">summary of findings Table for the main comparison</a>; <a href="./full#CD003053-tbl-0002">summary of findings Table 2</a>; <a href="./full#CD003053-tbl-0003">summary of findings Table 3</a> and <a href="#CD003053-fig-0003">Figure 3</a> and <a href="#CD003053-fig-0004">Figure 4</a>. However, sensitivity analysis on the studies with adequate sequence generation, allocation concealment and blinding method did not alter the clinical findings, except on fasting serum glucose concentrations. We classified the overall quality of evidence for metformin versus placebo as low for live birth rate and ovulation rate, and moderate for clinical pregnancy and miscarriage rate (<a href="./full#CD003053-tbl-0001">summary of findings Table for the main comparison</a>). This was due to a moderate risk of bias, marginal effect size and statistical imprecision. The evidence for D‐chiro‐inositol, rosiglitazone and pioglitazone was of moderate quality. The overall quality of evidence for metformin versus clomiphene citrate and for metformin plus clomiphene citrate versus clomiphene citrate alone was moderate. </p> </section> <section id="CD003053-sec-0136"> <h3 class="title" id="CD003053-sec-0136">Potential biases in the review process</h3> <p>We conducted a thorough search, used sound methodology and are not aware of any biases in the review process. </p> </section> <section id="CD003053-sec-0137"> <h3 class="title" id="CD003053-sec-0137">Agreements and disagreements with other studies or reviews</h3> <section id="CD003053-sec-0138"> <h4 class="title">Reproductive outcomes</h4> <p>A 2015 systematic review investigating the efficacy of metformin in women with anovulatory infertility for the improvement of reproductive outcomes (<a href="./references#CD003053-bbs2-0084" title="Abu HashimH . Twenty years of ovulation induction with metformin for PCOS; what is the best available evidence?. Reproductive BioMedicine Online2016;32:44‐53. ">Abu Hashim 2016</a>). For metformin versus placebo, only a previous version of this Cochrane Review was identified. The authors reviewed two meta‐analyses comparing metformin with clomiphene citrate for ovulation induction (<a href="./references#CD003053-bbs2-0128" title="PalombaS , PasqualiR , Orio JrF , NestlerJE . Clomiphene citrate, metformin or both as first‐step approach in treating anovulatory infertility in patients with polycystic ovary syndrome (PCOS): a systematic review of head‐to‐head randomized controlled studies and meta‐analysis. Clinical Endocrinology2009;70:311‐21. ">Palomba 2009</a> and <a href="./references#CD003053-bbs2-0137" title="Siebert , TI , ViolaMI , SteynDW , KrugerTF . Is metformin indicated as primary ovulation induction agent in women with PCOS? A systematic review and meta‐analysis. Gynecologic and Obstetric Investigation2012;73:304‐13. ">Siebert 2012</a>). In accordance with our findings, they found improved ovulation rates with clomiphene citrate rather than metformin. There was no conclusive benefit of either treatment on clinical pregnancy or live birth rate, with wide confidence intervals noted. They therefore conclude that clomiphene citrate remains the "gold standard first‐line pharmacological treatment for ovulation induction in anovulatory infertile women with PCOS". An analysis of four studies that compared metformin with clomiphene citrate in non‐obese women found no significant difference in reproductive outcomes (<a href="./references#CD003053-bbs2-0125" title="MissoML , CostelloMF , GarrubbaM , WongJ , HartR , RombautsL , et al. Metformin versus clomiphene citrate for infertility in non‐obese women with polycystic ovary syndrome: a systematic review and meta‐analysis. Human Reproduction Update2013;19:2‐11. ">Misso 2013</a>). The conclusions drawn by <a href="./references#CD003053-bbs2-0084" title="Abu HashimH . Twenty years of ovulation induction with metformin for PCOS; what is the best available evidence?. Reproductive BioMedicine Online2016;32:44‐53. ">Abu Hashim 2016</a> echo the ESHRE consensus, which documented that the first line treatment for anovulatory infertility is clomiphene citrate, whilst obese women should be advised to undergo lifestyle modifications (<a href="./references#CD003053-bbs2-0104" title="The Thessaloniki ESHRE/ASRM‐sponsored PCOS consensus workshop group. Consensus on infertility treatment related to polycystic ovary syndrome. Human Reproduction2008;23:462‐77. ">ESHRE/ASRM 2008</a>). </p> <p>When evaluating the <a href="./references#CD003053-bbs2-0128" title="PalombaS , PasqualiR , Orio JrF , NestlerJE . Clomiphene citrate, metformin or both as first‐step approach in treating anovulatory infertility in patients with polycystic ovary syndrome (PCOS): a systematic review of head‐to‐head randomized controlled studies and meta‐analysis. Clinical Endocrinology2009;70:311‐21. ">Palomba 2009</a> and <a href="./references#CD003053-bbs2-0137" title="Siebert , TI , ViolaMI , SteynDW , KrugerTF . Is metformin indicated as primary ovulation induction agent in women with PCOS? A systematic review and meta‐analysis. Gynecologic and Obstetric Investigation2012;73:304‐13. ">Siebert 2012</a> meta‐analyses, <a href="./references#CD003053-bbs2-0084" title="Abu HashimH . Twenty years of ovulation induction with metformin for PCOS; what is the best available evidence?. Reproductive BioMedicine Online2016;32:44‐53. ">Abu Hashim 2016</a> found no evidence of an improvement in live birth when metformin was used in combination with clomiphene citrate. Our review also found no conclusive evidence of a difference in live birth rate, although clinical pregnancy and ovulation were improved with co‐therapy. Given the increased side‐effect profile with metformin, as found in our review, <a href="./references#CD003053-bbs2-0084" title="Abu HashimH . Twenty years of ovulation induction with metformin for PCOS; what is the best available evidence?. Reproductive BioMedicine Online2016;32:44‐53. ">Abu Hashim 2016</a> do not recommend adding in metformin to clomiphene citrate therapy. However, their results are not stratified by BMI. </p> </section> <section id="CD003053-sec-0139"> <h4 class="title">Metabolic and anthropometric outcomes</h4> <p>Our review found mixed evidence of an effect of metformin on metabolic outcomes, which is of unclear clinical significance for the prevention of diabetes in the long term. These findings are supported by Diabetes Prevention Program Research group study of over 3000 obese women (mean BMI 34 kg/m<sup>2</sup>) with an average follow‐up period of 2.8 years (<a href="./references#CD003053-bbs2-0118" title="KnowlerWC , Barrett‐ConnorE , FowlerSE , HammanRF , LachinJM , WalkerEA , et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. New England Journal of Medicine2002;346:393‐403. ">Knowler 2002</a>). They reported that both metformin and lifestyle‐intervention groups (7.8 and 4.8 cases per 100 person years respectively) had a lower incidence of diabetes compared with placebo (11 per 100 person years). However, the lifestyle‐intervention group achieved a significantly better weight reduction compared with the metformin (58% versus 31%). Furthermore, the initial modest weight loss in the metformin group was not sustainable after three years of follow‐up. In contrast, in the lifestyle group an average of 4% weight loss was still maintained after four years. Likewise, the Finnish Diabetes Prevention Study demonstrated that weight loss improved insulin sensitivity, waist circumference and serum triglyceride levels compared with controls in 150 obese women with impaired glucose tolerance (<a href="./references#CD003053-bbs2-0143" title="UusitupaM , LouherantaA , LindstromJ , ValleT , SundvallJ , ErikssonJ , et al. The Finnish Diabetes Prevention Study. British Journal of Nutrition2000;83 Suppl 1:137‐42. ">Uusitupa 2000</a>). A 2007 meta‐analysis also concluded that the lifestyle interventions are more effective than metformin in obese women (<a href="./references#CD003053-bbs2-0109" title="GilliesCL , AbramsKR , LambertPC , CooperNJ , SuttonAJ , HsuRT , et al. Pharmacological and lifestyle interventions to prevent or delay type 2 diabetes in people with impaired glucose tolerance: systematic review and meta‐analysis. BMJ2007;334:299. ">Gillies 2007</a>). </p> </section> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD003053-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/urn:x-wiley:14651858:media:CD003053:CD003053-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/image_t/tCD003053-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram since publication" data-id="CD003053-fig-0001" src="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/image_n/nCD003053-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram since publication</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/full#CD003053-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/image_n/nCD003053-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003053-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/urn:x-wiley:14651858:media:CD003053:CD003053-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/image_t/tCD003053-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram 2017 update" data-id="CD003053-fig-0002" src="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/image_n/nCD003053-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Study flow diagram 2017 update</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/full#CD003053-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/image_n/nCD003053-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003053-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/urn:x-wiley:14651858:media:CD003053:CD003053-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/image_t/tCD003053-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies" data-id="CD003053-fig-0003" src="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/image_n/nCD003053-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/full#CD003053-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/image_n/nCD003053-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003053-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/urn:x-wiley:14651858:media:CD003053:CD003053-AFig-FIG04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/image_t/tCD003053-AFig-FIG04.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study" data-id="CD003053-fig-0004" src="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/image_n/nCD003053-AFig-FIG04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/full#CD003053-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/image_n/nCD003053-AFig-FIG04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003053-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/urn:x-wiley:14651858:media:CD003053:CD003053-AFig-FIG05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/image_t/tCD003053-AFig-FIG05.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Metformin versus placebo or no treatment, outcome: 1.1 Live birth rate" data-id="CD003053-fig-0005" src="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/image_n/nCD003053-AFig-FIG05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Metformin versus placebo or no treatment, outcome: 1.1 Live birth rate </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/full#CD003053-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/image_n/nCD003053-AFig-FIG05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003053-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/urn:x-wiley:14651858:media:CD003053:CD003053-AFig-FIG06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/image_t/tCD003053-AFig-FIG06.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 2 Metformin combined with clomiphene citrate versus clomiphene citrate alone, outcome: 2.1 Live birth rate" data-id="CD003053-fig-0006" src="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/image_n/nCD003053-AFig-FIG06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 6</div> <div class="figure-caption"> <p>Forest plot of comparison: 2 Metformin combined with clomiphene citrate versus clomiphene citrate alone, outcome: 2.1 Live birth rate </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/full#CD003053-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/image_n/nCD003053-AFig-FIG06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003053-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/urn:x-wiley:14651858:media:CD003053:CD003053-AFig-FIG07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/image_t/tCD003053-AFig-FIG07.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 3 Metformin versus clomiphene citrate, outcome: 3.1 Live birth." data-id="CD003053-fig-0007" src="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/image_n/nCD003053-AFig-FIG07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 7</div> <div class="figure-caption"> <p>Forest plot of comparison: 3 Metformin versus clomiphene citrate, outcome: 3.1 Live birth. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/full#CD003053-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/image_n/nCD003053-AFig-FIG07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003053-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/urn:x-wiley:14651858:media:CD003053:CD003053-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/image_t/tCD003053-CMP-001-01.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Metformin versus placebo or no treatment, Outcome 1 Live birth rate." data-id="CD003053-fig-0008" src="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/image_n/nCD003053-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Metformin versus placebo or no treatment, Outcome 1 Live birth rate.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/references#CD003053-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/image_n/nCD003053-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003053-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/urn:x-wiley:14651858:media:CD003053:CD003053-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/image_t/tCD003053-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Metformin versus placebo or no treatment, Outcome 2 Adverse events (gastrointestinal side effects)." data-id="CD003053-fig-0009" src="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/image_n/nCD003053-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Metformin versus placebo or no treatment, Outcome 2 Adverse events (gastrointestinal side effects). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/references#CD003053-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/image_n/nCD003053-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003053-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/urn:x-wiley:14651858:media:CD003053:CD003053-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/image_t/tCD003053-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Metformin versus placebo or no treatment, Outcome 3 Clinical pregnancy rate." data-id="CD003053-fig-0010" src="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/image_n/nCD003053-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Metformin versus placebo or no treatment, Outcome 3 Clinical pregnancy rate. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/references#CD003053-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/image_n/nCD003053-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003053-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/urn:x-wiley:14651858:media:CD003053:CD003053-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/image_t/tCD003053-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Metformin versus placebo or no treatment, Outcome 4 Ovulation rate." data-id="CD003053-fig-0011" src="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/image_n/nCD003053-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Metformin versus placebo or no treatment, Outcome 4 Ovulation rate.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/references#CD003053-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/image_n/nCD003053-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003053-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/urn:x-wiley:14651858:media:CD003053:CD003053-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/image_t/tCD003053-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Metformin versus placebo or no treatment, Outcome 5 Menstrual frequency." data-id="CD003053-fig-0012" src="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/image_n/nCD003053-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Metformin versus placebo or no treatment, Outcome 5 Menstrual frequency.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/references#CD003053-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/image_n/nCD003053-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003053-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/urn:x-wiley:14651858:media:CD003053:CD003053-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/image_t/tCD003053-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Metformin versus placebo or no treatment, Outcome 6 Miscarriage rate per woman." data-id="CD003053-fig-0013" src="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/image_n/nCD003053-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 Metformin versus placebo or no treatment, Outcome 6 Miscarriage rate per woman. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/references#CD003053-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/image_n/nCD003053-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003053-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/urn:x-wiley:14651858:media:CD003053:CD003053-CMP-001-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/image_t/tCD003053-CMP-001-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Metformin versus placebo or no treatment, Outcome 7 Sensitivity analysis: miscarriage rate per pregnancy." data-id="CD003053-fig-0014" src="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/image_n/nCD003053-CMP-001-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1 Metformin versus placebo or no treatment, Outcome 7 Sensitivity analysis: miscarriage rate per pregnancy. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/references#CD003053-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/image_n/nCD003053-CMP-001-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003053-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/urn:x-wiley:14651858:media:CD003053:CD003053-CMP-001-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/image_t/tCD003053-CMP-001-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Metformin versus placebo or no treatment, Outcome 8 Body mass index (kg/m2)." data-id="CD003053-fig-0015" src="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/image_n/nCD003053-CMP-001-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1 Metformin versus placebo or no treatment, Outcome 8 Body mass index (kg/m<sup>2</sup>). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/references#CD003053-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/image_n/nCD003053-CMP-001-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003053-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/urn:x-wiley:14651858:media:CD003053:CD003053-CMP-001-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/image_t/tCD003053-CMP-001-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Metformin versus placebo or no treatment, Outcome 9 Waist‐hip ratio." data-id="CD003053-fig-0016" src="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/image_n/nCD003053-CMP-001-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1 Metformin versus placebo or no treatment, Outcome 9 Waist‐hip ratio.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/references#CD003053-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/image_n/nCD003053-CMP-001-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003053-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/urn:x-wiley:14651858:media:CD003053:CD003053-CMP-001-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/image_t/tCD003053-CMP-001-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Metformin versus placebo or no treatment, Outcome 10 Blood pressure ‐ systolic (mm Hg)." data-id="CD003053-fig-0017" src="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/image_n/nCD003053-CMP-001-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1 Metformin versus placebo or no treatment, Outcome 10 Blood pressure ‐ systolic (mm Hg). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/references#CD003053-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/image_n/nCD003053-CMP-001-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003053-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/urn:x-wiley:14651858:media:CD003053:CD003053-CMP-001-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/image_t/tCD003053-CMP-001-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Metformin versus placebo or no treatment, Outcome 11 Blood pressure ‐ diastolic (mm Hg)." data-id="CD003053-fig-0018" src="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/image_n/nCD003053-CMP-001-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.11</div> <div class="figure-caption"> <p>Comparison 1 Metformin versus placebo or no treatment, Outcome 11 Blood pressure ‐ diastolic (mm Hg). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/references#CD003053-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/image_n/nCD003053-CMP-001-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003053-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/urn:x-wiley:14651858:media:CD003053:CD003053-CMP-001-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/image_t/tCD003053-CMP-001-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Metformin versus placebo or no treatment, Outcome 12 Serum testosterone (nmol/L)." data-id="CD003053-fig-0019" src="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/image_n/nCD003053-CMP-001-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.12</div> <div class="figure-caption"> <p>Comparison 1 Metformin versus placebo or no treatment, Outcome 12 Serum testosterone (nmol/L). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/references#CD003053-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/image_n/nCD003053-CMP-001-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003053-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/urn:x-wiley:14651858:media:CD003053:CD003053-CMP-001-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/image_t/tCD003053-CMP-001-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Metformin versus placebo or no treatment, Outcome 13 Serum sex hormone‐binding globulin (nmol/L)." data-id="CD003053-fig-0020" src="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/image_n/nCD003053-CMP-001-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.13</div> <div class="figure-caption"> <p>Comparison 1 Metformin versus placebo or no treatment, Outcome 13 Serum sex hormone‐binding globulin (nmol/L). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/references#CD003053-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/image_n/nCD003053-CMP-001-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003053-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/urn:x-wiley:14651858:media:CD003053:CD003053-CMP-001-14" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/image_t/tCD003053-CMP-001-14.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Metformin versus placebo or no treatment, Outcome 14 Fasting glucose (mmol/L)." data-id="CD003053-fig-0021" src="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/image_n/nCD003053-CMP-001-14.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.14</div> <div class="figure-caption"> <p>Comparison 1 Metformin versus placebo or no treatment, Outcome 14 Fasting glucose (mmol/L). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/references#CD003053-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/image_n/nCD003053-CMP-001-14.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003053-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/urn:x-wiley:14651858:media:CD003053:CD003053-CMP-001-15" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/image_t/tCD003053-CMP-001-15.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Metformin versus placebo or no treatment, Outcome 15 Fasting insulin (mIU/L)." data-id="CD003053-fig-0022" src="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/image_n/nCD003053-CMP-001-15.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.15</div> <div class="figure-caption"> <p>Comparison 1 Metformin versus placebo or no treatment, Outcome 15 Fasting insulin (mIU/L). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/references#CD003053-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/image_n/nCD003053-CMP-001-15.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003053-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/urn:x-wiley:14651858:media:CD003053:CD003053-CMP-001-16" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/image_t/tCD003053-CMP-001-16.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Metformin versus placebo or no treatment, Outcome 16 Total cholesterol (mmol/L)." data-id="CD003053-fig-0023" src="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/image_n/nCD003053-CMP-001-16.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.16</div> <div class="figure-caption"> <p>Comparison 1 Metformin versus placebo or no treatment, Outcome 16 Total cholesterol (mmol/L). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/references#CD003053-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/image_n/nCD003053-CMP-001-16.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003053-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/urn:x-wiley:14651858:media:CD003053:CD003053-CMP-001-17" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/image_t/tCD003053-CMP-001-17.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Metformin versus placebo or no treatment, Outcome 17 Triglyceride levels (mmol/L)." data-id="CD003053-fig-0024" src="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/image_n/nCD003053-CMP-001-17.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.17</div> <div class="figure-caption"> <p>Comparison 1 Metformin versus placebo or no treatment, Outcome 17 Triglyceride levels (mmol/L). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/references#CD003053-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/image_n/nCD003053-CMP-001-17.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003053-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/urn:x-wiley:14651858:media:CD003053:CD003053-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/image_t/tCD003053-CMP-002-01.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Metformin combined with clomiphene citrate versus clomiphene citrate alone, Outcome 1 Live birth rate." data-id="CD003053-fig-0025" src="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/image_n/nCD003053-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 Metformin combined with clomiphene citrate versus clomiphene citrate alone, Outcome 1 Live birth rate. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/references#CD003053-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/image_n/nCD003053-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003053-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/urn:x-wiley:14651858:media:CD003053:CD003053-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/image_t/tCD003053-CMP-002-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Metformin combined with clomiphene citrate versus clomiphene citrate alone, Outcome 2 Adverse events." data-id="CD003053-fig-0026" src="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/image_n/nCD003053-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 Metformin combined with clomiphene citrate versus clomiphene citrate alone, Outcome 2 Adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/references#CD003053-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/image_n/nCD003053-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003053-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/urn:x-wiley:14651858:media:CD003053:CD003053-CMP-002-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/image_t/tCD003053-CMP-002-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Metformin combined with clomiphene citrate versus clomiphene citrate alone, Outcome 3 Clinical pregnancy rate." data-id="CD003053-fig-0027" src="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/image_n/nCD003053-CMP-002-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2 Metformin combined with clomiphene citrate versus clomiphene citrate alone, Outcome 3 Clinical pregnancy rate. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/references#CD003053-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/image_n/nCD003053-CMP-002-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003053-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/urn:x-wiley:14651858:media:CD003053:CD003053-CMP-002-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/image_t/tCD003053-CMP-002-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Metformin combined with clomiphene citrate versus clomiphene citrate alone, Outcome 4 Ovulation rate." data-id="CD003053-fig-0028" src="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/image_n/nCD003053-CMP-002-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2 Metformin combined with clomiphene citrate versus clomiphene citrate alone, Outcome 4 Ovulation rate. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/references#CD003053-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/image_n/nCD003053-CMP-002-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003053-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/urn:x-wiley:14651858:media:CD003053:CD003053-CMP-002-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/image_t/tCD003053-CMP-002-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Metformin combined with clomiphene citrate versus clomiphene citrate alone, Outcome 5 Ovulation rate: subgroup analysis by sensitivity to clomiphene citrate." data-id="CD003053-fig-0029" src="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/image_n/nCD003053-CMP-002-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2 Metformin combined with clomiphene citrate versus clomiphene citrate alone, Outcome 5 Ovulation rate: subgroup analysis by sensitivity to clomiphene citrate. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/references#CD003053-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/image_n/nCD003053-CMP-002-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003053-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/urn:x-wiley:14651858:media:CD003053:CD003053-CMP-002-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/image_t/tCD003053-CMP-002-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Metformin combined with clomiphene citrate versus clomiphene citrate alone, Outcome 6 Miscarriage rate per woman." data-id="CD003053-fig-0030" src="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/image_n/nCD003053-CMP-002-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.6</div> <div class="figure-caption"> <p>Comparison 2 Metformin combined with clomiphene citrate versus clomiphene citrate alone, Outcome 6 Miscarriage rate per woman. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/references#CD003053-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/image_n/nCD003053-CMP-002-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003053-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/urn:x-wiley:14651858:media:CD003053:CD003053-CMP-002-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/image_t/tCD003053-CMP-002-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Metformin combined with clomiphene citrate versus clomiphene citrate alone, Outcome 7 Sensitivity analysis: miscarriage rate per pregnancy." data-id="CD003053-fig-0031" src="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/image_n/nCD003053-CMP-002-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.7</div> <div class="figure-caption"> <p>Comparison 2 Metformin combined with clomiphene citrate versus clomiphene citrate alone, Outcome 7 Sensitivity analysis: miscarriage rate per pregnancy. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/references#CD003053-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/image_n/nCD003053-CMP-002-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003053-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/urn:x-wiley:14651858:media:CD003053:CD003053-CMP-002-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/image_t/tCD003053-CMP-002-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Metformin combined with clomiphene citrate versus clomiphene citrate alone, Outcome 8 Multiple pregnancy rate per woman." data-id="CD003053-fig-0032" src="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/image_n/nCD003053-CMP-002-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.8</div> <div class="figure-caption"> <p>Comparison 2 Metformin combined with clomiphene citrate versus clomiphene citrate alone, Outcome 8 Multiple pregnancy rate per woman. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/references#CD003053-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/image_n/nCD003053-CMP-002-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003053-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/urn:x-wiley:14651858:media:CD003053:CD003053-CMP-002-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/image_t/tCD003053-CMP-002-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Metformin combined with clomiphene citrate versus clomiphene citrate alone, Outcome 9 Senstivity analysis: multiple pregnancy rate per pregnancy." data-id="CD003053-fig-0033" src="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/image_n/nCD003053-CMP-002-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.9</div> <div class="figure-caption"> <p>Comparison 2 Metformin combined with clomiphene citrate versus clomiphene citrate alone, Outcome 9 Senstivity analysis: multiple pregnancy rate per pregnancy. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/references#CD003053-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/image_n/nCD003053-CMP-002-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003053-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/urn:x-wiley:14651858:media:CD003053:CD003053-CMP-003-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/image_t/tCD003053-CMP-003-01.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Metformin versus clomiphene citrate, Outcome 1 Live birth." data-id="CD003053-fig-0034" src="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/image_n/nCD003053-CMP-003-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3 Metformin versus clomiphene citrate, Outcome 1 Live birth.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/references#CD003053-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/image_n/nCD003053-CMP-003-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003053-fig-0035"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/urn:x-wiley:14651858:media:CD003053:CD003053-CMP-003-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/image_t/tCD003053-CMP-003-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Metformin versus clomiphene citrate, Outcome 2 Clinical pregnancy rate." data-id="CD003053-fig-0035" src="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/image_n/nCD003053-CMP-003-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3 Metformin versus clomiphene citrate, Outcome 2 Clinical pregnancy rate.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/references#CD003053-fig-0035">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/image_n/nCD003053-CMP-003-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003053-fig-0036"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/urn:x-wiley:14651858:media:CD003053:CD003053-CMP-003-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/image_t/tCD003053-CMP-003-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Metformin versus clomiphene citrate, Outcome 3 Ovulation rate." data-id="CD003053-fig-0036" src="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/image_n/nCD003053-CMP-003-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3 Metformin versus clomiphene citrate, Outcome 3 Ovulation rate.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/references#CD003053-fig-0036">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/image_n/nCD003053-CMP-003-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003053-fig-0037"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/urn:x-wiley:14651858:media:CD003053:CD003053-CMP-003-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/image_t/tCD003053-CMP-003-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Metformin versus clomiphene citrate, Outcome 4 Miscarriage rate per woman." data-id="CD003053-fig-0037" src="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/image_n/nCD003053-CMP-003-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3 Metformin versus clomiphene citrate, Outcome 4 Miscarriage rate per woman.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/references#CD003053-fig-0037">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/image_n/nCD003053-CMP-003-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003053-fig-0038"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/urn:x-wiley:14651858:media:CD003053:CD003053-CMP-003-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/image_t/tCD003053-CMP-003-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Metformin versus clomiphene citrate, Outcome 5 Sensitivity analysis: miscarriage rate per pregnancy." data-id="CD003053-fig-0038" src="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/image_n/nCD003053-CMP-003-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.5</div> <div class="figure-caption"> <p>Comparison 3 Metformin versus clomiphene citrate, Outcome 5 Sensitivity analysis: miscarriage rate per pregnancy. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/references#CD003053-fig-0038">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/image_n/nCD003053-CMP-003-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003053-fig-0039"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/urn:x-wiley:14651858:media:CD003053:CD003053-CMP-003-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/image_t/tCD003053-CMP-003-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Metformin versus clomiphene citrate, Outcome 6 Multiple pregnancy rate per woman." data-id="CD003053-fig-0039" src="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/image_n/nCD003053-CMP-003-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.6</div> <div class="figure-caption"> <p>Comparison 3 Metformin versus clomiphene citrate, Outcome 6 Multiple pregnancy rate per woman. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/references#CD003053-fig-0039">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/image_n/nCD003053-CMP-003-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003053-fig-0040"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/urn:x-wiley:14651858:media:CD003053:CD003053-CMP-003-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/image_t/tCD003053-CMP-003-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Metformin versus clomiphene citrate, Outcome 7 Sensitivity analysis: multiple pregnancy rate per pregnancy." data-id="CD003053-fig-0040" src="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/image_n/nCD003053-CMP-003-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.7</div> <div class="figure-caption"> <p>Comparison 3 Metformin versus clomiphene citrate, Outcome 7 Sensitivity analysis: multiple pregnancy rate per pregnancy. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/references#CD003053-fig-0040">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/image_n/nCD003053-CMP-003-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003053-fig-0041"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/urn:x-wiley:14651858:media:CD003053:CD003053-CMP-004-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/image_t/tCD003053-CMP-004-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 D‐chiro‐inositol versus placebo or no treatment, Outcome 1 Ovulation." data-id="CD003053-fig-0041" src="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/image_n/nCD003053-CMP-004-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4 D‐chiro‐inositol versus placebo or no treatment, Outcome 1 Ovulation.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/references#CD003053-fig-0041">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/image_n/nCD003053-CMP-004-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003053-fig-0042"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/urn:x-wiley:14651858:media:CD003053:CD003053-CMP-004-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/image_t/tCD003053-CMP-004-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 D‐chiro‐inositol versus placebo or no treatment, Outcome 2 Body mass index (kg/m2)." data-id="CD003053-fig-0042" src="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/image_n/nCD003053-CMP-004-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4 D‐chiro‐inositol versus placebo or no treatment, Outcome 2 Body mass index (kg/m<sup>2</sup>). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/references#CD003053-fig-0042">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/image_n/nCD003053-CMP-004-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003053-fig-0043"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/urn:x-wiley:14651858:media:CD003053:CD003053-CMP-004-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/image_t/tCD003053-CMP-004-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 D‐chiro‐inositol versus placebo or no treatment, Outcome 3 Waist‐hip ratio." data-id="CD003053-fig-0043" src="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/image_n/nCD003053-CMP-004-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.3</div> <div class="figure-caption"> <p>Comparison 4 D‐chiro‐inositol versus placebo or no treatment, Outcome 3 Waist‐hip ratio. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/references#CD003053-fig-0043">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/image_n/nCD003053-CMP-004-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003053-fig-0044"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/urn:x-wiley:14651858:media:CD003053:CD003053-CMP-004-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/image_t/tCD003053-CMP-004-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 D‐chiro‐inositol versus placebo or no treatment, Outcome 4 Blood pressure ‐ systolic (mm Hg)." data-id="CD003053-fig-0044" src="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/image_n/nCD003053-CMP-004-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.4</div> <div class="figure-caption"> <p>Comparison 4 D‐chiro‐inositol versus placebo or no treatment, Outcome 4 Blood pressure ‐ systolic (mm Hg). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/references#CD003053-fig-0044">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/image_n/nCD003053-CMP-004-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003053-fig-0045"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/urn:x-wiley:14651858:media:CD003053:CD003053-CMP-004-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/image_t/tCD003053-CMP-004-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 D‐chiro‐inositol versus placebo or no treatment, Outcome 5 Blood pressure ‐ diastolic (mm Hg)." data-id="CD003053-fig-0045" src="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/image_n/nCD003053-CMP-004-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.5</div> <div class="figure-caption"> <p>Comparison 4 D‐chiro‐inositol versus placebo or no treatment, Outcome 5 Blood pressure ‐ diastolic (mm Hg). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/references#CD003053-fig-0045">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/image_n/nCD003053-CMP-004-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003053-fig-0046"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/urn:x-wiley:14651858:media:CD003053:CD003053-CMP-004-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/image_t/tCD003053-CMP-004-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 D‐chiro‐inositol versus placebo or no treatment, Outcome 6 Serum testosterone (nmol/L)." data-id="CD003053-fig-0046" src="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/image_n/nCD003053-CMP-004-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.6</div> <div class="figure-caption"> <p>Comparison 4 D‐chiro‐inositol versus placebo or no treatment, Outcome 6 Serum testosterone (nmol/L). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/references#CD003053-fig-0046">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/image_n/nCD003053-CMP-004-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003053-fig-0047"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/urn:x-wiley:14651858:media:CD003053:CD003053-CMP-004-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/image_t/tCD003053-CMP-004-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 D‐chiro‐inositol versus placebo or no treatment, Outcome 7 Serum sex hormone‐binding globulin (nmol/L)." data-id="CD003053-fig-0047" src="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/image_n/nCD003053-CMP-004-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.7</div> <div class="figure-caption"> <p>Comparison 4 D‐chiro‐inositol versus placebo or no treatment, Outcome 7 Serum sex hormone‐binding globulin (nmol/L). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/references#CD003053-fig-0047">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/image_n/nCD003053-CMP-004-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003053-fig-0048"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/urn:x-wiley:14651858:media:CD003053:CD003053-CMP-004-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/image_t/tCD003053-CMP-004-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 D‐chiro‐inositol versus placebo or no treatment, Outcome 8 Fasting glucose (mmol/L)." data-id="CD003053-fig-0048" src="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/image_n/nCD003053-CMP-004-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.8</div> <div class="figure-caption"> <p>Comparison 4 D‐chiro‐inositol versus placebo or no treatment, Outcome 8 Fasting glucose (mmol/L). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/references#CD003053-fig-0048">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/image_n/nCD003053-CMP-004-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003053-fig-0049"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/urn:x-wiley:14651858:media:CD003053:CD003053-CMP-004-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/image_t/tCD003053-CMP-004-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 D‐chiro‐inositol versus placebo or no treatment, Outcome 9 Fasting insulin (mIU/L)." data-id="CD003053-fig-0049" src="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/image_n/nCD003053-CMP-004-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.9</div> <div class="figure-caption"> <p>Comparison 4 D‐chiro‐inositol versus placebo or no treatment, Outcome 9 Fasting insulin (mIU/L). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/references#CD003053-fig-0049">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/image_n/nCD003053-CMP-004-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003053-fig-0050"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/urn:x-wiley:14651858:media:CD003053:CD003053-CMP-004-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/image_t/tCD003053-CMP-004-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 D‐chiro‐inositol versus placebo or no treatment, Outcome 10 Total cholesterol (mmol/L)." data-id="CD003053-fig-0050" src="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/image_n/nCD003053-CMP-004-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.10</div> <div class="figure-caption"> <p>Comparison 4 D‐chiro‐inositol versus placebo or no treatment, Outcome 10 Total cholesterol (mmol/L). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/references#CD003053-fig-0050">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/image_n/nCD003053-CMP-004-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003053-fig-0051"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/urn:x-wiley:14651858:media:CD003053:CD003053-CMP-004-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/image_t/tCD003053-CMP-004-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 D‐chiro‐inositol versus placebo or no treatment, Outcome 11 Triglyceride levels (mmol/L)." data-id="CD003053-fig-0051" src="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/image_n/nCD003053-CMP-004-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.11</div> <div class="figure-caption"> <p>Comparison 4 D‐chiro‐inositol versus placebo or no treatment, Outcome 11 Triglyceride levels (mmol/L). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/references#CD003053-fig-0051">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/image_n/nCD003053-CMP-004-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003053-fig-0052"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/urn:x-wiley:14651858:media:CD003053:CD003053-CMP-005-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/image_t/tCD003053-CMP-005-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Rosiglitazone versus placebo or no treatment, Outcome 1 Ovulation rate." data-id="CD003053-fig-0052" src="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/image_n/nCD003053-CMP-005-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.1</div> <div class="figure-caption"> <p>Comparison 5 Rosiglitazone versus placebo or no treatment, Outcome 1 Ovulation rate.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/references#CD003053-fig-0052">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/image_n/nCD003053-CMP-005-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003053-fig-0053"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/urn:x-wiley:14651858:media:CD003053:CD003053-CMP-005-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/image_t/tCD003053-CMP-005-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Rosiglitazone versus placebo or no treatment, Outcome 2 Menstrual frequency." data-id="CD003053-fig-0053" src="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/image_n/nCD003053-CMP-005-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.2</div> <div class="figure-caption"> <p>Comparison 5 Rosiglitazone versus placebo or no treatment, Outcome 2 Menstrual frequency.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/references#CD003053-fig-0053">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/image_n/nCD003053-CMP-005-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003053-fig-0054"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/urn:x-wiley:14651858:media:CD003053:CD003053-CMP-005-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/image_t/tCD003053-CMP-005-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Rosiglitazone versus placebo or no treatment, Outcome 3 Body mass index (kg/m2)." data-id="CD003053-fig-0054" src="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/image_n/nCD003053-CMP-005-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.3</div> <div class="figure-caption"> <p>Comparison 5 Rosiglitazone versus placebo or no treatment, Outcome 3 Body mass index (kg/m<sup>2</sup>). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/references#CD003053-fig-0054">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/image_n/nCD003053-CMP-005-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003053-fig-0055"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/urn:x-wiley:14651858:media:CD003053:CD003053-CMP-005-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/image_t/tCD003053-CMP-005-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Rosiglitazone versus placebo or no treatment, Outcome 4 Waist‐hip ratio." data-id="CD003053-fig-0055" src="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/image_n/nCD003053-CMP-005-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.4</div> <div class="figure-caption"> <p>Comparison 5 Rosiglitazone versus placebo or no treatment, Outcome 4 Waist‐hip ratio.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/references#CD003053-fig-0055">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/image_n/nCD003053-CMP-005-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003053-fig-0056"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/urn:x-wiley:14651858:media:CD003053:CD003053-CMP-005-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/image_t/tCD003053-CMP-005-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Rosiglitazone versus placebo or no treatment, Outcome 5 Blood pressure ‐ systolic (mm Hg)." data-id="CD003053-fig-0056" src="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/image_n/nCD003053-CMP-005-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.5</div> <div class="figure-caption"> <p>Comparison 5 Rosiglitazone versus placebo or no treatment, Outcome 5 Blood pressure ‐ systolic (mm Hg). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/references#CD003053-fig-0056">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/image_n/nCD003053-CMP-005-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003053-fig-0057"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/urn:x-wiley:14651858:media:CD003053:CD003053-CMP-005-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/image_t/tCD003053-CMP-005-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Rosiglitazone versus placebo or no treatment, Outcome 6 Blood pressure ‐ diastolic (mm Hg)." data-id="CD003053-fig-0057" src="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/image_n/nCD003053-CMP-005-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.6</div> <div class="figure-caption"> <p>Comparison 5 Rosiglitazone versus placebo or no treatment, Outcome 6 Blood pressure ‐ diastolic (mm Hg). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/references#CD003053-fig-0057">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/image_n/nCD003053-CMP-005-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003053-fig-0058"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/urn:x-wiley:14651858:media:CD003053:CD003053-CMP-005-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/image_t/tCD003053-CMP-005-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Rosiglitazone versus placebo or no treatment, Outcome 7 Serum testosterone (nmol/L)." data-id="CD003053-fig-0058" src="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/image_n/nCD003053-CMP-005-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.7</div> <div class="figure-caption"> <p>Comparison 5 Rosiglitazone versus placebo or no treatment, Outcome 7 Serum testosterone (nmol/L). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/references#CD003053-fig-0058">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/image_n/nCD003053-CMP-005-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003053-fig-0059"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/urn:x-wiley:14651858:media:CD003053:CD003053-CMP-005-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/image_t/tCD003053-CMP-005-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Rosiglitazone versus placebo or no treatment, Outcome 8 Serum sex hormone‐binding globulin (nmol/L)." data-id="CD003053-fig-0059" src="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/image_n/nCD003053-CMP-005-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.8</div> <div class="figure-caption"> <p>Comparison 5 Rosiglitazone versus placebo or no treatment, Outcome 8 Serum sex hormone‐binding globulin (nmol/L). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/references#CD003053-fig-0059">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/image_n/nCD003053-CMP-005-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003053-fig-0060"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/urn:x-wiley:14651858:media:CD003053:CD003053-CMP-005-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/image_t/tCD003053-CMP-005-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Rosiglitazone versus placebo or no treatment, Outcome 9 Fasting glucose (mmol/L)." data-id="CD003053-fig-0060" src="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/image_n/nCD003053-CMP-005-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.9</div> <div class="figure-caption"> <p>Comparison 5 Rosiglitazone versus placebo or no treatment, Outcome 9 Fasting glucose (mmol/L). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/references#CD003053-fig-0060">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/image_n/nCD003053-CMP-005-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003053-fig-0061"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/urn:x-wiley:14651858:media:CD003053:CD003053-CMP-005-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/image_t/tCD003053-CMP-005-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Rosiglitazone versus placebo or no treatment, Outcome 10 Fasting insulin (mIU/L)." data-id="CD003053-fig-0061" src="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/image_n/nCD003053-CMP-005-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.10</div> <div class="figure-caption"> <p>Comparison 5 Rosiglitazone versus placebo or no treatment, Outcome 10 Fasting insulin (mIU/L). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/references#CD003053-fig-0061">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/image_n/nCD003053-CMP-005-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003053-fig-0062"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/urn:x-wiley:14651858:media:CD003053:CD003053-CMP-005-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/image_t/tCD003053-CMP-005-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Rosiglitazone versus placebo or no treatment, Outcome 11 Total cholesterol (mmol/L)." data-id="CD003053-fig-0062" src="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/image_n/nCD003053-CMP-005-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.11</div> <div class="figure-caption"> <p>Comparison 5 Rosiglitazone versus placebo or no treatment, Outcome 11 Total cholesterol (mmol/L). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/references#CD003053-fig-0062">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/image_n/nCD003053-CMP-005-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003053-fig-0063"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/urn:x-wiley:14651858:media:CD003053:CD003053-CMP-005-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/image_t/tCD003053-CMP-005-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Rosiglitazone versus placebo or no treatment, Outcome 12 Triglyceride levels (mmol/L)." data-id="CD003053-fig-0063" src="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/image_n/nCD003053-CMP-005-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.12</div> <div class="figure-caption"> <p>Comparison 5 Rosiglitazone versus placebo or no treatment, Outcome 12 Triglyceride levels (mmol/L). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/references#CD003053-fig-0063">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/image_n/nCD003053-CMP-005-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003053-fig-0064"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/urn:x-wiley:14651858:media:CD003053:CD003053-CMP-006-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/image_t/tCD003053-CMP-006-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Pioglitazone versus placebo or no treatment, Outcome 1 Menstrual frequency." data-id="CD003053-fig-0064" src="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/image_n/nCD003053-CMP-006-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.1</div> <div class="figure-caption"> <p>Comparison 6 Pioglitazone versus placebo or no treatment, Outcome 1 Menstrual frequency.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/references#CD003053-fig-0064">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/image_n/nCD003053-CMP-006-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003053-fig-0065"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/urn:x-wiley:14651858:media:CD003053:CD003053-CMP-006-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/image_t/tCD003053-CMP-006-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Pioglitazone versus placebo or no treatment, Outcome 2 Body mass index (kg/m2)." data-id="CD003053-fig-0065" src="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/image_n/nCD003053-CMP-006-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.2</div> <div class="figure-caption"> <p>Comparison 6 Pioglitazone versus placebo or no treatment, Outcome 2 Body mass index (kg/m<sup>2</sup>). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/references#CD003053-fig-0065">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/image_n/nCD003053-CMP-006-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003053-fig-0066"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/urn:x-wiley:14651858:media:CD003053:CD003053-CMP-006-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/image_t/tCD003053-CMP-006-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Pioglitazone versus placebo or no treatment, Outcome 3 Waist‐hip ratio." data-id="CD003053-fig-0066" src="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/image_n/nCD003053-CMP-006-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.3</div> <div class="figure-caption"> <p>Comparison 6 Pioglitazone versus placebo or no treatment, Outcome 3 Waist‐hip ratio.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/references#CD003053-fig-0066">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/image_n/nCD003053-CMP-006-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003053-fig-0067"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/urn:x-wiley:14651858:media:CD003053:CD003053-CMP-006-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/image_t/tCD003053-CMP-006-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Pioglitazone versus placebo or no treatment, Outcome 4 Serum testosterone (nmol/L)." data-id="CD003053-fig-0067" src="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/image_n/nCD003053-CMP-006-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.4</div> <div class="figure-caption"> <p>Comparison 6 Pioglitazone versus placebo or no treatment, Outcome 4 Serum testosterone (nmol/L). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/references#CD003053-fig-0067">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/image_n/nCD003053-CMP-006-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003053-fig-0068"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/urn:x-wiley:14651858:media:CD003053:CD003053-CMP-006-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/image_t/tCD003053-CMP-006-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Pioglitazone versus placebo or no treatment, Outcome 5 Serum sex hormone‐binding globulin (nmol/L)." data-id="CD003053-fig-0068" src="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/image_n/nCD003053-CMP-006-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.5</div> <div class="figure-caption"> <p>Comparison 6 Pioglitazone versus placebo or no treatment, Outcome 5 Serum sex hormone‐binding globulin (nmol/L). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/references#CD003053-fig-0068">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/image_n/nCD003053-CMP-006-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003053-fig-0069"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/urn:x-wiley:14651858:media:CD003053:CD003053-CMP-006-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/image_t/tCD003053-CMP-006-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Pioglitazone versus placebo or no treatment, Outcome 6 Fasting insulin (mIU/L)." data-id="CD003053-fig-0069" src="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/image_n/nCD003053-CMP-006-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.6</div> <div class="figure-caption"> <p>Comparison 6 Pioglitazone versus placebo or no treatment, Outcome 6 Fasting insulin (mIU/L). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/references#CD003053-fig-0069">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/media/CDSR/CD003053/image_n/nCD003053-CMP-006-06.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD003053-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Metformin compared to placebo or no treatment for women with polycystic ovary syndrome</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Metformin compared to placebo or no treatment for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population</b> : women with polycystic ovary syndrome, oligo amenorrhoea and subfertility<br/> <b>Settings</b> : outpatient<br/> <b>Intervention</b> : metformin<br/> <b>Comparison</b>: placebo or no treatment </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Placebo or no treatment</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Metformin </b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Live birth rate per woman</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>141 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>208 per 1000<br/> (141 to 292) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 1.59</b> <br/> (1.00 to 2.51) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>435<br/> (4 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Adverse events</b> (gastrointestinal) per woman </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>106 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>362 per 1000</p> <p>(267 to 469)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR 4.76</p> <p>(3.06 to 7.41)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>670</p> <p>(7 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>a,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Clinical pregnancy rate per woman</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>110 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>193 per 1000<br/> (149 to 246) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 1.93</b> <br/> (1.42 to 2.64) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1027<br/> (9 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Menstrual frequency per woman</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>183 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>278 per 1000</p> <p>(203 to 368)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>OR 1.72</b> </p> <p>(1.14 to 2.61)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>427</p> <p>(7 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>a,d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Ovulation rate per woman</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>200 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>389 per 1000<br/> (312 to 473) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR</b> <br/> 2.55 </p> <p>(1.81 to 3.59)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>701<br/> (14 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Miscarriage rate per woman</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>40 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>43per 1000<br/> (20 to 89) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 1.08</b><br/> (0.50 to 2.35) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>748<br/> (4 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Miscarriage rate per pregnancy OR 0.58, 95% CI 0.25 to 1.34, 200 pregnancies</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> is the median control group risk across studies. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>OR:</b> odds ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence</p> <p><b>High quality</b>: we are very confident that the true effect lies close to that of the estimate of the effect </p> <p><b>Moderate quality</b>: we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of effect, but there is a possibility that it is substantially different </p> <p><b>Low quality</b>: our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect </p> <p><b>Very low quality</b>: we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level for serious risk of bias related to failure to report methods of randomisation and/or serious risk of attrition bias in some of the studies.<br/> <sup>b</sup>Downgraded one level for serious imprecision as the event rate is low and findings are compatible with benefit in one or both groups or with no meaningful difference between the groups.<br/> <sup>c</sup>Moderate inconsistency (I<sup>2</sup> = 61%), but not downgraded, as all heterogeneity is attributable to a single small study and the direction of effect largely consistent.<br/> <sup>d</sup>Downgraded one level for serious inconsistency (I<sup>2</sup>= 54%); largest study shows no evidence of effect. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Metformin compared to placebo or no treatment for women with polycystic ovary syndrome</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/full#CD003053-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD003053-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Metformin combined with clomiphene citrate versus clomiphene citrate alone for women with polycystic ovary syndrome</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>Metformin combined with clomiphene versus clomiphene alone for women with polycystic ovary syndrome </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Population</b> : women with polycystic ovary syndrome<br/> <b>Setting</b> : outpatient<br/> <b>Intervention</b> : metformin combined with ovulation induction agent clomiphene<br/> <b>Comparison</b>: clomiphene alone </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with clomiphene alone</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with metformin combined with clomiphene</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Live birth rate per woman</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>257 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>295 per 1000<br/> (241 to 355) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 1.21<br/> (0.92 to 1.59) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1079<br/> (9 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events</b> (gastrointestinal) per woman </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>134 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>381 per 1000<br/> (286 to 485) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 3.97<br/> (2.59 to 6.08) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>591<br/> (3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Clinical pregnancy rate per woman</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>243 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>338per 1000<br/> (330 to 436) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR 1.59<br/> (1.27 to 1.99) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1529<br/> (16 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Menstrual frequency per woman</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign=""> <p>Not reported by any of the included studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Ovulation rate per woman</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>381per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>491 per 1000<br/> (441to 542) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 1.57</p> <p>(1.28 to 1.92)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1624<br/> (21 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>a,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Miscarriage rate per woman</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Median rates not calculable as there were no events in the control group in 5/8 studies</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 1.59<br/> (1.03 to 2.46) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1096<br/> (9 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Miscarriage rate per pregnancy OR 1.30 95% CI 0.80 to 2.12, 400 pregnancies</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the median risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> confidence interval; <b>OR:</b> odds ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> we are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level for serious risk of bias related to failure to describe study methods and/or serious risk of attrition bias in several of the studies.<br/> <sup>b</sup>Downgraded one level for serious imprecision as findings are compatible with benefit in one or both groups or with no meaningful difference between the group.<br/> <sup>c</sup>High heterogeneity (I<sup>2</sup> = 62%), but not downgraded as direction of effect consistent and most inconsistency is due to a single small study. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Metformin combined with clomiphene citrate versus clomiphene citrate alone for women with polycystic ovary syndrome</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/full#CD003053-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD003053-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Metformin compared to clomiphene citrate for women with polycystic ovary syndrome</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>Metformin compared to clomiphene citrate for women with polycystic ovary syndrome</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Population</b> : women with polycystic ovary syndrome<br/> <b>Setting:</b> outpatient<br/> <b>Intervention</b> : metformin<br/> <b>Comparison</b>: clomiphene citrate </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with clomiphene citrate</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with metformin</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Live birth rate per woman</b> </p> <p>Participants with BMI &lt; 30 kg/m<sup>2</sup> or ≤ 32 kg/m<sup>2a</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>225 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>171 per 1000</p> <p>(124 to 227)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR 1.71 (1.00 to 2.94)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>241</p> <p>(3 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝</p> <p><b>very low</b><sup>c,d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>High heterogeneity (I<sup>2</sup> = 78%) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Live birth rate per woman</b> </p> <p>Participants with BMI ≥ 30 kg/m<sup>2a</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>198 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>69 per 1000</p> <p>(40 to 114)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR 0.30</p> <p>(0.17 to 0.52)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>500</p> <p>(2 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>c,d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>74 events</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Adverse events</b> </p> <p>(gastrointestinal)</p> </td> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign=""> <p>Not reported by any of the included studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Clinical pregnancy rate per woman</b> Participants with BMI &lt; 30 kg/m<sup>2</sup> or ≤ 32 kg/m<sup>2a</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>320 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>423 per 1000<br/> (331 to 523) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 1.56<br/> (1.05 to 2.33) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>490<br/> (5 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>c,d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>103 events</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Clinical pregnancy rate per woman</b> Participants with BMI ≥ 30 kg/m<sup>2a</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>234 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>94 per 1000<br/> (60 to 144) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 0.34<br/> (0.21 to 0.55) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>500<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>c,d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>98 events</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Menstrual frequency</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="4" rowspan="1" valign=""> <p>Not reported by any of the included studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Ovulation rate per woman</b> </p> <p>Participants with BMI &lt; 30 kg/m<sup>2b</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>625 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>574 per 1000<br/> (459 to 681) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 0.81<br/> (0.51 to 1.28) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>312<br/> (4 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Ovulation rate per woman</b> </p> <p>Participants with BMI ≥ 30 kg/m<sup>2b</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>534per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>250per 1,000<br/> (187 to 330) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 0.29<br/> (0.20 to 0.43) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>500<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Miscarriage rate per woman</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>29 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>26 per 1000</p> <p>(15 to 47)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR 0.92 (0.50 to 1.67)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>741<br/> (5 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝</p> <p><b>very low</b><sup>c,e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>High heterogeneity (I<sup>2</sup> = 52%) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the median risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> confidence interval; <b>OR:</b> odds ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> we are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Data subgrouped by BMI, as pooling of BMI groups resulted in high heterogeneity (I<sup>2</sup> &gt; 85%) with differing directions of effect.<br/> <sup>b</sup>Data subgrouped by BMI, as pooling of BMI groups resulted in high heterogeneity (I<sup>2</sup> = 74%), though direction of effect was consistent.<br/> <sup>c</sup>Evidence downgraded two levels for very serious risk of bias, due to failure to report study methods and/or risk of attrition bias in one or more studies and because findings are based on subgroup analysis.<br/> <sup>d</sup>Evidence downgraded one level for serious imprecision: low event rate (total 74 events).<br/> eEvidence downgraded for serious inconsistency (where further downgrading feasible). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Metformin compared to clomiphene citrate for women with polycystic ovary syndrome</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/full#CD003053-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD003053-tbl-0004"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Abbreviations used</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Abbreviation</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Definition</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>BMI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Body mass index</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clomiphene citrate</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Confidence interval</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Computerised tomography scan</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>DHEAS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Dehydroepiandrosterone sulphate</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>FSH</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Follicle stimulating hormone</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>GTT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Glucose tolerance test</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>HbA1C</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Glycosylated haemoglobin</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>HDL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>High‐density lipoprotein cholesterol</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IGFBP‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Insulin growth factor binding protein 1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>LDL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low‐density lipoprotein cholesterol</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>LH</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Luteinising hormone</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NIDDM</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Non insulin dependent diabetes mellitus</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PAI‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Plasminogen activator inhibitor 1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PCO</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Polycystic ovary</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PCOS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Polycystic ovary syndrome</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Randomised controlled trial</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>rFSH</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Recombinant follicle stimulating hormone</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Standard deviation</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Standard error of the mean</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SHBG</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sex hormone‐binding globulin</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>VLDL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Very low density lipoprotein cholesterol</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>vs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Versus</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mean difference</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Abbreviations used</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/full#CD003053-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD003053-tbl-0005"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Conversion factors</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Convert from</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Convert to</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Conversion factor</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cholesterol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>mg/dL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>mmol/L</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.026</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Triglycerides</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>mg/dL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>mmol/L</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.11</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Insulin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>pmol/L</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>mIU/L (= microIU/mL)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.1667</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Glucose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>mg/dL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>mmol/L</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.056</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Progesterone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ng/mL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>nmol/L</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.18</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Testosterone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ng/dL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>nmol/L</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.03467</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Androstenedione</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ng/dL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>nmol/L</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.0349</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Estradiol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ng/dL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>pmol/L</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>36.71</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17‐beta oestradiol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ng/dL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>pmol/L</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>36.71</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Dehydroepiandrosterone sulphate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>microg/dL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>micromol/L</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.02714</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sex hormone‐binding globulin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>microg/dL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>nmol/L</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>34.7</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Standard deviation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Standard error</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Standard deviation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sqrt n</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Confidence intervals</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Confidence intervals</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Standard error</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(upper limit ‐ lower limit)/3.92</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Conversion factors</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/full#CD003053-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD003053-tbl-0006"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Metformin vs placebo: ovulation rate per cycle</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Study ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Metformin</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Placebo</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>P value</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Events</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Cycles</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Events</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Cycles</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>BMI &lt; 30 kg/m<sup>2</sup> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003053-bbs2-0002" title="BaillargeonJP , JakubowiczDJ , IuornoMJ , JakubowiczS , NestlerJE . Effects of metformin and rosiglitazone, alone and in combination, in nonobese women with polycystic ovary syndrome and normal indices of insulin sensitivity. Fertility and Sterility2004;82:893‐902. ">Baillargeon 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003053-bbs2-0007" title="CarminaE , LoboRA . Does metformin induce ovulation in normoandrogenic anovulatory women?. American Journal of Obstetrics and Gynecology2004;191:1580‐4. ">Carmina 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003053-bbs2-0032" title="NgEHY , WatNMS , HoPC . Effects of metformin on ovulation rate, hormonal and metabolic profiles in women with clomiphene‐resistant polycystic ovaries: a randomized, double‐blinded placebo‐controlled trial. Human Reproduction2001;16(8):1625‐31. ">Ng 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003053-bbs2-0033" title="OnalanG , GoktolgaU , CeyhanT , BagisT , OnalanR , PabuccuR . Predictive value of glucose‐insulin ratio in PCOS and profile of women who will benefit from metformin therapy: obese, lean, hyper or normoinsulinemic?. European Journal of Obstetrics, Gynecology, and Reproductive Biology2005;123:204‐11. ">Onalan 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>153</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>150</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003053-bbs2-0047" title="YaraliH , YildizBO , DemirolA , ZeynelogluHB , YigitN , BukulmezO , et al. Co‐administration of metformin during rFSH treatment in patients with clomiphene citrate‐resistant polycystic ovarian syndrome: a prospective randomized trial. Human Reproduction2002;17(2):289‐94. YaraliH , YyldyzB , DemirolA , ZeynelogluH , YigitN , BukulmezO . Co‐administration of metformin during recombinant follicle stimulating hormone (recombinant FSH) treatment using the low‐dose step protocol in patients with clomiphene citrate resistant polycystic ovary syndrome (PCOS): a prospective randomized trial. Fertility and Sterility2001;76 Suppl(3):36. ">Yarali 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>BMI ≥ 30 kg/m<sup>2</sup> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003053-bbs2-0011" title="FlemingR , HopkinsonZE , WallaceAM , GreerIA , SattarN . Ovarian function and metabolic factors in women with oligomenorrhea treated with metformin in a randomized double blind placebo‐controlled trial. Journal of Clinical Endocrinology and Metabolism2002;87(2):569‐74. FlemingR , HopkinsonZE , WallaceE , GreerIA , SattarN . Metformin treatment improves ovulation frequency in women with oligomenorrhoea: a randomized, double blind placebo trial. Human Fertility2000; Vol. 3, issue 4:389‐90. ">Fleming 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003053-bbs2-0014" title="HoegerKM , KochmanL , WixomN , CraigK , MillerRK , GuzickDS . A randomized, 48‐week, placebo‐controlled trial of intensive lifestyle modification and/or metformin therapy in overweight women with polycystic ovary syndrome: a pilot study. Fertility and Sterility2004;82:421‐9. ">Hoeger 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003053-bbs2-0014" title="HoegerKM , KochmanL , WixomN , CraigK , MillerRK , GuzickDS . A randomized, 48‐week, placebo‐controlled trial of intensive lifestyle modification and/or metformin therapy in overweight women with polycystic ovary syndrome: a pilot study. Fertility and Sterility2004;82:421‐9. ">Hoeger 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003053-bbs2-0016" title="JakubowiczDJ , SeppalaM , JakubowiczS , Rodriguez‐ArmasO , Rivas‐SantiagoA , KoistinenH , et al. Insulin reduction with metformin increases luteal phase serum glycodelin and insulin‐like growth factor‐binding protein 1 concentrations and enhances uterine vascularity and blood flow in the polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism2001;86(3):1126‐33. ">Jakubowicz 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003053-bbs2-0023" title="LordJ , ThomasR , FoxB , AcharyaU , WilkinT . The effect of metformin on fat distribution and the metabolic syndrome in women with polycystic ovary syndrome‐‐a randomised, double‐blind, placebo‐controlled trial. British Journal of Obstetrics and Gynaecology2006;113:817‐24. ">Lord 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003053-bbs2-0030" title="NestlerJE , JakubowiczDJ , EvansWS , PasqualiR . Effects of metformin on spontaneous and clomiphene‐induced ovulation in the polycystic ovary syndrome. New England Journal of Medicine1998;338(26):1876‐80. ">Nestler 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003053-bbs2-0033" title="OnalanG , GoktolgaU , CeyhanT , BagisT , OnalanR , PabuccuR . Predictive value of glucose‐insulin ratio in PCOS and profile of women who will benefit from metformin therapy: obese, lean, hyper or normoinsulinemic?. European Journal of Obstetrics, Gynecology, and Reproductive Biology2005;123:204‐11. ">Onalan 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>51</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003053-bbs2-0034" title="OttaCF , WiorM , IraciGS , KaplanR , TorresD , GaidoMI , et al. Clinical, metabolic, and endocrine parameters in response to metformin and lifestyle intervention in women with polycystic ovary syndrome: a randomized, double‐blind, and placebo control trial. Gynecological Endocrinology2010;26(3):173‐8. ">Otta 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003053-bbs2-0037" title="JohnsonNP , BontekoeS , StewartAW . Analysis of factors predicting success of metformin and clomiphene treatment for women with infertility owing to PCOS‐related ovulation dysfunction in a randomised controlled trial. Australian &amp; New Zealand Journal of Obstetrics &amp; Gynaecology2011;51:252‐6. JohnsonNP , StewartAW , FalkinerJ , FarquharCM , MilsomS , SinghV‐P , et al. on behalf of REACT‐NZ (REproduction And Collaborative Trials in New Zealand), a multi‐centre fertility trials group. PCOSMIC: a multi‐centre randomized trial in women with Polycystic Ovary Syndrome evaluating Metformin for Infertility with Clomiphene. Human Reproduction2010;25(7):1675‐83. [MEDLINE: 10.1093/humrep/deq100] ">PCOSMIC 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003053-bbs2-0042" title="SturrockNDC , LannonB , FayTN . Metformin does not enhance ovulation induction in clomiphene resistant polycystic ovary syndrome in clinical practice. British Journal of Clinical Pharmacology2002;53(5):469‐73. [MEDLINE: 2002180629] ">Sturrock 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003053-bbs2-0045" title="VandermolenDT , RattsVS , EvansWS , StovallDW , KaumaSW , NestlerJE . Metformin increases the ovulatory rate and pregnancy rate from clomiphene citrate in patients with polycystic ovary syndrome who are resistant to clomiphene citrate alone. Fertility and Sterility2001;75:310‐5. ">Vandermolen 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Metformin vs placebo: ovulation rate per cycle</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/full#CD003053-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD003053-tbl-0007"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Metformin + clomiphene citrate vs clomiphene citrate: ovulation rate per cycle</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Study ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Metformin +<br/> clomiphene citrate</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Clomiphene<br/> citrate alone</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>P value</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Events</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Cycles</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Events</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Cycles</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>BMI &lt; 30 kg/m<sup>2</sup> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003053-bbs2-0001" title="AyazA , AlwanY , FarooqMU . Efficacy of combined metformin‐clomiphene citrate in comparison with clomiphene citrate alone in infertile women with polycystic ovarian syndrome (PCOS). Journal of Medicine and Life2013;6:199‐201. AyazA , AlwanY , FarooqMU . Metformin‐clomiphene citrate vs. clomiphene citrate alone: polycystic ovarian syndrome. Journal of Human Reproductive Sciences2013;6:15‐8. ">Ayaz 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003053-bbs2-0004" title="Ben AyedB , Dammak Dit MlikS , Ben ArabH , TrabelssiH , ChahtourH , MathlouthiN . Metformin effects on clomifene‐induced ovulation in the polycystic ovary syndrome. Tunisie Medicale2009;87(1):43‐8. ">Ben Ayed 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003053-bbs2-0005" title="BoudhrâaK , JellouliMA , AmriM , FarhatM , TorkhaniF , GaraMF . Indication of metformin in the management of hormonal dysfunction secondary to polycystic ovarian syndrome: prospective comparative study of 63 cases. [La metformine dans la prise en charge de l'infertilite du SOPK hors FIV etude prospective comparative a propos de 63 cas]. Tunisie Medicale2010;88(5):335‐40. ">Boudhraa 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003053-bbs2-0010" title="El‐BielyMM , HabbaM . The use of metformin to augment the induction of ovulation in obese infertile patients with polycystic ovary syndrome. Middle East Fertility Society Journal2001;6(1):43‐9. ">El‐Biely 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003053-bbs2-0015" title="HwuYM , LinSY , HuangWY , LinMH , LeeRK . Ultra‐short metformin pretreatment for clomiphene citrate‐resistant polycystic ovary syndrome. International Journal of Gynaecology and Obstetrics2005;90:39‐43. ">Hwu 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003053-bbs2-0024" title="MachadoRC , MachadoNA , GeberS . Evaluation of the use of metformin for ovulation in patients with PCOS resistant to isolated use of clomiphene citrate. Brazilian Journal Assisted Reproduction2012;16(1):27‐31. ">Machado 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003053-bbs2-0026" title="MalkawiHY , QublanHS . The effect of metformin plus clomiphene citrate on ovulation and pregnancy rates in clomiphene‐resistant women with polycystic ovary syndrome. Saudi Medical Journal2002;23(6):663‐6. [MEDLINE: 22065897] ">Malkawi 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003053-bbs2-0028" title="MollE , BossuytPM , KorevaarJC , LambalkCB , Van derVeenF . Effect of clomifene citrate plus metformin and clomifene citrate plus placebo on induction of ovulation in women with newly diagnosed polycystic ovary syndrome: randomised double blind clinical trial. BMJ2006;332:1485. [original article] MollE , KorevaarJC , BossuytPM , van derVeenF . Does adding metformin to clomifene citrate lead to higher pregnancy rates in a subset of women with polycystic ovary syndrome?. Human Reproduction2008;23(8):1830‐4. MollE , VanWelyM , LambalkCB , BossuytPM , Van derVeenF . Health‐related quality of life in women with newly diagnosed polycystic ovary syndrome randomized between clomifene citrate plus metformin or clomifene citrate plus placebo. Human Reproduction2012;27:3273‐8. ">Moll 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>84</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>141</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>98</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>168</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003053-bbs2-0032" title="NgEHY , WatNMS , HoPC . Effects of metformin on ovulation rate, hormonal and metabolic profiles in women with clomiphene‐resistant polycystic ovaries: a randomized, double‐blinded placebo‐controlled trial. Human Reproduction2001;16(8):1625‐31. ">Ng 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003053-bbs2-0037" title="JohnsonNP , BontekoeS , StewartAW . Analysis of factors predicting success of metformin and clomiphene treatment for women with infertility owing to PCOS‐related ovulation dysfunction in a randomised controlled trial. Australian &amp; New Zealand Journal of Obstetrics &amp; Gynaecology2011;51:252‐6. JohnsonNP , StewartAW , FalkinerJ , FarquharCM , MilsomS , SinghV‐P , et al. on behalf of REACT‐NZ (REproduction And Collaborative Trials in New Zealand), a multi‐centre fertility trials group. PCOSMIC: a multi‐centre randomized trial in women with Polycystic Ovary Syndrome evaluating Metformin for Infertility with Clomiphene. Human Reproduction2010;25(7):1675‐83. [MEDLINE: 10.1093/humrep/deq100] ">PCOSMIC 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>BMI ≥ 30 kg/m<sup>2</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003053-bbs2-0016" title="JakubowiczDJ , SeppalaM , JakubowiczS , Rodriguez‐ArmasO , Rivas‐SantiagoA , KoistinenH , et al. Insulin reduction with metformin increases luteal phase serum glycodelin and insulin‐like growth factor‐binding protein 1 concentrations and enhances uterine vascularity and blood flow in the polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism2001;86(3):1126‐33. ">Jakubowicz 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003053-bbs2-0020" title="KhorramO , HelliwellJP , KatzS , BonpaneCM , JaramilloL Khorram O , et al. Two weeks of metformin improves clomiphene citrate‐induced ovulation and metabolic profiles in women with polycystic ovary syndrome. Fertility and Sterility2006;85:1448‐51. ">Khorram 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003053-bbs2-0022" title="CataldoN , BarnhartH , LegroR , MyersE , SchlaffW , CarrB , et al. Extended‐release metformin does not reduce the clomiphene citrate dose required to induce ovulation in polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism2008;93(8):3147‐7. LegroRS , BarnhartHX , SchlaffWD , CarrBR , DiamondMP , CarsonSA , et al. Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome. New England Journal of Medicine2007;356:551‐66. [original article] ">Legro 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>582</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>964</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>462</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>942</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003053-bbs2-0030" title="NestlerJE , JakubowiczDJ , EvansWS , PasqualiR . Effects of metformin on spontaneous and clomiphene‐induced ovulation in the polycystic ovary syndrome. New England Journal of Medicine1998;338(26):1876‐80. ">Nestler 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003053-bbs2-0040" title="SahinY , YirmibesU , KelestimurF , AygenE . The effects of metformin on insulin resistance, clomiphene‐induced ovulation and pregnancy rates in women with polycystic ovary syndrome. European Journal of Obstetrics, Gynecology, and Reproductive Biology2004;113:214‐20. ">Sahin 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>51</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003053-bbs2-0041" title="SiebertT , KrugerT , LombardC . Evaluating the equivalence of clomiphene citrate with and without metformin in ovulation induction in PCOS patients. Journal of Assisted Reproduction and Genetics2009;26(4):165‐71. ">Siebert 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003053-bbs2-0042" title="SturrockNDC , LannonB , FayTN . Metformin does not enhance ovulation induction in clomiphene resistant polycystic ovary syndrome in clinical practice. British Journal of Clinical Pharmacology2002;53(5):469‐73. [MEDLINE: 2002180629] ">Sturrock 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003053-bbs2-0045" title="VandermolenDT , RattsVS , EvansWS , StovallDW , KaumaSW , NestlerJE . Metformin increases the ovulatory rate and pregnancy rate from clomiphene citrate in patients with polycystic ovary syndrome who are resistant to clomiphene citrate alone. Fertility and Sterility2001;75:310‐5. ">Vandermolen 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003053-bbs2-0048" title="ZainMM , JamaluddinR , IbrahimA , NormanRJ . Comparison of clomiphene citrate, metformin, or the combination of both for first‐line ovulation induction, achievement of pregnancy, and live birth in Asian women with polycystic ovary syndrome: a randomized controlled trial. Fertility and Sterility2009;91(2):514‐21. ">Zain 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Metformin + clomiphene citrate vs clomiphene citrate: ovulation rate per cycle</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/full#CD003053-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD003053-tbl-0008"> <div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Metformin vs clomiphene citrate: ovulation rate per cycle</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Metformin</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Clomiphene citrate</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Events</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Cycles</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Events</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Cycles</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>P value</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>BMI &lt; 30 kg/m<sup>2</sup> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003053-bbs2-0035" title="PalombaS , OrioFJr , FalboA , MangusoF , RussoT , CascellaT , et al. Prospective parallel randomized, double‐blind, double‐dummy controlled clinical trial comparing clomiphene citrate and metformin as the first‐line treatment for ovulation induction in nonobese anovulatory women with polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism2005;90(7):4068‐74. [original article] PalombaS , OrioFJr , FalboA , RussoT , TolinoA , ZulloF . Effects of metformin and clomiphene citrate on ovarian vascularity in patients with polycystic ovary syndrome. Fertility and Sterility2006;86:1694‐701. ">Palomba 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>129</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>205</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>148</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>221</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003053-bbs2-0037" title="JohnsonNP , BontekoeS , StewartAW . Analysis of factors predicting success of metformin and clomiphene treatment for women with infertility owing to PCOS‐related ovulation dysfunction in a randomised controlled trial. Australian &amp; New Zealand Journal of Obstetrics &amp; Gynaecology2011;51:252‐6. JohnsonNP , StewartAW , FalkinerJ , FarquharCM , MilsomS , SinghV‐P , et al. on behalf of REACT‐NZ (REproduction And Collaborative Trials in New Zealand), a multi‐centre fertility trials group. PCOSMIC: a multi‐centre randomized trial in women with Polycystic Ovary Syndrome evaluating Metformin for Infertility with Clomiphene. Human Reproduction2010;25(7):1675‐83. [MEDLINE: 10.1093/humrep/deq100] ">PCOSMIC 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>BMI ≥ 30 kg/m<sup>2</sup> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003053-bbs2-0022" title="CataldoN , BarnhartH , LegroR , MyersE , SchlaffW , CarrB , et al. Extended‐release metformin does not reduce the clomiphene citrate dose required to induce ovulation in polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism2008;93(8):3147‐7. LegroRS , BarnhartHX , SchlaffWD , CarrBR , DiamondMP , CarsonSA , et al. Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome. New England Journal of Medicine2007;356:551‐66. [original article] ">Legro 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>296</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1019</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>462</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>942</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003053-bbs2-0048" title="ZainMM , JamaluddinR , IbrahimA , NormanRJ . Comparison of clomiphene citrate, metformin, or the combination of both for first‐line ovulation induction, achievement of pregnancy, and live birth in Asian women with polycystic ovary syndrome: a randomized controlled trial. Fertility and Sterility2009;91(2):514‐21. ">Zain 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Metformin vs clomiphene citrate: ovulation rate per cycle</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/full#CD003053-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD003053-tbl-0009"> <div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">D‐Chiro‐inositol vs placebo: ovulation rate per cycle</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Inositol</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Placebo</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Events</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Cycles</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Events</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Cycles</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>P value</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>BMI &lt; 30 kg/m<sup>2</sup> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003053-bbs2-0012" title="GerliS , MignosaM , DiRenzoGC . Effects of inositol on ovarian function and metabolic factors in women with PCOS: a randomized double blind placebo‐controlled trial. European Review for Medical and Pharmacological Sciences2003;7:151‐9. [Original article] GerliS , PapaleoE , FerrariA , DiRenzoGC . Randomized, double blind placebo‐controlled trial: effects of myo‐inositol on ovarian function and metabolic factors in women with PCOS. European Review for Medical and Pharmacological Sciences2007;11(5):347‐54. ">Gerli 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>128</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>136</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>130</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>147</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003053-bbs2-0031" title="NestlerJE , JakubowiczDJ , ReamerP , GunnRD , AllanG . Ovulatory and metabolic effects of D‐chiro‐inositol in the polycystic ovary syndrome. New England Journal of Medicine1999;340(17):1314‐20. ">Nestler 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">D‐Chiro‐inositol vs placebo: ovulation rate per cycle</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/full#CD003053-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD003053-tbl-0010"> <div class="table-heading"><span class="table-label">Table 7.</span> <span class="table-title">Rosiglitazone vs placebo: ovulation rate per cycle</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Rosiglitazone</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Placebo</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Events</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Cycles</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Events</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Cycles</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>P value</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>BMI ≥ 30 kg/m<sup>2</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD003053-bbs2-0002" title="BaillargeonJP , JakubowiczDJ , IuornoMJ , JakubowiczS , NestlerJE . Effects of metformin and rosiglitazone, alone and in combination, in nonobese women with polycystic ovary syndrome and normal indices of insulin sensitivity. Fertility and Sterility2004;82:893‐902. ">Baillargeon 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 7.</span> <span class="table-title">Rosiglitazone vs placebo: ovulation rate per cycle</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/full#CD003053-tbl-0010">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003053-tbl-0011"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Metformin versus placebo or no treatment</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Live birth rate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>435</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.59 [1.00, 2.51]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Participants with BMI &lt; 30 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>370</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.51 [0.94, 2.44]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Participants with BMI ≥ 30 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.87 [0.51, 16.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Adverse events (gastrointestinal side effects) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>670</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.76 [3.06, 7.41]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Participants with BMI &lt; 30 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>393</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.61 [2.89, 10.88]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Participants with BMI ≥ 30 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>277</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.13 [2.28, 7.49]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Clinical pregnancy rate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1027</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.93 [1.42, 2.64]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Participants with BMI &lt; 30 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>733</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.89 [1.35, 2.65]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Participants with BMI ≥ 30 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>294</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.21 [0.98, 4.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Ovulation rate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>701</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.55 [1.81, 3.59]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Participants with BMI &lt; 30 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>229</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.15 [2.31, 7.45]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Participants with BMI ≥ 30 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>472</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.96 [1.28, 3.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Menstrual frequency <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>427</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.72 [1.14, 2.61]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Participants with BMI &lt; 30 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>21.15 [1.01, 445.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 Participants with BMI ≥ 30 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>404</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.57 [1.03, 2.41]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Miscarriage rate per woman <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>748</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.08 [0.50, 2.35]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Participants with BMI &lt; 30 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>683</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.19 [0.52, 2.71]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 Participants with BMI ≥ 30 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.5 [0.04, 5.80]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Sensitivity analysis: miscarriage rate per pregnancy <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>200</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.58 [0.25, 1.34]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 Participants with BMI &lt; 30 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>188</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.63 [0.26, 1.53]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 Participants with BMI ≥ 30 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.25 [0.02, 4.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Body mass index (kg/m<sup>2</sup>) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>827</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.08 [‐0.33, 0.17]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 Participants with BMI &lt; 30 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>419</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.06 [‐0.33, 0.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2 Participants with BMI ≥ 30 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>408</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.20 [‐0.92, 0.52]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Waist‐hip ratio <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>702</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.01 [‐0.01, ‐0.00]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1 Participants with BMI &lt; 30 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>389</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.01 [‐0.01, ‐0.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.2 Participants with BMI ≥ 30 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>313</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.01 [‐0.02, 0.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Blood pressure ‐ systolic (mm Hg) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>379</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.59 [‐5.13, ‐2.04]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1 Participants with BMI &lt; 30 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>96</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.52 [‐5.29, ‐1.76]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.2 Participants with BMI ≥ 30 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>283</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.80 [‐5.00, ‐0.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Blood pressure ‐ diastolic (mm Hg) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>292</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.14 [‐1.35, 1.07]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.1 Participants with BMI &lt; 30 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>96</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.21 [‐1.55, 1.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.2 Participants with BMI ≥ 30 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>196</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.18 [‐2.65, 3.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Serum testosterone (nmol/L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>863</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.49 [‐0.59, ‐0.39]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.1 Participants with BMI &lt; 30 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>419</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.71 [‐0.86, ‐0.56]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.2 Participants with BMI ≥ 30 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>444</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.29 [‐0.44, ‐0.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 Serum sex hormone‐binding globulin (nmol/L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>823</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.49 [‐1.82, 2.81]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.1 Participants with BMI &lt; 30 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>387</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.22 [‐6.73, 6.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.2 Participants with BMI ≥ 30 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>436</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.60 [‐1.88, 3.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14 Fasting glucose (mmol/L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>849</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.14 [‐0.21, ‐0.07]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.1 Participants with BMI &lt; 30 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>364</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.13 [‐0.22, ‐0.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.2 Participants with BMI ≥ 30 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>485</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.16 [‐0.27, ‐0.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15 Fasting insulin (mIU/L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>573</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐4.13 [‐5.67, ‐2.58]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.1 Participants with BMI &lt; 30 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>85</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐6.20 [‐8.56, ‐3.84]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.2 Participants with BMI ≥ 30 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>488</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.57 [‐4.62, ‐0.53]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16 Total cholesterol (mmol/L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>562</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.14 [‐0.31, 0.02]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.1 Participants with BMI &lt; 30 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>276</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.02 [‐0.26, 0.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.2 Participants with BMI ≥ 30 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>286</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.26 [‐0.48, ‐0.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">17 Triglyceride levels (mmol/L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>309</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.14 [‐0.05, 0.32]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.1 Participants with BMI &lt; 30 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.00 [‐0.33, 0.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.2 Participants with BMI ≥ 30 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>256</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.20 [‐0.02, 0.42]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Metformin versus placebo or no treatment</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/references#CD003053-tbl-0011">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003053-tbl-0012"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Metformin combined with clomiphene citrate versus clomiphene citrate alone</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Live birth rate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1079</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.21 [0.92, 1.59]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Participants with BMI &lt; 30 kg/m2 or ≤ 32 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>531</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.14 [0.78, 1.67]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Participants with BMI ≥ 30 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>548</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.28 [0.86, 1.91]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>591</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.97 [2.59, 6.08]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Participants with BMI &lt; 30 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>591</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.97 [2.59, 6.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Clinical pregnancy rate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1529</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.59 [1.27, 1.99]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Participants with BMI &lt; 30 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>834</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.46 [1.08, 1.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Participants with BMI ≥ 30 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>695</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.76 [1.26, 2.47]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Ovulation rate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1624</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.57 [1.28, 1.92]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 BMI &lt; 30 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>755</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.79 [1.32, 2.41]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 BMI ≥ 30 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>814</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.52 [1.15, 2.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3 BMI not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.43 [0.13, 1.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Ovulation rate: subgroup analysis by sensitivity to clomiphene citrate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>271</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.69 [2.61, 8.44]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 PCOS and clomiphene‐sensitive</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>56</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.55 [0.65, 19.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 PCOS and clomiphene‐resistant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>215</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.89 [2.62, 9.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Miscarriage rate per woman <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1096</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.59 [1.03, 2.46]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Participants with BMI &lt; 30 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>548</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.41 [0.76, 2.62]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 Participants with BMI ≥ 30 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>548</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.79 [0.97, 3.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Sensitivity analysis: miscarriage rate per pregnancy <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>400</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.30 [0.80, 2.12]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 Participants with BMI &lt; 30 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>228</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.27 [0.65, 2.51]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 Participants with BMI ≥ 30 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>172</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.34 [0.67, 2.68]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Multiple pregnancy rate per woman <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1003</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.56 [0.18, 1.68]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 Participants with BMI &lt; 30 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>476</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.50 [0.12, 2.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2 Participants with BMI ≥ 30kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>527</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.66 [0.11, 4.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Senstivity analysis: multiple pregnancy rate per pregnancy <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>342</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.46 [0.15, 1.42]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1 Participants with BMI &lt; 30 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>178</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.43 [0.10, 1.85]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.2 Participants with BMI ≥ 30 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>164</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.50 [0.08, 3.12]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Metformin combined with clomiphene citrate versus clomiphene citrate alone</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/references#CD003053-tbl-0012">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003053-tbl-0013"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Metformin versus clomiphene citrate</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Live birth <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>741</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.71 [0.49, 1.01]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Participants with BMI &lt; 30 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>241</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.71 [1.00, 2.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Participants with BMI ≥ 30 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>500</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.30 [0.17, 0.52]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Clinical pregnancy rate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Participants with BMI &lt; 30 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>490</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.56 [1.05, 2.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Participants with BMI ≥ 30 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>500</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.34 [0.21, 0.55]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Ovulation rate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Participants with BMI &lt; 30 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>312</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.81 [0.51, 1.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Participants with BMI ≥ 30 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>500</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.29 [0.20, 0.43]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Miscarriage rate per woman <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>741</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.50, 1.67]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Participants with BMI &lt; 30 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>241</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.58 [0.61, 4.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Participants with BMI ≥ 30 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>500</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.61 [0.27, 1.38]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Sensitivity analysis: miscarriage rate per pregnancy <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Participants with BMI &lt; 30 kg/m2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 Participants with BMI ≥ 30 kg/m2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Multiple pregnancy rate per woman <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>858</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.29 [0.06, 1.43]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Participants with BMI &lt; 30 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>358</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.46 [0.07, 3.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 Participants with BMI ≥ 30 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>500</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.14 [0.01, 2.76]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Sensitivity analysis: multiple pregnancy rate per pregnancy <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>201</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.06, 1.68]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 Participants with BMI &lt; 30 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>103</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.32 [0.05, 2.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 Participants with BMI ≥ 30 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>98</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.02, 6.69]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Metformin versus clomiphene citrate</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/references#CD003053-tbl-0013">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003053-tbl-0014"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">D‐chiro‐inositol versus placebo or no treatment</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Ovulation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>327</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.57 [1.72, 7.45]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Participants with BMI &lt; 30 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>327</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.57 [1.72, 7.45]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Body mass index (kg/m<sup>2</sup>) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.5 [‐0.86, 1.86]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Waist‐hip ratio <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.01 [‐0.05, 0.03]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Blood pressure ‐ systolic (mm Hg) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.0 [‐5.85, 1.85]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Blood pressure ‐ diastolic (mm Hg) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐4.0 [‐7.26, ‐0.74]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Serum testosterone (nmol/L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.63 [‐1.37, 0.11]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Serum sex hormone‐binding globulin (nmol/L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>69.44 [34.97, 103.91]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Fasting glucose (mmol/L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.28 [‐0.99, 0.43]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Fasting insulin (mIU/L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐20.0 [‐43.43, 3.43]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Total cholesterol (mmol/L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.23 [‐0.99, 0.53]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Triglyceride levels (mmol/L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.20 [‐6.23, 1.83]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">D‐chiro‐inositol versus placebo or no treatment</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/references#CD003053-tbl-0014">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003053-tbl-0015"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Rosiglitazone versus placebo or no treatment</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Ovulation rate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.91 [0.70, 5.22]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Participants with BMI ≥ 30 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.91 [0.70, 5.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Menstrual frequency <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.59 [2.20, 14.19]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Body mass index (kg/m<sup>2</sup>) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>132</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.68 [0.40, 0.96]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Waist‐hip ratio <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>132</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.01 [‐0.02, ‐0.00]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Blood pressure ‐ systolic (mm Hg) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.0 [‐3.95, ‐0.05]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Blood pressure ‐ diastolic (mm Hg) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.20 [‐1.72, 1.32]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Serum testosterone (nmol/L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>54</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.20 [‐0.34, 0.74]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Serum sex hormone‐binding globulin (nmol/L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>132</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.69 [‐10.37, 8.98]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Fasting glucose (mmol/L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>132</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.21 [‐0.39, ‐0.04]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Fasting insulin (mIU/L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.98 [‐9.38, 1.42]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Total cholesterol (mmol/L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.20 [‐0.21, ‐0.19]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Triglyceride levels (mmol/L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.0 [0.89, 1.11]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Rosiglitazone versus placebo or no treatment</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/references#CD003053-tbl-0015">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003053-tbl-0016"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Pioglitazone versus placebo or no treatment</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Menstrual frequency <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>8.88 [2.35, 33.61]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Participants with BMI &lt; 30 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>10.23 [1.12, 93.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Participants with BMI ≥ 30 kg/m2 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>8.0 [1.52, 42.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Body mass index (kg/m<sup>2</sup>) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [‐1.88, 3.70]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Waist‐hip ratio <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.02 [‐0.02, 0.06]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Serum testosterone (nmol/L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.12 [‐0.53, 0.29]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Serum sex hormone‐binding globulin (nmol/L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.75 [‐5.26, 10.77]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Fasting insulin (mIU/L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.46 [‐3.97, 1.06]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Pioglitazone versus placebo or no treatment</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003053.pub6/references#CD003053-tbl-0016">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD003053.pub6&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD003053-note-0001">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD003053-note-0003">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD003053-note-0004">فارسی</a> </li> <li class="section-language"> <a class="" href="pl#CD003053-note-0002">Polski</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD003053-note-0010">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734739000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734739000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773542000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773471000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003053\x2epub6\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003053\x2epub6\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003053\x2epub6\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD003053\x2epub6"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003053\x2epub6\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003053\x2epub6\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003053\x2epub6\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003053\x2epub6\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003053\x2epub6\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD003053\x2epub6"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003053\x2epub6\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003053\x2epub6\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003053\x2epub6\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD003053\x2epub6"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003053\x2epub6\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003053\x2epub6\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003053\x2epub6\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD003053\x2epub6"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=9mpoajSI&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD003053.pub6&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD003053.pub6';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD003053.pub6/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD003053.pub6/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD003053.pub6%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740728208821"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD003053.pub6/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740728208825"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD003053.pub6/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918ebedf6b17f46e',t:'MTc0MDcyODIwOS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 